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Enterococci were first known to cause human infections in the early 1900s; however, it was not until the 
last three decades that they emerged as one of the most important common nosocomial pathogens. 
Enterococci, and particularly Enterococcus faecium, are now considered as one of the 21
st
 century 
medical challenges due to the increasing prevalence of multi-drug resistant (MDR) strains, particularly 
those resistant to ampicillin and vancomycin. The increasing importance of E. faecium as nosocomial 
pathogen prompted a series of studies regarding its population structure and prevalence of antibiotic 
resistance particularly in hospitalized patients. Available knowledge regarding the E. faecium 
populations of community-based humans and individuals of different ages is still scarce. Furthermore, 
little is known about the mobile genetic elements (MGE) associated with antibiotic resistance 
determinants, particularly vancomycin, which is one of the last therapeutic options to treat infections 
caused by multidrug resistant isolates of Gram positive species. As such, the main objective of this PhD 
dissertation is to assess the influence that antibiotic resistance and more specifically, that of the MGEs 
associated with ampicillin and vancomycin resistance have had in shaping the population structure and 
evolution of E. faecium. 
Chapters 1 and 2 describe the comprehensive analysis of MLST data of E. faecium isolates from faeces of 
hospitalized and healthy humans of different ages and E. faecium isolates causing bloodstream 
infections (BSI), via Bayesian Analysis of Population Structure (BAPS) used for analysing the population 
structure of recombinant bacterial species as E. faecium. Such analysis permitted the identification of 
differences in the content of enterococcal species at different ages, to confirm that ST18, ST17 and ST78 
lineages, previously within CC17, have a separate origin, and to validate the suitability of BAPS for 
analysing the diversity of E. faecium populations. The recovery from BSI of all E. faecium BAPS groups 
including those associated with members of the commensal human flora (e.g. BAPS 1 and BAPS 3.3b) 
pointed out the human gut as the origin of BSI. Changes in the GI tract microbiota of hospitalized 
patients due to host factors (e.g. age) or different selective pressures in the hospital setting, would have 
facilitated the selection and the consequent increase in the population size of MDR E. faecium clones, 
leading to a shift in the composition of E. faecium populations that increases the chances to be infected 
by MDR and the chances to transmit MDR strains.  
Chapter 3 focuses on a network-based analysis of plasmids that carry resistance to antimicrobials in 
members of the Firmicutes phylum, and it shows the frequent but heterogeneous horizontal gene 
transfer (HGT) events that occurred among species-specific plasmids. Such results helped to understand 
the heterogeneous occurrence of resistance to different antibiotics in E. faecium. However, to explain 
the contribution of antibiotic resistance to the increasing recovery of E. faecium from hospital infections 
in the last decades, we further explore the genetic context of resistance to first line therapeutic options, 
ampicillin and vancomycin, among isolates of predominant in major human lineages of this species.  
Chapter 6 showed how ampicillin resistance (pbp5) has shaped the population structure of the species 
through convergent evolution and also horizontal gene transfer, leading to the high prevalence and 
xx 
 
further fixation of different clonal lineages of ampicillin resistant E. faecium in hospitals, probably 
assoĐiated ǁith the seleĐtiǀe pƌessuƌe eǆeƌted ďǇ β-lactams in the nosocomial setting since 1940s.  
Chapters 4 and 5 describe the diversity of plasmids among vancomycin resistant E. faecium from 
different geographical locations, and we comprehensively characterize those carrying Tn1546. These 
studies reflect the influence of specific narrow- and broad-host range plasmids in the spread of 
vancomycin resistance in the USA and Europe (pRUM and Inc18, respectively). The diversity of Tn1546-
vanA carrying plasmids, mostly chimeras of narrow and broad host range plasmids, reflects the frequent 
HGT events between populations of enterococci and other Firmicutes. The species specificity of these 
plasmids besides the significant fitness burden that they confer to the host, and their high stability in the 
absence of selective pressure, comprehensively described in Chapter 7, would partially explain the 
confinement of vancomycin resistance to E. faecium. 
In summary, this PhD dissertation showed the existence of specific populations in both non-hospitalized 
and hospitalized patients of different ages. The enrichment of such E. faecium populations in antibiotic 
resistance determinants and MGEs appears to be essential for the evolution and adaptation of these 
lineages to the survival in settings under high selective pressures as hospitals. Even though, the 
presence of resistant determinants and MGEs might cause a significant burden for the E. faecium host, 
the stability and the frequent HGT events among strains and/or MGEs would justify their maintenance 
and spread within E. faecium populations. 
 
Key Words: Enterococcus faecium, mobile genetic elements, plasmids, biological cost, Tn1546, pbp5, 
vancomycin, ampicillin. 
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La prevalencia de infecciones hospitalarias causadas por especies del género Enterococcus ha sido baja 
desde su descripción como patógenos oportunistas al inicio del siglo XX, hasta finales de los años 70s, 
coincidiendo con la aparición de las primeras cepas resistentes a antibióticos. La especie Enterococcus 
faecium es actualmente uno de los principales patógenos nosocomiales debido en parte a la alta 
prevalencia de cepas resistentes a ampicilina y vancomicina. La estructura poblacional de E. faecium ha 
sido analizada mayoritariamente considerando cepas resistentes a antibióticos y de origen hospitalario 
pero se desconoce su diversidad en individuos no hospitalizados o de diferentes edades. El 
conocimiento de los elementos genéticos móviles (EGM) que facilitan la transferencia de genes de 
resistencia a antibióticos entre clones de la misma o diferente especie, principalmente vancomicina (una 
de las ultimas opciones terapéuticas para el tratamiento de bacterias Gram positivas multi resistentes a 
los antibióticos), es también muy reducido. El principal objetivo de esta tesis de doctorado es 
determinar la influencia en la estructura poblacional y evolvabilidad de E. faecium de los determinantes 
de resistencia y de los EGM que facilitan su adquisición, transferencia y persistencia. Los capítulos 1 y 2 
consisten en el análisis Bayesiano (BAPS) de los datos de MLST procedentes de heces de pacientes 
hospitalizados y no-hospitalizados de diferentes edades y de aislados de E. faecium causantes de 
bacteriemias. Este análisis permitió separar los linajes clonales que constituyen el complejo clonal 
(CC)17 que había sido identificado con la aplicación de metodologías previas en tres líneas clonales de 
diferente origen, ST18, ST17 y ST78. El aislamiento de cepas de E. faecium pertenecientes a grupos BAPS 
asociados con la flora comensal humana (BAPS 1 y BAPS 3.3b) sugiere la frecuente adquisición endógena 
a partir de la microbiota intestinal de las bacteriemias causadas por E. faecium, bien forma directa o a 
través de infecciones en territorios cercanos (infección urinaria, infección abdominal). Los cambios 
ocurridos en la microbiota intestinal de los pacientes hospitalizados debido a factores asociados al 
hospedador (edad) o diferentes presiones selectivas en el medio hospitalario, habrían facilitado la 
selección (aumento de la densidad poblacional) y la consecuente expansión de las poblaciones de clones 
de E. faecium resistentes a antibióticos y aumentando por tanto las oportunidades de infección y 
transmisión de E. faecium.  
El capítulo 3 describe el análisis de redes de los plásmidos asociados a resistencia a antimicrobianos en 
las especies del phylum Firmicutes, y la resultante demostración de la frecuente pero heterogénea 
transferencia horizontal de genes (THG) entre plásmidos de muy estrecho rango de hospedador. Estos 
resultados ayudan a comprender la distribución asimétrica de genes de resistencia a antibióticos en 
diferentes poblaciones de E. faecium. Para poder explicar la contribución de los determinantes de 
resistencia en el aumento de la prevalencia de E. faecium en infecciones nosocomiales en las últimas 
décadas se estudió detalladamente el contexto genético de los determinantes responsables de 
resistencia a ampicilina y vancomicina, antibióticos de primera elección para el tratamiento de 
infecciones graves E. faecium.  
El capítulo 6 describe la región del cromosoma en la que se localiza el gen responsable de la resistencia a 
la ampicilina (pbp5), sus variaciones y su transferibilidad en poblaciones de E. faecium. El análisis 
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comparativo de genomas de E. faecium resistentes y sensibles a ampicilina, indica la influencia de esta 
región en la estructura poblacional de E. faecium a través de procesos de evolución convergente y THG.  
Los capítulos 4 y 5 recogen dos trabajos que analizan la diversidad de los plásmidos portadores de 
Tn1546-vanA en cepas de E. faecium resistentes a la vancomicina a nivel local (Portugal) y a nivel global 
(en diferentes áreas de globo terrestre). Estos estudios demuestran la relevancia de plásmidos 
particulares de amplio (Inc18) y reducido (pRUM) espectro de hospedador en la diseminación de 
Tn1546-vanA en los Estados Unidos y en Europa. La diversidad de los plásmidos asociados al Tn1546, 
principalmente quimeras de plásmidos de reducido y amplio espectro de hospedador, reflejan la 
frecuencia de eventos de THG entre diferentes especies de enterococos y otros géneros de Firmicutes. 
El reducido rango de hospedador de los plásmidos Tn1546, así como su coste biológico y su estabilidad 
en ausencia de presión selectiva, descritos en el capítulo 7, podrían contribuir a explicar la casi exclusiva 
presencia de resistencia a la vancomicina en E. faecium dentro del género Enterococcus. 
En resumen, esta Tesis Doctoral demuestra la existencia de poblaciones especializadas de E. faecium 
asociadas a individuos hospitalizados y no-hospitalizados de diferentes edades. Las poblaciones 
predominantes en individuos hospitalizados están enriquecidas en determinantes de resistencia a 
antibióticos y EGM que parecen tener un papel esencial en la adaptación y evolvabilidad de E. faecium 
en condiciones de elevada y variable presión selectiva como el hospital. No obstante, a pesar del 
significativo coste biológico que los determinantes de resistencia y sus EGM pueden conferir al 
hospedador, su estabilidad, y a la vez su su variabilidad-adaptabilidad, junto con su capacidad de 
propagación por eventos de THG, podrían explicar su mantenimiento y diseminación en poblaciones de 
E. faecium a nivel global.  
 
Palabras clave: Enterococcus faecium, estructura poblacional, elementos genéticos móviles, plásmidos, 
ampicilina, vancomicina, coste biológico, pbp5, Tn1546. 
 
 
 
 
 1 
 
 
 
 
 
Real knowledge is to know the extent of one's ignorance. 
Confucius 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 
 
 
 
 2 
 
 
  
Ana P. Tedim  Introduction 
  
3 
 
1. The Genus Enterococcus an Historic Perspective 
Enterococci emerged as a cause of human infections in the early 1900s and have, in the last three 
decades, emerged as one of the most important common nosocomial pathogens (1, 2). Enterococci are 
capable of causing a wide variety of infections as urinary tract infections (UTIs), peritonitis, hepatobiliary 
sepsis, endocarditis, surgical wound infections, bacteraemia and neonatal sepsis (2, 3).  
The teƌŵ ͞eŶteƌoĐoĐĐus͟ ǁas fiƌstlǇ used iŶ the ϭϵth century to describe a saprophytic Gram positive 
diploĐoĐĐus, of iŶtestiŶal oƌigiŶ, Đapaďle of ĐausiŶg huŵaŶ iŶfeĐtioŶ. The teƌŵ ͞eŶteƌoĐoƋue͟ ǁas 
proposed in order to emphasize the bacteria morphology and its intestinal origin. This enteric bacteria 
was found to colonize the GI tract of a patient with diarrhoea and to cause septicaemia afterwards (1, 
4). In the same year, MacCallum and Hastings reported a case of acute endocarditis, followed by 
septicaemia and eventual death, caused by Micrococcus zymogenes, latter classified as Streptococcus 
faecalis and now known as Enterococcus faecalis (1, 5).  
In 1906 Streptococcus faecalis was described for the first time, associated with an endocarditis  infection 
(1, 6). In 1919 and 1935 Streptococcus faecium and Streptococcus durans were firstly described (1, 7, 8). 
Then, Sherman proposed a classification of Streptococcus into four groups: pyogenic, viridans, lactic and 
͞eŶteƌoĐoĐĐal gƌoup͟ (1, 9). The creation of an Enterococcus taxon, based on cellular arrangement and 
pheŶotǇpiĐ ĐhaƌaĐteƌistiĐs of the ͞eŶteƌoĐoĐĐal gƌoup͟ ǁas fiƌstlǇ suggested iŶ ϭϵϳϬ. Hoǁeǀeƌ, it ǁas 
not until 1984 that this taxon was created based on genetic evidences that showed that S. faecalis and S. 
faecium were distant members of the Streptococcus genus (1, 10, 11).  
Nowadays, the genus Enterococcus is classified within the phylum Firmicutes, class Bacilli, order 
Lactobacillales and family Enterococcaceae. This genus is composed of more than 50 species 
(http://www.bacterio.net/enterococcus.html), of which E. faecium and E. faecalis are the species most 
commonly recovered from humans. However, several other species (E. avium, E. durans, E. hirae, E. 
casseliflavus, E. gallinarum) are also able to colonize the GI tract of humans and may sporadically cause 
human infections (1, 2).  
 
1.1. Physiology and Ecology 
Enterococci are Gram-positive cocci (spherical cells) frequently arranged in pairs (diplococci). They are 
non-spore-forming facultative anaerobes that have their optimum growth temperature at 35ºC, but 
they can grow in a wide range of temperatures (10-45ºC). This bacterial genus can also grow in broth 
containing 6.5% of NaCl and are able to hydrolyze esculin in the presence of 40% bile salts. Enterococci 
do not produce a catalase reaction in the presence of hydrogen peroxidase although some species can 
exhibit a pseudocatalase reaction in blood agar. This behaviour is due to the lack of cytochrome 
enzymes which also influences the homofermentative metabolism, lactic acid being the end product of 
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glucose fermentation. In addition, its ability to metabolize a broad range of energy sources (complex 
carbohydrates, glycerol, lactate, citrate, malate, amino acids such as arginine, and some alpha-keto 
acids), their capacity to tolerate oxidative stress as well as a wide variety of compounds (heavy metals, 
azide, detergents, biocides) and prolonged desiccation allows this bacterial genus the survival in diverse 
habitats (1, 12, 13). Enterococci are also known for being somewhat fastidious bacterial needing a 
certain number of amino acids and vitamins for maximum growth. This genus reacts with the Lancefield 
anti-D serum, which allows to differentiate enterococci of other streptococci (1, 13).  
Facklam et al. proposed a classification based on phenotypic characteristics (hydrolysis of mannitol, 
sorbose, arginine, arabinose, sorbitol, raffinose and sucrose methyl-α-D-glucopyranoside, motility and 
pigmentation) that grouped enterococcal species in 5 categories designed by roman numerals (Table 1). 
Recently Lebreton et al described a new group (VI) that includes Enterococcus ureilyticus that did not fit 
in any of the previously described groups (1, 13). This classification remains useful for diagnostic and 
ecological purposes, as species from the same groups with similar metabolic characteristics might have 
similar functional roles. However, it does not reflect any evolutionary relationship between 
Enterococcus species, as accessed by 16S rRNA sequence phylogeny (1). In fact, it has been recently 
described that some of Enterococcus metabolic characteristics might be encoded on plasmids (e. g. 
raffinose metabolism gene cluster encoded in an E. faecium megaplasmid) what might favour the 
survival in different environments (1, 14). Some species are motile (E. gallinarum and E. casseliflavus) or 
shown yellow-pigmentation (E. sulfureus, E. casseliflavus, and E. mundtii) (1, 12, 13).  
Table 1 – Facklam et al Enterococci classification 
Group  Species MAN SOR ARG 
I 
E. avium, E. malodoratus, E. raffinosus, E. pseudoavium, E. 
saccharolyticus, E. pallens, E. gilvus, E. phoeniculicoa, E. devriesei, 
E. canis 
+ + - 
II 
E. faecalis, E. faecium, E. casseliflavus, E. gallinarum, E. canintestini, 
E. lactis, E. thailandicus, E. sanguinicola 
+ - + 
III E. villorum, E. durans, E. dispar, E. hirae, E. silesiacus, E. rotai* - - + 
IV 
E. asini, E. sulfureus, E. cecorum, E. aquamarinus, E. plantarum, E. 
caccae, E. termitis 
- - - 
V E. columbae, E. rivorum, E. hermaniensis, E. camelliae, E. viikiensis + - - 
VI E. ureilyticus - + - 
*some variants of E. faecium and E. faecalis that do not hydrolyse mannitol can also be found in this group. **some variants of E. 
casseliflavus, E. gallinarum and E. faecalis that do not hydrolyse arginine can also be included in this group. Abbreviations: MAN, 
mannitol; SOR, sorbose; ARG, Arginine. 
Enterococci have been found to colonize a great number of habitats such as the GI tract of humans and 
other mammals, reptiles and birds, and evironments as: food, water, plants or soil (1, 13, 15).  
 
1.2. Antibiotic Resistance in Enterococci 
Enterococcal infections are one of the 21
st
 century medical challenges due to the increasing prevalence 
of strains that are resistant to therapeutic concentrations of the majority of antibiotics with a 
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bactericidal activity against enterococci (Section 3, below). In fact, the increase of E. faecium infections, 
described in this section, together with antibiotic resistance led to the inclusion of this species, by the 
IDSA (Infectious Disease Society of America), in the list of ESKAPE pathogens (Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter spp., Pseudomonas aeruginosa, and 
Enterobacter spp.), for all of which new therapies are urgently needed. Furthermore, the CDC (Centers 
for Disease Control and Prevention) has classified Vancomycin Resistant Enterococci (VRE) as a serious 
threat to human health as VRE is responsible for about 30% of the 66,000 Enterococcus healthcare-
associated infections registered every year in the USA. (16–18). 
Enterococci resistance to antimicrobials (antibiotics, heavy metals, disinfectants and antiseptics) can be 
classified in intrinsic, acquired and phenotypic tolerance (12, 16). Tolerance can be defined as the ability 
of a microorganism to resist killing by any antimicrobial well above normal minimal inhibitory 
concentrations (MIC), and it is caused by a proportion of microbial cells that exist in a transient non-
dividing state their bacterial target. Enterococci can exhibit tolerance to antibiotics that target bacteria 
cell-ǁall as β-laĐtaŵs aŶd ǀaŶĐoŵǇĐiŶ. It ĐaŶ ďe oǀeƌĐoŵe ďǇ usiŶg β-lactams besides high 
concentrations of aminoglycosides. These therapeutic regimens that combine different antibiotic classes 
(often including a cell wall active agent) are frequently used to treat severe infections as synergy 
between different classes of drugs provides a bactericidal effect that is not possible to achieve using 
monotherapy regimens (17).  
Intrinsic resistance is defined as an inherent property of a species, making them naturally unsusceptible 
to particular drugs, and thus chromosomally encoded and present in all species strains. The genus 
Enterococcus is iŶtƌiŶsiĐallǇ ƌesistaŶt to β-lactams, in particular to cephalosporins, low-medium 
concentrations of aminoglycosides, and trimethoprim-sulfamethoxazole. Some species are also 
intrinsically resistant to lincosamides and streptogramins A (E. faecalis, E. gallinarum, E. avium and E. 
casseliflavus) or to glycopeptides (E. gallinarum, E. flavescens and E. casseliflavus).  
Acquired resistance may result from one or several mutations in existing gene(s) or the acquisition of 
exogenous DNA (12, 17). Enterococci have acquired resistance to all families of antibiotics (phenicols, 
tetƌaĐǇĐliŶes, ŵaĐƌolides, aŵiŶoglǇĐosides, β-lactams, glycopeptides, quinolones, streptogramins, 
oxazolidinones, lipopeptides and glycylcyclines) [for comprehensive review see (12, 17)]. We will focus 
here on the ŵoƌe fƌeƋueŶt aŶd ĐliŶiĐallǇ ƌeleǀaŶt ;β-lactams and glycopeptides). 
ϭ.Ϯ.ϭ. β-lactams resistance 
β-lactams are able to inhibit cell-wall synthesis by serving as subtracts for penicillin-binding proteins 
(PBPs, D,D-transpeptidases) that catalyse the union of the peptidoglycan pentapeptide side chains 
duƌiŶg the sǇŶthesis of ŵatuƌe peptidoglǇĐaŶ. EŶteƌoĐoĐĐi aƌe iŶtƌiŶsiĐallǇ ƌesistaŶt to β-lactams due to 
the presence of PBPs with low affinity for these antibiotics, particularly PBP5 in E. faecium. However, the 
leǀel of toleƌaŶĐe to diffeƌeŶt Đlasses of β-lactams varies, penicillins exhibiting the highest activity 
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against enterococci (particularly ampicillin, an aminopenicillin), followed by carbapenems and 
cephalosporins, which barely exhibit activity against enterococci. The level of activity reflects the 
usefulŶess of these aŶtiďiotiĐs to tƌeat eŶteƌoĐoĐĐal iŶfeĐtioŶs. While aŵpiĐilliŶ is the β-lactam more 
commonly used to treat enterococcal infections, administration of cephalosporins for the treatment of 
other bacterial infections constitutes a risk factor for acquiring enterococcal infections (12, 17, 19). 
Up to date two acquired mechaŶisŵs of ƌesistaŶĐe to β-lactams have been described, namely 
production of -laĐtaŵase aŶd ŵutatioŶ of PBP geŶes. β-lactamase production, firstly described in early 
1980s in E. faecalis, has scarcely been reported up to date (11 cities and 4 countries including some 
hospital outbreaks). E. faecium β-lactamase producers were firstly described in 1992 in the USA but no 
fuƌtheƌ ƌepoƌts ǁeƌe puďlished uŶtil ƌeĐeŶtlǇ, ǁheŶ eight β-lactamase producing E. faecium strains were 
reported in Italy (20). β-lactamase producing strains were found to be resistant to penicillins, 
aminopenicillins, ureido-penicillins and present loǁ leǀel ƌesistaŶĐe to iŵipeŶeŵ. The EŶteƌoĐoĐĐal β-
lactamase is inhiďited ďǇ ĐlassiĐal β-lactamase inhibitors (clavulanate, sulbactam and tazobactam) (12, 
16, 20–23). 
The ŵost ĐoŵŵoŶ ŵeĐhaŶisŵ of aĐƋuiƌed ƌesistaŶĐe to β-lactams occurs through mutations and/or 
hyperproduction of pbp genes. This mechanism of resistance was firstly described in the 1970s and 
1980s in American hospitals associated with the pbp5 gene of E. faecium and less frequently, E. 
raffinosus (24–26). The chromosomal region in which E. faecium pbp5 gene is located has proven to be 
transferable in independent experiments (27). Recently, other genes that might be responsible for 
ampicillin resistance were also identified in E. faecium, such as, ddcP (encoding for D-alanyl-D-alanine 
carboxypeptidase), ldtfm (encoding for a L,D-transpeptidase), pgt predicted to encode a glycosyl 
transferase group 2 family protein) and lytG (predicted to encode an exo-glucosaminidase that might be 
acting as a peptidoglycan hydrolase) (28). In E. faecalis, either the hyperproduction of PBP5 together 
with deficient binding of penicillin to PBP1 and PBP6 or point mutations in the PBP4, confer resistance to 
β-lactams (29, 30). The frequency of penicillin resistant E. faecalis remains low in most European 
countries and also in the USA (31–33). 
1.2.2. Glycopeptides resistance 
Glycopeptides bind specifically to the C-terminus of the pentapeptide precursor of peptidoglycan D-
Alanine-D-Alanine (D-Ala-D-Ala); blocking the linkage of the precursors impedes the formation of 
mature peptidoglycan (17, 34, 35). Enterococci become resistant to glycopeptides by target modification 
with elimination of the high-affinity peptidoglycan precursors throughout enzymes present in the van-
operons (34, 35).  
Currently eight genotypes coding for acquired glycopeptide resistance have been described in 
enterococci, which are named by capital letters (vanA/B/D/E/G/L/M/N). They differ in the ligase gene, 
the resistance phenotype, gene sequence similarity and synteny (Table 2). The ligase gene encodes 
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either for a D-Alanine-D-Lactate (D-Ala-D-Lac) or D-Alanine-D-Serine (D-Ala-D-Ser) ligases leading to the 
synthesis of peptidoglycan precursors with low affinity for glycopeptides. Aside from the ligase genes 
van-operons enclose other 4-6 genes encoding for similar gene functions (17, 34, 35) 
E. gallinarum, E. casseliflavus and E. flavescens have intrinsic low level resistance to vancomycin due to 
the presence of van operons in their genomes (designed as vanC1, vanC2 and vanC3 operons, 
respectively). VanC elements convert precursors D-Ala-D-Ala into D-Ala-D-Ser. The VanC phenotype, 
which may be constitutive or inducible, is characterized by the low level of vancomycin and teicoplanin 
susceptibility (31, 34). Recently, the vanC operon has also been identified in E. faecium and E. faecalis 
(36, 37). 
The first glycopeptide resistant enterococcal strains were two E. faecium isolates recovered almost 
simultaneously in the UK (1986) and France (1987). In the USA, the first VRE was identified as E. faecalis 
in 1988 (34, 38–40). 
Table 2 – Enterococci acquired van genotypes characteristics 
Phenotype VanA VanB VanD VanE vanG VanL VanM VanN 
Ligase gene vanA vanB vanD vanE vanG vanL vanM vanN 
MICVAN(mg/L) 16-1000 4-32(-1000) 64-128 8-32 16 8 >256 12-16 
MICTEI(mg/L) (4)16-512 0.5-1 4-64 0.5 0.5 S 1-96 0.5 
Expression inducible inducible constitutive inducible inducible inducible inducible constitutive 
Location Pl/Ch Pl/Ch Ch Ch Ch Ch? Pl/Ch Pl 
Transferable 
by conjugation 
+/- +/- - - + - + + 
Distribution 
among 
enterococcal 
species 
E. faecium 
E. faecalis 
E. durans 
E. hirae 
E. gallinarum 
E. casseliflavus 
E. raffinosus 
E. avium 
E. mundtii 
E. faecium 
E. faecalis 
E. durans 
E  gallinarum 
E. faecium 
E. faecalis 
E. raffinosus 
E. faecalis E. faecalis E. faecalis E. faecium E. faecium 
MGE Tn1546 
Tn5382 
Tn1547, Tn1549 
 Tn6202     
Isolation date 1987, 1989 1988 1993 2001 1998 2008 2005 2008 
Abbreviations: MIC, Minimal Inhibitory Concentration; MGE, Mobile Genetic Element; VAN, vancomycin; TEI, teicoplanin; Ch, 
Chromosome; Pl,Plasmid 
The most frequent van genotypes found in Enterococci are vanA and vanB, which have also been found 
in corynebacteria, streptococci and staphylococci (vanA) and different Clostridum species (vanB and 
vanG) (35, 41–44).  
The vanA genotype is located in Tn1546 (Tn3 family transposon) that in turn is located in highly 
conjugative broad host range plasmids (35, 45, 46). The vanB genotype is normally located in a 
conjugative transposon, Tn1549 and Tn5382, normally chromosomal located although it can also be 
located in conjugative plasmids (35, 47, 48) (Table 2). 
Operons vanA, vanB, vanD and vanM harbor several genes: vanR (response regulator) and vanS (sensor 
histidine kinase), encoding for a two component regulatory system; vanH, encoding for a 
dehydrogenase that reduces pyruvate to D-Lac (rare in nature and so has to be synthesized) producing 
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the substrate for the ligases, vanA, vanB, vanD and vanM, that catalyze the formation of D-Ala-D-Lac; 
vanX (encoding for a D,D-dipeptidase) and vanY (encoding for a D,D-carboxypeptidase) responsible for 
hydrolysis of D-Ala-D-Ala peptidoglycan precursors that make strains susceptible for glycopeptides. vanA 
and vanB operons encode genes of accessory unknown function vanZ and vanW, respectively (17, 34, 
35, 49). 
Operons vanE, vanL and vanN have a similar organization to that of vanC: i) vanC, vanE, vanL and vanN 
ligases; ii) vanXY D,D-dipeptidase-D,D- carboxypeptidase responsible for the hydrolysis of D-Ala-D-Ala 
peptidoglycan precursors; iii) vanT coding for a serine racemase responsible for the production of D-Ser; 
and iv) vanR and vanS the two component regulatory system (34, 35, 50, 51). The vanG operon is 
composed of 7 genes that seem to have been recruited from the other van-operons. It is composed of 3 
regulatory genes, vanU, vanR and vanS, a vanY, a vanW, a vanG, a vanXY and vanT (34, 35, 52) 
 
1.3. Biological Cost of Antibiotic Resistance Determinants 
The acquisition of antibiotic resistance either by point mutations or by HGT leads to a loss of fitness 
(biological cost) for the bacterial host. The acquisition of mobile genetic elements (MGE), like plasmids, 
is expected to be associated with a biological cost for the host due to the additional energetic and 
metabolic burden related with the MGE replication and expression of its genetic content. Furthermore, 
different resistance mechanisms for the same antibiotic family with different biological cost can be 
found within the same bacterial population (53–57).  
The biological cost of antibiotic resistance has mostly been analysed in vitro studies comparing the 
behaviour of susceptible and resistant strains (competition essays relative growth rates, cost-                    
-compensation, and resistance segregation vs stability and adaptation) and is highly influenced by the 
experimental conditions used. The difficulties to simulate in vitro the physiological conditions to which a 
bacterial population is subjected makes it difficult to extrapolate the results obtained in the laboratory 
to physiological conditions (53, 57). However, the evidence of differences between susceptible and 
resistant strains in bacteria growing under well defined conditions certainly should qualitatively 
correspond to those expected to occur under natural circumstances. The biological costs of resistance 
influencing environmental survival, colonization, transmission, or infection rates should be considered 
to this respect. 
Fitness differences between antibiotic susceptible and antibiotic resistant populations due to the lower 
growth rate and/or lower colonization and inter-host transmission of the antibiotic resistant population 
should lead to the reduction in frequency and reversion of the resistant phenotype in the absence of 
selective pressure. However, it has been demonstrated that antibiotic resistant bacteria are able to 
acquire compensatory mutations that reduce the biological cost of resistance determinants leading to 
growth rates similar to those of the susceptible strains, making phenotype reversion a rare event (53, 
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55, 58). Plasmid-host coevolution experiments suggest that compensatory mutations, the presence of 
post segregational killing (PSK) systems like those in widespread plasmids pRUM (Axe-Txe) or those 
Đlassified iŶ the IŶĐϭϴ faŵilǇ ;εζͿ oƌ ĐoseleĐtioŶ ďǇ aŶtiŵiĐƌoďials oƌ ;aŶtiďiotiĐs, heaǀǇ ŵetals, biocides) 
both at high and low concentrations influence the persistence of plasmids. The factors make the loss of 
MDR plasmids by vegetative segregation unlikely (53, 56, 57, 59).  
Biological cost of antibiotic resistance in enterococci has been focused on vancomycin resistant strains 
aŶd theiƌ geŶetiĐ eleŵeŶts ;eitheƌ tƌaŶsposoŶs oƌ plasŵidsͿ due to the ͞seƌious ŵiĐƌoďial thƌeat͟ that 
VRE represent (32, 33, 60). The high complexity of vancomycin resistance mechanism (see above) led to 
the hypothesis of a high fitness cost for this mechanism of antibiotic resistance. In fact, the expression of 
vancomycin resistance operon (Tn1546-vanA) in S. aureus showed a high fitness loss in this host, which 
justify the low dissemination of vancomycin resistance in S. aureus (54)., Another study focused on the 
biological cost of plasmids carrying Tn1546-vanA showed a fitness loss for approximately 4% for the host 
harbouring these plasmids. Other work showed the vancomycin resistance plasmid pVEF1 was stable on 
its host after 20 days of serial passages. These preliminary works suggest a low fitness cost and high 
stability for vancomycin resistance and for vancomycin resistant plasmid (45, 56, 57). In spite these few 
studies using specific plasmids and laboratory strains many issues about the biological cost of 
vancomycin resistance in Enterococci remain open. 
 
1.4. Enterococcal Human GI tract colonization 
The concentration of bacterial cells vary along the human GI tract from 10
2
 to 10
3
 bacterial cells in the 
stomach to 10
9
 to 10
12
 bacterial cells in the colon (1, 61, 62). Different studies estimated that more than 
1,000 different bacterial species are inhabitants of the human gut microbiota although the intestinal 
biodiversity, particularly among minority populations, still remains largely unknown (63–66).  
Next generation sequencing (NGS) metagenomics analysis, mostly based on 16S rDNA, has provided a 
great deal of information regarding the full genetic content of the bacteria colonizing the human GI tract 
(human gut metagenome), as well as the influence of host factors (age, diet, health and immunological 
status) and also external factors (e.g. antibiotic treatment, aĐĐess to otheƌ hosts͛, food, ǁateƌ aŶd 
environmental microbiota) might have on the diversity and dynamics of different bacterial groups (61, 
64, 67–72). The studies based on 16S rDNA are limited by the specificity of the techniques that not only 
overemphasize majority populations, but preclude obtaining information at subspecies level. 
In spite of their relevance producing invasive infections, Enterococcus constitute a minor part of the GI 
tract flora (<1% in the ileum and jejunum and about 1% in the colon), E. faecium and E. faecalis being 
the species more commonly found in the human GI tract,. Other species as E. durans, E. hirae, E. avium, 
E. gallinarum, E., are also able to colonize the human GI tract (1, 73, 74). 
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1.4.1. Factors that influence gastrointestinal flora  
ϭ.ϰ.ϭ.ϭ. Host’s Age.  
Establishment of the gut microbiota has been shown to be a complex and dynamic process that, suffers 
important changes during the first and second years of life, is optimized during infancy and adolescence 
to reach it optimal composition in adulthood and changes again in elderly (64, 75). Enterococci appear 
to be one of the first bacteria to colonize the human GI tract, being found within days after birth. In 
most studies, E. faecalis tends to be the most abundant enterococcal species (approximately 50% of all 
enterococci) followed by E. faecium and, to a lesser extent,  other E. durans, E. casseliflavus/E. 
flavescens, E avium or E. raffinosus (76–78). Only one study, performed in a neonatal ICU, were E. 
faecium (48%) and E. casseliflavus (31%) more prevalent than E. faecalis. The hospital setting might 
account for the high prevalence of MDR E. faecium colonizing infants gut in this study (79).  
Changes in the abundance and diversity of commensal species occur in the intestinal microbiota of 
elderly, probably related to the immunological alterations and changes in the GI tract physiology (64, 68, 
75). They include a shift in the dominant bacterial anaerobic flora (Bacteroides and Bifidofacterium), an 
increase in the numbers of fungi and enterobacteria and other facultative anaerobes (lactobacilli, 
streptococci, staphylococci), as well as, certain Clostridium groups (64, 68, 75).  
Up to now no studies were performed in order to determine what enterococcal species present in the 
gut of elderly individuals. In one study enterococci were found in high numbers in antibiotic treated 
individuals whereas they were absent from the GI tract of elderly healthy individuals (68).  
1.4.1.2. Antibiotic treatment  
The effect of antibiotics on the GI tract microbiota depends on the antibiotic class. Broad-spectrum 
antibiotics are usually associated with a decrease in the diversity of gut microbiota (66, 80). Prophylaxis 
of Gƌaŵ Ŷegatiǀe iŶfeĐtioŶs ǁith leǀofloǆaĐiŶ iŶ ŶeutƌopeŶiĐ ĐaŶĐeƌ patieŶts͛ led to a pƌedoŵiŶaŶĐe of 
Gram Positive bacteria that often cause bacteraemia in these patients (81, 82). Narrow host antibiotics, 
such as vancomycin, seem to lead to expansion of otherwise uncommon Enterobacteriaceae and also to 
a remarkable decrease of Bacteroidetes and Lactobacillaceae. Mice models have demonstrated that 
orally administered antibiotic treatment, particularly those active against Gram-negative anaerobic 
ďaĐteƌia, as β-lactam-β-lactamase inhibitors, cefoxitin, clindamycin, and metronidazole favour the 
colonization by VRE (66, 83, 84).  
Antibiotics can greatly modify the gut microbiota of mammals. Even though the overall bacterial 
numbers may be rapidly recovered, persistent changes in microbiota composition are usually 
maintained for at least a few months (66, 80, 85, 86). A dominance of Enterobacteriaceae,  Clostridium 
and Enterococcus occurs during antibiotic treatment which is matter of concern as these prokaryotic 
groups are frequently involved in hospital-acquired infections, particularly bacteraemia of intestinal 
origin (32, 33, 61, 66, 87). 
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1.4.1.3. Bacterial adaptive factors  
Different factors enhance the ability of enterococci to colonize, persist, and cause infection in different 
hosts. They include bacteriocins, microbial surface component recognizing adhesive matrix molecules 
(MSCRAMM), cell-wall-anchored LPxTG proteins, or those that confer the ability to form biofilms (16). 
Bacteriocins are small peptides capable of inhibiting growth of similar or related bacteria. Gram-positive 
bacteriocins can be classified in two major classes of heat-stable peptides, namely class I or Lantibiotics 
(which contain amino acids lanthionine or methyllanthionine, dehydroalanine and 2-aminoisobutyric 
acid) and class II (unmodified non-lantibiotics). Most enterococcal bacteriocins belong to the class II, 
some of them having been fully characterized (As-48, Bac21, Bac31, Bac41, Bac43, Bac32, Bac51, 
Entl50a/L50b, EntQ, EntA, EntB and EntP (88). Most of them have been identified in E. faecalis and E. 
faecium although can also be found in other species as E. mundti, E. avium, E. hirae and E. durans (88). 
Most enterococcal bacteriocins have activity against Listeria spp., Clostridium spp. and S. aureus (3). 
Bacteriocin producing strains have been isolated from a wide variety of environments but they appear 
to be more common in food samples (cheese, meat, fish and vegetable), and human and animals GI 
tract. Some enterococcal bacteriocin producers have been used for more than 20 years in the food 
industry as preservatives and more recently as probiotics to prevent the overgrowth of pathogens in the 
human gut (88, 89).  
Cell surface determinants (aggregation substances, MSCRAMMs, among others) contribute to colonize 
the human GI tract either by direct action or by enabling biofilm formation. Aggregation substance (e.g. 
asa1, asc10, asp1) are a group of E. faecalis proteins, normally encoded in pheromone responsive 
plasmids (16, 90–92). A pathogenicity island encoding esp (enterococcal surface proteins that contribute 
to biofilm formation) has been described in E. faecium and E. faecalis. An adhesion molecules 
MSCRAMMs (Acm in E. faecium and Ace and ElrA in E. faecalis), contribute to colonization and early 
stages of infection (16). Some enterococcal proteins with cell-wall anchored LPxTG motifs, such as the 
loci ebp (endocarditis and biofilm-associated pili) and bee (biofilm enhancer in enterococci), are 
attached to pili and play an important role in colonization and infection (16, 93–96).  
Secreted proteins as haemolysin-cytolysin (Cyl) or gelatinase (GelE) have been traditionally considered 
as virulence factors in E. faecalis. Cyl is a toxin able to lyse blood cells from humans, cows and horses 
(97). It is located either on pheromone-responsive plasmids or a pathogenicity island that is present in 
approximately 30% of the E. faecalis isolates making them more virulent than non-Cyl producing isolates 
in several animal models (16, 98, 99). The protease GelE, seems to be involved in the degradation of the 
host tissues and modulation of the host immune response as well as in the activation of autolysin 
(enzyme capable of degrading peptidoglycan) leading to the release of DNA from the bacterial cell and 
also biofilm formation. This and other E. faecalis proteases are regulated by a double component system 
Fsr, which appears to also influence this bacterial pathogenesis (16). 
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Megaplasmids (>150kb) containing genes that favour the metabolism of different carbohydrate (e.g. 
hylEfm, a glycosyltransferase that allows using complex carbohydrates) are present in the majority of E. 
faecium strains isolated nowadays. Transfer of these plasmids to a plasmid free commensal E. faecium 
strain increased both the colonization and the virulence capabilities of laboratory strains (16, 87, 100). 
 
1.5. Enterococcal infections 
Enterococci are opportunistic pathogens able to cause a wide variety of clinical manifestations. 
Bacteraemia and endocarditis are life-threatening diseases that require bactericidal therapeutic options. 
Urinary tract infections, intra-abdominal, pelvic, and soft tissue infections caused by enterococci are also 
frequent and often associated with other microbial species.  
The increasing number of enterococcal infections, often caused by antibiotic resistant strains, the high 
mortality rate of infected patients (from 46% to 75% in individuals with severe underlying diseases) and 
the ability of enterococci to acquire and transfer antibiotic resistance genes to more pathogenic species 
as S. aureus make enterococci one of the pathogens of concern in the hospital setting (2).  
Risks factors to acquire enterococcal infections caused by antibiotic resistant strains include extended 
hospitalization periods, particularly in surgical or intensive care wards, hospitalization in long-term 
health care facilities, multiple antibiotic therapy courses, close proximity to colonized or infected 
patients, transplantation, co-morbidities (e. g. renal failure, diabetes or haemodialysis) and the presence 
of catheters (e. g. urinary tract, for chemotherapy) (16, 101). Transmission between hospitalized 
patients, mostly associated with healthcare works hands, has been demonstrated, leading either to 
directly infection or, more likely, to GI tract colonization (due to reduced colonization resistance) that 
might, in turn, lead to infection (2).  
In the 1970s-80s, E. faecalis accounted for 90-95% of the enterococcal clinical isolates. However, the 
emergence of ampicillin and vancomycin resistant E. faecium at the end of the 1980s favoured a change 
in the occurrence of infections caused by E. faecium in hospitals at global level and to a decrease in the  
ratio of E. faecalis:E. faecium infections (particularly systemic infections) (102). Nowadays, E. faecalis is 
responsible for approximately 76% of enterococcal infections, while E. faecium accounts for most of the 
remaining infections (approximately 24%) in American hospitals (1, 2). Approximately 21% of the 
enterococci in USA hospitals were vancomycin resistant the majority (75%) of them being E. faecium. 
Ampicillin resistant E. faecium (AREfm) are endemic in USA hospitals with a prevalence close to 90% (1, 
2, 16, 33).  
This change in the epidemiology of enterococci infections was also observed in Europe. While all 
European countries reported a high prevalence of AREfm among clinical isolates (ranging from >50% to 
100%), vancomycin resistant E. faecium (VREfm) occurrence greatly varied among countries (from 0% in 
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Estonia, Lithuania, Malta and Sweden to 42.7% in Ireland) with an overall prevalence of was 8.9% (Fig. 1 
to 4) (16, 31, 32, 103).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. European map showing prevalence of 
ampicillin resistant E. faecalis (source EARSS). 
Figure 2. European map showing prevalence of 
vancomycin resistant E. faecalis (source EARSS). 
Figure 3. European map showing prevalence of 
ampicillin resistant E. faecium (source EARSS). 
Figure 4. European map showing prevalence of 
vancomycin resistant E. faecium (source EARSS). 
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Vancomycin resistance is more frequently detected in E. faecium than in E. faecalis although some areas 
in different continents (Detroit in the USA and Spain in Europe) consistently describe outbreaks caused 
by ST6 Vancomycin resistant E. faecalis (VREfc) strain throughout years (104). Despite the low 
occurrence, VREfc is of concern as they can successfully transfer plasmid carrying vancomycin resistance 
to S. aureus (Tn1546-vanA) (32, 33, 60). 
 
1.6. Enterococcus Population Structure 
A great variety of methods have been used to establish the population structure and epidemiological 
relationship among bacterial strains within a given species. They include AFLP (Amplified Fragment 
Length Polymorphism), PFGE (Pulsed Field Gel Electrophoresis), MLVA (Multilocus Variable number 
tandem repeats Analysis), MLEE (Multilocus Enzyme Electrophoresis), MLST (Multilocus Sequence 
Typing) and whole genome sequencing (WGS). A variety of algorithms are used to analyse MLST data 
including eBURST, goeBURST and BAPS (Bayesian Analysis of Population Structure). Recently, in order to 
compare fully sequenced E. faecium data from WGS a core genome MLST (cgMLST) was described for 
this species. Mauve, ARTEMIS, SynView and ssahaSNP (Sequence Search and Alignment by Hashing 
Algorithm) are used in comparative genomics (105, 106). 
1.6.1. E. faecium population structure 
MLST using eBURST revealed that clinical and outbreak hospital strains of E. faecium grouped in one 
Clonal Complex (CC), designated CC17 as all STs appeared to descend from the founder ST17, and that 
these strains were different from those isolated from healthy community humans (gut colonization) and 
animals (107–111). Strains within CC17 were labelled as hospital-associated E. faecium and have been 
isolated from hospitals worldwide. Most CC17 strains are MDR (resistant to vancomycin, ampicillin, 
aminoglycosides and fluoroquinolones) and their genomes appears to be enriched in genes coding for 
putative virulence genes, megaplasmids, and insertion sequences (ISs) (108, 110, 112–115).  
Initial studies of E. faecium population structure were performed using MLST and eBURST (107). 
However, this algorithm is not adequate for bacterial species in which recombination, blurring 
phylogeny, plays an important role in the species evolution (110, 116). Further analysis of concatenated 
sequences of the 7 MLST genes with neighbour-net tree or Clonalframe indicated that former CC17 was 
a consequence of large chromosomal recombination events within ST17, ST18 and ST78 lineages of 
hospital-associated E. faecium (109, 110, 117). Later analysis using BAPS (a statistical model based on 
both clonal ancestry and recombination patterns using concatenated sequences of the 7 MLST genes) 
revealed the existence of two BAPS groups (2-1 and 3-3) associated with antibiotic resistance (ampicillin 
and vancomycin) and the hospital setting. Further analysis showed that clinical isolates of these groups 
are related to ST17 and ST18 lineages (BAPS 3-3), and ST78 lineage (BAPS 2-1). BAPS analysis also 
showed that strains normally colonized healthy (community) humans belong to BAPS 1 and that these 
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isolates can be genetic and evolutionary different from hospital associated strains; these hospital strains 
were more closely related with to animal strains indicating a possible role of animals in the emergence 
of current hospital associated isolates (110, 115). The recent description of a cgMLST allowed to further 
look in these lineages and revealed epidemiological links (or lack thereof) in groups off strains where 
this links were not apparent (106) making it a valuable tool for future epidemiological analysis. 
In 2012, the first E. faecium closed genome has published (118) and up to date only three more closed E. 
faecium genomes have been released (119–121). Three of these strains are representatives of major 
lineages of hospital-associated E. faecium (ST16, ST17 and ST203) (115, 118–120). The other E. faecium 
genome correspond  to ST860, a clonal lineage associated with healthy humans, that has been used for 
years as a probiotic (121). Comparative genomics of these and other sequenced E. faecium strains from 
clinical and non-clinical environments allows to firstly suggest a core (±1600 genes) and an accessory 
genome for this species (2272-3318 coding sequences (CDS) that represent 29% to 59% of the E. 
faecium genome (115, 118). 
Recent comparative genomic studies using WGS consistently split the E. faecium populations in two 
major groups, Community associated (CA) or Clade B and Hospital associated (HA) or Clade A (also 
includes animals isolates) (122, 123). Clade A was further divided in A1, including most clinical isolates, 
and A2, including most animal strains (122). Clade B corresponded to BAPS 1 and clade A1 with BAPS 
subgroups 2-1 and 3-3 (115, 122). These classifications should be considered as dynamic ones as 
recombination can occur between strains from the different clades generating new hybrid genomes 
(122, 124, 125). 
The genome size of strains in clade A1 is larger than that of clades A2 and B, consistently with the 
suggested recent emergence of the former clade. Conversely, clade A2 had a larger pan-genome, which 
would reflect the diverse origins of the strains that form this clade. Clade A1 is also enriched in MGE as 
plasmids, ISs, phages and genomic islands compared to clades A2 and B (122). These findings indicates 
that E. faecium has an open pan-genome capable of effectively acquire and incorporate novel DNA into 
the collective gene pool as most ubiquitous bacteria and opportunistic pathogens (115, 118, 122, 123). 
The eŶƌiĐhŵeŶt iŶ geŶetiĐ deteƌŵiŶaŶts seeŵs to ďe a Đuŵulatiǀe pƌoĐess, Đalled ͞geŶetiĐ Đapitalisŵ͟, 
where the acquisition and integration of adaptive elements facilitates the acquisition of additional 
adaptive elements and afterwards, the transition of E. faecium (particularly of clade A1) from 
commensal to nosocomial pathogen (114, 126). 
1.6.2. E. faecalis population structure 
The population structure of E. faecalis was also initially establish using MLST and eBURST analysis. In this 
case, an overrepresentation of hospital associated strains within CC2 and CC9 was observed (127). 
Further studies associated early E. faecalis antibiotic resistance isolates with CC2, CC8 and CC9, while a 
more recent European study revealed that MDR E. faecalis isolates were classified within CC16, CC2 and 
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CC87, the latter two CCs being found almost exclusively in hospitals (128, 129). Even though CC2 is 
mostly found among hospital strains, it may also be identified in farm animals reflecting the epidemic E. 
faecalis population structure (128, 130, 131). CC21, CC16 and CC40 have been widely isolated from 
hospitalized and non-hospitalized humans, meat and farm animals. Similarly to that reported in other 
continents, a decrease in the occurrence of CC9 and an increase in CC2 has been observed in the EU 
(127, 128). 
Analysis of the MLST alleles revealed the E. faecalis has a high recombination:mutation rate, gene trees 
for three individual MLST loci were incongruent and individual MLST alleles are widely distributed 
among concatenated MLST phylogeny. All these observations indicate that E. faecalis has an epidemic 
population structure that frequently recombines (109, 115, 127). CCϮ, paƌtiĐulaƌlǇ “Tϲ β-lactamase-
producing Mid-Atlantic clone, are widely disseminated seem to be enriched in MGE and genes coding 
for virulence and colonization, and antibiotic resistance. However, an epidemiologic study using an 
historic E. faecalis strain collection (1900s-2006) revealed that CC2 was not found prior to the 1980s, 
suggesting that this CC might have a recent origin (115, 129, 132, 133). Another feature that is absent of 
CC2 strains, but present in other less successful CCs in the hospital environment, was the CRISPR 
(clustered regularly interspaced short palindromic repeat) loci. This is a defence mechanism against 
foreign DNA (phages, transposons and plasmids) so the lack of this system would facilitate the 
acquisition of new genes (115, 128, 134). The CC87 isolates have a common phenotype that may 
contribute to colonization and virulence, cylA
+
, asa1
+
, esp
+
 and gelE
-
. The absence of gelE seems to 
improve the adherence of bacteria to the host tissue due to the increased production of MSCRAMM Ace 
(128, 135). 
1.6.3. Genome Immunity  
Bacteria have multiple mechanisms that can protect against acquisition of foreign DNA such as CRISPR 
(Clustered, regularly interspaced short palindromic repeats) and restriction modification (RM) systems 
(125, 136, 137).  
Among Enterococci, CRISPR were first identified in E. faecalis OG1RF and the presence of CRISPR in this 
strain was proposed to account for the low number of phages and MGEs (124, 129, 138). CRISPR analysis 
in several E. faecalis strains indicated that CRISPR distribution is variable in different genomes. The 
identification of spacer regions within the E. faecalis CRISPR loci revealed identities with phage and 
plasmid (as those of pheromone-responsive plasmids and other plasmids found in V583 genome) 
sequences indicating that these loci confer immunity against these sequences (125, 134, 137). 
Dissemination of antibiotic resistance genes is frequently associated with plasmids and as these CRISPR 
loci confer immunity for some of the plasmids more frequently associated with antibiotic resistance it 
has been hypothesize that CRISPR act as a barrier for the acquisition of these resistance genes. These 
was further supported by the finding that CRISPR were absent from several E. faecalis genomes, 
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belonging to hospital associated CCs, that had encoded in their genomes both antibiotic resistance and 
several virulence traits absent in strains were CRISPR had been identified (125, 134). 
In E. faecium the CRISPR loci have scarcely been studied (8 genomes analysed to date) but the spacers 
CRISPR loci found so far have spacers that encode sequences from Clostridium novyi and Lactococcus 
lactis phages͛. IŶteƌestiŶglǇ, C‘I“P‘ loĐi iŶ E. faecium have only been found in clade B or community 
associated or the hybrid strains suggesting that the absence of this immunity system might facilitate the 
acquisition of genes favouring the emergence of MDR hospital adapted strains (125).  
RM systems were firstly described in the 1950s. They inhibit (restrict) the growth of viruses that were 
able to grow in other strains. This activity is based on the activity of two enzymes: a restriction 
endonuclease and a methyltransferase. They are highly ubiquitous (approximately 90% of genomes have 
at least one RM system) and often considered the primitive immune systems in bacteria. (139). Four 
types of RM have been described (I, II, III and IV), being type II the most common. The presence of RM 
systems in important for the stabilization of selfish genes or elements (plasmids) and genomes, 
immigration control, maintenance of species identity and control speciation and recombination and 
genome rearrangements and therefore genome evolution (139). There is little evidence of the presence 
of RM systems in enterococci. However, some type II restriction endonucleases have been identified 
such as SfaGU and SfaNI and M.SfeI and R.SfeI. These enzymes as other possible RM systems identified 
in enterococci have been identified in MGEs. It remains to be seen if these RM systems can act as 
barriers to the uptake of additional MGEs (125, 140).  
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The possession of knowledge does not kill the sense of wonder and mystery. There is 
always more mystery. 
Anaïs Nin 
 
 
 
 
 
 
 
 
 
 
 
Hypothesis and Objectives 
 
 
 
 
 
 26 
 
 
  
Ana P. Tedim   Hypothesis and Objectives 
 
27 
 
Previous studies have demonstrated the influence of age and antibiotic treatment on the bacterial 
populations (at phyla, genera and/or species level) colonizing the human GI tract. However, the 
information regarding the influence of age, hospitalizations and other factors on population changes at 
the subspecies level is still scarce. We are addressing this knowledge gap focusing Enterococcus faecium 
intestinal populations. 
Some genomic studies directed to elucidate E. faecium population structure have shown differences 
between ecological groups colonizing the GI tract of healthy volunteers and/or community individuals, 
which are mostly antibiotic susceptible, and those causing nosocomial infections, which are enriched in 
adaptive traits (e.g. antibiotic resistance, adhesion, virulence). Nevertheless, longitudinal studies 
regarding the population structure of E. faecium causing nosocomial infections also remain scarce.  
Finally, the contribution of MGEs to the adaptation of bacteria to different ecological niches (and 
microniches), including human pathogenic species, has been traditionally analysed under the dominant 
͞speĐies-centric͟ ǀieǁ. Hoǁeǀeƌ, a global, integrated view of the effects of MGEs at population level 
was needed in order to understand the emergence and dynamics of some relevant traits as antibiotic 
resistance.  This is a necessary requirement for the better understanding of the emergence, spread and 
persistence of certain ecologic/clonal niche-specialized groups within species. 
Our HYPOTHESIS postulates that the combination of both human host characteristics (e. g. age), and 
bacterial factors (e.g. the presence of MGEs) might explain the successful adaptation of particular 
bacterial populations to well-defined local ecological challenges (e.g. the use of antibiotics in the 
hospital setting). The biological cost of carrying antibiotic resistance determinants (e. g. pbp5 and 
Tn1546-vanA) and the MGEs in which they are located would play an important role in the possibilities 
for selection and persistence of specialized populations of E. faecium in particular selective 
environments.  
The MAIN OBJECTIVE of this dissertation is to assess the influence that MGE and antibiotic resistance 
have in shaping the population structure and evolution of E. faecium, an important nosocomial 
pathogen. 
 
The more specific OBJECTIVES (O) and ACTIVITIES (A) are the following: 
O1. To comprehensively analyse the diversity of E. faecium populations in different age groups and 
the longitudinal dynamics E. faecium in the hospital setting. 
A1.1. To analyse the population structure of E. faecium faecal isolates from hospitalized and 
non-hospitalized individuals of different age groups.  
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A1.2. To assess the population structure of E. faecium causing bacteraemia in Hospital 
Universitario Ramón y Cajal (1995-2015) and its relation with epidemiological patient data in 
a geographical area where vancomycin resistant E. faecium is sporadic. 
O2. To characterize the diversity of MGEs responsible for the transmission of antibiotic resistance in 
E. faecium, with emphasis in those conferring resistance to vancomycin. 
A2.1. To analyse, using gene exchange networks, based on sequences available in databases, 
the role of plasmids in the emergence, dissemination and maintenance of antimicrobial 
resistance determinants (antibiotics, heavy metals and biocides).  
A2.2. To comprehensively characterize the plasmids and transposons conferring resistance to 
glycopeptides since their description in 1986, by analysing documented strains causing 
outbreaks in different geographical areas of the world, along a 20 years period. 
A2.3. To address the dynamics of vancomycin resistance among enterococci by analysing the 
clonal and plasmid backgrounds influencing the spread and persistence of Tn1546 in Portugal, 
one of the developed countries with higher rates of both VREfm (21–23%) and VREfs (1.8–
4.1%), and where VanA is prevalent over VanB. 
O3. To determine the biological cost of antibiotic resistance determinants and their associated MGEs 
might have on the fitness of bacterial populations. 
A3.1. To assess the genetic context of the pbp5 gene as well as its transferability and stability 
in different E. faecium clonal backgrounds by analysing a large E. faecium collection (obtained 
from different origins collected in Portugal for more than 20 years) and available E. faecium 
genomes in NCBI database. 
A3.2. To determine the fitness cost and the stability of plasmids carrying different Tn1546-
vanA variants as well as the intrinsic fitness of a well-documented collection of E. faecium 
susceptible and resistant to ampicillin and vancomycin. 
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I was gratified to be able to answer promptly, and I did. I said I didn’t know. 
Mark Twain 
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ABSTRACT 
The diversity of enterococcal populations from fecal samples from hospitalized (n=133) and non-
hospitalized individuals (n=173) of different age groups (group I, ages 0 to 19 years; group II, ages 20 to 
59 years; group III, ages>60 years) was analyzed. Enterococci were recovered at similar rates from 
hospitalized and non-hospitalized persons (77.44% to 79.77%) of all age groups (75.0% to 82.61%). 
Enterococcus faecalis and Enterococcus faecium were predominant, although seven other Enterococcus 
species were identified. E. faecalis and E. faecium (including ampicillin-resistant E. faecium) colonization 
rates in non-hospitalized persons were age independent. For inpatients, E. faecalis colonization rates 
were age independent, but E. faecium colonization rates (particularly the rates of ampicillin-resistant E. 
faecium colonization) significantly increased with age. The population structure of E. faecium and E. 
faecalis was determined by superimposing goeBURST and Bayesian analysis of the population structure 
(BAPS). Most E. faecium sequence types (STs; 150 isolates belonging to 75 STs) were linked to BAPS 
groups 1 (22.0%), 2 (31.3%), and 3 (36.7%). A positive association between hospital isolates and BAPS 
subgroups 2.1a and 3.3a (which included major ampicillin-resistant E. faecium human lineages) and 
between community-based ampicillin-resistant E. faecium isolates and BAPS subgroups 1.2 and 3.3b was 
found. Most E. faecalis isolates (130 isolates belonging to 58 STs) were grouped into 3 BAPS groups, 
BAPS groups 1 (36.9%), 2 (40.0%), and 3 (23.1%), with each one comprising widespread lineages. No 
positive associations with age or hospitalization were established. The diversity and dynamics of 
enterococcal populations in the fecal microbiota of healthy humans are largely unexplored, with the 
available knowledge being fragmented and contradictory. The study offers a novel and comprehensive 
analysis of enterococcal population landscapes and suggests that E. faecium populations from 
hospitalized patients and from community-based individuals differ, with a predominance of certain 
clonal lineages, often in association with elderly individuals, occurring in the hospital setting.  
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INTRODUCTION 
Enterococci are relatively minor constituents of the human gastrointestinal microbiota (less than 1%) 
but are able to cause a wide diversity of infections mostly in patients with underlying diseases (1, 2). 
High-density colonization by antibiotic resistant enterococci increases the risk of bacteremia and 
transmission, however the population structure and ecological and evolutionary forces influencing 
population dynamics of gut colonizers remains largely uncomprehended (3–5). Next generation 
sequencing has provided a wealth of data about the influence of the host (age, diet, health status, and 
antibiotic treatment) on the diversity and population frequency of different bacterial groups, in which 
enterococci are included (6–10). However, the information provided by current metagenomic analysis, 
based on 16S rRNA (11, 12), or by the traditional culture based studies (1, 13, 14) preclude any possible 
analysis of enterococci at subspecies level. Furthermore, available information about the frequency and 
diversity of enterococcal species in fecal microbiota with age is fragmented and contradictory (1, 15). 
Different methods based on Multilocus Sequence Typing (MLST), comparative genomic hybridization 
and whole genome sequencing revealed intra-species diversity for Enterococcus faecalis and 
Enterococcus faecium which are the predominant enterococcal species colonizing the human 
gastrointestinal tract (16–25). E. faecium has a population structure that has split in two major 
phǇlogeŶoŵiĐ Đlusteƌs desigŶated as ͞Đlade B͟, that iŶĐludes ĐoŵŵuŶitǇ-based human isolates, and 
͞Đlade A͟ that Đoŵpƌises isolates fƌoŵ huŵaŶs aŶd aŶiŵals, ǁith a Đlade Aϭ eŶƌiĐhed ǁith isolates fƌoŵ 
hospitalized patients. Specifically, strains belonging to ST17, ST18 and ST78 lineages, within clade A1, 
are often resistant to antibiotics and the most frequently associated with the hospital environment (21, 
26, 27). E. faecalis, on the other hand, seems to lack such a clear clade structure probably because this 
species occupies a higher variety of ecological microniches, having thus access to more heterogeneous 
spectrum of alleles than E. faecium (28). As a result, no clear genotypic differences are observed 
between hospital and community isolates (25, 28, 29), even though some clonal complexes (CCs) are 
more prevalent either among hospitalized patients as CC6-ST6, CC9-ST9, CC28-ST87, and CC40-ST40; or 
among community healthy volunteers, as ST16 and CC58 (30–33). Recombination, as detected 
previously in enterococci (17, 34, 35), may have a considerable impact on patterns of evolutionary 
descent as displayed by sequence-based gene trees or even by popular allele-based population 
snapshots provided by eBURST. This may obscure the genetic relatedness of strains and clones and as 
such interfere with epidemiological and clinical investigations, in particular when strains are assigned to 
specific CCs. In addition, knowledge about the population structure of enterococcal species is biased by 
an overrepresentation of contemporary multi-drug resistant clinical isolates belonging to a few high-risk 
clonal complexes often associated with nosocomial outbreaks and frequently associated with elderly 
(36–38). Studies analyzing early isolates document a more diverse enterococcal population able to cause 
disease, either of nosocomial or community acquisition, and often associated with adults and children. 
Isolates causing infections or colonizing these populations have less frequently been analyzed at the 
molecular level (33, 39–41).  
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The objective of this study was to assess for the first time the population structure of enterococci in the 
feces of both hospitalized and non-hospitalized individuals within different age groups. In addition, 
Bayesian Analysis of Population Structure (BAPS), a non-phylogenetic method able to find the best 
partition of a set of isolates into sub-populations, was applied, broadening former results obtained for E. 
faecium, and providing the first analysis to probabilistically assign E. faecalis strains to evolutionary 
groups.  
MATERIAL AND METHODS 
Bacterial samples. Three hundred and six faecal samples were collected between April 2009 and April 
2011 at Ramón y Cajal University Hospital (HRyC) and its community-care area of influence. HRyC is a 
tertiary care public hospital with 1,155 beds that provides specialized attention to a population of about 
600,000 habitants in the Northern area of Madrid (Spain) which is primarily attended at 20 Primary 
Health Centers (PHC) of the Madrid Health Service (SERMAS). This study was conducted according to 
applicable government regulations and approved studies by institutional research policies (e.g., 
reference CEIC-106/09 [A. M. Sánchez-Díaz, C. Cuartero, J. D. Rodríguez, S. Lozano, J. M. Alonso, M. J. 
Rodríguez-Domínguez, A. P. Tedim, R. del Campo, J. López, R. Cantón, and P. Ruiz-Garbajosa, 
unpublished data]). 
The samples analysed were recovered from 173 patients with non-severe diseases that attended a PHC 
or a consult in HRyC (with no hospitalization registered in the 6 months prior to the sample collection) 
and from 133 hospitalized patients admitted at HRyC. The faecal samples were submitted to HRyC for 
stool culture, with/without specific request for Clostridium difficile or for parasites detection, and were 
aŶoŶǇŵouslǇ pƌoĐessed keepiŶg ĐoŶfideŶtial patieŶts͛ deŵogƌaphiĐ iŶfoƌŵatioŶ. Hospitalized patieŶts 
were mostly located at medical (78.2%), surgical wards (8.3%) and intensive care units (ICU, 9.8%). All 
but 20 samples from hospitalized patients were collected after more than 48h of hospital admission. 
However, these 20 patients had history of several recent previous hospitalizations (see Tables S1 and S2 
in the supplemental material).  
“aŵples ǁeƌe also Đlassified aĐĐoƌdiŶg ǁith host͛s age iŶ thƌee age gƌoups desigŶed ǁith ƌoŵaŶ 
numerals as group I (young people, 0-19 years old; n=92 [30%]; 57 non-hospitalized persons and 35 
hospitalized patients), group II (adults, 20-59 years old; n=108 [35%]; 62 non-hospitalized persons and 
ϰϲ hospitalized patieŶtsͿ aŶd gƌoup III ;eldeƌlǇ, шϲϬ Ǉeaƌs old; Ŷ=ϭϬϲ [ϯϱ%]; ϱϰ ŶoŶ-hospitalized persons 
and 52 hospitalized patients). Only one sample per patient was analysed (see Tables S1 and S2in the 
supplemental material). 
Sample processing. About 0.5 g of each faecal sample was suspended in 1mL of saline solution, plated 
on m-Enterococcus agar (Difco, Detroit, USA) plain or supplemented either with ampicillin (10 µg/mL) or 
vancomycin (6 µg/mL), and incubated 48h at 37ºC. For each sample one colony per morphology and 
plate was selected (28) for further studies. In order to enhance the recovery of minority populations of 
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ampicillin and vancomycin resistant enterococci (VRE), 0.1 mL of the original suspension of each sample 
was pre-enriched in Brain-Heart Infusion (BHI) broth (Difco, Detroit, MI, USA) supplemented with 2 
µg/mL of ampicillin or 2 µg/mL of vancomycin, incubated 24h at 37ºC and subsequently, plated on m-
Enterococcus agar (Difco, Detroit, USA) containing ampicillin (10 µg/mL) or vancomycin (6 µg/mL), 
respectively.  
Identification, antibiotic susceptibility and virulence traits. Bacterial identification was performed 
by the amplification of species-specific genes: E. faecalis D-Alanine-D-Alanine ligase (ddl) and E. faecium 
aaĐ;6’Ϳ-Ii as previously described (42, 43) and by MALDI-TOF MS (Bruker, Daltonics, Bremen, Germany). 
Susceptibility for ampicillin, vancomycin, teicoplanin, streptomycin, gentamicin, ciprofloxacin, 
levofloxacin, erythromycin, tetracycline and chloramphenicol (Oxoid, Basingstoke, UK) was determined 
by disc diffusion according to CLSI guidelines (44).  
The presence of putative virulence genes encoding the E. faecium enterococcal surface protein (esp), 
glycosyl hydrolase (hylEfm) and collagen-binding adhesin (acm), and the E. faecalis enterococcal surface 
protein (esp), hyaluronidase (hylEfc), cytolysin/haemolysin (cylA), gelatinase (gelE) and aggregation 
substance (asa1) were investigated by PCR and sequencing as described before (45, 46). 
Clonal Relatedness. Clonal relationship among isolates of each enterococcal species were established 
by Pulsed Field Gel Electrophoresis (PFGE) and MLST as previously described (16, 47) and it is detailed in 
Tables S1 and S2 in the supplemental material. Clusters of related STs for E. faecalis (differing in no more 
than two of the seven MLST loci) were considered as belonging to the same clonal complex (CC) using 
the goeBURST algorithm (48, 49). CCs were defined based of goeBURST analysis of the 524 STs present 
in the E. faecalis MLST database (http://efaecalis.mlst.net/).  
Analysis of population structure. A BAPS software was used to probabilistically assign E. faecalis and 
E. faecium STs to non-overlapping evolutionary groups (27, 50). BAPS clustering was performed with the 
second-order Markov model and the standard MLST data input option in a hierarchical manner. For E. 
faecium, the major clusters identified at the first stage were re-analysed after excluding the remaining 
data. The rationale for this approach is to increase statistical power to detect more fine-scale genetic 
structure of a population when analyzing particular lineages separately from the remaining population. 
In all BAPS analyses, 10 runs of the estimation algorithm were performed using a priori upper bounds 
(10-30 for the major groups analysis and 2-10 for subgroups analysis) for the number of clusters over 
the interval and in each case the runs converged to a nearly identical partition of the data in question, 
indicating a high level of peakedness of the posterior distribution (estimated p=1.000).  
The accuracy of BAPS for establishing E. faecium population structure was determined using different 
sample sizes and discarding the inclusion of E. faecalis as outgroup (see Fig. S1 to S3 in supplemental 
material) (27). Correlation analysis was performed for each of the comparisons mentioned above using 
Microsoft Excel 2010. This study constitutes the first application of BAPS to investigate E. faecalis 
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population and evolutionary genetics, following the same approach that was previously used for E. 
faecium (27).  
Statistical analysis. Statistical significance of the results was calculated by the Chi-square test; P values 
<0.05 were considered as being statically significant. 
The STATA Generalized Estimating Equations (GEE) model (takes into account clone related data) (51) 
ǁas used foƌ ĐalĐulatiŶg odd ƌatios ;O‘sͿ aŶd ϵϱ% ĐoŶﬁdeŶĐe iŶteƌǀals ;CIsͿ ƌelated to the ĐoloŶizatioŶ 
isolates. They were done in comparison with major BAPS 3.3a for E. faecium, and relative to BAPS 1 for 
E. faecalis.  
For the analysis of all isolates available at MLST databases, ORs were calculated between BAPS groups 
and different sources (hospitalized patients, non-hospitalized persons and animals). Environmental, food 
and other sources were also considered but due to the low number of isolates in these categories ORs 
analysis was not performed. 
RESULTS 
Prevalence and diversity of enterococcal species in human faecal samples. Enterococci were 
recovered by culture from 78.8% of the individuals analysed (n=241/306), at similar rates among 
hospitalized and non-hospitalized individuals (77.4% vs 79.8%) and among all age groups (75.0-82.6%). 
They corresponded to three of the five groups of enterococci previously described by Facklam et al on 
the basis of phenotypic and genotypic characteristics which used to be designed by roman numerals (1, 
52). The rate of individuals colonized by different species varied in each age group, with E. faecalis and 
E. faecium being the predominant species identified (Fig. 1 and 2). Among non-hospitalized persons, E. 
faecalis and E. faecium colonization rates were age-independent (E. faecalis/E. faecium ratios 1.14, 0.71, 
1.12 for age groups I, II and III, respectively). E. faecalis colonization rate was also age-independent 
among hospitalized patients but E. faecium, and particularly ampicillin resistant E. faecium colonization 
rate, significantly (P<0.01) increased with age (E. faecalis/E. faecium ratios 1.90, 0.71, 0.65, for age 
groups I, II and III, respectively) (Fig. 1 and 3). Besides E. faecium and E. faecalis, both classified within 
the enterococcal Facklam´s group II, other species within enterococcal groups I (20 E. avium, 7 E. 
raffinosus, 2 E. malodoratus); II (4 E. casseliflavus, 3 E. gallinarum, 1 E. thailandicus) and group III (8 E. 
hirae) were identified (Fig. 2).  
Ampicillin resistance (22.2%, n=68/306) was detected among E. faecium (94.1%, n=64/68) and E. 
raffinosus (5.9%, n=4/68) isolates. Ampicillin-resistant E. faecium were significantly associated with 
hospitalized patients (44.7%, n=46/103), when compared with non-hospitalized individuals (13.0%, 
n=18/138). A low number of individuals colonized with VRE, all identified as E. faecalis, was also 
detected (1.6%, n=5/306, consisting of 2 non-hospitalized and 3 hospitalized individuals of different 
ages) (see Table S2 in the supplemental material). 
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Figure 1. Proportion (%) of Non-hospitalized and Hospitalized individuals colonized by Enterococci by 
age group. 
E. faecalis/E. faecium colonization ratios in non-hospitalized persons per age group were: group I (0-19 years old)=1.08, group II 
(20-ϱϵ Ǉeaƌs oldͿ=Ϭ.ϲϴ, aŶd gƌoup III ;шϲϬ Ǉeaƌs oldͿ=ϭ.Ϭϴ. E. faecalis/E. faecium colonization ratios in hospitalized patients were: 
group I (0-19 years old)= 2.25, group II (20-ϱϵ Ǉeaƌs oldͿ= Ϭ.ϳϱ, aŶd gƌoup III ;шϲϬ Ǉeaƌs oldͿ= Ϭ.ϲϴ. 
 
Figure 2. Proportion (%) of Non-hospitalized and Hospitalized individuals colonized by different 
Enterococcus spp by age group. 
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The population structure of the E. faecium and E. faecalis isolates is detailed below. For other 
enterococci, isolates of the same species exhibited different PFGE-types with the exception of some E. 
avium isolates (data not shown). All these species were resistant to quinupristin-dalfopristin, often 
resistant to erythromycin (E. avium, E. hirae, E. raffinosus, E. gallinarum, E. casseliflavus) and 
tetracycline (E. raffinosus) and eventually to levofloxacin (E. raffinosus, E. gallinarum), and high 
concentrations of streptomycin (E. avium, E. raffinosus, E. gallinarum) and gentamicin (E. avium, E. 
raffinosus).  
 
Figure 3. Proportion (%) of Non-hospitalized and Hospitalized individuals colonized by Ampicillin-
resistant E. faecium by age group.  
The proportion of Hospital/Non-hospital Ampicillin-resistant E. faecium for the different age groups was: Group I (0-19 years 
old)=0.75; Group II (20-ϱϵ Ǉeaƌs oldͿ=Ϯ.ϭϰ aŶd Gƌoup III ;шϲϬ Ǉeaƌs oldͿ=ϰ. 
BAPS analysis of E. faecium population structure. A BAPS analysis was used to infer the population 
structure of E. faecium according with previous findings that demonstrated that eBURST is not sufficient 
to reliably delineate the patterns of recent evolutionary descent of E. faecium (27, 53). The analysis was 
repeated taking in account the significant enlargement of the MLST database 
(http://efaecium.mlst.net/) in which the number of STs increased from 492 to 837 in the 2 years since 
the time of publication of the original 2012 study (27). 
A hierarchical BAPS clustering analysis of the currently available 837 E. faecium STs representing 2,402 
isolates of different origins yield 8 BAPS groups. The majority of STs grouped in BAPS 1, BAPS 2, BAPS 3 
and BAPS 7 (15.1%, 39.7%, 31.5%, and 8.5%, respectively) while BAPS 4, BAPS 5, BAPS 6 and BAPS 8 
were much more infrequently detected (1.9%, 1.3%, 0.8% and 1.2%, respectively). BAPS nested analysis 
subdivided BAPS 1 in six subgroups (BAPSs 1.1-1.6) and BAPS 2 (BAPSs 2.1a, 2.1b, 2.3a, 2.3b), BAPS 3 
(BAPSs 3.1, 3.2, 3.3a, 3.3b) and BAPS 7 (BAPSs 7.1-7.4) in four subgroups each (Table 1). The original 
BAPS subgroups 2.1, 2.3, and 3.3 described by Willems et al. (27), were now split in two subgroups each, 
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arbitrarily designed here as BAPS 2.1a and 2.1b, BAPS 2.3a and 2.3b, and BAPS 3.3a and 3.3b, for 
backwards compatibility (see Fig. S3 in the supplemental material).  
Table 1. E. faecium BAPS analysis data. 
BAPS Group BAPS Subgroup No STs % STs No isolates 
BAPS 1 1.1 9 1.08% 11 
 
1.2 61 7.29% 100 
 
1.3 12 1.43% 16 
 
1.4 2 0.24% 2 
 
1.5 36 4.30% 41 
 
1.6 6 0.72% 6 
 
Subtotal 126 15.05% 176 
BAPS 2 2.1a 88 10.51% 577 
 
2.1b 133 15.89% 321 
 
2.3a 78 9.32% 135 
 
2.3b 33 3.94% 49 
 
Subtotal 332 39.67% 1082 
BAPS 3 3.1 72 8.60% 122 
 
3.2 28 3.35% 59 
 
3.3a 107 12.78% 679 
 
3.3b 57 6.81% 92 
 
Subtotal 264 31.54% 952 
BAPS 4 
 
11 1.31% 11 
BAPS 5 
 
16 1.91% 19 
BAPS 6 
 
7 0.84% 9 
BAPS 7 7.1 54 6.45% 120 
 
7.2 6 0.72% 6 
 
7.3 10 1.19% 14 
 
7.4 1 0.12% 2 
 
Subtotal 71 8.48% 142 
BAPS 8 
 
10 1.19% 11 
     
TOTAL 
 
837 
 
2402 
 
Next, we analyzed the congruence between the BAPS grouping of 492 STs using the BAPS assignment as 
described previously by Willems et al (27), and the BAPS grouping from this study. A correlation 
coefficient of 0.5958 indicates some discrepancies between the partitioning of the 492 STs. These 
discrepancies, probably related with the presence of an E. faecalis outgroup in Willems et al (27) BAPS 
analysis, are mostly due to STs that moved from the BAPS 2 (15 STs), BAPS 3 (25 STs), and BAPS 5 (1 ST) 
in the 2012 study to BAPS 7 in our study (see Fig. S1 in the supplemental material). Subsequently, the 
492 E. faecium STs included in the work of Willems et al (27) were compared to BAPS grouping of the 
same 492 STs using the extended E. faecium MLST database of 837 STs in order to infer the influence of 
the sample size on BAPS assignment. The correlation coefficients analysis revealed almost perfect 
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correlations for classification of BAPS groups (0.9996) and BAPS subgroups (0.9988) based on 492 and 
837 STs (see Fig. S2 and S3 in the supplemental material) and that only a small number of changes 
occurred (44/837 STs, 5.2%) in BAPS assignment, either at a group or subgroup level, when the number 
of STs analysed was significantly increased. This further indicates that, for E. faecium, BAPS analysis is 
both reproducible and robust and may accurately describe the E. faecium population structure. 
Since the extended dataset of 837 STs slightly changed BAPS grouping of STs, we decided to recalculate 
ORs to assess significance between BAPS groups and the origin of isolates (see Table S3 in the 
supplemental material). This revealed that isolates from hospitalized individuals were positively 
associated with BAPS 2.1a and 3.3a and negatively associated with all other BAPS groups. Conversely, 
isolates of all BAPS groups from non-hospitalized individuals were negatively associated with BAPSs 2.1a 
and 3.3a but positively associated with BAPS 1.2 and BAPS 3.3b (Fig. 4).  
Isolates of animal origin were negatively associated with BAPS 3.3a and BAPS 1.2 but showed a positive 
association with BAPSs 1.5, 2.1a, 2.1b, 2.3a, 2.3b, 3.1, 3.2, and 7.1 (Fig. 4; see also Table S3 in the 
supplemental material). 
Genotypic relatedness of E. faecium colonizing different age groups. The 150 E. faecium 
isolates, obtained from 142 samples in this study, corresponded to 75 distinct STs. Forty-seven STs, 
representing 62.7% of the studied isolates, were STs firstly reported here (see Table S1 in the 
supplemental material). The remaining ones corresponded to globally spread STs like ST78, (n=34, 7 
STs), ST17 (n=14, 1 ST), and ST18 (n=6, 1 ST), and also ST102 (n=20, 7 STs), ST22 (n=13, 9 STs), ST94 
(n=12, 7 STs), ST9 (2, 2 STs) and ST5 (1 ST), which were previously detected among community based 
isolates (see Table S1 in the supplemental material). The 75 STs were partitioned into BAPS 1 (24 STs, 
22.0% of isolates), BAPS 2 (19 STs, 31.3% of isolates), BAPS 3 (20 STs, 36.7% of isolates), BAPS 7 (8 STs, 
7.3% of isolates), and BAPS 8 (3 STs, 2.7% of isolates) (Fig. 5). 
STs classified as BAPS 1 mainly corresponded to subgroup 1.2 (n=27 [81.2%], 19 STs). The proportion of 
isolates with STs that group in BAPS 1 steadily decreased with age (Fig. 5 and 6), but isolates of this 
group were still prevalent among the adults of group II (15/27). All strains within BAPS 1 were ampicillin 
susceptible, mainly recovered from non-hospitalized persons (23/27, P<0.01).  
Within BAPS 2, the subgroup 2.1a was predominant (70.2%, 33/47) and increasingly detected with age, 
constituting the leading group in elderly patients (Fig. 5 and 6). Most isolates were recovered in 
hospitals, exhibited ampicillin-resistance and harboured genes encoding adhesive surface protein (Esp) 
and collagen-adhesin (Acm) (27/33 and 31/33, respectively) that are associated with colonization and 
pathogenicity (see Table S1 in the supplemental material). 
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Figure 4. E. faecium BAPS group distribution by origin.  
This distribution by origin included all isolates present in the E. faecium MLST database (http://efaecium.mlst.net/) on August 
2013. 
STs contained within BAPS 2.1a were ST117 (n=25), ST203 (n=4), ST80 (n=1), ST323 (n=1), ST324 (n=1) 
and ST612 (n=1). E. faecium ST117 (CEfm1) is, apart from being predominantly a colonizing clone, also 
frequently associated with severe infections in our institution (54). The other BAPS 2 subgroups, namely 
BAPS 2.3b (n=6 [12.8%], 5 STs), BAPS 2.3a (n=4 [8.5%], 4 STs) and BAPS 2.1b (n=4 [8.5%], 4 STs) were 
detected among both hospitalized and non-hospitalized individuals (Fig. 5 and 6). 
BAPS 3 was represented by subgroups 3.1, 3.2, 3.3a and 3.3b. Most isolates in BAPS 3.1 (6 STs, 18.2% of 
isolates) were ampicillin-susceptible E. faecium (9/10) from non-hospitalized individuals (7/10, P<0.01) 
of age groups I and II (Fig. 5 and 6; see also Table S1 in the supplemental material). The subgroups BAPS 
3.3a and BAPS 3.3b, previously described as BAPS 3.3 differed in the susceptibility to ampicillin. BAPS 
3.3a (n=20 [36.4%] 14 ST17 and 6 ST18) comprised ampicillin-resistant E. faecium isolates (19/20, 
P<0.01) containing hylEfm (16/20) and predominantly recovered from hospitalized patients (16/20, 
P<0.01). Conversely, the BAPS 3.3b subgroup (11 STs 43.6% of isolates) was significantly associated with 
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ampicillin-susceptible E. faecium isolates (21/24 P<0.01), mostly from non-hospitalized persons (18/24, 
P<0.01).  
 
Figure 5. E. faecium colonization population structure. 
A) by origin; B) by age group; C) by susceptibility to Ampicillin. 
BAPS subgroup 7.1 is most predominant within BAPS 7 comprised of 5 STs, representing 8 isolates. 
Finally, 3 STs comprising BAPS 8 and representing four isolates (2 ST698, 1 ST689 and 1 ST690) were all 
ampicillin-susceptible E. faecium (of which 3 where esp
+
) and were recovered from non-hospitalized 
persons (see Table S1 in the supplemental material). 
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Differences in the recovery rate of ampicillin resistant enterococci were noticed when samples were 
cultured without or with selective enrichment (56.3%, 36/64) but not for those resistant to vancomycin 
(100%, 5/5). Ampicillin-resistant E. faecium isolates that were only cultured after enrichment mostly 
belonged to BAPS 2.1a (n=14, 9 ST117, 3 ST203, 1 ST80 and 1 ST323) and BAPS 3.3a (n=8, 6 ST17 and 2 
ST18), the majority of these isolates were recovered from hospitalized patients. Isolates of other BAPS 
groups were also found and are described in Table S1 in the supplemental material. 
BAPS analysis of E. faecalis population structure. Previous studies based on MLST have suggested 
that recombination may play an important role in the diversification of E. faecalis (17, 20, 22). As 
methods to infer evolutionary descent are highly influenced by recombination, we analyzed the E. 
faecalis population structure using Bayesian-based population genetic modeling implemented in BAPS 
software in addition to goeBURST. The sample included 1,310 isolates corresponding to 523 STs 
available at public database (http://efaecalis.mlst.net/).  
A maximum likelihood based phylogenetic reconstruction of STs using concatenated MLST gene 
sequences, placed ST80 far apart from all other STs. When this ST80 (amounting to only 1 isolate from 
the MLST database) was excluded from the analysis to better observe differences among tree features, 
practically all clades showed low bootstrap support, which supports previous analyses indicating that 
recombination may obscure the phylogenetic signal in nucleotide-based phylogenetic reconstructions in 
E. faecalis. A hierarchical BAPS clustering analysis subdivided the E. faecalis population into 5 BAPS 
groups (Fig. 7). Most of STs and isolates were distributed among BAPSs 1, 2 and 3 (44.7%, 27.5%, and 
20.6%, respectively), while BAPSs 4 (1.0%) and 5 (6.1%) only represented a small fraction of the STs 
analyzed (see Table S4 in supplemental material). 
ORs calculations revealed that isolates from hospitalized patients were not significantly associated with 
any of the BAPS groups, while BAPS 2 was positively associated with isolates from non-hospitalized 
persons (ORs=1.8507, P<0.01) and negatively associated with animal isolates (ORs=0.4659, p<0.01) (Fig. 
7; see also Table S5 in supplemental material). Although signals of microevolutionary hospital 
specialization within the different BAPS groups were not found, some STs were enriched in isolates from 
hospitalized patients as ST6 (107/123), ST64 (12/18), ST9 (22/25), ST28 (16/17), ST87 (15/16), ST49 
(4/4), ST88 (4/4) and ST159 (4/4). Furthermore, ST58 (8/8), ST82 (25/27) and ST174 (11/11) were 
frequently found in isolates from animals. We also analysed traces of significant admixture in the E. 
faecalis population as recombination is the driving force of admixture dynamics and it might influence 
the evolvability of specific amplified lineages. Admixture was significantly present in some STs from 
animal and community-based hosts. However, additional analyses revealed that admixture was not 
significantly found in STs that are unique or shared between hosts, STs from hospital or non-hospital 
origin, STs from human and non-human origin or STs that represent antibiotic resistant isolates (data 
not shown). The combination of these results suggests that the majority of E. faecalis seems to belong 
to one single recombining population that exchanges alleles regardless of the genetic background (BAPS 
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groups), ecological origin (isolation source; hospital or non-hospital; human or non-human) or antibiotic-
resistance phenotype. 
 
Figure 6. E. faecium BAPS distribution by age group in human colonization. 
The influence of the sample size (and therefore the underlying diversity) in the accuracy of BAPS for 
establishing the E. faecalis population structure was assessed using two datasets (see Fig. S4 in 
supplemental material). The first dataset consisted of 433 STs available at MLST database 
(http://efaecalis.mlst.net/) before including the new E. faecalis STs found in this study. The second 
dataset included 523 STs available in the MLST database (end 2013). In both analyses ST80 was 
excluded. The negative correlation coefficient of 0.6439 obtained when comparing ST assignments to 
BAPS groups of the 433 ST and 523 ST set, is due to the split of BAPS groups 1 and 2 and the existence of 
three more BAPS groups when using the second larger dataset (see Fig. S4 in supplemental material). 
These results indicate that in E. faecalis, BAPS analysis is highly influenced by the sample size, as larger 
samples contain a representation of a higher diversity of strains of different spatial-temporal origins. 
Genotypic relatedness of E. faecalis colonizing different age groups. The 130 E. faecalis isolates 
identified in this study represented 58 STs (see Table S2 in supplemental material) that were partitioned 
into E. faecalis groups BAPS 1 (36.9%), BAPS 2 (40.0%) and BAPS 3 (23.1%). ORs calculations revealed 
that none of the three BAPS groups were significantly associated with a particular source or age group 
as all the BAPS groups contained isolates from both hospitalized and non-hospitalized individuals of all 
ages in more or less equal numbers (Fig. 8).  
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Figure 7. E. faecalis BAPS group distribution by origin.  
This distribution by origin included all isolates present in the E. faecalis MLST database (http://efaecalis.mlst.net/) on August 2013. 
Within BAPS 1 (n=48/130 [36.9%], 20 STs), ST6 (n=16) was predominant and mainly comprised isolates 
from hospitalized patients (13/16) and elderly (11/13) (Fig. 8; see also Table S2 in supplemental 
material). All were multi-drug resistant (MDR) showing resistance to high levels of gentamicin or 
streptomycin, and also to erythromycin (100% of isolates), tetracycline (93.8%, 15/16) and levofloxacin 
(87.5%, 14/16) and exhibiting a highly similar PFGE-profile (ST6-H10 profile) identical to the widespread 
international Mid-Atlantic clone, which also causes bacteraemia infections in our hospital (55). The 5 
VREfc isolates (vanA, data not shown) found in this study are also ST6-H10. Putative virulence factors 
asa1 (100%) and gelE (81.3%) were identified in most ST6 isolates while cylA (56.3%) and esp (37.5%) 
were less frequent. Other STs were represented by a very few number of isolates, usually susceptible to 
antibiotics and with a highly variable presence of virulence factors.  
Within BAPS 2 (n=52/130 [40.0%], 26 STs), ST40 isolates (n=15) were predominant. These isolates were 
recovered from both non-hospitalized and hospitalized individuals of different ages that often 
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harboured gelE (88.2%) and less frequently asa1 (41.2%) and esp (47.1%) and were resistant to 
tetracycline (70.6%) and erythromycin (47.1%). Similarly to BAPS 1, other STs were represented by single 
or very few isolates that often contain esp (Table S2). Among them were STs that were identified over 
several decades as ST55, ST30 or ST19 (31, 33). 
 
Figure 8. E. faecalis colonization population structure: A) by origin; B) by age group; C) by 
susceptibility to gentamicin. 
Finally, BAPS 3 (n=30/130, 12 STs) was predominantly comprised of ST16 and ST179, previously 
classified as CC16 by goeBURST (7 ST16 and 11 ST179). These STs also included isolates from both non-
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hospitalized and hospitalized individuals of different ages that often harboured asa1 (99.4%), esp 
(77.8%) or gelE (61.1%), often resistant to different antibiotics (see Table S2 in supplemental material). 
Other STs classified before as CC28 by goeBURST (1 ST333, 1 ST518 and 1 ST519), were recovered from 
adults or elderly hospitalized patients were also enriched in putative virulence factors (all harboured 
asa1, gelE, esp and cylA) and were also MDR (all showing high level of resistance to gentamicin and 
streptomycin, tetracycline and erythromycin and levofloxacin) (see Table S2 in supplemental material). 
DISCUSSION 
This study describes a consistent high recovery rate of enterococci in human faeces, both in hospitalized 
and non-hospitalized individuals and different age groups, similar to that reported in other studies, that 
ranges from 71% to 80% (1, 56, 57). These equilibrated constant rates of colonization indicate a major 
resiliency for the genus Enterococcus along heterogeneous conditions imposed by age, changing 
environments, and highly variable host niches. Previous studies (6, 58–60) have described changes in the 
recovery rates of the genus Enterococcus in faecal microbiota with ageing, which was not confirmed in 
our work, and a consistent predominance of the species E. faecalis in the fecal flora of young individuals 
and elderly, which is essentially consistent with our findings, with the important exception of the 
growing predominance of E. faecium in elderly particularly in hospitalized patients. Other studies 
yielded contradictory information about the frequency and diversity of E. faecium and other 
enterococcal species in faecal microbiota (1, 15). Shifts in the prevalence of Enterococcus populations 
might result from fluctuating changes in the environmental conditions over time as diet (10), health 
status or antibiotic treatment (1, 5, 61–64), all of them delineating particular selective landscapes in 
hospitals (58, 61). Aging interacts with these conditions, and age dependent enterococcal colonization 
dynamics has also been demonstrated for chicken and calves (1, 65), probably in interaction with 
antibiotic consumption (1, 66, 67).  
Considering the currently available diversity of known genotypes, the superimposing of goeBURST 
analysis of clonal relationship among multiple isolates with BAPS allowed the detection of a low number 
of presumptive evolutionary and functionally heterogeneous clades for the E. faecium species (21, 25–
27). BAPS 1 E. faecium, assoĐiated ǁith the ͞Đlade B͟ phǇlogeŶetiĐ liŶeage ;a Đlade ǁith pathǁaǇs of 
complex carbohydrate utilization linked to host diet and with a majority of ASEfm strains) was highly 
represented in the different age groups although its incidence was slightly reduced in the elderly (26, 
27). Conversely, BAPS 2.1a and BAPS 3.3a subgroups (containing most of the AREfm strains), associated 
with the ͞Đlade Aϭ͟ (26, 27) and mostly found in elderly hospitalized patients, represent E. faecium 
strains that are spreading in hospitals and causing clinical infections. The rates of these populations in 
the nosocomial and the community settings might be underestimated, as we have demonstrated here 
that if you do not pre-enrich the sample some of the even more widespread clones might escape 
screening, probably due to low colonization densities. The observed population structure of E. faecium 
indicates a certain specialization of subpopulations in colonization of particular age-groups which are 
usually associated with several other host associated factors, and also differences in harboured 
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selectable characters, as antibiotic resistance genes. Interestingly, some groups evolve independently 
from the acquisition of ampicillin resistance, suggesting a certain genetic isolation as seems to be the 
case of different lineages within BAPS 3.3b, BAPS 1 and BAPS 2. These results further confirm a 
population structure comprised of ecotypes representing specialization in different hosts (16, 68).  
E. faecalis populations showed a considerable level of genetic diversity. Because of that, and in contrast 
with E. faecium, no BAPS groups were significantly associated with ageing, hospital exposure, or host 
species and, with the exception of BAPS 2, showed positive association with non-hospitalized 
individuals. The wide recovery of certain STs (e.g. ST6, ST16, ST40 or ST55) able to colonize hospitalized 
and non-hospitalized humans (this study) and also animals (30, 31, 69), may be related with the more 
generalist lifestyle of this enterococcal species that weakens the possibility of recognition of ecotypes 
associated with a particular environment, at least, by using the same approach that was so useful with E. 
faecium. However, despite possible limitations in the available methods analysing the E. faecalis 
population structure, it is now clear that certain multihost E. faecalis subpopulations as ST6 or ST16 
have developed different strategies of adaptation to harsh and fluctuating habitats (31, 33). Among 
them, the lack of CRISPR loci (Cluster Regulatory Interspaced Short Palindromic Repeats, a bacterial 
defense system against foreign DNA that facilitates the acquisition of foreign DNA as antibiotic 
resistance and virulence genes) (70), and the frequent acquisition of phages (71). 
Other enterococcal species have been largely recognized as part of human faeĐal ŵiĐƌoďiota͛s aŶd this is 
confirmed in our study (1). The inverse parallel trends in the population frequencies of these species and 
that of E. faecium is of particular interest. Dynamics of colonization by these might reflect differences in 
the functional requirements of the host with the age and deserves further analysis. 
This study provides a novel, integrated and comprehensive image of the landscape of Enterococcus 
populations in a balanced amount of non-hospital and hospital-based individuals of different ages, and 
suggests that a number of enterococcal lineages might be predominant in certain age groups and/or 
hospital environment. However, a number of clones are spread in different types of individuals, and its 
prevalence is reduced in others, in a kind of source-sink dynamics (72–74), with frequent cases of 
coexistence, and preservation of rare clonal populations. That suggests a frequency-dependent 
evolution of enterococcal populations, which prevents the extinction of different genotypes playing not 
equivalent ecological roles (75–78). 
The work also illustrates a high plasticity of E. faecium and E. faecalis genomes reflected by admixture 
analysis (27; this study), with variable intra-clonal PFGE patterns (31, 69) (see Tables S1 and S2 in the 
supplemental material), and recombination of large fragments of the chromosome  (79–83, our 
unpublished results). The consequences of such large variability has been scarcely explored on a 
population-based perspective. However, it can be expected that genome plasticity would contribute to 
variation and selection of genes from a common genetic intra-species pool, needed for the adaptation 
to environments imposing different stress conditions. Future progresses in understanding enterococcal 
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population biology requires global analysis combining many ecological features, population dynamics, 
and population genetics (78, 84, 85).  
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*the numbers in after the bar (/) corresponds to the number of Ampicillin-resistant (AREfm) isolates that were only cultured after 
culture enrichment; PFGE clones were named as CEfm plus the number of the clone, or eventually ASEfm and AREfm to highlight 
the ampicillin susceptibility or resistance phenotype; atwo strains have a PFGE pattern that has 3 different bands; bPFGE patterns 
with 1 band of difference; calthough strains have different STs they have the same PFGE-type; dPFGE pattern that has up to 5 
bands of difference; e3 of the 25 strains that belong to this PFGE-type have 2 bands of difference; fPFGE-type with 5 bands of 
difference regarding ST102-PFGE-type; gPFGE-type with 1 band of difference; hPFGE-type with 6 bands of difference regarding 
ST102-PFGE-type; iPFGE-type with 3 bands of difference regarding ST102-PFGE-type; jPFGE-type with 1 band of difference 
regarding ST102-PFGE-type; kPFGE pattern that has up to 2 bands difference; lHigh level resistance; mIt is of note that these ST17 
strains were among those more frequently detected from samples of patients with bacteremia in our hospital admitted to 
different wards and locations; nIsolates classified as ST102 and its SLVs (ST709, ST708, ST710 and ST711) showed very similar PFGE 
types (ASEfm7, up to 5 bands difference). Abbreviations: BAPS, Bayesian Analysis of Population Structure; ST, Sequence Type; 
AREfm, Ampicillin resistance E. faecium; VF, Virulence factors; esp, Enterococcal Surface Protein; hylEfm, Glycosyl Hydrolase; acm, 
Collagen-binding Adhesin Gene ; NH, Non-Hospital; H, Hospital; O, Outpatient; M, Medical; S, Surgical; I, ICU; ND, Not determined; 
Group I, 0-19 years old; Group II, 20-ϱϵ Ǉeaƌs old; Gƌoup III, шϲϬ Ǉeaƌs old; C, CaƌdiologǇ; CV, CaƌdioǀasĐulaƌ; CP, CaƌdiopediatƌiĐs; 
E, Endocrinology; ER, Emergency room; G, Gastroenterology; GDS, General and Digestive Surgery; GI, Gynecology; HE, 
Hematology; ID, Infectious Diseases; IM, Internal Medicine; NE, Neurology; NM, Pneumology; NP, Nephrology; OC, Oncology; OT, 
Otorhinolaryngology; P, Pediatrics; PS, Plastic Surgery; PHC, Primary health center; R, Rheumatology; T, Traumatology; UR, 
Urology; AMP, Ampicillin; ERY, Erythromycin; VAN, Vancomycin; TEI, Teicoplanin; CIP, Ciprofloxacin; LEV, Levofloxacin; STR, 
Streptomycin; GEN, Gentamicin; TET, Tetracycline; CHL, Chloramphenicol.  
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Figure S1. Correlation between the E. faecium BAPS groups obtained by Willems et al (27) using a 
MLST dataset of 492 E. faecium STs plus 29 E. faecalis (Y) and those obtained by us when using the 
same 492 E. faecium STs but excluding E. faecalis STs (X).  
The size of each circle represents the population size included in each group. Dotted red line, groups with no correlation. 
 
 
Figure S2. Correlation between the E. faecium BAPS groups obtained using the E. faecium dataset (492 
STs) (Y) or using an updated database (837 STs) (X).  
The size of each circle represents the population size included in each group. Green line, groups that change with the is increase in 
size of the population analyzed (27). 
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Figure S4. Correlation between the E. faecalis BAPS subgroups obtained using the first dataset of 433 
STs (Y) and the second dataset of 523 STs (X).  
The size of each circle represents the population size included in each group. 
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87 
To acquire knowledge, one must study; but to acquire wisdom, one must observe. 
Marilyn vos Savant 
Chapter 2 
 66 
 
 
  
Ana P. Tedim  Chapter 2 
 
67 
 
 
 
 
 
 
 
 
 
 
Long-Term Clonal Dynamics of Enterococcus faecium Strains 
causing Bloodstream Infections (1995-2015) in an area with 
low occurrence of vancomycin resistance.  
 
Ana P. Tedima,b,c; Patricia Ruíz-Garbajosaa,b,d; Maria Concepción Rodrígueza,b,c; Mercedes Rodríguez-
Bañosa,b,c, Val F. Lanzaa,b,c, Laura Derdoye; Gonzalo Cardenas Zuritaf; Elena Lozaa; Rafael Cantóna,b,d; 
Fernando Baqueroa,b,c; Teresa M. Coquea,c,b# 
Microbiology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación 
Sanitaria (IRYCIS), Madrid, Spaina; Unidad de Resistencia a Antibióticos y Virulencia Bacteriana asociada 
al Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spainb; Centros de Investigación 
Biomédica en Red de Epidemiología y Salud Pública, (CIBER-ESP)c; Spanish Network for the Research in 
Infectious Diseases (REIPI)d; Microbiology Department, Laboratory Division, Hospital General de Agudos 
Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentinae; Clinical Laboratory, Microbiology and 
Infectious Diseases Department, Clinica San Francisco, Quito, Ecuadorf. 
 
 
Journal of Antimicrobial Chemotherapy, accepted Augutst 2nd 2016. 
 
Ana P. Tedim  Chapter 2 
 
68 
 
 
 
 
 
ABSTRACT 
Objectives. Emergence of multi-drug resistant (MDR) Enterococcus faecium in hospitals is associated 
with lineages 17, 18, and 78. The lack of unbiased long-term longitudinal studies of E. faecium causing 
infections limits our knowledge about the emergence and dynamics of high risk clonal complexes. The 
population structure of E. faecium causing bloodstream infections (BSI) in a tertiary Spanish hospital 
with low glycopeptide resistance is provided. 
Methods. All available BSI (n=413) registered in our hospital (1995-2015) were analysed for antibiotic 
susceptibility (CLSI), putative virulence traits (PCR) and clonal relationship (SmaI-PFGE, MLST evaluated 
by goeBURST and BAPS). 
Results. B“I iŶĐideŶĐe deĐƌeased duƌiŶg the studǇ ;ϯϵ‰ patieŶts iŶ ϭϵϵϲ to ϯϬ‰ patieŶts iŶ ϮϬϭϰͿ. The 
increased iŶ iŶĐideŶĐe iŶ eŶteƌoĐoĐĐal B“I ;Ϯ.ϯ‰ patieŶts iŶ ϭϵϵϲ to ϯ.Ϭ‰ patieŶts iŶ ϮϬϭϰͿ appeaƌed to 
be related with E. faecium B“I ͞ďlooŵiŶg͟ ;Ϭ.ϯϯ‰ patieŶts iŶ ϭϵϵϲ to ϭ.ϯ‰ patieŶts iŶ ϮϬϭϰ; E. 
faecalis:E. faecium BSI ratio changed from 5:1 in 1996 to 1:1 in 2012) paralleling E. faecium BSI episodes 
in cancer patients (10.9% in 1995-2005 and 37.1% in 2006-2015). Ampicillin-susceptible (ASEfm, 
different STs/BAPS) and ampicillin-resistant (AREfm, ST18-BAPS3.3a1) isolates were recovered 
throughout the study. Successive waves of BAPS2.1a-AREfm (ST117, ST203 and ST80) partially replaced 
ASEfm and ST18-AREfm since 2006.  
Conclusions. A high diversity of E. faecium populations can cause BSI. The increase of major E. faecium 
hospital associated lineages, in areas with different rates of MDR-E. faecium, suggests the relevance of 
common sociodemographic factors responsible for the emergence of E. faecium as nosocomial 
pathogen at global level. 
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INTRODUCTION 
Enterococci, especially Enterococcus faecalis and Enterococcus faecium, have long been recognized as 
important causes of major nosocomial infections.
1,2
 These species currently represent the second or 
third leading cause of healthcare-associated bacteraemia in American and European hospitals
1,3
, in 
contrast with studies from the 1980s that ranked enterococci as the sixth most common hospital 
opportunistic pathogens.
4
  
Most enterococcal nosocomial infections were caused by E. faecalis up to the early 1990s when a steady 
increase in the number of cases of multi-drug resistant (MDR) E. faecium, started to be detected.
2,4–6
 
Some of these studies also reported a change in the ratio of E. faecalis:E. faecium causing disease from 
10:1 before 1990 to 3:1 in the late 1990s
5,7
, suggesting a coming challenge in the management of the 
enterococcal infections.  
With a few exceptions, most of the available information regarding E. faecium population structure is 
based on cross-sectional targeted studies, often focused on MDR or vancomycin resistant enterococcal 
(VRE) isolates.
8–11
 The majority of MDR E. faecium causing nosocomial infections belong to the major 
hospital lineages 17, 18 and 78 (originated from ST17, ST18 and ST78, respectively) that have 
progressively acquired traits coding for antibiotic resistance and traits that provide colonization 
advantages.
11
 Although isolates of these lineages are now predominant in hospitals worldwide, 
temporal and spatial differences have been observed within and between different geographical 
areas.
10–13
 Thus, long-term population genetics studies seem to be needed in order to understand the 
transmission, evolutionary biology, and the resulting changes in the dynamics of this species in the 
hospital setting. 
Available information is mostly based on eBURST analysis of data obtained by multilocus sequence 
typing (MLST) 
14,15
 data but this approach does not reliably establish evolutionary descent patterns for 
recombinant species as E. faecium. The recent application of Bayesian Analysis of Population Structure 
(BAPS) to E. faecium seems to accurately establish relatedness among populations within this 
species.
11,12
 Such approaches seem necessary to analyse the bacterial shifts in pathogenicity and 
antibiotic resistance in response to changes in patient demographics and medical strategies, within the 
paƌadigŵ of the ͞HaŵiltoŶiaŶ ŵediĐiŶe͟ ;ďased oŶ the appliĐatioŶ of soĐial-evolution theory in order to 
understand kinship interactions between the human host and core medicine issues as bacterial 
opportunistic pathogens) and the increasing demand for evolutionary biology studies to understand 
medical problems.
16
 The objective of this work was to comprehensively analyse the population structure 
of E. faecium strains recovered from BSI and its relation with epidemiological patient data in a 
geographical area where the occurrence of vancomycin resistant enterococci is still very low. 
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MATERIAL AND METHODS 
Epidemiological data and Bacterial samples  
A total 21,695 positive blood cultures were detected in Hospital Universitario Ramón y Cajal (HRyC) 
between January of 1996 and May of 2015. HRyC is a tertiary care public hospital with 1,155 beds that 
provides specialized attention to a population size of about 600,000 habitants in the Northern area of 
Madrid (Spain). Isolates up to 2002 were previously analysed elsewhere.
3,17
 Of the total number of 
microorganisms isolated from positive blood cultures, 1,816 were identified as enterococci (8.4%), of 
which 531 were E. faecium (2.4%). To avoid duplications, only one positive sample per Bloodstream 
infection (BSI) was considered. E. faecium isolates obtained from the same patient at different 
hospitalizations more than one month apart (n=6 patients) were also included. Using this criterion we 
identified 403 cases of E. faecium BSI between 1996 and 2015 corresponding to 395 patients. Due to the 
changes in the softǁaƌe used iŶ H‘ǇC͛s MiĐƌoďiologǇ DepaƌtŵeŶt iŶ ϭϵϵϲ, data fƌoŵ ϭϵϵϱ ǁas Ŷot 
available for epidemiological analysis. We were, however, able to recover 10 E. faecium BSI isolates 
from 1995 making the total number of E. faecium isolates analyzed 413 (405 patients). The study was 
approved by the local ethics committee.  
E. faecium BSI were classified as community-acquired if the sample was obtained within the first 48h 
after hospital admission and the patients had no history of previous hospitalization or antibiotic therapy 
in the 6 months previous to the positive blood culture. Otherwise, we considered that the BSIs were 
acquired in the hospital setting.
12
 
Bacterial identification and antibiotic susceptibility 
Bacterial identification was performed using WIDER, MICROSCAN (Francisco Soria Melguizo, Madrid, 
Spain) and MALDI-TOF MS (Bruker, Bellerica, Massachusetts, USA). Susceptibility to twelve antibiotics 
was determined using WIDER and MICROSCAN standard panels and also by the agar dilution method 
(Oxoid, Basingstoke, UK) according to CLSI guidelines.
18
  
Clonal Relationship 
Clonal relationship was established by Pulsed Field Gel Electrophoresis (PFGE) and MLST as previously 
described.
14,17
 E. faecium population structure was further characterized using the BAPS scheme 
previously described.
11,12
 updated for this paper in order to include new STs described in this work (a 
total sample of 1115 STs; MLST database updated in February 2016, see supplementary data). 
Presence of putative virulence factors 
The presence of known E. faecium putative virulence genes, esp (Enterococci surface protein) and hylEfm 
(glycosyl hydrolase) were investigated by PCR and further sequencing. The presence of IS16, a marker of 
hospital-associated infections, was carried out as previously described.
19,20
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Statistical analysis 
Statistical significance was calculated using Chi-square test using RStudio; p values <0.05 were 
considered as statically significant.
21
 
RESULTS 
The rising trend of enterococcal BSI is due to the increase in the number of MDR E. faecium. 
Figure 1 represents the number of BSI cases (total BSI cases, incidence of BSI, BSI caused by 
Enterococcus spp, E. faecium and E. faecalis) in our institution. Despite some fluctuations, the incidence 
of BSI in our hospital showed a decreasing trend (p<0.001) throughout the study period (39 cases per 
1000 patients in 1996 to 30 cases per 1000 patients in 2014) (Figure 1 and Figure S1). A decrease in the 
number of positive blood cultures was recorded in and 2009. The last one was coincidental with a better 
adherence to the rule that each culture flask should be extracted from different arms in order to reduce 
false positives due to skin microbiota contamination.  
 
Figure 1. Trend of BSI in Hospital Ramón y Cajal, 1996 to 2014.  
The incidence of Enterococcus spp B“I iŶĐƌease fƌoŵ Ϯ.ϯ‰ patieŶts ;Ŷ=ϲϴ, ϱ.ϴ% of the total B“IͿ iŶ ϭϵϵϲ 
to a ϯ.Ϭ‰ patieŶts ;Ŷ=ϵϴ, ϵ.ϱ% of the total BSI) in 2014. Such increase in incidence was paralleled that 
of E. faecium B“I that ĐhaŶged fƌoŵ Ϭ.ϯϯ‰ patieŶts ;Ŷ=ϭϬ, Ϭ.ϴϱ% of total B“IͿ iŶ ϭϵϵϲ to ϭ.ϯ‰ patieŶts 
(n=42, 4.6% of the total BSI) in 2014. The incidence of E. faecalis BSI was steadily maintained during the 
studǇ ;ϭ.ϴ‰ patieŶts ;Ŷ=ϱϯͿ iŶ ϭϵϵϲ aŶd ϭ.ϲ‰ patieŶts ;Ŷ=ϱϬͿ iŶ ϮϬϭϰͿ, thus the ƌatio of E. faecalis:E. 
faecium BSI decreased throughout the study from 5:1 in 1996 to 1:1 in 2014. The increase in E. faecium 
BSI is probably due to the increase in the number of E. faecium strains resistant to different antibiotics, 
mainly ampicillin, levofloxacin and high-level resistance (HLR) to streptomycin (Figure 1 and 2).  
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The number of E. faecium BSI increased with age (average, 62.7±20.0 years; range, 0-95 years old) and 
ǁas ŵostlǇ assoĐiated ǁith the eldeƌlǇ ;шϲϬǇ, Ϯϱϳ/ϰϬϱ, p<Ϭ.ϬϬϬϭͿ Đoŵpaƌed ǁith adults ;ϮϬ-59y, 
133/405) and young people (0-19y, 15/405). E. faecium BSI was also more frequent among males 
(59.8%, p<0.0001) and hospitalized patients (85.9%, p<0.0001) (Figure 3). 
Inpatients were located at medical wards (56.8%, mainly in Gastroenterology, Haematology, Internal 
Medicine and Oncology; 28.3% 19.1%, 16.1% and 15.2%, respectively), surgical areas (17.0%) and ICUs 
(12.1%). An increase in E. faecium BSI at Oncology, Haematology and Internal Medicine (from 10.9% to 
37.1% in the periods of 1995-2005 and 2006-2015, respectively) was observed (Figure S2 and S3 
supplementary data). 
 
Figure 2. Trend of antibiotic resistance in E. faecium BSI.  
A 32.7% of E. faecium BSI were polymicrobial. E. coli (n=36), Staphylococcus (n=30), Klebsiella (n=15), 
other Enterococcus (n=13), Pseudomonas (n=10), Streptococcus (n=6), Morganella (n=5) and yeasts 
(n=11) were the most common microorganisms isolated with E. faecium. 
Genotypic heterogeneity of E. faecium isolates: dominance of a few lineages  
The 413 E. faecium isolates were classified in 53 STs, 12 of these STs (22.6%) being described here for 
the first time. Most STs correspond to major hospital associated lineages 78 (n=154, 6 STs), 17 (n=119, 5 
STs) and 18 (n=82, 2 STs) originated from ST17, ST78 and ST18 respectively.
11
 Other STs less frequently 
detected are shown in Figure 3.  
The 53 STs were partitioned into 6 BAPS groups (supplementary text and Figure S2). The most prevalent 
were BAPS 3 (54.3%) and BAPS 2 (40.8%), whereas BAPS 1, BAPS 7, BAPS 6 and BAPS 9 (3.2%, 1.0%, 
0.5%, and 0.2% respectively) were sporadically detected (Figures 4 and 5).  
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Figure 3. Population structure of E. faecium by sex (A) and by age group (B). 
BAPS 3 comprises both ampicillin resistant E. faecium (AREfm, 90.5%) and ampicillin susceptible E. 
faecium (ASEfm, 9.5%) isolates, some recovered for long periods of time. BAPS 3.3a1 (37.1%; e.g. lineage 
18) and BAPS 3.3a2 (53.8%; e.g. lineage 17) were often MDR strains
22
 that contained IS16 (97.5% and 
92.8%, respectively), putative virulence traits, as hylEfm (50.0% and 72.3%, respectively) or esp genes 
(37.8% and 66.4%, respectively). They account for 52.4% of E. faecium BSI in elderly patients at medical 
wards. The other BAPS 3 subgroups, namely BAPS 3.3b (2.3%, 3 STs; e.g. ST102), BAPS 3.1 (5.9%, 6 STs; 
e.g. ST22) and BAPS 3.2 (0.9%, 2 STs), comprise mostly ASEfm corresponding to diverse STs and PFGE-
types. They were susceptible to the majority of antibiotics tested and only sporadically harboured 
putative virulence genes or IS16 (Figures 4-5; Figure S4 supplementary data).  
BAPS 2 also comprises both AREfm (91.0%) and ASEfm (9.0%) isolates. While ASEfm were recovered 
during the whole study period, most of AREfm isolates were detected since 2006. Within BAPS 2, 
subgroup BAPS 2.1a was predominant (89.8%). It includes the major hospital associated lineage 78, and 
comprises MDR isolates, enriched in esp (59.7%) and IS16 (91.2%), which eventually harboured hylEfm, 
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(42.3%). Isolates of BAPS subgroups 2.1b, 2.3a, and 2.3b were scarcely identified in our sample (Figure 4-
5; Figure S4 supplementary data). 
 
 
Figure 4. Distribution of BAPS groups and subgroups in Hospital Ramón y Cajal per year. 
BAPS 1 (BAPS 1.2, BAPS 1.5 and BAPS 1.1, 10 STs), one of the most abundant enterococcal groups 
among colonized healthy individuals 
12
, was only sporadically represented in this study and most isolates 
were susceptible to antibiotics and/or lacked virulence genes and IS16 (Figure 4-5; Figure S4 
supplementary data). 
Clonal dynamics of E. faecium causing BSI.  
Figures 5 and 6 showed the clonal dynamics of E. faecium in our institution. We identified apparent 
͞ǁaǀes͟ of E. faecium clones belonging to different lineages. Genetically diverse ASEfm (STs of BAPS 1, 
BAPS 3.1, BAPS 3.3b) which commonly colonized non-hospitalized persons in our setting 
12
, and also 
AREfm ST18 isolates (PFGE-types AREF-A and AREF-D) were recovered throughout the period of study, 
particularly from 1995 to 2006. The low numbers of isolates of these STs since then parallel the 
emergence in our setting of AREfm clones belonging to the 78 and 17 lineages. 
BAPS 3.3a1 (ST16 and ST17) strains were also detected in early years. While the peak of ST16 was due to 
clonal spread (AREF-T) in the Gastroenterology ward between 2001 and 2006 
17
, the rise of ST17 isolates 
in 2007 reflects the emergence of different clones (AREF-38, AREF-73, AREF-74, AREF-75) in several 
wards (manly Gastroenterology, Oncology, Haematology and Internal Medicine). 
Ana P. Tedim  Chapter 2 
 
75 
 
 
Figure 5. Distribution of AREfm and ASEfm by ST per year in Hospital Ramón y Cajal. 
The steady increase in the number of E. faecium BSI (Figure 1) in our hospital appears to be also linked 
to subsequent outbreaks of clones belonging to lineage 78. After the blooming of different ST203 clonal 
variants (AREF-9 and later also AREF-15 and AREF-20) in 2006, a ST117 strain (AREF-25) became endemic 
in our hospital from 2009 to 2015. An ST80 clone (AREF-68) firstly identified in 2011, is frequently 
detected in our hospital nowadays. Isolates exhibiting related PFGE-types (up to six bands of difference) 
and persistently recovered for years (e.g. ST117-AREF-25, ST203-AREF-9, ST16-AREF-T, ST18-AREF-D 
among others) differed in the number, size and type of plasmids they harboured (data not shown). 
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Figure 6. Distribution of prevalent PFGE-types in Hospital Ramón y Cajal throughout the study period. 
It is of note that some ASEfm strains were also identified over the entire period of study as ASEF-21 
(1999-2008, corresponding to ST102 and SLV ST888 within BAPS 3.3b) or ASEF-2 (1995-2011; ST22, BAPS 
3.1). These strains have previously been identified in non-hospitalized colonized individuals.
12
  
DISCUSSION 
This work constitutes one of the few long-term longitudinal studies addressing the occurrence of 
enterococcal infections in the hospital setting during 20 years and documents a remarkable increase of E 
faecium BSI in the last decade in our Hospital. The coincidental increase in the number of E. faecium BSI 
cases and the number of cancer patients with BSI E. faecium episodes ǁith the ͞ďlooŵiŶg͟ of ĐeƌtaiŶ 
AREfm lineages in our hospital during the 2006-2015 period, can also be indirectly inferred from the 
data of multicentre studies
1,23
, studies confined to a single institution
13
,or surveys focused on VREf, MDR 
isolates, or particular groups of patients (e.g. cancer patients).
9
 
Previous antibiotic treatment is traditionally considered as one of the main risk factors for acquisition of 
BSI by enterococci.
24
 NowadaǇs, theƌapǇ ǁith ďƌoad speĐtƌuŵ β-lactams (including carbapenems) or 
levofloxacin, to treat or prevent infections caused by MDR Enterobacteriaceae in onco-haematological 
patients with febrile neutropenia
9
 has dramatically increased since the mid-2000s in many hospitals, 
including ours
25
, and is recognized as one of the main risk factors for acquisition of BSI by MDR Gram 
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positive organisms.
9,26,27
 Differences in chemotherapy composition or clinical practice guidelines also 
seem influence acquisition and intestinal persistence of AREfm.
25
  
The recovery of E. faecium of 7 BAPS groups that are normal components of the human gut microbiota 
from blood cultures
12
, suggest that bacterial translocation and invasive processes of stochastic nature 
can eventually be enhanced when an increase in the populations size occurs (classically known as 
͞ĐoloŶizatioŶ pƌessuƌe͟Ϳ28. However, STs of major hospital associated lineages ST17, ST18 and ST78, 
pƌeǀiouslǇ desigŶed as ͞high-ƌisk ĐloŶal Đoŵpleǆes͟ ;Hi‘CCsͿ iŶ ŵost ĐliŶiĐal suƌǀeǇs29,30 were also 
predominant in our series when the whole sample was considered. At a first glance, the high rate of E. 
faecium isolates ǁould ďe the ƌesult of ĐloŶal ͞ǁaǀes͟ dǇŶaŵiĐs iŶǀolǀiŶg diffeƌeŶt Hi‘CCs as 
suggested.
10,11
 This trend, initially observed for Staphylococcus aureus
31
, seems to imply the successive 
selection, expansion, and evolution of certain clones, following hospital microepidemics.
2
 Besides clonal 
expansion of specific strains, an increasingly high intra-clonal diversification of E. faecium strains 
belonging to ST17, ST18 and ST78 lineages, was found in this and also in other works
8, ƌefleĐtiŶg the ͞ex 
unibus plurum͟ eǀolutioŶaƌǇ dǇŶaŵiĐs.32  
The contemporary increase of isolates within BAPS 2.1a (ST117, ST192, ST203) and BAPS 3.3a2 (ST17) in 
the hospital environment is intriguing. Recent studies have recently highlighted the relevance of 
microbial inheritance in basic processes of infectious diseases
33
 and the impact of antibiotic treatments 
in the composition and structure of microbial communities.
34
 Although cross transmission among 
individuals remains a key factor in the epidemiology of E. faecium, the importance of the various 
resident E. faecium populations, eventually changing in frequency with antibiotic exposure and age, 
comes to light in this and other works.
12
 It has been recently demonstrated that heterogeneity of S. 
aureus populatioŶs that ĐoloŶize huŵaŶs, desigŶated as ͞Đlouds͟, leads to a possiďle gloďal adaptiǀe 
benefit for certain clones and finally for the overall species, that is enhanced by horizontal gene transfer 
(HGT).
35,36
 This might also explain what was observed in E. faecium. One of the most remarkable 
features of major E. faecium lineages of this species is the content of mobile genetic elements.
37
 HGT 
among co-occurring related clones assuring a common pool of adaptive plasmids interacting between 
clones and clonal variants is increasingly documented.
38
  
In summary, the increasing occurrence of invasive infections caused by MDR E. faecium strains in 
hospitalized elderly patients and particularly among cancer patients, associated with high mortality 
rates, constitutes an emerging problem that is becoming as serious antibiotic resistance threat as VRE.
39
 
Detailed longitudinal studies of changes in the E. faecium population structure will be required to 
associate different clones and subclones with particular types of patients and drug exposures and to 
understand the relative risks of the different enterococcal populations. 
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SUPPLEMENTARY MATERIAL 
 
Figure S1. Trend line throughout the study period of BSI incidence in Hospital Ramón y Cajal.  
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Figure S3. Wards with significant increase in E. faecium BSI in the period of 2006 to 2015.  
Ana P. Tedim  Chapter 2 
 
83 
 
 
Figure S4. Population structure of E. faecium by A) ampicillin susceptibility, B) by presence/absence 
esp; and C) by presence/absence hylEfm (C). 
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E. faecium population BAPS analysis 
BAPS software was used to probabilistically assign E. faecium STs to non-overlapping evolutionary 
groups as previously described using a dataset corresponding to 1115 STs.
1–3
 ST998 was excluded from 
the analysis because its ddl allele (ddl_67) was truncated by an ISEfm1 and the consequent change in 
the fragment size greatly influenced the analysis. The accuracy of this BAPS analysis for establishing E. 
faecium population structure was determined by comparison with the most recent dataset described by 
Tedim et al (see supplementary data Figure S4). Correlation analysis was performed using Microsoft 
Excel 2010.
3
  
A hierarchical BAPS clustering analysis of the currently available 1115 E. faecium STs yield 9 BAPS 
groups. The majority of STs grouped in BAPS 1, BAPS 2, BAPS 3 and BAPS 7 (15.9%, 39.2%, 30.4%, and 
7.0%, respectively) while BAPS 4, BAPS 5, BAPS 6, BAPS 8 and BAPS 9 were much more infrequently 
detected (1.2%, 1.5%, 1.1%, 1.2% and 2.5%, respectively). BAPS nested analysis subdivided BAPS 1 in six 
subgroups (BAPS1.1-1.6), BAPS 2 in four subgroups (BAPS 2.1a, 2.1b, 2.3a, 2.3b), and BAPS 3 in 5 
subgroups (3.1, 3.2, 3.3a1, 3.3a2, 3.3b) (Figure S5 supplementary data). The main change regarding 
Tedim et al BAPS analysis is the split of BAPS 3.3a in to subgroups BAPS 3.3a1 corresponding to lineage 
17 and BAPS 3.3a2 corresponding to lineage 18 and the split of BAPS 7 originating the new BAPS group 
BAPS 9. BAPS 7 from this study comprises all BAPS 7.1 isolates from Tedim et al and BAPS 9 comprises all 
isolates from BAPS 7.2-7.4 and one BAPS 1.6 isolate 
3
. 
We analyzed the congruence between the BAPS grouping of 837 STs using the BAPS assignment as 
described previously by Tedim et al 
3
 and the BAPS grouping from this study. A correlation coefficient of 
0.9795 indicates an almost perfect correlation between these two analysis, indicating that only a small 
number of changes occurred (41/1115 STs, 3.7%) in BAPS assignment, either at a group or subgroup 
level, when the number of STs analyzed was significantly increased. This result further confirms the 
conclusion from the last BAPS analysis for E. faecium performed by our group highlighting this tool is 
both reproducible and robust and may accurately describe the E. faecium population structure. 
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I don’t pretend we have all the answers. But the questions are certainly worth 
thinking about 
Arthur C. Clarke 
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ABSTRACT 
The phylum Firmicutes is one of the most abundant groups of prokaryotes in the microbiota of humans 
and animals and includes genera of outstanding relevance in biomedicine, health care, and industry. 
Antimicrobial drug resistance is now considered a global health security challenge of the 21
st
 century, 
and this heterogeneous group of microorganisms represents a significant part of this public health issue. 
The presence of the same resistant genes in unrelated bacterial genera indicates a complex history of 
genetic interactions. Plasmids have largely contributed to the spread of resistance genes among 
Staphylococcus, Enterococcus, and Streptococcus species, also influencing the selection and ecological 
variation of specific populations. However, this information is fragmented and often omits species 
outside these genera. To date, the antimicrobial resistance probleŵ has ďeeŶ aŶalǇzed uŶdeƌ a ͞siŶgle 
ĐeŶtƌiĐ͟ peƌspeĐtiǀe ;͞geŶe tƌaĐkiŶg͟ oƌ ͞ǀehiĐle ĐeŶtƌiĐ͟ iŶ ͞siŶgle host-siŶgle pathogeŶ͟ sǇsteŵsͿ that 
has greatly delayed the understanding of gene and plasmid dynamics and their role in the evolution of 
bacterial communities. 
This work analyzes the dynamics of antimicrobial resistance genes using gene exchange networks; the 
role of plasmids in the emergence, dissemination, and maintenance of genes encoding resistance to 
antimicrobials (antibiotics, heavy metals, and biocides); and their influence on the genomic diversity of 
the main Gram-positive opportunistic pathogens under the light of evolutionary ecology. A revision of 
the approaches to categorize plasmids in this group of microorganisms is given using the 1,326 fully 
sequenced plasmids of Gram-positive bacteria available in the GenBank database at the time the article 
was written. 
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INTRODUCTION 
Firmicutes constitutes one of the dominant bacteria phyla of human and animal gut microbiota. It 
comprises a number of genera of outstanding relevance in health care and industry such as 
Staphylococcus, Listeria, and lactic acid bacteria (LAB), a group of microorganisms that ferment 
carbohydrates into lactic acid and that includes the genera Enterococcus, Lactobacillus, Lactococcus, 
Leuconostoc, Pediococcus, Streptococcus, and Weisella. Furthermore, species of Negativicutes 
(Selenomonas, Veillonella) and Clostridium have clinical interest for humans and animals (Table 1). 
Antibiotic resistance (AbR) in this heterogeneous group of organisms constitutes a significant part of the 
public health problem. The most recent report by the Centers for Disease Control and Prevention in the 
United States provides a ranking list of AbR human pathogens according to their threat level to society 
and the attention that such a problem requires. Gram-positive organisms were grouped in the 
Đategoƌies of ͞uƌgeŶt͟ ;Clostridium difficileͿ, ͞seƌious͟ ;ŵethiĐilliŶ-resistant Staphylococcus aureus 
[MRSA], antibiotic-resistant Streptococcus pneumoniae, vancomycin-resistant Enterococcus [VRE]), and 
͞ĐoŶĐeƌŶiŶg͟ ;eƌǇthƌoŵǇĐiŶ-resistant Streptococcus pyogenes and clindamycin-resistant Streptococcus 
agalactiae) on the basis of the limited therapeutic options to treat infections caused by these bacteria-
resistant variants (1).  
LAB, which are used as probiotics and in the preparation of various products (dairy, fermented meat and 
seafood, feƌŵeŶted Đeƌeals aŶd ǀegetaďles, ǁiŶeͿ, aƌe defiŶed as ͞geŶeƌallǇ ƌegaƌded as safe͟ ;G‘A“Ϳ 
microorganisms by the U.S. Food and Drug Administration. However, the potential risk to transfer 
acquired AbR genes recently found in LAB species to animal and human pathogens is a cause for 
concern. AbR LAB may also contaminate industrial processes, leading to economic losses (2). In addition, 
the possibility that opportunistic or commensal bacteria and non-pathogen organisms could serve as 
reservoirs of AbR genes is increasingly recognized (3). Consequently, several European and American 
regulatory agencies have recently recommended the mandatory screening of some species such as 
Enterococcus faecalis and Enterococcus faecium as indicators of the presence of AbR in foods and food 
animals and as a mirror of the patterns of antibiotic use in veterinary medicine and agriculture (4, 5). 
Finally, it is worth mentioning that AbR in a context of the wide use of antibiotics favors the selection of 
clonal lineages of multihost species with zoonotic potential (e.g. S. aureus, E. faecium, Clostridium 
perfringens) as well as emblematic zoonotic species such as Listeria monocytogenes (see below). 
The presence of the same AbR genes in ecologically connected (but also in unconnected) bacterial 
genera, mentioned above, indicates a complex history of genetic interactions in which AbR genes have 
parasitized the natural circuits of adaptive gene flow. Plasmids have largely contributed to the spread of 
AbR and other adaptive genes among members of Staphylococcus, Enterococcus, and to a lesser extent, 
species of the Streptococcus pyogenic group (6–8), thus influencing the selection of particular 
subspecies populations due to the acquisition of AbR (8–10). However, the global adaptive role of 
plasmids of other genera remains largely unexplored outside single pathogens colonizing or infecting 
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siŶgle ͞ƌeleǀaŶt͟ hosts. The ͞siŶgle ĐeŶtƌiĐ͟ peƌspeĐtiǀe, foĐusiŶg oŶ ͞geŶe tƌaĐkiŶg͟ oƌ ͞ǀehiĐle ĐeŶtƌiĐ͟ 
(plasmid, transposon, or other ŵoďile geŶetiĐ eleŵeŶts [MGEs]Ϳ iŶ ͞siŶgle host-siŶgle pathogeŶ͟ 
systems hampers a comprehensive view of gene and plasmid dynamics and their role in the evolvability 
of bacterial communities. An integrative view of plasmid ecology is needed to understand community 
evolvability. 
Table 1. Fully characterized plasmids from low G+C bacteria available in GenBank database  
Phylum/class Order Family 
Plasmid 
Total AbR Met
R
 AbR+Met
R
 
Actinobacteria   252 16 40 7 
 Actynomicetales Streptomycetaceae 56 2 4 2 
  Corynebacteriaceae 38 10 7 3 
  Nocardiaceaea 30 0 9 0 
  Mycobacteriaceaeb 29 2 7 2 
  Micrococcaceaec 27 1 7 0 
  Pseudonocardiaceaed 9 0 1 0 
  Propionibacteriaceae 7 0 0 0 
  Gordonaciaee 6 0 3 0 
  Microbacteriaceaee 4 0 0 0 
  Streptosporangiaceaef 2 0 0 0 
  Nocardiopsaceae 1 0 0 0 
  Nocardioidaceae 1 0 0 0 
  Promicromonosporaceaeg 1 0 0 0 
  Micromonosporaceae 1 0 0 0 
  Kineosporiineae 2 0 1 0 
  Brevibacteriaceae 2 0 0 0 
  Frankiaceae 3 0 0 0 
  Tsukamurellaceae 1 0 0 0 
 Bifidobacteiales Bifidobacteriaceae 29 0 0 0 
       
Firmicutes   1073 244 178 85 
Negativicutes Selenomonadales  17 0 1 0 
Clostridia   86 7 4 0 
Erysipelotrix   1 0 0 0 
Bacilli   969 237 121 85 
 Lactobacillales      
  Lactobacillaceae 172 16 19 3 
  Streptococcaceae 133 15 4 0 
  Enterococacceae 74 24 3 2 
  Leuconostoc 29 0 9 0 
  Carnobacteriaceae 6 0 1 0 
  Oenococcus 6 0 0 0 
  Weisella 4 0 0 0 
 Bacillales Staphylococcaceae 275 175 118 80 
  Bacillaceae 223 5 9 0 
  Listeriaceae 14 1 8 0 
  Paenobacillaceae 9 0 0 0 
  Macrococcus 8 1 0 0 
  Planococaceae 6 0 1 0 
  Bacillales group XII 4 0 0 0 
  Alyciclobacillaceae 3 0 0 0 
  Bhargaceae 2 0 0 0 
aNocardiaceae (4 Nocardia 25 Rhodococcus); bMycobacteriaceae (Mycobacterium plus Amycolicicoccus.); cMicrococcaceae (4 
Micrococcus 23 Arthrobacter); dPseudonocardiaceae (2 Amycolatopsis, 6 Pseudonocardia, 1 Saccharomonospora); 
eMicrobacteriaceae (4 Clavibacter);  fStreptosporangiaceae (1 Planobispora, 1 ;Streptosporangium); gPromicromonosporaceae 
(Xylanimonas); (updated September 2014). 
In this work, we analyze the development of AbR in Firmicutes within an ecological framework using 
gene exchange networks. We also discuss the role of plasmids in the emergence, spread, and 
maintenance of genes encoding resistance to antimicrobials (antibiotics, heavy metals, and biocides) 
and their influence on the genomic diversity of the main Gram-positive opportunistic pathogens in the 
light of evolutionary ecology. Finally, a critical revision of plasmid classifications in this group of 
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microorganisms is also provided under this eco-evo perspective by analyzing the 1,326 fully sequenced 
plasmids of Gram-positive bacteria (Firmicutes and Actinobacteria) available in the GenBank database at 
the time this article was written. 
AN ECO-EVO PERSPECTIVE TO ANALYZE HGT IN FIRMICUTES 
Recent phylogenomic analyses using networks revealed a history of horizontal gene transfer (HGT) 
events even among highly structured and ecologically disconnected groups of bacteria (11–13). These 
events are more likely to occur in the case of donors and recipients with a similar G+C content (differing 
in <5% for 86% of connected pairs) (14) and involving plasmids able to mediate exchange of information 
between close or distant chromosomal backgrounds (12, 15). Although limited by the current number of 
available genome sequences, such studies eǀideŶĐed souŶd diffeƌeŶĐes iŶ ͞ďetǁeeŶess͟ aŵoŶg 
different bacterial groups and plasmids of Firmicutes. LAB frequently undergo HGT events among similar 
species (11), with streptococci acting as a hub for interactions with more distant ecological groups (12), 
and some plasmids of the Inc18 family possibly contributing to the spread of AbR genes among different 
bacterial species (15). To analyze this situation in more detail, we constructed a gene exchange network 
that comprises all genes conferring resistance to antibiotics and heavy metals described in Firmicutes so 
far (Fig. 1 and 2). This network clearly shows that many resistance genes in different bacterial genera 
can present plasmid and/or chromosomal locations, illustrating the diversity of interactions, often 
plasmid mediated, within bacterial communities (Fig. 1 and 2). Available (and often fragmented) 
knowledge from different fields enabled us to state that the dynamics of bacterial populations are 
influenced by the interplay of selection processes at different levels of organization (genes, MGEs, 
clones, species) and their associated environments (16–20). Because of that, the complexity resulting 
from such interplay cannot be understood using either single centric studies or the above-mentioned 
phylogenomic analysis of HGT networks. 
The presence of the same genes in different genetic contexts implies contacts and exchanges between 
bacteria belonging to different genera, probably facilitated in complex biofilms and environments 
allowing high local bacterial densities. HGT via transduction or conjugative mechanisms has been 
extensively documented in Lactobacillales and is a prominent process for niche-specific adaptation in 
different genera (12, 21–23), with plasmids and conjugative transposons being the most relevant 
providers of communal adaptive gene pools in microbial ensembles sharing complex niches. 
An important question is if resistance genes contributed to the recombination between different 
replicons and, consequently, to their evolvability. The frequent association of resistance genes with site-
specific recombination systems and insertion sequences located either in plasmids or in chromosomes 
favors homologous recombination and therefore different events of integration or excision, as well as 
the interplay among different elements (19, 24–28). Restriction-modification (RM) systems and 
clustered regularly interspaced short palindromic repeats (CRISPR) are the main post-transfer barriers 
protecting a given host cell from invasion by foreign DNA either by conjugation, transformation or 
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transduction (9, 29, 30). Some RM systems specifically limit the acquisition of plasmids to some 
pathogens which may influence their clonal structure (e.g., RM types I, III, and IV in S. aureus) (31, 32). 
This may also explain the lack of plasmids in certain species such as S. pneumonia or the narrow host 
range of plasmids from some Clostridium species (33, 34). Anti-RM systems such as analogues of ArdA 
(alleviation of restriction of DNA) proteins that act against type I restriction systems (detected in Tn916 
and CTn6000) or other genes predicted to be involved in methylation (e.g., in CTn6000 and Tn1721) are 
involved in the restricted spread of certain MGEs, as well as in certain clonal expansions. There is 
evidence that the presence of complete CRISPR loci is inversely proportional to the presence of MGEs in 
Clostridium and Staphylococcus (34, 35), a situation that has also been suggested to occur for 
Streptococcus and Enterococcus (34, 36, 37). In agreement with this statement, Fig. 1 and 2 reflect a 
heterogeneous distribution of AbR and heavy metal and biocide resistance (MetR and BcR) genes in 
different genera. Particularly interesting is the confinement of vancomycin resistance within enterococci 
and of some AbR, MetR, and BcR genes within staphylococci and clostridia, a situation that is in part due 
to the barriers shaping different populations (see next sections). 
Fluctuating environments, concentration gradients, and high population sizes, all frequent in different 
͞souƌĐe-siŶk͟ eĐologies such as bacterial populations under antimicrobial selective pressure, favor DNA 
transfer and the selection of some clonal and plasmid variants (38–42). Such selective processes favor 
the emergence of novel variants, resulting from genetic drift, or migration to heterogeneous 
environments. Recent studies demonstrated that plasmid transfer occurs in vivo more frequently than in 
experimental evolution assays (43), and that gradients in populations under selection pressure by 
diverse antimicrobials favor selection of multi-drug resistance (MDR) plasmids (44, 45). 
The influence of plasmids has been extensively discussed in the literature from different evolutionary 
perspectives (20, 46–48), but only limited information about plasmid ecology and the specific roles that 
plasmids actively play within microbial systems in situ is available. Mosaic MGEs have often been 
documented in Firmicutes, reflecting a different epidemiological history of contacts with strains of the 
same or different species. Some mosaic MGEs have been fixed, making the interpretation of results by 
using traditional classification schemes extremely difficult (49). 
  
PLASMID DIVERSITY AND CLASSIFICATION SYSTEMS 
Efforts in plasmid characterization and classification are justified for the understanding of plasmid 
biology. Nowadays, plasmid categorization is relevant from the public and environmental health 
perspective to follow the movement of genes coding for resistance to antimicrobials (antibiotics, heavy 
metals, biocides), colonization and virulence factors for humans and animals, and/or other adaptive 
traits that drive ecological success (bacteriocins, metabolic traits) and consequently increase the 
populatioŶ size of ďaĐteƌia haƌďoƌiŶg MGEs. IŶ faĐt, oŶlǇ a ͞ƌepƌeseŶtatiǀe diǀeƌsitǇ͟ of ďaĐteƌial 
plasmids has been systematically analyzed in a few genera of multihost opportunistic pathogens of 
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interest in biomedicine, with a particular emphasis on species of the Enterobacteriaceae, 
Pseudomonadaceae, Staphylococcaceae, and Enterococcaceae families (7, 50–53). The diversity of 
plasmids from Lactococcus (54), Lactobacillus (55), C. perfringens (56), Micrococcus (57), and 
Bifidobacterium (58) has also been analyzed from different perspectives. 
 
 
Figure 1. Protein content network (PCN) of AbR proteins found in plasmids and chromosomes of 
Firmicutes and Actinobacteria.  
To determine the AbR protein catalog of Gram-positive strains (chromosomes and plasmids), a Blastp search was performed of all 
their proteomes against the ARG-ANNOT database (http://en.mediterranee-infection.com/article.php?laref=283&titre=arg-annot) 
using a cut-off of 1e-30 and 85% of identity. The presence of the Gram-positive AbR proteins identified above in all bacterial 
species (only complete sequences, not partial) was determined using a similar Blast search (blastp, 1e-30 E-value and 85% identity) 
against the NCBI GenBank database. The nodes correspond to bacterial species (circular nodes; each color indicates one genus) 
and AbR proteins (square nodes). Nodes were connected by an edge when a positive hit between AbR proteins and one or more 
strains of a given species were identified. Edges further indicate the location of the AbR genes associated with each AbR protein of 
the Gram-positive catalog. Solid lines represent chromosomal location, and dotted lines represent plasmid location. When an AbR 
gene was located in both chromosomes and plasmids, both lines were plotted. 
Plasmid diversity within a particular bacterial species in the Firmicutes phylum started to be 
comprehensively analyzed in the 1960s just after the discovery of staphylococcal plasmids. These 
elements were initially categorized into three main classes designated by roman numerals on the basis 
of size, replication machinery, ability to be transferred, phenotypic and functional characteristics, and 
host range (7, 51, 53, 59, 60). Class I comprised high copy number plasmids (10 to 60 copies per cell) of 
less than 5 kb with a rolling circle replication (RCR) mechanism that often harbored one or two AbR 
genes (usually conferring resistance to tetracycline, chloramphenicol, macrolides, and trimethoprim). 
Class II comprised low copy number plasmids (4 to 6 copies per cell) of 15 to 40 kb, with a theta 
ƌepliĐatioŶ ŵeĐhaŶisŵ, ǁhiĐh tǇpiĐallǇ Đaƌƌied ƌesistaŶĐe to aŶtiďiotiĐs ;β-lactams, aminoglycosides, and 
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macrolides), heavy metals (arsenic, cadmium, and mercury), and/or antiseptics (quaternary ammonium 
compounds). Class III comprised plasmids similar to those found in class II which were transferred by 
conjugation (61). Afterward, Richard Novick and others classified staphylococcal plasmids in 15 
incompatibility (Inc) groups based on the finding that two plasmids with the same replication (rep) 
proteins cannot be stably maintained in the same cell (50, 62, 63). Plasmids of most Inc groups 
correspond to class I (10 Inc groups of apparently closely related plasmids) and class II (diverse plasmids 
that belong to the same Inc group) (53). Following the same Inc numeral designation criteria, Brantl et al 
categorized a few streptococcal plasmids that replicated via a theta mechanism and that were regulated 
by an antisense RNA that mediated transcriptional attenuation, such as the Inc18 family (64) (see 
below). Pheromone-responsive plasmids of enterococci were also subgrouped into different 
incompatibility groups on the basis of distinct responses to small peptides or pheromones which are 
secreted by plasmid-free donors (65). 
 
 
Figure 2. PCN of metal-biocide (MetR/BcR) proteins found in plasmids and chromosomes of Firmicutes 
and Actinobacteria.  
To determine the MetR/BcR protein catalog of Gram-positive strains (chromosomes and plasmids), a Blastp search was performed 
of all their proteomes against the BacMet database (http://bacmet.biomedicine.gu.se/) using a cut-off of 1e-30 and 85% of 
identity. The presence of the Gram-positive MetR/BcR proteins identified above in all bacterial species (only complete sequences, 
not partial) was determined using a similar Blastp search (blastp, 1e-30 evalue and 85% identity) against the NCBI GenBank 
database. The nodes correspond to bacterial species (circular nodes) and MetR/BcR proteins (triangular nodes). Nodes were 
connected by an edge when a positive hit between MetR/BcR proteins on one or more strains of a given species was identified. 
Edges further indicate the location of the MetR/BcR genes associated with each MetR/BcR protein of the Gram-positive catalog. 
Solid lines represent chromosomal location, and dotted lines represent plasmid location. When a MetR/BcR gene was located in 
both chromosomes and plasmids, both lines were plotted. 
A multiplex-PCR typing system based on the diversity of replication initiator proteins (RIPs) developed by 
Jensen et al (59) has recently been applied for the characterization of Firmicutes plasmids, mainly 
staphylococci (66) and enterococci (67–71) of human, animal, and environmental origin. According to 
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this tǇpiŶg sǇsteŵ, ‘IP ǀaƌiaŶts aƌe desigŶated as ͞ƌep͟ folloǁed ďǇ a suďiŶdeǆ Ŷuŵďeƌ aŶd aƌe 
arbitrarily called Rep families. Although this system is very useful to enlarge the knowledge of scarcely 
explored plasmid diversity in contemporary isolates of enterococci and staphylococci, its application is 
limited to known plasmids, mainly AbR plasmids of these genera, as illustrated in various surveys and 
this study (59, 66, 68, 71). 
The diversity of mobilization (MOB) systems has also recently been used to classify plasmids and other 
conjugative elements in different bacterial groups including Firmicutes (72, 73). The approach relies on 
the variability of relaxases (RELs), which form part of the plasmid MOB region, are involved in the 
initiation of DNA transfer, and that, aside from the origin of transfer (oriT), are present in both 
conjugative and mobilizable plasmids as well as in other conjugative elements (74). To date, only five 
(MOBP, MOBQ, MOBV, MOBC, and MOBT) out of seven known REL families have been identified in 
Firmicutes (7, 72, 74). MOBQ, MOBC, and MOBT are present in conjugative elements, and MOBV is 
present in mobilizable plasmids. MOBP has been identified in both conjugative and mobilizable elements 
(7, 72, 73). The application of this PCR-based classification scheme is obviously limited to the typing of 
kŶoǁŶ ‘ELs. FƌeƋueŶt plasŵid ŵosaiĐisŵ, ƌeduŶdaŶĐǇ, aŶd ĐoeǆisteŶĐe of diffeƌeŶt ͞Đoƌe͟ geŶes, aŶd 
the interplay of plasmids with other conjugative elements that contain homologs of RIPs and RELs, 
complicates the establishment of a robust plasmid core ontology and precludes the use of typing 
approaches similar to those used in Gram-negative organisms such as plasmid multilocus sequence type 
(http://pubmlst.org/plasmid/). 
Whole-genome (plasmid/chromosome) sequencing provides accurate and non-biased information on 
plasmid backbones. Although the number of fully sequenced plasmids in databases is still limited, we 
used a plasmid homology network analysis of the 1,326 fully sequenced plasmids of Firmicutes and 
Actinobacteria to study the diversity of plasmids carrying genes coding for AbR and MetR/BcR and the 
impact of plasmids in the evolvability of contemporary AbR bacterial populations of Firmicutes. 
Figures 3 and 4 illustrate the existence of group-specific plasmid populations, with a number of plasmids 
being shared between Lactobacillales (mainly Enterococcus and Streptococcus) and Bacillales 
(Staphylococcus), which are greatly implicated in the spread of AbR and MetR/BcR. These shared 
plasmids include RCR and theta-replicating plasmids of different families, which have been recently 
analyzed at the molecular level (7, 75, 76). Next in this section, we will analyze the diversity of these 
groups and highlight the usefulness of current typing systems for each group. However, it is of note that 
the main genera of Firmicutes carry a variable number of plasmids containing several replication and 
transfer systems, some of them being able to be transferred. The interplay between genes, plasmids, 
aŶd populatioŶs ǁill ďe aŶalǇzed uŶdeƌ aŶ eĐologiĐal peƌspeĐtiǀe iŶ the seĐtioŶ ͞GeŶe aŶd Plasŵid Floǁ 
Shapes the EǀolutioŶaƌǇ EĐologǇ of FiƌŵiĐutes.͟   
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Rolling Circle Replication Plasmids 
RCR plasmids are classified in a few families according to the RIP and the double origin of replication 
(dso) (see comprehensive reviews in references) (75, 77–79). Most of the RCR plasmids known to date 
have been found in species of Firmicutes, Proteobacteria, Cyanobacteria, and Spirochaetes, and some of 
them have been identified in genetically distant hosts. The production of single-stranded DNA and the 
mechanism of replication of these plasmids enhance their ability to recombine, by either homologous 
recombination or illegitimate recombination with other RCRs and theta replicating plasmids (Fig. 5 to 10 
and text below). RCR plasmids are also frequently integrated into chromosomes (e.g., pUB110 within 
SCCmec cassettes in methicillin-resistant S. aureus or pC194/pUB110 [catA] in S. pneumonia genomes) 
(80). 
In Firmicutes, four groups of RCR plasmids have been defined according to RIP similarity, namely 
Rep_trans (PF025486), Rep_1 (PF14046), Rep_2 (PF01719), and Rep_L, which are historically 
represented by plasmids pT181, pUB110, pMV158, and pSN2, respectively (53, 75, 77, 78). Within these 
families, some members have been fixed by selection and might be maintained by the vertical expansion 
of certain clones, aside from HGT, with the emergence of variants from time to time. Figures 11 to 14 
and Supplementary Table S1 show the similarity of genes encoding RIPs of all available fully sequenced 
plasmids and the correspondence to the Rep families described by Jensen et al. (59). These plasmids 
may contain different adaptive genes (AbR, heat shock proteins, or bacteriocins), although most of them 
aƌe Đlassified as ͞ĐƌǇptiĐ,͟ ǁithout aŶǇ Đleaƌ adaptiǀe fuŶĐtioŶ. 
The Rep_1 family 
The Rep_1 family comprises plasmids with RIPs of the families rep13 (associated with catA7, which 
encodes resistance to chloramphenicol), rep21 (cryptic or eventually carrying lnuA, coding for resistance 
to lincosamides), rep22 (carrying a variety of AbR genes), and other underrepresented members 
categorized as repUnique7. However, the available typing systems are unable to classify relevant Rep_1 
plasmid members including plasmids containing heat shock proteins in Streptococcus thermophilus, 
plasmid-borne bacteriocins in S. pyogenes (82), or S. pneumoniae plasmids (80, 83), among others (Fig. 
11). Remarkably, RIPs of this Rep_1 group are often detected in mosaic plasmids of staphylococci and 
enterococci (Fig. 5 and 7), some plasmid chimeras being fixed and persistently recovered for years. For 
example, emblematic mosaics theta/RCR plasmids of staphylococci (e.g., cointegrates of RepA_N/pSK41 
and Rep_1/pUB110, which encode resistance to gentamicin) and E. faecalis ;e.g., pAMαϭͿ have both 
been selected in those lineages since the early 1970s (7, 71, 84). 
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Figure 6. Hierarchical clustering dendrogram of plasmids from enterococci. 
The matrix distance used for building the UPGMA dendrogram is based on the Raup-Crick distance of the orthologous protein 
profile of each plasmid. For each plasmid, a presence/absence protein profile was made using cut-off values of 80% identity and 
80% coverage. Protein clustering was made by using CD-HIT (81). Different background colors are used to emphasize branches of 
related plasmids and are the same as those defined in Fig. 5. Names to the left of the dendrogram indicate the RIP family. 
Background colors were used to point out plasmid groups frequently involved in mobility of AbR genes and E. faecalis pheromone-
responsive plasmids. Circles indicate RIPs identified in each plasmid according to data shown in Fig. 7.  
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The Rep_trans group 
Plasmids of the Rep_trans group are clustered in two large branches (Fig. 12). One branch comprises 
plasmids of Staphylococcus that harbor tetK (rep7) and catA8/catA7 (rep7b) with different MOB genes. 
Such plasmids have been reported in S. aureus since their first detection in the early 1950s (84) and 
were eventually described in contemporary E. faecalis isolates (68, 85). A second branch contains pRI1-
like plasmids (rep14), which correspond to plasmids of different enterococcal species (E. faecium, 
Enterococcus hirae, Enterococcus mundtii) isolated from foodborne animals and hospital patients (7, 59, 
71, 86). These plasmids can be mobilized by other AbR conjugative theta replicating plasmids present in 
the same cell (71, 87), and it seems they are widely spread among enterococcal populations. 
The Rep_2 group 
The Rep_2 group (Fig. 13) comprises numerous promiscuous elements able to replicate in distant hosts 
which have been extensively analyzed at the molecular level by Espinosa et al. using pMV158 as a model 
(75). Plasmids carrying ermT (an inducible methylase conferring resistance to first-line macrolide-
lincosamide antibiotics such as erythromycin and clindamycin), from group A Streptococci (GAS) and 
group B Streptococci (GBS), are the sole representatives of AbR in this group. They appear to be 
responsible for the rise of macrolide resistance among GAS and GBS in hospitals since the mid-1990s (8). 
The Rep_L group 
In contrast to the above-mentioned RCR plasmid groups, proteins within the Rep_L family (Fig. 14) are 
represented in public gene databases by a very few RIPs of Staphylococcus, Selenomonas (class 
Negativicutes), and Butyrivibrio (Clostridia) species, all these genera being frequent components of the 
oral flora of humans and the rumen of some animal species. These plasmids are responsible for the 
widespread ermC in staphylococci (rep10). Interestingly, the emergence of both ermT-Rep_2 and ermC-
Rep_L plasmids seems to be associated with the abusive use of tylosin in cattle, amplified by the 
location of these AbR genes in RCR plasmids, and further transferred to other populations of Firmicutes 
(8, 88, 89). 
RCR plasmids were associated with REL of the group MOBV1 (72, 73, 75), although representatives of all 
the RCR groups mentioned above that lack REL were detected in databases. Interestingly, RELs of MOBP1 
and MOBT families were also found, and their presence is probably due to the co-integration of RCR with 
theta-replicating plasmids (see below). 
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Figure 11. Similarity of rep-like sequences encoding RIPs of the Rep_1 family.  
A neighbor-joining tree of gene sequences coding for RIPs of the Rep_1 family was built using MEGA 6.06. A cut-off equal to or 
higher than 80% and a bootstrap analysis based on 1,000 permutations were applied to the analysis. Alignment of nucleotide 
sequences was performed using ClustalW2 (http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/), and sequences 
showing an identity equal to or higher than 80% were clustered in groups that were highlighted by different backgrounds colors. 
Black dots indicate the RIP of the plasmid used for further comparison in Figs. 5 to 10. 
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Figure 12. Similarity of rep-like sequences encoding RIPs of the Rep_trans family.  
A neighbor-joining tree of gene sequences coding for RIPs of the Rep_trans family was built using MEGA 6.06. A cut-off equal to or 
higher than 80% and a bootstrap analysis based on 1,000 permutations were applied to the analysis. Alignment of nucleotide 
sequences was performed using ClustalW2 (http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/), and sequences 
showing an identity equal to or higher than 80% were clustered in groups that were highlighted by different backgrounds colors. 
Black dots indicate the RIP of the plasmid used for further comparison in Figs. 5 to 10. *Truncated gene. **Similar to E. faecalis 
ant6-Ia and aadE. Abbreviations: ND, not determined.  
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Figure 13. Similarity of rep-like sequences encoding RIPs of the Rep_2 family.  
A neighbor-joining tree of gene sequences coding for RIPs of the Rep_2 family was built using MEGA 6.06. A cut-off equal to or 
higher than 80% and a bootstrap analysis based on 1,000 permutations were applied to the analysis. Alignment of nucleotide 
sequences was performed using ClustalW2 (http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/), and sequences 
showing an identity equal to or higher than 80% were clustered in groups that were highlighted by different background colors. 
Black dots indicate the RIP of the plasmid used for further comparison in Figs. 5 to 10. 
Theta-Replicating Plasmids 
Four families of plasmids that replicate by a theta mechanism, three that comprise conjugative plasmids 
(RepA_N, Inc18, and pMG1) and one in groups of small non-conjugative elements (Rep_3), are involved 
in the capture, spread, and maintenance of AbR among different genera of Firmicutes. Members of the 
RepA_N and Inc18 families are often enriched in insertion sequences, mainly IS257, IS256, IS1216, ISL3, 
and IS431, that facilitate co-integration, rearrangements, and deletions among elements of 
Staphylococcus, Enterococcus, LAB, and Clostridium of different origins (6, 7, 28, 90–95). Such 
recombination events seem to have facilitated the origin of the great mosaicism of MDR plasmids that 
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often carry more than one RIP, lack transfer and maintenance modules, and eventually carry more than 
one REL (Fig. 5 and 7). The transfer mechanisms of RepA_N pSK41-like plasmids and the Inc18-like 
plasmids are similar and are categorized as type IV secretion systems (96). 
 
 
Figure 14. Similarity of rep-like sequences encoding RIPs of the Rep_L family.  
A neighbor-joining tree of gene sequences coding for RIPs of the Rep_L family was built using MEGA 6.06. A cut-off equal to or 
higher than 80% and a bootstrap analysis based on 1,000 permutations were applied to the analysis. Alignment of nucleotide 
sequences was performed using ClustalW2 (http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/), and sequences 
showing an identity equal to or higher than 80% were clustered in groups that were highlighted by different background colors. 
Black dots indicate the RIP of the plasmid used for further comparison in Figs. 5 to 10. 
The Rep_3 family 
Plasmids containing RIPs with the Rep_3 domain (Fig. 15) are common among disparate bacterial genera 
including Staphylococcus, Enterococcus, Streptococcus, Lactobacillus, and Enterobacteriaceae (7). Figure 
15 shows the diversity of RIPs among fully sequenced plasmids of Firmicutes, and Fig. 5 to 10 reflect the 
features of known members of this family within each genus of biomedical interest. In enterococci, 
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Rep_3 plasmids (<15 kb) have been found in isolates recovered from hospitalized patients, animals (pigs, 
cows), cheese, milk, and dry-fermented sausage, frequently associated with the production of 
bacteriocins that are active against a variety of Gram-positive genera (7). In Lactobacillus and 
Lactococcus, they harbor bacteriocins and, eventually, AbR genes. Rep_3 plasmids play a relevant role as 
vehicles of AbR among staphylococci. Plasmids from S. aureus are overrepresented by closely related 
variants containing rep5, which are associated with genes coding for penicillinase and resistance to 
heavy metals (cadmium and arsenic) (51, 53, 66, 84). Staphylococcal plasmids within this group include 
AbR plasmids from coagulase-negative strains of animal origin, some of them with RIPs that would not 
be detected by current typing systems (97, 98). 
The Inc18 family 
First described in the 1990s, the Inc18 family comprises a highly heterogeneous group of broad host 
range, low copy number plasmids (<10 per cell) that replicate by a theta mechanism, regulated by an 
antisense RNA that mediates transcriptional attenuation and that are able to conjugate on solid media 
at high frequencies (64, 99). The transfer system of pIP501 has been extensively studied and constitutes 
a paradigm of conjugation systems, showing significant similarity with the tra regions of RepA_N 
plasmids pGO1 and pSK41 from S. aureus and pMRC01 from Lactococcus lactis (96, 100). 
The Inc18 group is traditionally represented by three emblematic plasmids: pSM19035 (101) and pIP501 
from S. agalactiae aŶd pAMβϭ fƌoŵ E. faecalis (64, 101–104). It gets its name from the apparent 
incompatibility of these plasmids with each other described in seminal studies in the field and following 
the nomenclature of Inc groups started by Richard Novick for staphylococcal plasmids (50, 60, 64, 105). 
Inc18 plasmids frequently carry the post-segƌegatioŶal killiŶg sǇsteŵs, ες, aŶd tǇpe I paƌtitioŶ Đassette 
prgPprgO, which are associated with a variety of RIPs and seem to contribute to their persistence in 
different populations in the absence of antibiotic selection pressure (7, 106, 107). Detailed molecular 
characterization of such plasmids is described elsewhere (64, 99, 108) and shows a remarkably high 
modular interplay among different Inc18 plasmids, leading to the high modularity observed in plasmid 
sequences (see Fig. 5 to 10 and text below). 
Inc18 plasmids have contributed remarkably to the spread of AbR (macrolides, chloramphenicol, 
aminoglycosides, and glycopeptides) and MetR (copper and mercury) among streptococci and other 
phylogenetically distant genera of Gram-positive (S. aureus, Listeria, Bacillus subtilis, Lactobacillus, 
Leuconostoc, various Clostridium species) and Gram-negative bacteria (108–111). 
Plasŵid ƌelatiǀes of pAMβϭ ;haƌďoƌiŶg ermAM, later on recognized as ermB, and conferring resistance 
to macrolides, lincosamides, and streptogramines) and pIP501 (carrying ermB and catA7pC221, which 
confers resistance to chloramphenicol) were rapidly spread during the 1970s and have frequently been 
detected among streptococci of groups A, B, and D (enterococci) since then (110, 112–114) (see also 
Supplementary Table S1 for contemporary representatives of this plasmid group). 
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Figure 15. Similarity of rep-like sequences encoding RIPs of the Rep_3 family.  
A neighbor-joining tree of gene sequences coding for RIPs of the Rep_3 family was built using MEGA 6.06. A cut-off equal to or 
higher than 80% and a bootstrap analysis based on 1,000 permutations were applied to the analysis. Alignment of nucleotide 
sequences was performed using ClustalW2 (http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/), and sequences 
showing an identity equal to or higher than 80% were clustered in groups that were highlighted by different background colors. 
Black dots indicate the RIP of the plasmid used for further comparison in Figs. 5 to 10. Abbreviations: ND, not determined. 
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Initially, the successful spread of intact AbR plasmids among clones of various streptococcal genera, 
including S. pneumoniae, and S. aureus was reported, despite the lack of stability in these last two clonal 
backgrounds (110, 113). Inc18 plasmids conferring resistance to aminoglycosides (kanamycin, 
streptomycin, and neomycin) and to macrolides were also detected in 1972, in the emblematic 
Streptococcus (Enterococcus) faecalis strain JH1 that carried pJH1 (an MDR plasmid, presumably Inc18) 
and pJH2 (a RepA_N pheromone-responsive plasmid carrying hemolysin and bacteriocins). pJH1 
represented the first description of conjugative transfer of AbR plasmids in enterococci (114). 
Aminoglycoside resistance in pJH1 relatives was due to the presence of Tn5405, a transposon 
comprising three genes in tandem (an aminoglycoside 6-adenyltransferase [aad], a streptothricin 
acetyltransferase [sat], and an aminoglycoside-phosphotransferase [aph3]). These genes were identified 
later on in S. pyogenes, S. agalactiae, S. aureus, Campylobacter coli, C. perfringens, and C. difficile (now 
Peptoclostridium difficile). 
More recently, diverse Inc18 plasmids carrying Tn1546 in enterococci and staphylococci have emerged 
in different locations. In Europe, Inc18::Tn1546 plasmids (such as pVEF1, pEVF2, pVEF3, and pVEF4) 
seem to have evolved from pIP816 (the first Inc18::Tn1546 was isolated in France in 1987). They lack a 
transfer system and appear to be confined to E. faecium (70, 115, 116). Inc18::Tn1546 plasmids from the 
United States are linked to E. faecalis isolates (pWZ909, pWZ1668, pWZ7140) and contain a complete 
transfer system (117, 118). A plethora of multiresistant mosaic Inc18 plasmids containing up to three 
RIPs, including RepR of pIP501 (CAA35647.1) and RepS of pRE25 (YP_783890.1), have been described in 
different Firmicutes (70, 71, 116, 119). These plasmids have an arsenal of insertion sequences, mainly 
IS1216 and ISL3, which facilitate genetic exchange with different genetic elements of different origins 
and the acquisition of different AbR (tetS) and MetR (tcrB, mer operon). These ISs also facilitate the co-
integration with other RCR (e.g., pC221, which is cointegrated in pRE25) or theta replication plasmids as 
pheromone responsive (115, 119–121) or some pSK41-like elements. Figure 16 shows the diversity of 
Inc18 RIPs that can be identified by typing systems. All these RIPs have a primase domain PriCT_1 that 
allowed their identification as belonging to the Inc18 family. Fig. 6, 7, and 9 illustrate the mosaicism of 
Inc18 plasmids in enterococci and Listeria. 
The pMG1/pHT plasmids 
The pMG1/pHT plasmids are related to those of the Inc18 family (RIP homolog approximately 30% 
identical to Inc18 initiators, including the PriCT_1 domain [Fig. 16]) (122), although they also show high 
homology with the pXO2 virulence plasmid from Bacillus anthracis. Because many open reading frames 
of pHT and pMG1 plasmids do not show significant homology with any reported proteins, they used to 
be categorized as a new type of highly efficient conjugative plasmids with a MOBP family REL. 
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Figure 16. Similarity of rep-like sequences encoding RIPs with the PriCT_1 domain. 
A neighbor-joining tree of gene sequences coding for RIPs with PriCT_1 domains was built using MEGA 6.06. A cut-off equal to or 
higher than 80% and a bootstrap analysis based on 1,000 permutations were applied to the analysis. Alignment of nucleotide 
sequences was performed using ClustalW2 (http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/), and sequences 
showing an identity equal to or higher than 80% were clustered in groups that were highlighted by different background colors. 
Black dots indicate the RIP of the plasmid used for further comparison in Figs. 5 to 10. Abbreviations: ND, not determined.  
This plasŵid gƌoup is ƌepƌeseŶted ďǇ ƌelatiǀes of pHT ;pHTα, pHTβ, aŶd pHTγͿ aŶd pMGϭ, ǁhiĐh haǀe 
greatly facilitated the dissemination of resistance to glycopeptides (Tn1546-vanA) and high-level 
resistance to aminoglycosides (Tn4001-like elements) among human E. faecium and E. avium isolates 
from the United States and Japan (123, 124) and, to a lesser extent, European countries (7, 70, 71, 122). 
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The RepA_N family 
This is a large family of plasmids (also including a few phages) that are widespread among the low G+C 
Gram-positive bacteria and which possess RIP homologs to the RepA protein of pAD1 (76). The five 
groups of RepA homologs identified are phylogenetically congruent with their host background (Fig. 17), 
suggesting that the replicons have evolved along with their current hosts and that inter-genus 
movement of RepA_N plasmids does not often occur. Such RepA_N clusters correspond to plasmids 
from Staphylococcus (MetR/bla pSK1 and pSK41 MDR plasmids), plasmids from Enterococcus (E. faecalis 
pheromone-responsive plasmids and E. faecium non-pheromone-responsive plasmids related to pRUM, 
pLG1, or untypeable megaplasmids), plasmids from Lactobacillus and Lactococcus, phage homologs 
from Streptococcus (S. pneumoniae, S. thermophilus), and plasmids from B. subtilis (e.g., pLS32). 
Staphylococcal and enterococcal RepA_N plasmids have greatly contributed to the spread of AbR genes 
among humans and, eventually, animals and will be further described below. They also facilitate the 
movement of other non-conjugative plasmids and large genomic regions (36, 125, 126). 
RepA_N staphylococcal plasmids (Fig. 5) 
Large staphylococcal MDR plasmids use evolutionarily related theta-mode replication, although they can 
be further divided into three types: the MetR/beta-lactamase-producing plasmids, the pSK1 family, and 
pSK41-like conjugative elements. All these are compatible and can be identified as the rep19, rep20, and 
rep15 families, respectively, according to Jensen's plasmid typing system (59, 127, 128). The pSK41 family 
(rep15) is the largest group of conjugative plasmids in staphylococci, traditionally represented by pSK41, 
pG01, and pJE1, which emerged in the early 1980s associated with resistance to gentamicin due to the 
presence of Tn4001 (84, 129). They often confer resistance to other antibiotics such as neomycin, 
tobramycin and kanamycin (due to the integration of pUB110 plasmids that harbor the aadD gene), 
antiseptics (due to the presence of qac genes) (130), and eventually trimethoprim (mediated by 
Tn4001), penicillins (due to the presence of Tn552::blaZ), and others. Plasmids of this group may also 
confer resistance to mupirocin (131–133) and vancomycin (134, 135), represented by pUSA03 (which 
harbors ileS and tetK) and pWL1043 (which contains Tn1546, Tn4001, Tn4002, Tn552, and qacC). The 
pSK41-like plasmids are able to mobilize other plasmids present in the same bacterial cell (133, 136, 
137). The pSK1 and MetR/beta-lactamase plasmids belong to the same incompatibility groups and are 
also compatible with pSK41 plasmids. Despite their inability to self-transfer, these groups of plasmids 
have been detected in many staphylococcal species. 
RepA_N enterococcal plasmids 
This cluster groups pheromone-responsive plasmids of E. faecalis and pRUM- and pLG1-like plasmids of 
E. faecium (7) (Fig. 6 and 7). 
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Figure 17. Similarity of rep-like sequences encoding RIPs of the RepA_N family.  
A neighbor-joining tree of gene sequences coding for replication initiator proteins of the RepA_N family was built using MEGA 
6.06. A cut-off equal to or higher than 80% and a bootstrap analysis based on 1,000 permutations were applied to the analysis. 
Alignment of nucleotide sequences was performed using ClustalW2 (http://www.ebi.ac.uk/Tools/phylogeny/ 
clustalw2_phylogeny/), and sequences showing an identity equal to or higher than 80% were clustered in groups that were 
highlighted by different background colors. Black dots indicate the RIP of the plasmid used for further comparison in Figs. 5 to 10. 
*Truncated gene. +Similar to E. faecalis ant6-Ia and aadE. Abbreviations: ND, not determined. 
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Pheromone-responsive plasmids 
Pheromone-responsive plasmids represent a paradigm of elements in the biology of MGEs and are, 
together with Inc18 plasmids, the best-known plasmids described to date. For details about the 
mechanism of replication, conjugation, and evolvability of this plasmid group see references (7, 49, 65, 
92, 138). Plasmids that respond to pheromones are present in most contemporary E. faecalis isolates 
from humans and birds but are only occasionally found among E. faecium. Synthesis of pheromones is 
confined to E. faecalis, although Enterococcus hirae, S. aureus, and Streptococcus gordonii may secrete 
cAM373-like peptides that facilitate the conjugation of pAM373 from E. faecalis (139). The description 
of cAM373-responsive plasmids coding for resistance to glycopeptides (Tn1546-vanA) highlights the 
potential risk of the spread of glycopeptide resistance in staphylococci in institutions where VRE are 
endemic (134, 140). Although pheromone plasmids are unable to replicate in S. aureus, their 
transference and establishment in this host might occur by co-integration with other plasmids able to 
replicate in this species. In addition, some pAD1 relatives enhance the rate of mobilization of plasmids, 
conjugative transposons, and PAIs (125). 
Plasmids of this family can be classified on the basis of responses to pheromones in different 
incompatibility groups (139) or according to RIP diversity (59, 68) within rep8(pAM373) and rep9 (further 
split into subgroups rep9a(pAD1) and rep9b(pTEF2)) families (59, 68). Transfer systems of MOBC or MOBP 
families have been detected in plasmids of this family. 
Pheromone-responsive plasmids may encode putative virulence traits (aggregation substance, 
hemolysin/bacteriocin) and a diversity of AbR elements located on transposable elements such as 
Tn916-like (tetM), Tn4001 (aac-aph), Tn1546 (vanA), Tn1549 (vanB), and a composite transposon 
ĐoŶtaiŶiŶg a β-lactamase gene flanked by two IS4 copies (7). The par locus encodes a unique antisense-
regulated toxin-antitoxin system present in the plasmid pAD1, but par homologs have been detected on 
other plasmids and chromosomes of E. faecalis and Staphylococcus, Clostridium, Listeria, and 
Lactobacillus species (141). Toxin-aŶtitoǆiŶ sǇsteŵs assoĐiated ǁith otheƌ plasŵid faŵilies suĐh as ες 
and relBE have been detected on members of this plasmid group, reflecting rearrangements with 
representatives of other plasmid families (7). Even though to date, only a few members of pheromone-
responsive plasmids have been fully sequenced, typing surveys reveal a wide diversity of plasmids 
among populations, often containing RIPs, RELs, or regions from plasmids of different origins (68, 71). 
pRUM-like plasmids 
pRUM-like plasmids (represented by pRUM, p5373c, pS177, and pDO2) are mosaic plasmids of variable 
size (>30 kb) that comprise diverse genetic elements of different origins (transposons, insertion 
sequences, small theta-replicating plasmids, bacteriocin clusters). They can be identified as the rep17 
family according to PCR-based typing systems (59) but differ in the RIP sequence, the MOB system, and 
the presence of the toxin-antitoxin Axe-Txe locus (71, 142, 143). Both Inc18 and pRUM plasmids are 
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driving the spread of glycopeptide resistance among contemporary isolates of E. faecium by carrying 
Tn1546 (vanA) or Tn1549 (vanB). Two types of pRUM plasmids are currently widespread among VRE and 
vancomycin-susceptible E. faecium isolates from different hosts. One contains RepA and Axe-Txe from 
pRUM and, eventually, the mobilization system of pC223 from S. aureus (70, 71, 142–144). The other 
type is characterized by a RepA protein that is 95% identical to RepA-pRUM, lacking postsegregational 
killing Axe-Txe and the presence of a MOBP7 relaxase originally detected in pEF1, a plasmid with an 
environmental origin. Tn1546 is frequently located on both types of pRUM plasmids, frequently 
containing replicons of other plasmid families (author's unpublished results). 
Large plasmids 
Plasmids larger than 150 kb are widely distributed among E. faecium, Enterococcus durans, and E. hirae 
from different origins, but they have not been detected among E. faecalis (71, 144–150). To date, only a 
handful of E. faecium megaplasmids have been fully sequenced (AUS0085_p1 [NC_021987], pNB2354_1 
[NC_020208], DO_3 [NC_017963], and pLG1, although this last one has not been closed (148)). All of 
them contain a RIP similar to RepApAD1, making them part of the RepA_N family (Fig. 7 and 17, 
Supplementary Table S1) (59, 71, 148). A similar RIP has also been found in a 130-kb plasmid 
(NC_021987) from a VRE ST203 E. faecium strain isolated in 2009 in Australia (151). Although RIP 
sequences of pLG1 plasmids are often identified among enterococcal megaplasmids, most of them do 
not hybridize with known RIP genes included in published schemes (71, 148, 152). Enterococcal 
megaplasmids carry genes involved in sugar metabolism (mannitol, glycerol, sorbitol, raffinose, complex 
carbohydrates), AbR (macrolides, glycopeptides, aminoglycosides), MetR (copper-tcrYAZB), and 
enhanced adhesion (71, 126, 144, 147–149, 152–154). They are frequently involved in the acquisition or 
persistence of AbR among E. faecium isolates from food animals (148, 150). 
  
GENE AND PLASMID FLOW SHAPES THE EVOLUTIONARY ECOLOGY OF FIRMICUTES 
As described in previous sections, the acquisition of novel traits encoding adaptive resistance to 
antimicrobials in Firmicutes is mainly due to genes located on plasmids and transposable elements. This 
acquisition is, certainly, regulated by interactions at genetic and ecological (social) levels. Interplay 
between genes, mobile genetic elements, and microbial populations and their relation with the host 
population and local or global environments shapes the plasmid flow. Such flow can be modified by 
͞eǆteƌŶal͟ ;supƌa-cellular) changes, including variations in the host population structure and size (e.g., 
mass rearing, crowding) and their associated chemical or behavioral landscape (e.g., use of different 
antimicrobials, immunization, global food supply, international travel). These changes ultimately 
determine the density and diversity of particular bacterial populations in particular habitats, leading to 
ecological specialization, clonalization, and gradual emergence of gene flow barriers (23, 155, 156) , a 
process that mimics the general dynamics of speciation, as bacterial clones and species constitute 
ecological units of microbial biodiversity. 
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The ĐhalleŶge to defiŶe ͞uŶits of ďiodiǀeƌsitǇ͟ iŶ ŵiĐƌoďial ĐoŵŵuŶitǇ eĐologǇ has appƌoaĐhed the 
ĐoŶĐept of geŶes as ͞defiŶiŶg eleŵeŶts of Ŷetǁoƌks aŶd ŵetaĐoŵŵuŶities͟ (155). In such a context, 
extra-chromosomal elements greatly influence the HGT interactions between microbial organisms and 
aƌe the ďuildiŶg foƌĐes foƌ the estaďlishŵeŶt of ͞geŶe eǆĐhaŶge ĐoŵŵuŶities͟ (155, 157). The selective 
power of antimicrobials (antibiotics [Ab], heavy metal, biocides) may then shape this multilevel bacterial 
population biology (158, 159), involving genes, plasmids (MGEs), bacterial clones and species, and gene 
exchange communities. The evolutionary tradeoff between early and late stages of adaptation to such 
selective pressures may determine the local evolvability of clonal and plasmid populations by increasing 
the number of genotypes resulting from chromosomal and plasmid recombination processes that 
facilitate further ecological differentiation (18). To establish effective public health interventions to fight 
the AbR problem in its eco-biological dimension, we then need to define the gene exchange 
communities relevant for the acquisition, evolution, and spread of resistance (160, 161). Below, we will 
specifically discuss the role of AbR genes and plasmids in the ecological differentiation of bacterial 
populations of the main Firmicutes genera. 
Antimicrobial Resistance Genes and Bacterial Population Ecology 
The environmental origin of AbR genes has been extensively discussed, but very few AbR genes 
identified in the environment are found in human or animal pathogens, which indicates severe 
bottlenecks for their acquisition and transmission (162, 163). However, the gut microbiota is increasingly 
considered a significant reservoir of AbR genes (3), which is supported by studies that associate widely 
spread AbR genes of relevance in clinical therapy, such as ermB, ermT, ermC (encoding resistance to 
macrolides), vanB (coding for resistance to glycopeptides), and cfr (coding for resistance to different 
antimicrobials), with members of the normal microbiota such as species of the Clostridium group XIVa 
now reclassified as family Lachnospiraceae (Clostridium bolteae, Clostridium innocuum–like, Clostridium 
lavalense, Clostridium symbiosum) and some lactic bacteria (3, 88, 164–168). 
Recent work demonstrates that a given AbR gene (or genetic element such as Tn1549-vanB) may be 
independently acquired by different clonal populations in the intestine of a particular host (165). Once 
an AbR gene is present in gut commensals (independent of the origin of the gene), members of the 
normal intestinal flora of humans and animals can exchange such genes among themselves or with 
bacterial pathogens, which might be present in low numbers or just be passing through the intestine 
after being transferred from other body sites or with food intake, using different intermediates in the 
case of distant bacteria (3, 165, 169). 
The rapid emergence in Firmicutes of genes coding for AbR, MetR, and BcR immediately after their 
introduction and significant (often massive) use in different settings has been demonstrated for 
chloramphenicol (catA), tetracyclines (tetL), macrolides (ermB), neomycin (aad), gentamicin (aac6-
aph2), trimethoprim (dfr), beta-lactams (blaZ), and antiseptics (qac) in hospitals during the 1950s to 
1970s, and for tylosin (ermC, ermT), phenicols (fex), pleuromutilins (cfr), and zinc-bacitracin in animals 
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during the 1990s, thus supporting the hypothesis of the existence of a previous gastrointestinal 
reservoir of genes that were selected for the first time as AbR genes (gene exaptation) (84, 88, 91). 
Plasmids and Bacterial Population Ecology 
The number and types of Firmicutes plasmids and integrative-conjugative elements [currently 
considered as plasmids under the perspective of evolutionary biology (22)] greatly vary with the 
different bacterial species, certainly as a result of both ecological specialization and selective events 
resulting from exposure to different anthropogenic activities. Most (if not all) of the contemporary 
isolates belonging to different species of staphylococci, enterococci, lactobacilli, and others contain 
plasmids of different families in a consistent pattern (for instance, RCR, small theta, or megaplasmids in 
E. faecium; pheromone plasmids in E. faecalis) (7, 68, 71). Such frequent plasmid-bacteria host 
correspondence indicates a basic co-adaptive evolutionary relation between two different types of 
organisms. 
Foƌ a loŶg tiŵe, plasŵids ǁeƌe ĐoŶsideƌed as ͞oƌgaŶisŵs,͟ uŶits of a ĐoŶtiŶuous liŶeage ǁith aŶ 
individual evolutionary history, and hence producing evolved populations, in line with the Luria and 
other seminal works in the field (46, 170). However, plasmids are not necessarily discrete units or 
individuals as classically considered in evolutionary theory (20, 170, 171). Organisms are units of 
seleĐtioŶ, eǀolutioŶaƌǇ uŶits iŶ a seŶse ͞eǀolutioŶaƌǇ iŶdiǀiduals,͟ defiŶed as aŶǇ eŶtitǇ that, 
independently from the number of elements that enters into its composition or from its hierarchical 
level of complexity, is selected and evolves as a unit (171, 172). The frequent out-of-equilibrium events 
that characterize the interplay between bacterial hosts, plasmids, and gene populations is explained 
because selective events might act independently on these different evolutionary individuals, as 
pƌediĐted iŶ the ͞leǀels of seleĐtioŶ͟ ĐoŶĐeptual fƌaŵe (20, 173–175). However, it is of note that we 
should ƌeĐogŶize ͞leǀels of iŶdiǀidualitǇ͟; foƌ iŶstaŶĐe, a suďstaŶtial Ŷuŵďeƌ of Firmicutes plasmids have 
a lower-level self-identity than their bacterial hosts (18, 155), because of the more complex genetic 
iŶteƌplaǇ ǁith otheƌ ŵoďile geŶetiĐ eleŵeŶts ǁhiĐh iŶ tuƌŶ aƌe also ͞leakǇ iŶdiǀiduals,͟ fƌeƋueŶtlǇ 
mosaics of individuals with a partial or contingent self-identity, produced under the effect of adaptive 
challenges when confronting variable environments (155, 176). EǀeŶ if this pƌoďleŵ of ͞iŶdiǀidual 
ĐoŶstaŶĐǇ͟ (177) makes it difficult to study the network of plasmids and hosts in Firmicutes, and such a 
network were biased by sampling, we should accept the existence of a certain interactive frame. 
Valeria Souza, still following Maynard Smith's ideas about the population structure of bacteria, proposed 
in 1997 to classify plasmid-bacteria interactions in four patterns, namely, (i) the plasmid-host clonal 
pattern, where the plasmid phylogeny is mirrored by host phylogeny; (ii) the limited transfer pattern, in 
which the plasmid flow is limited to closely related (genetically and/or ecologically) strains; (iii) 
panmictic plasmid spread, in the case of plasmids that circulate among a variety of hosts (the stability of 
the association being dependent on the benefits and costs of plasmid carriage); and (iv) epidemic 
plasmid dispersal, in whiĐh ͞suĐĐessful͟ plasŵids spƌead iŶ ďaĐteƌial populatioŶs ďeĐause theǇ pƌoǀide a 
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clear advantage in high-potency selective landscapes (49, 171). Although illustrative and useful for 
epidemiological purposes, this single centric view should not replace the complex interplay between 
different elements that may result in the emergence of different chimeric configurations (49, 178). 
Theƌefoƌe, these ͞patteƌŶs͟ should ďe ĐuƌƌeŶtlǇ understood as possible interactive states, even though 
some of them could be more ephemeral than others, depending on the co-evolutionary history, the 
adaptive demands of the plasmids, and the bacterial populations and communities. 
Plasmids and Population Biology of Firmicutes 
This section will focus on the genera of Firmicutes that are relevant to the problem of AbR (1). 
Streptococcus 
The genus Streptococcus, a main hub in gene networks in this and other studies (11, 12), is one of the 
most heterogeneous groups within the phyla Firmicutes. Remarkably, the 138 known species of 
streptococci found as opportunistic pathogens or commensals (many of them zoonotic pathogens) in 
humans, horses, pigs, cows, and fish have recently been divided into seven species groups on the basis 
of 16S rDNA gene sequencing, chemotaxonomic approaches, and DNA hybridization, namely the bovis, 
pyogenic, mitis, mutans, salivarius, anginosus, and unknown groups (179–181). HGT seems to play a 
relevant role in the adaptation and cohesiveness of the groups (180). Available information about 
streptococcal plasmids is scarce, with only a few plasmids being fully sequenced, representing an 
unbalanced sample of species and ecological groups (Supplementary Table S1). Figure 10 illustrates the 
20 AbR plasmids currently found in streptococci. 
The streptococcal groups bovis and mutans rarely harbor plasmids, although they can be relevant in the 
adaptation of particular species. S. thermophilus, a non-pathogenic species in the bovis group that is 
used in the dairy industry (182), contains a set of plasmids harboring heat shock proteins; Streptococcus 
mutans, a member of the human indigenous flora that is transmitted mostly from mother to child, often 
carries 5- to 6-kb cryptic plasmids that parallel the evolution of lineages associated with racial cohorts 
and geographical locations (183). Megaplasmids in the group salivarius coding for different lantibiotics 
favor their persistence in the oral cavity (184). Conversely, the pyogenic group, which is represented by 
species of clinical interest such as S. agalactiae and S. pyogenes (also called GAS and GBS, respectively), 
frequently carry plasmids that code for AbR genes aside from bacteriocins. Inc18 plasmids are widely 
spread among streptococci and seem to have determined the selection of certain populations resistant 
to chloramphenicol, aminoglycosides, and macrolides since the late 1970s in different groups of 
streptococci and enterococci (105, 110, 185). Rep_2 plasmids carrying erm(T) seem to have recently 
spread among GAS and GBS clinical isolates of different countries, having contributed to the increase of 
macrolide resistance rates in these species since the mid-1990s, either by clonal expansion, in the case 
of GAS, or by plasmid transference among unrelated clonal backgrounds, in the case of GBS (8, 186). 
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These erm(T)-containing plasmids are also spread among other non-streptococcal species, such as 
Enterococcus, Staphylococcus, and Lactobacillus (89, 187, 188). Often, streptococcal plasmids are 
mobilized by coresident integrative-conjugative elements belonging to the ICESa2603 family (189). 
Resistance to macrolides (ermB, mefA), tetracyclines (tetM, tetS, and other mosaic tet genes), 
aminoglycosides (aph3, aadA6, Tn4001), or vancomycin (vanA, vanB) is commonly detected among 
isolates of this group, but the location of determinants seems to be linked to transposable elements 
often involving insertion sequences (reviewed in reference (182)). Streptococcus suis, a particularly 
virulent emerging zoonotic pathogen that remains an outlier to the mitis, sanguinis, and anginosus 
groups is known to carry plasmids, although they have been scarcely characterized (190, 191). Relevant 
AbR genes coding for chloramphenicol (cfr and fexA) and lincosamides (lnu) embedded in composite 
regions similar to those present in plasmids of E. faecalis have been located in streptococcal plasmids of 
approximately 100 kb (192). Smaller plasmids carrying tetB associated with Gram-negative species have 
been described (193). 
Enterococcus 
The genus Enterococcus comprises different species, members of the intestinal flora of animals and 
humans able to cause disease in their hosts (194). Although seminal works in the field of plasmid biology 
focus on particular enterococcal plasmids and transposons, such as pheromone-responsive plasmids or 
Tn916, which became paradigms of different mechanisms of conjugation, the plasmidome of 
enterococcal species has scarcely been analyzed (7). Recent studies revealed that most strains of E. 
faecium and E. faecalis, the two main species detected in humans and animals, carry a number of 
plasmids of different families that include species-specific plasmids (e.g., narrow host range RCRs and 
RepA_N plasmids such as megaplasmids in E. faecium and pheromone-responsive plasmids in E. 
faecalis) and broad host range plasmids (e.g., Inc18), plasmid chimeras being abundant and still difficult 
to classify (Fig. 6 and 7; see previous section and comprehensive reviews in references (7, 141)). 
Megaplasmids of E. faecium or pheromone-responsive E. faecalis plasmids enhance the ability to 
colonize, invade, and form biofilms (65, 126, 154). Conjugative plasmids may influence the mobilization 
of non-conjugative elements and chromosomal regions and facilitate the acquisition of different 
adaptive traits and genome evolvability (71, 125, 126). Most enterococcal plasmids are able to acquire 
and disseminate AbR genes by different mechanisms of genetic exchange. However, the role of plasmids 
in the population structure and evolvability of these enterococcal species has been poorly addressed 
(195–198) due to the overrepresentation of recent clinical and animal isolates of specific lineages 
commonly associated with AbR included in most studies (7, 141) and due to the lack of available plasmid 
sequences. Similar plasmids have been found in E. faecium and other enterococcal species that may play 
equivalent functional roles in the gastrointestinal tract such as Enterococcus avium, Enterococcus 
raffinosus, E. durans, and E. hirae (196, 199). 
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AbR genes are located on plasmids that often contain different replicons associated with different 
narrow (RCR, RepA_N) and broad host range (Inc18) plasmids. Inc18 streptococcal plasmids greatly 
influenced the worldwide increase of aminoglycoside-macrolide resistance among E. faecalis isolates 
from humans and animals during the 1970s (200). They also contributed to the spread of vancomycin 
resistance among E. faecium of animal origin in Europe and E. faecalis from hospitalized patients in the 
United States (7, 70, 71). Diverse narrow host range plasmids have been involved in local expansions of 
enterococci conferring resistance to first-line antibiotics such as gentamicin (Tn4001) or beta-lactams 
;ΔTn552-blaZ) (152) and beta-lactamase-producing E. faecalis and E. faecium (152, 201–203), which 
highlights the role of endogenous plasmids and recombination in the adaptation of particular lineages 
(E. faecium ST17, ST18, ST78 and E. faecalis ST6 and ST16) (7, 67, 144, 204). 
Analysis of the same AbR genes in different species (cfr, bac, lincosamide resistance genes) reflects the 
impact of recombination events between genes, MGEs, and different populations of Firmicutes 
(Staphylococcus, Clostridium, Lactobacillus, Lactococcus, and Enterococcus) and other Gram-negative 
organisms (201, 205) in the gastrointestinal tract of animals and humans (120, 144, 206, 207). 
Staphylococci 
These organisms are opportunistic pathogens and members of the commensal flora of skin and mucous 
membranes of humans and animals (208–210) and, thus, are part of a microbial community with limited 
contact with members of other main genera of Firmicutes that inhabit distinct body sites (211). Figures 1 
and 2 show the limited plasmid connectivity of staphylococci with other genera. However, HGT and the 
acquisition of AbR and MetR is relevant in the evolvability of this genus, mainly due to genetic exchange 
events between closely related species (Fig. 5) (9, 212–214). Comprehensive reviews address the 
essentially clonal population structure of S. aureus (215–217) and other staphylococcal species (208) 
and also the impact of HGT in the evolutionary history of staphylococcal populations (9, 218–220), with 
emphasis on the description of the plasmids associated with AbR genetic elements (9, 51, 84, 221) and 
their influence on the variability of lineages (218, 220, 222–225). 
Plasmids, transposons, and staphylococcal chromosomal cassettes (SCCmec) are infrequently 
transferred among isolates of a different origin. A close association of MGE and particular 
staphylococcal lineages has been suggested (31, 226), with country-specific variations (209, 227). This 
highlights the relevance of local conditions and the emergence of gene flow barriers in the ecological 
differentiation of staphylococcal lineages such as in the case of S. aureus CC30 (220, 228). The origin, 
rapid spread, and evolution of staphylococcal populations resistant to beta-lactams was mainly 
influenced by the interplay of genetic elements including plasmids (84, 178). 
Clostridium 
Clostridium is a large and extremely heterogeneous genus that has traditionally grouped more than 100 
species widely distributed in the gut microbiota of mammals, amphibians, and insects and in soils. An 
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extensive update of clostridial classification is included in the latest edition of Bergey's Manual, although 
many unrelated species still retain the Clostridium name, causing major confusion in the clostridial 
taxonomy (229). To date, only 60 plasmids have been fully sequenced, mainly corresponding to C. 
perfringens, Clostridium botulinum, and other group I clostridia species (1 Clostridium butyricum, 2 
Clostridium kluyveri, 3 Clostridium acetobutylicum). Some species in which plasmids were analyzed have 
been moved to other genera such as Clostridium aciduricidi (now Anaerococcus prevotii type XII) and 
Clostridium thermocellum (now belonging to the family Ruminococcaceae). Several sequenced plasmids 
correspond to the same strain and are mostly from contemporary isolates, thus limiting the possible 
knowledge about the role of plasmids in the evolution of these species (Supplementary Table S1). Only 
narrow host range conjugative plasmids of C. perfringens (CpCP) or linear megaplasmids from C. 
butyricum have been associated with AbR. 
CpCP plasmids belong to the pCW3 family and are widely spread among isolates of C. perfringens, 
carrying genes encoding AbR (tetracycline [tetAB(P)], chloramphenicol [catP-Tn4451], lincomycin [lnuP-
tISCpe8]Ϳ aŶd/oƌ eŶteƌotoǆiŶs, ε-toxin, or iota-toxin production that determine different toxinotypes 
(56, 230–232). All pCW3-like plasmids have a conjugative transfer locus of 11 open reading frames (orfs) 
(tcp [transfer C. perfringens]) that includes an integrase and a T4CP protein but lacks relaxase (73, 232). 
A transposable origin similar to that of Tn916 has been suggested for the tcp module of pCW3-like 
plasmids, which would have acquired a replication machinery specific to this species. Often, C. 
perfringens isolates harbor more than one pCW3 plasmid, which carry different adaptative traits and 
partition machineries. The presence of different partition systems explains the coexistence of different 
plasmids with the same type of RIP in the same cell (56, 232–234). 
These plasmids can be transferred (and eventually serve as donors of AbR genes) but cannot replicate in 
other species such as P. difficile, Clostridium sordelli, or Clostridium septicum, which could explain the 
confinement of some AbR genes in these populations (235). An evolutionary scenario for CpCP has been 
reported, with pCW3 (tetAB-P) and pIP401 (tetAB-P and Tn4451) being suggested as the precursors of 
this family, which would have acquired different toxins by homologous recombination involving 
composite transposons flanked by insertion sequences (56). Large linear plasmids containing AbR have 
recently been described in neurotoxigenic C. butyricum, one of the six phylogroups able to produce the 
botulinum toxin (34, 236). These plasmids contain four beta-lactamase genes, transcriptional regulators 
and two-component regulatory systems, involved in the regulation of expression of the bont/A gene and 
a region with a functional CRISPR-cas locus that provides a defense against invading genetic elements 
present in the intestinal environment. 
Acquired resistance to tetracyclines (tetM, tetL, tetK, tetO, tetW), chloramphenicol, macrolides (ermB, 
lnu), and bacitracin (a bacitracin efflux pump and an overproduced undercaprenol kinase gene located 
on a genetic island flanked by copies of IS1216) has been reported in human and animal clostridium 
species including C. perfringens, often associated with conjugative transposons and plasmids 
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widespread in other species (235, 237, 238). A detailed analysis of AbR networks suggests further 
ecological connections with mobile genetic elements of other prokaryotic groups (Fig. 1 and 2). 
  
CONCLUSION 
This work offers for the first time an integrated and comprehensive analysis of the dynamics of AbR 
genes in Gram-positive bacteria and highlights the need for a population view to analyze the problem of 
antibiotic resistance. The article analyzed the relevance of the plasmidome in the emergence, spread, 
and maintenance of genes encoding resistance to antimicrobials (antibiotics, heavy metals, and 
biocides) and their influence on the structure of bacterial populations in the light of evolutionary 
ecology. A critical revision of plasmid typing systems highlights the limitation of available knowledge 
about plasmid diversity in this group of bacteria. 
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SUPPLEMENTARY MATERIAL 
Table S1. List of all plasmids analysed. 
 
Due to the size of the table it will be provided only in digital format.  
 
 
 
 
Accesion Strain Length Plasmid Name Taxonomy Metals and Biocides AbR Typing
NC_000906 Lactococcus lactis IL964 plasmid pIL105, complete sequence. 8506 pIL105 Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Lactococcus. - - -
NC_000937 Streptococcus thermophilus ST135 plasmid pER35, complete sequence. 9531 pER35 Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Streptococcus. - - -
NC_000938 Streptococcus thermophilus ST136 plasmid pER36, complete sequence. 3498 pER36 Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Streptococcus. - - -
NC_001272 Bacillus thuringiensis serovar kurstaki str. YBT-1520 plasmidpBMB9741, complete sequence. 6578 pBMB9741 Bacteria;Firmicutes;Bacilli;Bacillales;Bacillaceae;Bacillus;Bacilluscereusgroup. - - -
NC_001277 Pediococcus pentosaceus ATCC43200 plasmid pMD136, completesequence. 19515 pMD136 Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Pediococcus. - - -
NC_001370 Lactobacillus plantarum plasmid pC30il, complete sequence. 2140 pC30il Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus. - - -
NC_001376 Bacillus subtilis plasmid pIM13, complete sequence. 2246 pIM13 Bacteria;Firmicutes;Bacilli;Bacillales;Bacillaceae;Bacillus. - ErmC, AadC 10
NC_001379 Lactobacillus helveticus subsp. jugurti plasmid pLJ1, completesequence. 3292 pLJ1 Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus. - - -
NC_001380 Streptococcus agalactiae plasmid pLS1, complete sequence. 4408 pLS1 Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Streptococcus. - TetL -
NC_001381 Mycobacterium fortuitum plasmid pAL5000, complete sequence. 4837 pAL5000 Bacteria;Actinobacteria;Actinobacteridae;Actinomycetales;Corynebacterineae;Mycobacteriaceae;Mycobacterium. - - -
NC_001384 Staphylococcus aureus plasmid pUB110, complete sequence. 4548 pUB110 Bacteria;Firmicutes;Bacilli;Bacillales;Staphylococcus. - AadD 22
NC_001385 Corynebacterium glutamicum plasmid pAM330 DNA, complete sequence. 4448 plasmid pAM330 Bacteria;Actinobacteria;Actinobacteridae;Actinomycetales;Corynebacterineae;Corynebacteriaceae;Corynebacterium. - - -
NC_001387 Streptomyces lividans plasmid pIJ101, complete sequence. 8830 pIJ101 Bacteria;Actinobacteria;Actinobacteridae;Actinomycetales;Streptomycineae;Streptomycetaceae;Streptomyces. - - -
NC_001388 Clostridium perfringens plasmid pIP404, complete sequence. 10206 pIP404 Bacteria;Firmicutes;Clostridia;Clostridiales;Clostridiaceae;Clostridium. - - -
NC_001390 Staphylococcus epidermidis plasmid pNE131, complete sequence. 2355 pNE131 Bacteria;Firmicutes;Bacilli;Bacillales;Staphylococcus. - AadC, ErmC -
NC_001391 Staphylococcus aureus plasmid pNS1, complete sequence. 3879 pNS1 Bacteria;Firmicutes;Bacilli;Bacillales;Staphylococcus. - TetK 7
NC_001393 Staphylococcus aureus plasmid pT181, complete sequence. 4439 pT181 Bacteria;Firmicutes;Bacilli;Bacillales;Staphylococcus. - TetK, TetK 7
NC_001395 Staphylococcus aureus strain T48 plasmid pT48, complete sequence. 2475 pT48 Bacteria;Firmicutes;Bacilli;Bacillales;Staphylococcus. - AadC, ErmC 10
NC_001415 Corynebacterium glutamicum strain 22243 R-plasmid pAG1, completesequence. 19751 R-plasmid pAG1 Bacteria;Actinobacteria;Actinobacteridae;Actinomycetales;Corynebacterineae;Corynebacteriaceae;Corynebacterium. - TetZ -
NC_001425 Streptomyces flavovirens plasmid pSN22 DNA, complete sequence. 11046 pSN22 Bacteria;Actinobacteria;Actinobacteridae;Actinomycetales;Streptomycineae;Streptomycetaceae;Streptomyces. - - -
NC_001446 Bacillus thuringiensis sv israelensis HI4 plasmid pTX14-3, completesequence. 7649 pTX14-3 Bacteria;Firmicutes;Bacilli;Bacillales;Bacillaceae;Bacillus;Bacilluscereusgroup. - - -
NC_001456 Corynebacterium glutamicum ATCC 19223 plasmid pSR1, completesequence. 3054 pSR1 Bacteria;Actinobacteria;Actinobacteridae;Actinomycetales;Corynebacterineae;Corynebacteriaceae;Corynebacterium. - - -
NC_001496 Bacillus anthracis virulence plasmid PX01, complete sequence. 181654 virulence plasmid PX01 Bacteria;Firmicutes;Bacilli;Bacillales;Bacillaceae;Bacillus;Bacilluscereusgroup. - - -
NC_001670 Lactobacillus delbrueckii plasmid pWS58, complete sequence. 7921 pWS58 Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus. - - -
NC_001705 Bacillus cereus plasmid pBC16, complete sequence. 4630 pBC16 Bacteria;Firmicutes;Bacilli;Bacillales;Bacillaceae;Bacillus;Bacilluscereusgroup. - TetL 22
NC_001738 Streptomyces clavuligerus ATCC 27064 plasmid pSCL, completesequence. 11696 pSCL Bacteria;Actinobacteria;Actinobacteridae;Actinomycetales;Streptomycineae;Streptomycetaceae;Streptomyces. - - -
NC_001757 Lactobacillus reuteri 100-23 plasmid pGT232, complete sequence. 5113 pGT232 Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus. - - -
NC_001758 Ruminococcus flavefaciens R13e2 cryptic plasmid pBAW301, completesequence. 1768 pBAW301 Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Ruminococcus. - - -
NC_001759 Streptomyces phaeochromogenes plasmid pJV1, complete sequence. 11143 pJV1 Bacteria;Actinobacteria;Actinobacteridae;Actinomycetales;Streptomycineae;Streptomycetaceae;Streptomyces. - - -
NC_001763 Staphylococcus aureus plasmid J3358, complete sequence. 6024 pT181 Bacteria;Firmicutes;Bacilli;Bacillales;Staphylococcus. - TetK 7
NC_001764 Bacillus subtilis plasmid pTA1040, complete sequence. 7837 pTA1040 Bacteria;Firmicutes;Bacilli;Bacillales;Bacillaceae;Bacillus. - - -
NC_001765 Bacillus subtilis plasmid pTA1015, complete sequence. 5807 pTA1015 Bacteria;Firmicutes;Bacilli;Bacillales;Bacillaceae;Bacillus. - - -
NC_001766 Bacillus subtilis plasmid pTA1060, complete sequence. 8737 pTA1060 Bacteria;Firmicutes;Bacilli;Bacillales;Bacillaceae;Bacillus. - - -
NC_001767 Staphylococcus aureus plasmid pKH6, complete sequence. 4439 pKH6 Bacteria;Firmicutes;Bacilli;Bacillales;Staphylococcus. - TetK 7
NC_001772 Clostridium sp. MCF-1 indigenous plasmid, complete sequence. 2450 indigenous plasmid Bacteria;Firmicutes;Clostridia;Clostridiales;Clostridiaceae;Clostridium. - - -
NC_001787 Trueperella pyogenes plasmid pAP1, complete sequence. 2439 pAP1 Bacteria;Actinobacteria;Actinobacteridae;Actinomycetales;Actinomycineae;Actinomycetaceae;Trueperella. - - -
NC_001791 Corynebacterium glutamicum strain 1014 plasmid pXZ10145.1, completesequence. 4885 pXZ10145.1 Bacteria;Actinobacteria;Actinobacteridae;Actinomycetales;Corynebacterineae;Corynebacteriaceae;Corynebacterium. - Cmr -
NC_001797 Streptococcus agalactiae plasmid pGB354, complete plasmid sequence. 6437 pGB354 Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Streptococcus. - Cat-pC221 1, 7
NC_001858 Bacillus pumilus plasmid pPL10, complete plasmid sequence. 7028 pPL10 Bacteria;Firmicutes;Bacilli;Bacillales;Bacillaceae;Bacillus. - - -
NC_001949 Lactococcus lactis DPC3147 plasmid pMRC01, complete sequence. 60232 pMRC01 Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Lactococcus. - - -
NC_001988 Clostridium acetobutylicum ATCC 824 plasmid pSOL1, completesequence. 192000 pSOL1 Bacteria;Firmicutes;Clostridia;Clostridiales;Clostridiaceae;Clostridium. arsB - -
NC_001994 Staphylococcus aureus plasmid pSK3, complete sequence. 1658 pSK3 Bacteria;Firmicutes;Bacilli;Bacillales;Staphylococcus. - - 10b
NC_001995 Staphylococcus aureus plasmid pSK6, complete sequence. 1551 pSK6 Bacteria;Firmicutes;Bacilli;Bacillales;Staphylococcus. - - 10b
NC_002013 Staphylococcus aureus plasmid pC194, complete sequence. 2910 pC194 Bacteria;Firmicutes;Bacilli;Bacillales;Staphylococcus. - CatA9 13
NC_002059 Butyrivibrio fibrisolvens plasmid pOM1, complete genome. 2804 pOM1 Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Butyrivibrio. - - -
NC_002062 Geobacillus stearothermophilus plasmid pSTK1 DNA, completesequence. 1883 pSTK1 Bacteria;Firmicutes;Bacilli;Bacillales;Bacillaceae;Geobacillus. - - -
NC_002075 Bacillus subtilis plasmid p1414, complete plasmid sequence. 7949 p1414 Bacteria;Firmicutes;Bacilli;Bacillales;Bacillaceae;Bacillus. - - -
NC_002091 Bacillus thuringiensis sv israelensis plasmid pTX14-1, completesequence. 5415 pTX14-1 Bacteria;Firmicutes;Bacilli;Bacillales;Bacillaceae;Bacillus;Bacilluscereusgroup. - - -
NC_002093 Staphylococcus lugdunensis strain 995 cadmium resistance plasmidpLUG10, complete sequence. 3117 pLUG10 Bacteria;Firmicutes;Bacilli;Bacillales;Staphylococcus. cadD - -
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ABSTRACT 
Objectives. Vancomycin-resistant Enterococcus faecium (VREfm) have been increasingly reported since 
the 1980s. Despite the high number of published studies about VRE epidemiology, the dynamics and 
evolvability of these microorganisms is still not fully understood. A multilevel population genetic analysis 
of VREfm outbreak strains since 1986, representing the first comprehensive characterization of plasmid 
content in E. faecium, was performed to provide a detailed view of potential transmissible units. 
Methods. From a comprehensive MeSH search, we identified VREfm strains causing hospital outbreaks 
(1986-2012). In total, 53 VanA and 18 VanB isolates (27 countries, 5 continents) were analysed and 82 
vancomycin-susceptible E. faecium (VSEfm) were included for comparison. Clonal relatedness was 
established by PFGE and MLST (goeBURST/Bayesian Analysis of Population Structure, BAPS). 
Characterization of van transposons (PCR mapping, RFLP, sequencing), plasmids (transfer, ClaI-RFLP, 
PCR-typing of relaxases, replication-initiation proteins and toxin-antitoxin systems, hybridization, 
sequencing), bacteriocins and virulence determinants (PCR, sequencing) was performed.  
Results. VREfm were mainly associated with major human lineages ST17, ST18 and ST78. VREfm and 
VSEfm harboured plasmids of different families [RCR, small-theta plasmids, RepA_N (pRUM/pLG1) and 
Inc18] able to yield mosaic elements. Tn1546-vanA was mainly located on pRUM/Axe-Txe (USA), and 
Inc18-pIP186 (Europe) plasmids. VanB2 (Tn5382/Tn1549) was predominant (chromosome and 
plasmids). 
Conclusions. Both strains and plasmids contributed to the spread and persistence of vancomycin 
resistance among E. faecium. Horizontal gene transfer events among genetic elements from different 
clonal lineages (same or different species) result in chimeras with different stability and host range 
complicating the surveillance of epidemic plasmids.  
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INTRODUCTION 
VRE have increasingly been reported since their first description in 1986, with remarkable 
epidemiological differences in diverse geographical areas.
1,2
 Acquired vancomycin resistance has mostly 
been detected in Enterococcus faecium, even though Enterococcus faecalis is the main species 
recovered from human infections. 
Different acquired operons (vanA/B/D/E/G/L/M/N) confer resistance to vancomycin although vanA and 
vanB gene clusters remain predominant.
2,3
 The vanA cluster is often part of a Tn3 element named 
Tn1546 which may be located in plasmids of different families.
4
 Of the three vanB operons (vanB1, 
vanB2, vanB3), vanB2 (CTn5382/1549) is the most commonly found. It can be located in a transferable 
chromosomal region, eventually linked to pbp5 conferring resistance to ampicillin, or in plasmids.
5–10
 
Other van operons were sporadically observed in E. faecium (vanM, vanN), E. faecalis (vanE, vanG, vanL) 
or several enterococcal species (vanD).
3
 
To date, only few studies provided information of the plasmids involved in the transmission of 
vancomycin resistance, most of them confined to the analysis of local collections or to the comparison 
of isolates of particular clones collected in Europe.
9,11–16
 Additionally, the short length fragments 
provided by most available next generation sequencing (NGS) methods and the high cost of those that 
offer long reads as PacBio, makes extremely difficult to analyse the plasmid content of a large set of 
enterococcal isolates.
17–20
 Thus, the fractionated information about transmission of vancomycin 
resistance between isolates from different locations, and the lack of knowledge about early VRE isolates, 
hinder the full comprehension of its epidemiology and evolution at global level.  
This work provides a comprehensive multilevel molecular analysis of vancomycin-resistant E. faecium 
(VREfm) by characterizing for the first time representative strains causing hospital outbreaks in different 
continents since 1986, mainly America, Europe and Australia from where most studies have been 
published. 
MATERIAL AND METHODS 
Selection of VREfm outbreak strains. We searched PubMed indexed records in MEDLINE for VREfm 
outbreaks using the medical subject headings (MeSH) terms ͞Enterococcus faecium͟, ͞disease 
outďƌeaks͟ aŶd ͞ǀaŶĐoŵǇĐiŶ ƌesistaŶĐe͟. We ideŶtified ϭϳϭ eŶtƌies, ǁhiĐh ƌesulted iŶ ϭϮϰ puďliĐatioŶs 
that documented outbreaks due to strains carrying vanA, vanB or vanA+vanB. The identification of van 
genes was not available in 19 cases. An additional refined search for interhospital disseminated strains 
ǁith the Me“H teƌŵs ͞Enterococcus faecium͟ aŶd ͞ǀaŶĐoŵǇĐiŶ ƌesistaŶĐe͟ plus the ǁoƌds 
͞iŶteƌhospital͟ oƌ ͞iŶteƌ-hospital͟ gave 10 additional entries (Table 1). Only full-text articles with an 
English abstract were suitable for inclusion. Strains reported in these publications were requested 
(n=86). In some cases, strains were not available or no response was obtained from the authors.  
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Bacterial strains and epidemiological background. Table S1 and Fig. S1 shows the 71 VREfm 
isolates (53 vanA, 18 vanB) studied, which were responsible for documented hospital outbreaks (one 
single isolate per outbreak and phenotype), or disseminated in more than one healthcare institution 
(1986-2012, 27 countries). Vancomycin-susceptible blood isolates (VSEfm, n=82) from Spain, Norway 
and Denmark, countries with low VREfm prevalence rates, were analysed for comparison (Table S1). 
Antimicrobial susceptibility testing was performed for 14 antibiotics by the disk diffusion method 
(Oxoid) following CLSI guidelines.
21
 Clonal relatedness was established by PFGE and MLST following 
standard procedures (http://pubmlst.org/efaecium/).
11
 Sequence types (ST) were partitioned into BAPS 
(Bayesian Analysis Population Structure) (sub)groups as described.
22,23
 The presence of genes specifying 
enterococcal surface protein (esp), glycosidase (hylEfm), and bacteriocins (Bac) previously identified on 
enterococci at chromosome (entA, entB) or plasmids (entP, entQ, L50A, L50B, Bac32 and Bac43) were 
assessed by PCR (Table S2). Bacterial strains and plasmids used as controls are described in Tables S3 
and S4. 
Characterization of transposons encoding glycopeptide resistance. The backbone structure of 
Tn1546 (vanA) was determined by PCR mapping and further sequencing of fragments with unusual 
size.
11
 Transposons containing vanB alleles were discriminated by comparing BspHI/DraI digested DNA 
profiles of the 5,959-bp vanRSYWHBX amplicons and analysing sequences corresponding to the right 
junction of Tn5382, the vanSB-vanYB intergenic region and the relaxase of Tn1549 (this study; Figure 
S2).
6,7
 The link between pbp5 and Tn5382 was investigated according to Carias et al.
5
 Transferability of 
vanA/vanB genes was analysed by filter mating using E. faecium strains GE-1 and BM4105RF as 
recipients (Table S3). Genomic location of van elements was assessed by hybridization of I-CeuI-digested 
genomic DNA hybridization with vanA/vanB and 23S rRNA probes.
11,15
 
Plasmid characterization. The plasmid content (number and size) of both wild-type strains and 
transconjugants was determined using the methods described by Kado & Liu (<10 kb) and Barton et al. 
(10 kb->300 kb).
11,24
 Plasmids were classified according to the presence of sequences associated with 
replication (replication initiator proteins, RIPs), mobilization (relaxases, REL) and stability (toxin-antitoxin 
systems, TA), which were detected by PCR typing schemes
4,11,25–27 
(Table S2) and further hybridization of 
plasmid DNA (Kado gels), S1- and/or I-CeuI-digested genomic DNA with specific probes. Southern blot 
DNA transfer and hybridization were performed by using the Gene Images AlkPhos Direct labelling and 
detection system (Amersham GB/GE Healthcare Life Sciences UK Ltd).
11
 Relationship among 
vancomycin-resistant plasmids of similar size and RIP-REL content was established by RFLP using EcoRI 
and ClaI (Promega, Woods Hollow Road-Madison, WI, USA).
11
 Cluster analysis of RFLP patterns was 
performed with fingerprinting II Informatix version 3.0 software (Bio-Rad Laboratories, Hercules, CA, 
USA) using the unweighted pair group method with arithmetic averages (UPGMA clustering; 
optimization 0.5%, tolerance 1.00%). 
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Nucleotide sequence accession number. The new vanB transposon sequence has been deposited in 
the GenBank database under the accession number KT20162.  
RESULTS 
VREfm outbreak strains correspond to major human lineages ST17, ST18 and ST78. The 71 
VREfm analysed represented 26 STs that were mainly classified into the BAPS groups 3 and 2 (62.0% 
versus 33.8%), followed by BAPS groups 5 and 7 (1.4% versus 2.8%). The 31 STs of the 82 VSEfm mainly 
clustered into BAPS groups 3, 2 and also 1 (73.2%, 15.9%, and 8.5%, respectively), followed by BAPS 6 
and 7 (1.2% each) (Table S1). A highly similar or identical PFGE type was observed between VREfm 
isolates collected in either distant areas or the same country over long periods (2-6 years); VREfm and 
VSEfm isolates recovered during outbreaks in single hospitals in Finland,
28
 Portugal,
11
 and Spain;
24
 and 
VREfm outbreak strains (this study) and VSEfm strains of different countries (outbreak or predominant 
strains where VREfm outbreak strains analysed here were described, or strains typed by the authors) 
(Table S1).  
Within BAPS 3, most VREfm isolates corresponded to subgroup 3.3a that further split in 3.3a1 (n=13, 4 
STs, mainly ST18) and 3.3a2 (n=27, 5 STs, mainly ST16 and ST17), both comprising strains collected since 
1992. Early large VREfm outbreaks in the USA were caused by isolates of BAPS 3.3a2. Most isolates 
within BAPS 3.3a were resistant to ciprofloxacin (100% each), erythromycin (96-100%), ampicillin (92-
100%), and contained entA (85%). The presence of esp and hyl was differently observed in the 3.3a1 and 
3.3a2 subgroups (38% versus 85% and 37 versus 38%, respectively). VSEfm isolates of groups BAPS 3.3a1 
(n=36, ST18) and 3.3a2 (n=12, mainly ST16 and ST17) were also frequently detected, with a similar 
occurrence of virulence traits and antibiotic resistance. VREfm and VSEfm often harboured entB (25-
100%). 
Within BAPS 2, BAPS 2.3a included the first two VREfm strains (both ampicillin-susceptible) described in 
France in 1986-87 (ST25), and the first VREfm outbreak strain from Brazil in 1998 (ST114). The ST25 
isolates were isolated from colonized patients in two French hospitals and differed in the number of 
plasmids and the presence of entB. Although their PFGE patterns exhibited a high number of common 
bands, they were classified as clonally unrelated following standard criteria, confirming the difficulty in 
discriminate VREfm by traditional molecular methods.
29
 They were classified as ampicillin susceptible 
(AmpS) according to CLSI criteria, but their MIC values to ampicillin were slightly increased in 
comparison with those of AmpS isolates of the VSEfm group (MIC of 8 mg/L and 4 mg/L for BM4147 and 
BM4165 strains, respectively).  
BAPS subgroup 2.1a, comprising the major ST78 E. faecium lineage, was predominant in the strains 
recovered since 1998 (n=18 VREfm, 8 STs, including ST78, ST203, ST117, and ST412, all widespread in 
different countries nowadays).
20,30,31
 Most strains were resistant to ciprofloxacin (100%), ampicillin and 
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erythromycin (94% each) and carried esp and entA (89% each), as well as other analysed markers at 
variable rates. 
BAPS 5 was represented by a vanB-type VREfm (ST484) strain from Finland in early 90s, which was 
involved in one of the largest VRE outbreaks described to date. Besides the vanB ST484 strain, a vanA-
type VREfm ST17 was detected (103 persons carried ST484 and 34 persons carried ST17 which were 
designated as types I and II in the original publication, respectively). Some ST484 isolates carried both 
vanB and vanA transposons.
28
 BAPS 7 comprised two VREfm strains described in the USA in early 1990s 
(ampicillin-resistant ST20 and ST182, both esp
+
/entA
+
). Both strains caused large outbreaks involving 
interhospital clonal spread in Detroit and Texas (6 hospitals each).
32,33
  
vanA (Tn1546) is mainly located on RepA_N (pRUM/pLG1) and Inc18 plasmid families. 
Diversity of Tn1546. Twenty-five vanA elements were identified according to indels and mutations in 
relation to the Tn1546 prototype (Fig. S3). In order to simplify the reading and to be consistent with the 
liteƌatuƌe, theǇ ǁill ďe desigŶated heƌe as ͞TŶ1546 ǀaƌiaŶts͟ although most of vanA elements lack key 
components of the transposon.
34–36
 The ͞Tn1546 variants͟ that contains IS1251 within the vanS-vanH 
region were predominant (n=21/53 isolates; from Europe and America). They were designated as ͞F͟ (F1-
6) in agreement with previous reports that designed Tn1546 carrying this IS as ͞tǇpe F͟ oƌ ͞U“ hospital 
tǇpe͟.1,35 ͞Tn1546 variants͟ containing IS1216 within vanX-vanY (n=9), in both vanX-vanY and vanS-vanH 
(n=1), in both vanX-vanY and upstream vanR (n=1) or within vanS-vanH (n=2) regions were also common 
(n=13/53), and mainly found in VREfm from Europe. ͞Tn1546 variants͟ carrying both IS1251 and IS1216 
within vanS-vanH and vanX-vanY regions, respectively, corresponded to two isolates from South 
America. Variants carrying ISEf1 within vanX-vanY (n=5/53; from Germany, Portugal and Spain) or 
IS1485 upstream vanR (one isolate from Saudi Arabia) were also observed. Other Tn1546 with/without 
indels upstream vanR (types A, n=6/53; ͞D͟, n=5/53; aŶd ͞M͟, n=1/53) corresponded to isolates from 
Europe, Brazil or Australia. Tn1546-vanA was located on plasmids in all but one ST117 isolate from 
Germany for which vanA and rel6 probes hybridized in the chromosome. 
Plasmids carrying Tn1546 belonged to either RepA_N (pRUM or pLG1) or Inc18 families or were mosaics 
containing RIPs of these two plasmid families (see below, Fig. S4). They were transferred by conjugation 
in most cases (79%), the plasmid size being increased after in vitro transfer in three cases (1 Inc18, 1 
pRUM and 1 Inc18-pRUM chimera). 
Inc18::Tn1546  plasmids (rep1 and/or rep2, n=12; 30-145 kb) included the 30kb plasmid isolated from 
one of the very first VanA-VREfm strain (ST25) reported in France in 1986 and designed as pIP186 years 
later.
37,38
 Rep1/Rep2 plasmids were commonly detected in different clonal lineages (BAPS 2.1a, BAPS 
3.3a2) and different continents since 1992. Tn1546 variants in these isolates were often truncated by 
IS1216 or IS1485. 
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pRUM-like plasmids (rep17; n=17) differed in the rep sequence and the presence of the TAAxe-Txe. Those 
with TAAxe-Txe (30-60kb, n=11) mostly carried Tn1546 variants ͞F-like͟, aŶd ǁeƌe isolated fƌoŵ clonally 
unrelated isolates (9 STs of 4 BAPS subgroups) of America, Australia, and Europe since 1992 (cluster I, 
Fig. S5). pRUM-like plasmids (rep17.1) lacking the Axe-Txe system (80-90 kb, n=3) contained Tn1546 
variants truncated by ISEf1, and were recovered in Portugal
11
 and Poland.
14
  
Mosaic vanA plasmids appeared in isolates collected since 1988. The second VREfm isolated in France 
had three plasmids, a mosaic Inc18-pRUM::Tn1546, a pLG1 and a pHTß-like (see below). Inc18-pRUM 
chimeras (30-60 kb; n=12) with several RIPs (rep17+rep1+rep2), RELs (rel6+rel7) and TAs (TAAxe-Txe+TA-) 
contained either Tn1546 tǇpe ͞F͟ ;Euƌope aŶd AŵeƌiĐa siŶĐe ϭϵϵϱͿ, I“1216-Tn1546 variants (Europe, 
2001-2006) or Tn1546 tǇpe ͞A͟ ;FƌaŶĐe, ϭϵϴϴͿ. It is of note that mosaic plasmids with 
rep1+rep2+rep17+rel6+TAAxe-Txe from different countries exhibited similar RFLP patterns. Among them, the 
first strains identified in France in 1986-1988 (ST25), and the first outbreak strains reported in Brazil 
(ST114) and Argentina (ST17) in 1998 (cluster IIa; Fig. S5). 
Inc18-pHTβ ŵosaiĐ plasŵids ;Ŷ=Ϯ; ϱϬ-85 kb; rep22+rep1+rel8, one of them also containing rep2+TA-) 
carried IS1216-Tn1546 and were identified in a ST18 isolate from the UK (1992), a ST16 isolate from the 
Netherlands (2002) and a transconjugant obtained from a ST132 isolate from Portugal that harboured 
these two plasmids (Fig. S4). Their RFLP patterns were closely related to the prototype pMG1 (cluster 
IIb; Fig. S5).  
Finally, vanA large mosaic plasmids (n=11; 150-300 kb; rep20+rep1+rep2+rel6) were present in clonally 
unrelated strains from America and Europe since 1992. They contained either Tn1546 variants without 
ISs (n=7) or Tn1546 tǇpe ͞F͟ ;Ŷ=ϰͿ.  
vanB transposons are chromosomally and plasmid located. The backbone of vanB operons is 
shown in Fig. S2. Most were Tn5382/1549 (vanB2) with an additional BspHI site within the 1,086-bp 
vanSB-vanYB region (RFLP-2, n=15). They were categorized as variants with ISEnfa110 insertions 
downstream the left inverted repeat of the transposon (Chile) or with ISEnfa200 insertions within vanSB-
vanYB and a pbp5 region upstream Tn5382 (Finland, Australia and the USA).  
Two of the three vanB1 isolates detected were similar to that found in strain BM4281 (RFLP-1, n=2) and 
corresponded to strains causing large outbreaks in New York and Texas in early 90s. A vanB transposon 
showing an RFLP-3 was a hybrid resulting from recombination between the vanB1 (BM4281) cluster and 
vanB2 (Tn1549) transposon (this study, GenBank accession number KT201628) and corresponded to a 
ST209 isolate recovered in Italy in 2002. Mosaic structures in elements with RFLP-1 cannot be discarded 
as only the left arm of the transposon is usually analysed (this study).
6
 
All but four vanB operons were chromosomally located. The four vanB2 plasmids (50-60 kb) had variable 
rep content, similar RFLP patterns (data not shown) and correspond to two clonally related ST17 isolates 
from Spain (rep1+rel6 and rep17+rel6 plasmids); a ST265 isolate also from Spain (rep17+TAAxe-Txe+rep1), and 
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a ST280 from Singapore (rep17+rep2) (Fig. S4). It is of note that vanB2 located on pRUM plasmids of 
variable sizes (70-130 kb) have been recently detected in Sweden associated with hospital outbreaks.
9
 
The 70-kb pRUM plasmids were chimeras with rep2 or an unknown replicon.
9
  
Plasmid content of VREfm and VSEfm isolates. A variable number of plasmid bands (n=1-8) was 
observed for VREfm isolates (Fig. S4 and Fig. S6). Most isolates contained RCR, small theta, and 
megaplasmids while pRUM, Inc18 or pHTß were variably detected (Fig. 1 and Fig. S4). Similar plasmid 
content was detected in VSEfm (Fig. S7).  
 
Figure 1. Plasmid content (rep/rel/TA) of VREfm and VSEfm isolates. 
Percentages of rep (replication), rel (relaxase), and TA (toxin-antitoxin) genes for isolates of each BAPS subgroup are represented. 
The prototype or main plasmids associated with a given gene are indicated above. 
RCR plasmids (2-4 kb) were present in VREfm and VSEfm isolates (65% versus 29%). Most were positive 
for rep14a, the presence of RELMOBV4 (pRI1/pJS42) being variable.  
Small mobilizable theta-replicating plasmids were detected in VREfm and VSEfm isolates (65% versus 
61%). Rep18a or rep18c (8-18kb) occasionally contained the bac32 (5-14%) or entQ (2% in VSEfm) while 
rep18b plasmids (5-7 kb) often harboured bac43 (5/7 plasmids, 71% VREfm, all collected after 2005). 
Most of them had a REL of the MOBP7 family (65%-72%). Both RCR and small theta-replicating plasmids 
were often co-transferred with vancomycin-resistance plasmids. 
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Megaplasmids (135-295kb) were present in all but the first VREfm isolates described in France (1986-
1988) and the UK (1992). They were often positive for rep20 (present in 72% of VREfm and 93% of 
VSEfm) while the relpLG1 was only identified in one ST74 VSEfm isolate. Some of them also hybridized 
with probes specific for rel6 and/or rel5. Megaplasmids often carried hylEfm (18-30%) and entP (7- 21%).  
Finally, pRUM, Inc18 or pHTß were present at different rates in both VREfm and VSEfm. The pRUM-like 
plasmids that do not carry van genes had similar size (20-25 kb) and identical rep17 and TAAxe-Txe genes to 
that of the original pRUM sequence.
39
 The rel3, detected in the original pRUM, is the rel of pC223 of 
Staphylococcus aureus, and was only identified in a few VREfm (4%) and VSEfm (7%). All early US strains 
contained pRUM with or without Tn1546. Plasmids carrying RIP and TA sequences of the Inc18 plasmid 
family (rep1, rep2, rep21, Ȝ-ȝ, ω-ț; 20-280 kb) in VREfm and VSEfm usually had a rel6 of the MOBP7 
family (86% versus 78%, respectively) instead the REL prototype of Inc18 plasmids (rel7 of the MOBQ3 
family, <5%). Rep22 plasmids (50-90 kb) were detected in isolates since 1988 although at lower rates 
than other plasmid families (32% versus 5% of VREfm and VSEfm, respectively). They may also contain 
other RIPs (rep1 or rep2) and different RELs (rel8 or rel6).  
Some large and small plasmids could not be classified. A recent search also demonstrated that the 
plasmid pool in fully sequenced enterococci available at gene databases is larger than that detectable by 
the available PCR typing schemes used here.27 
DISCUSSION 
This study showed the influence of both clonal lineages and plasmids in the spread and persistence of 
vancomycin resistance among E. faecium, by characterizing for the first time available strains causing 
outbreaks in different continents. Predominant ampicillin-resistant strains of major E. faecium human 
lineages ST17, ST18 and ST78 have contributed to reach high rates of vancomycin resistance after 
acquisition of van transposons.
40
 This is reflected by the emblematic clonal VREfm outbreaks in the US 
(NY 1991-1992, Detroit, Texas-San Antonio 1993-1994, Cleveland 1996, Chicago 1995 or Alabama 2004-
2005 mostly caused by either ST16 or ST17, all included in this study), Australia (2007-2009, ST203), 
Sweden (2007-2011, ST192), Portugal (2001-2003, ST18/ST132), Brazil and Canada (2006-2008, ST412) 
or Netherlands (ST117) (Table 1).
9,11,33,40–43
 However, horizontal gene transfer (HGT) events often 
occurred when the prevalence of VRE rapidly increase or when they became endemic
2,11
 as reflect the 
examples of polyclonal and plasmid outbreaks (New York, 1991-92;
43
 Texas-Houston, 1993-94;
33
 Korea, 
1997-2001
44
) or the surveillance studies of colonized hospitalized patients (Finland, 1996-1998,
28
 
Belgium, 1993,
42
 The Netherlands, 1995-1996,
45
 and China, 2001-2005
46
).  
The diversity of plasmids able to acquire van operons and their ability to recombine and yield plasmid 
mosaics played a critical role in the spread of vanA. Frequent HGT events between clonally related 
populations of S. aureus and their mobile genetic elements generated loĐal ͞ĐloŶal Đlouds͟ that ƌesult in 
genetic variants with variable levels of fitness confronting local selective forces.
47,48 
It is tempting to 
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suggest a similar scenario in E. faecium, where HGT not only plays a relevant role in shaping the 
transmission dynamics of VREfm, but also may influence the global presence of E. faecium lineages that 
have already been circulating for decades;
41,49
 and also the diversity of plasmid and chimeras of narrow 
host E. faecium plasmids even for isolates of the same clone.
11
 The recovery of pRUM::Tn1546 highly 
related to the original pRUM
39
 among VREfm from the USA and Inc18::Tn1546 similar to the first vanA 
plasmid pIP816
37,38
 among VREfm from humans and animals in Europe since late 80s to date,
11–13,50
 
revealed the outstanding contribution of pRUM and pIP186 to the evolvability of Tn1546. However, the 
lack of isolates from Asian and African countries in the study precludes a real global vision of VREfm 
dynamics.  
The high mosaicism of enterococcal plasmids linked to antibiotic resistance was also observed after the 
sequencing of few strains
18,51,52
 and van plasmids.
37,39,50,53
 Although the similarity of plasmid chimeras in 
strains causing early outbreaks in different countries
9,11,13,14
 could suggest selection of some hybrids, 
independent recombination events between plasmids cannot be discarded taking in account the 
frequent in vivo transfer of vanA between E. faecium strains in food and gut flora.
54
 Besides the 
dominant impact of these pRUM and Inc18 plasmids, we showed how any enterococcal plasmid may be 
a vehicle of Tn1546 or CTn5382, eventually causing self-limited outbreaks. An example of this is the 
pLG1-like megaplasmids that often carry vanA and other genes linked to persistence or colonization (e.g. 
hylEfm or pilA) or antibiotic resistance [aaĐ;6’Ϳ-Ie-aph;2’’Ϳ-Ia].14,24,41,55–57 Although pHTß plasmids were 
significantly involved in the early spread of resistance to high levels of glycopeptides or gentamicin in 
Japan and the USA,
58
 they are less frequently recovered in most contemporary collections including that 
analysed in this study although this might be caused by the absence of strains from Asian countries. 
Finally, mosaics carrying sequences of E. faecium plasmids and pheromone responsive plasmids of E. 
faecalis (this study)
11,59
 or S. aureus,
39 
indicate close HGT events between E. faecium and species of 
Enterococcus, Streptococcus and Staphylococcus. Besides the antibiotic resistance, plasmids carry a 
diversity of genes that confer adaptive traits (metabolic, bacteriocins, RM-systems) that would have 
facilitated the persistence of different hierarchical units.  
In contrast with what has been observed for vanA, some vanB2-Tn5382/Tn1549 types are widely 
spread.
9,60
 Studies in areas with high prevalence of vanB as Australia, demonstrated that vanB 
transposon is repeatedly acquired by E. faecium from anaerobes of the gut flora in hospitalized patients 
treated with antibiotics.
61
 Gut flora may also be the origin of vanD and vanG transposons, each 
independently acquired by different species of enterococci.
62  
In conclusion, we document the clonal and plasmid backgrounds responsible for the acquisition, spread 
and persistence of vancomycin resistance in different areas by studying available outbreak E. faecium 
strains from 1986. The high content of plasmid and mobile genetic elements in E. faecium human 
lineages seems to be relevant in the emergence and persistence of antibiotic resistance. The narrow 
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host range of the plasmids carrying Tn1546 might partially explain why this resistance has not yet been 
widely disseminated to other species.
63
  
ACKNOWLEDGEMENTS 
We greatly thank (in alphabetical order) Cesar Arias (The University of Texas Health Science Center, USA; 
Universidad El Bosque, Bogota, Columbia), José Campos (Instituto de Salud Carlos III, Majadahonda, 
Madrid, Spain), Maciej Chebicki (Singapore General Hospital, Singapore), Keryn Christiansen (Royal Perth 
Hospital, Australia), Alejandra Corso (Instituto Nacional de Enfermedades Infecciosas, Buenos Aires, 
Argentina), Patrice Courvalin (Institut Pasteur, France), Ana Lucia Darini (Universidade São Paulo, Brazil), 
Rosa del Campo (Hospital Ramón y Cajal, Madrid, Spain), John Hays (Department of Medical 
Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands), Hermínia de 
Lencastre (The Rockefeller University, NY; ITQB/UNL, Oeiras, Portugal), Balasz Libisch (National Center 
for Epidemiology, Budapest, Hungary), Rosario Mato (ITQB/UNL, Oeiras, Portugal), Graeme Nimmo 
(Queensland Hospital Campus, Australia), Annalisa Pantosti (Instituto Superiore di Sanità, Rome, Italy), 
Susan Richardson and Anne Matlow (The Hospital for Sick Children, Ontario, Canada), Abbassi Mohamed 
Salah (Université de Tunis El Manar Tunis, Tunisia), Saara Salmenlinna (National Public Health Institute, 
Helsinki, Finland), Jose Silva (Universidad de Antofagasta, Chile), Carmen Torres (Universidad de La Rioja, 
Spain), Sylvia Valdezate (Centro Nacional de Microbiología, Madrid, Spain), Jaana Vuopio (University of 
Turku), Keith Weaver (University of South Dakota, USA) and Neil Woodford (Health Protection Agency, 
London, United Kingdom) for the gift of the strains.  
FUNDING 
This work was supported by the European Commission (LSHE-2007-037410 ACE for ARF, APT, MVF, LBJ, 
CN, AS, KH, GW, ES, AMH, LGM, RJW, FB and TMC and EvoTAR-282004 for APT, TMC, FB, RJW); the Plan 
Nacional de I+D+i 2008-2011: Instituto de Salud Carlos III (PS09/02381 and PI12-01581 for TMC) and 
CIBER (CB06/02/0053 for APT, TMC and FB) co-financed by the European Development Regional Fund 
͚͚A ǁaǇ to aĐhieǀe Euƌope͛͛ ;E‘DFͿ; the ‘egioŶal GoǀeƌŶŵeŶt of Madƌid iŶ “paiŶ ;P‘OMPT-
S2010/BMD2414 for APT, TMC and FB); and the Fundação para a Ciência e Tecnologia (FCT) of Portugal 
(UID/MULTI/04378/2013 for ARF, CN and LP). ARF was supported by a fellowship (grant 
SFRH/BPD/96148/2013) from FCT through Programa Operacional Capital Humano (POCH) and a 
Research Grant (2013) from the European Society of Clinical Microbiology and Infectious Diseases 
(ESCMID).  
REFERENCES 
1. Bonten MJ, Willems R, Weinstein RA. Vancomycin-resistant enterococci: why are they here, and where do 
they come from? Lancet Infect Dis 2001; 1: 314–25. 
2. Werner G, Coque TM, Hammerum AM et al. Emergence and spread of vancomycin resistance among 
enterococci in Europe. Euro Surveill 2008; 13: pii: 19046. 
Ana P. Tedim  Chapter 4 
 
158 
 
3. Miller WR, Munita JM, Arias CA. Mechanisms of antibiotic resistance in enterococci. Expert Rev Anti Infect 
Ther 2014; 12: 1221–36. 
4. Clewell DB, Weaver KE, Coque TM et al. Extrachromosomal and Mobile Elements in Enterococci: Transmission, 
Maintenance, and Epidemiology. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, eds. Enterococci: From Commensals 
to Leading Causes of Drug Resistant Infection. Boston: Massachusetts Eye and Ear Infirmary, 2014. 
5. Carias LL, Rudin SD, Donskey CJ et al. Genetic linkage and cotransfer of a novel, vanB-containing transposon 
(Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium 
isolate. J Bacteriol 1998; 180: 4426–34. 
6. Dahl KH, Simonsen GS, Olsvik O et al. Heterogeneity in the vanB gene cluster of genomically diverse clinical 
strains of vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999; 43: 1105–10. 
7. Dahl KH, Lundblad EW, Rokenes TP et al. Genetic linkage of the vanB2 gene cluster to Tn5382 in vancomycin-
resistant enterococci and characterization of two novel insertion sequences. Microbiology 2000; 146: 1469–79. 
8. Dahl KH, Mater DDG, Flores MJ et al. Transfer of plasmid and chromosomal glycopeptide resistance 
determinants occurs more readily in the digestive tract of mice than in vitro and exconjugants can persist stably in 
vivo in the absence of glycopeptide selection. J Antimicrob Chemother 2007; 59: 478–86. 
9. Sivertsen A, Billström H, Melefors Ö et al. A multicentre hospital outbreak in Sweden caused by introduction of 
a vanB2 transposon into a stably maintained pRUM-plasmid in an Enterococcus faecium ST192 clone. PLoS One 
2014; 9: e103274. 
10. Umeda A, Garnier F, Courvalin P et al. Association between the vanB2 glycopeptide resistance operon and 
Tn1549 in enterococci from France. J Antimicrob Chemother 2002; 50: 253–6. 
11. Freitas AR, Novais C, Tedim AP et al. Microevolutionary Events Involving Narrow Host Plasmid Influences 
Local Fixation of Vancomycin-Resistance in Enterococcus. PLoS One 2013: e60589. 
12. Garcia-Migura L, Sanchez-Valenzuela AJ, Jensen LB. Presence of glycopeptide-encoding plasmids in 
enterococcal isolates from food and humans in Denmark. Foodborne Pathog Dis 2011; 8: 1191–7. 
13. Rosvoll TCS, Pedersen T, Sletvold H et al. PCR-based plasmid typing in Enterococcus faecium strains reveals 
widely distributed pRE25-, pRUM-, pIP501- and pHTbeta-related replicons associated with glycopeptide resistance 
and stabilizing toxin-antitoxin systems. FEMS Immunol Med Microbiol 2010; 58: 254–68. 
14. Wardal E, Markowska K, Zabicka D et al. Molecular analysis of vanA outbreak of Enterococcus faecium in two 
Warsaw hospitals: the importance of mobile genetic elements. Biomed Res Int 2014; 2014: 575367. 
15. Freitas AR, Coque TM, Novais C et al. Human and swine hosts share vancomycin-resistant Enterococcus 
faecium CC17 and CC5 and Enterococcus faecalis CC2 clonal clusters harboring Tn1546 on indistinguishable 
plasmids. J Clin Microbiol 2011; 49: 925–31. 
16. Valdezate S, Miranda C, Navarro A et al. Clonal outbreak of ST17 multidrug-resistant Enterococcus faecium 
harbouring an Inc18-like::Tn1546 plasmid in a haemo-oncology ward of a Spanish hospital. J Antimicrob Chemother 
2012; 67: 832–6. 
17. de Been M, Pinholt M, Top J et al. A core genome MLST scheme for high-resolution typing of Enterococcus 
faecium. J Clin Microbiol 2015. 
18. Lam MMC, Seemann T, Tobias NJ et al. Comparative analysis of the complete genome of an epidemic 
hospital sequence type 203 clone of vancomycin-resistant Enterococcus faecium. BMC Genomics 2013; 14: 595. 
19. Lebreton F, van Schaik W, McGuire AM et al. Emergence of epidemic multidrug-resistant Enterococcus 
faecium from animal and commensal strains. MBio 2013; 4. 
20. Pinholt M, Larner-Svensson H, Littauer P et al. Multiple hospital outbreaks of vanA Enterococcus faecium in 
Denmark, 2012-13, investigated by WGS, MLST and PFGE. J Antimicrob Chemother 2015; 70: 2474–82. 
21. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 
Twenty-Second Informational Supplement M100-S22. CLSI, Wayne, PA, USA; 2012. 
22. Tedim AP, Ruiz-Garbajosa P, Corander J et al. Population Biology of Intestinal Enterococcus Isolates from 
Hospitalized and Nonhospitalized Individuals in Different Age Groups. Appl Environ Microbiol 2015; 81: 1820–31. 
23. Willems RJL, Top J, van Schaik W et al. Restricted gene flow among hospital subpopulations of Enterococcus 
faecium. MBio 2012; 3: e00151–12. 
24. Freitas AR, Tedim AP, Novais C et al. Global spread of the hyl(Efm) colonization-virulence gene in 
megaplasmids of the Enterococcus faecium CC17 polyclonal subcluster. Antimicrob Agents Chemother 2010; 54: 
2660–5. 
Ana P. Tedim  Chapter 4 
 
159 
 
25. Goicoechea P, Romo M, Coque TM et al. Identification of enterococcal plasmids by multiplex-PCR-based 
relaxase typing (Abstract number: P1669). In: 18
th
 European Congress of Clinical Microbiology and Infectious 
Diseases. Barcelona, Spain, 2008. 
26. Jensen LB, Garcia-Migura L, Valenzuela AJS et al. A classification system for plasmids from enterococci and 
other Gram-positive bacteria. J Microbiol Methods 2010; 80: 25–43. 
27. Lanza VF, Tedim AP, Martínez JL et al. The Plasmidome of Firmicutes: Impact on the Emergence and the 
Spread of Resistance to Antimicrobials. Microbiol Spectr 2015; 3: PLAS – 0039–2014. 
28. Suppola JP, Kolho E, Salmenlinna S et al. vanA and vanB incorporate into an endemic ampicillin-resistant 
vancomycin-sensitive Enterococcus faecium strain: effect on interpretation of clonality. J Clin Microbiol 1999; 37: 
3934–9. 
29. Morrison D, Woodford N, Barrett SP et al. DNA banding pattern polymorphism in vancomycin-resistant 
Enterococcus faecium and criteria for defining strains. J Clin Microbiol 1999; 37: 1084–91. 
30. Johnson PDR, Ballard SA, Grabsch EA et al. A sustained hospital outbreak of vancomycin-resistant 
Enterococcus faecium bacteremia due to emergence of vanB E. faecium sequence type 203. J Infect Dis 2010; 202: 
1278–86. 
31. Coombs GW, Pearson JC, Daley DA et al. Molecular epidemiology of enterococcal bacteremia in Australia. J 
Clin Microbiol 2014; 52: 897–905. 
32. Dunne WM, Wang W. Clonal dissemination and colony morphotype variation of vancomycin-resistant 
Enterococcus faecium isolates in metropolitan Detroit, Michigan. J Clin Microbiol 1997; 35: 388–92. 
33. Moreno F, Grota P, Crisp C et al. Clinical and molecular epidemiology of vancomycin-resistant Enterococcus 
faecium during its emergence in a city in southern Texas. Clin Infect Dis 1995; 21: 1234–7. 
34. Novais C, Freitas AR, Sousa JC et al. Diversity of Tn1546 and its role in the dissemination of vancomycin-
resistant enterococci in Portugal. Antimicrob Agents Chemother 2008; 52: 1001–8. 
35. Willems RJ, Top J, van den Braak N et al. Molecular diversity and evolutionary relationships of Tn1546-like 
elements in enterococci from humans and animals. Antimicrob Agents Chemother 1999; 43: 483–91. 
36. Woodford N, Adebiyi AM, Palepou MF et al. Diversity of VanA glycopeptide resistance elements in 
enterococci from humans and nonhuman sources. Antimicrob Agents Chemother 1998; 42: 502–8. 
37. Sletvold H, Johnsen PJ, Wikmark O-G et al. Tn1546 is part of a larger plasmid-encoded genetic unit 
horizontally disseminated among clonal Enterococcus faecium lineages. J Antimicrob Chemother 2010; 65: 1894–
906. 
38. Leclercq R, Derlot E, Duval J et al. Plasmid-mediated resistance to vancomycin and teicoplanin in 
Enterococcus faecium. N Engl J Med 1988; 319: 157–61. 
39. Grady R, Hayes F. Axe-Txe, a broad-spectrum proteic toxin-antitoxin system specified by a multidrug-
resistant, clinical isolate of Enterococcus faecium. Mol Microbiol 2003; 47: 1419–32. 
40. Willems RJL. Genetic Evolution of E. faecium and E. faecalis: Similarities and Differences. In: 4th ASM 
Conference on Enterococci. Cartagena, Colombia: American Society for Microbiology, 2014. 
41. Galloway-Peña JR, Nallapareddy SR, Arias CA et al. Analysis of clonality and antibiotic resistance among early 
clinical isolates of Enterococcus faecium in the United States. J Infect Dis 2009; 200: 1566–73. 
42. Gordts B, Van Landuyt H, Ieven M et al. Vancomycin-resistant enterococci colonizing the intestinal tracts of 
hospitalized patients. J Clin Microbiol 1995; 33: 2842–6. 
43. Mato R, de Lencastre H, Roberts RB et al. Multiplicity of genetic backgrounds among vancomycin-resistant 
Enterococcus faecium isolates recovered from an outbreak in a New York City hospital. Microb Drug Resist 1996; 2: 
309–17. 
44. Yoo SJ, Sung H, Cho Y-U et al. Role of horizontal transfer of the transposon Tn1546 in the nosocomial spread 
of vanA vancomycin-resistant enterococci at a tertiary care hospital in Korea. Infect Control Hosp Epidemiol 2006; 
27: 1081–7. 
45. Endtz HP, van den Braak N, van Belkum A et al. Fecal carriage of vancomycin-resistant enterococci in 
hospitalized patients and those living in the community in The Netherlands. J Clin Microbiol 1997; 35: 3026–31. 
46. Zheng B, Tomita H, Xiao YH et al. Molecular characterization of vancomycin-resistant enterococcus faecium 
isolates from mainland China. J Clin Microbiol 2007; 45: 2813–8. 
Ana P. Tedim  Chapter 4 
 
160 
 
47. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 
2009; 7: 629–41. 
48. Stanczak-Mrozek KI, Manne A, Knight GM et al. Within-host diversity of MRSA antimicrobial resistances. J 
Antimicrob Chemother 2015; 70: 2191–8. 
49. Willems RJL, Top J, van Santen M et al. Global spread of vancomycin-resistant Enterococcus faecium from 
distinct nosocomial genetic complex. Emerg Infect Dis 2005; 11: 821–8. 
50. Sletvold H, Johnsen PJ, Simonsen GS et al. Comparative DNA analysis of two vanA plasmids from 
Enterococcus faecium strains isolated from poultry and a poultry farmer in Norway. Antimicrob Agents Chemother 
2007; 51: 736–9. 
51. Kopit LM, Kim EB, Siezen RJ et al. Safety of the surrogate microorganism Enterococcus faecium NRRL B-2354 
for use in thermal process validation. Appl Environ Microbiol 2014; 80: 1899–909. 
52. Qin X, Galloway-Peña JR, Sillanpaa J et al. Complete genome sequence of Enterococcus faecium strain TX16 
and comparative genomic analysis of Enterococcus faecium genomes. BMC Microbiol 2012; 12: 135. 
53. Xu X, Lin D, Yan G et al. vanM, a new glycopeptide resistance gene cluster found in Enterococcus faecium. 
Antimicrob Agents Chemother 2010; 54: 4643–7. 
54. Lester CH, Frimodt-Møller N, Sørensen TL et al. In vivo transfer of the vanA resistance gene from an 
Enterococcus faecium isolate of animal origin to an E. faecium isolate of human origin in the intestines of human 
volunteers. Antimicrob Agents Chemother 2006; 50: 596–9. 
55. Arias CA, Panesso D, Singh K V et al. Cotransfer of antibiotic resistance genes and a hylEfm-containing 
virulence plasmid in Enterococcus faecium. Antimicrob Agents Chemother 2009; 53: 4240–6. 
56. Laverde Gomez JA, van Schaik W, Freitas AR et al. A multiresistance megaplasmid pLG1 bearing a hylEfm 
genomic island in hospital Enterococcus faecium isolates. Int J Med Microbiol 2011; 301: 165–75. 
57. Rosvoll TCS, Lindstad BL, Lunde TM et al. Increased high-level gentamicin resistance in invasive Enterococcus 
faecium is assoĐiated ǁith aaĐ;6’ͿIe-aph(2″)Ia-encoding transferable megaplasmids hosted by major hospital-
adapted lineages. FEMS Immunol Med Microbiol 2012; 66: 166–76. 
58. Tomita H, Tanimoto K, Hayakawa S et al. Highly conjugative pMG1-like plasmids carrying Tn1546-like 
transposons that encode vancomycin resistance in Enterococcus faecium. J Bacteriol 2003; 185: 7024–8. 
59. Freitas AR, Novais C, Ruiz-Garbajosa P et al. Clonal expansion within clonal complex 2 and spread of 
vancomycin-resistant plasmids among different genetic lineages of Enterococcus faecalis from Portugal. J 
Antimicrob Chemother 2009; 63: 1104–11. 
60. Lam MMC, Seemann T, Bulach DM et al. Comparative analysis of the first complete Enterococcus faecium 
genome. J Bacteriol 2012; 194: 2334–41. 
61. Howden BP, Holt KE, Lam MMC et al. Genomic insights to control the emergence of vancomycin-resistant 
enterococci. MBio 2013; 4: e00412–3 – . 
62. Domingo M-C, Huletsky A, Giroux R et al. vanD and vanG-like gene clusters in a Ruminococcus species 
isolated from human bowel flora. Antimicrob Agents Chemother 2007; 51: 4111–7. 
63. Werner G, Freitas AR, Coque TM et al. Host range of enterococcal vanA plasmids among Gram-positive 
intestinal bacteria. J Antimicrob Chemother 2011; 66: 273–82. 
ϲϰ. Cilo BD, AğĐa H, Efe K et al. Investigation of vancomycin resistant Enterococcus faecium outbreak in neonatal 
intensive care unit. Int J Clin Exp Med 2014; 7: 5342–7. 
65. Marcadé G, Micol J-B, Jacquier H et al. Outbreak in a haematology unit involving an unusual strain of 
glycopeptide-resistant Enterococcus faecium carrying both vanA and vanB genes. J Antimicrob Chemother 2014; 69: 
500–5. 
66. Yang J, Li T, Ning Y et al. Molecular characterization of resistance, virulence and clonality in vancomycin-
resistant Enterococcus faecium and Enterococcus faecalis: A hospital-based study in Beijing, China. Infect Genet Evol 
2015; 33: 253–60. 
67. Campos PA, Batistão DWF, Gontijo-Filho PP et al. A sustained endemic outbreak of vancomycin-resistant 
Enterococcus faecium: A 30-month surveillance study. Scand J Infect Dis 2014; 46: 547–54. 
68. Resende M, Caierão J, Prates JG et al. Emergence of vanA vancomycin-resistant Enterococcus faecium in a 
hospital in Porto Alegre, South Brazil. J Infect Dev Ctries 2014; 8: 160–7. 
Ana P. Tedim  Chapter 4 
 
161 
 
69. Szakacs TA, Kalan L, McConnell MJ et al. Outbreak of vancomycin-susceptible Enterococcus faecium 
containing the wild-type vanA gene. J Clin Microbiol 2014; 52: 1682–6. 
70. Lee S-C, Wu M-S, Shih H-J et al. Identification of vancomycin-resistant enterococci clones and inter-hospital 
spread during an outbreak in Taiwan. BMC Infect Dis 2013; 13: 163. 
71. Thierfelder C, Keller PM, Kocher C et al. Vancomycin-resistant Enterococcus. Swiss Med Wkly 2012; 142: 
w13540. 
72. Fournier S, Brossier F, Fortineau N et al. Long-term control of vancomycin-resistant Enterococcus faecium at 
the scale of a large multihospital institution: a seven-year experience. Euro Surveill 2012; 17. 
73. Pusch T, Kemp D, Trevino S et al. Controlling outbreak of vancomycin-resistant Enterococcus faecium among 
infants caused by an endemic strain in adult inpatients. Am J Infect Control 2013; 41: 51–6. 
74. Tuon FF, Penteado-Filho SR, Camilotti J et al. Outbreak of vancomycin-resistant Enterococcus in a renal 
transplant unit. Braz J Infect Dis 15: 403–5. 
75. Cheng VCC, Chan JFW, Tai JWM et al. Successful control of vancomycin-resistant Enterococcus faecium 
outbreak in a neurosurgical unit at non-endemic region. Emerg Health Threats J 2009; 2: e9. 
76. Werner G, Klare I, Fleige C et al. Vancomycin-resistant vanB-type Enterococcus faecium isolates expressing 
varying levels of vancomycin resistance and being highly prevalent among neonatal patients in a single ICU. 
Antimicrob Resist Infect Control 2012; 1: 21. 
77. Xu H, Tian R, Chen D et al. Nosocomial spread of hospital-adapted CC17 vancomycin-resistant Enterococcus 
faecium in a tertiary-care hospital of Beijing, China. Chin Med J (Engl) 2011; 124: 498–503. 
78. Henard S, Gendrin V, Simon L et al. Control of a regional outbreak of vanA glycopeptide-resistant 
Enterococcus faecium, Eastern France, 2004-2009. Int J Hyg Environ Health 2011; 214: 265–70. 
79. Liu Y, Cao B, Gu L et al. Successful control of vancomycin-resistant Enterococcus faecium nosocomial 
outbreak in a teaching hospital in China. Am J Infect Control 2012; 40: 568–71. 
80. Iosifidis E, Evdoridou I, Agakidou E et al. Vancomycin-resistant Enterococcus outbreak in a neonatal intensive 
care unit: epidemiology, molecular analysis and risk factors. Am J Infect Control 2013; 41: 857–61. 
81. Valdezate S, Labayru C, Navarro A et al. Large clonal outbreak of multidrug-resistant CC17 ST17 Enterococcus 
faecium containing Tn5382 in a Spanish hospital. J Antimicrob Chemother 2009; 63: 17–20. 
82. Panesso D, Reyes J, Rincón S et al. Molecular epidemiology of vancomycin-resistant Enterococcus faecium: a 
prospective, multicenter study in South American hospitals. J Clin Microbiol 2010; 48: 1562–9. 
83. Park SY, Kang J-H, Kim J-H et al. Vancomycin-resistant Enterococcus faecium outbreak caused by patient 
transfer in 2 separate intensive care units. Am J Infect Control 2012; 40: 565–7. 
84. Servais A, Mercadal L, Brossier F et al. Rapid curbing of a vancomycin-resistant Enterococcus faecium 
outbreak in a nephrology department. Clin J Am Soc Nephrol 2009; 4: 1559–64. 
85. Hoshuyama T, Moriguchi H, Muratani T et al. Vancomycin-resistant enterococci (VRE) outbreak at a 
university hospital in Kitakyushu, Japan: case-control studies. J Infect Chemother 2008; 14: 354–60. 
86. Dendle C, Ballard SA, Grabsch EA et al. Outbreak of vancomycin-resistant Enterococcus faecium containing 
both vanA and vanB gene clusters. J Hosp Infect 2009; 71: 379–81. 
87. Al-Mohri HA, Tadros MA, Louie L et al. Utility of direct, real-time PCR in the management of a nosocomial 
outbreak of vancomycin-resistant Enterococcus faecium (vanB genotype). Eur J Clin Microbiol Infect Dis 2008; 27: 
321–2. 
88. Kirdar S, Sener AG, Arslan U et al. Molecular epidemiology of vancomycin-resistant Enterococcus faecium 
strains isolated from haematological malignancy patients in a research hospital in Turkey. J Med Microbiol 2010; 59: 
660–4. 
89. Pereira GH, Müller PR, Zanella RC et al. Outbreak of vancomycin-resistant enterococci in a tertiary hospital: 
the lack of effect of measures directed mainly by surveillance cultures and differences in response between 
Enterococcus faecium and Enterococcus faecalis. Am J Infect Control 2010; 38: 406–9. 
90. Lester CH, Olsen SS, Schønheyder HC et al. Typing of vancomycin-resistant enterococci obtained from 
patients at Danish hospitals and detection of a genomic island specific to CC17 Enterococcus faecium. Int J 
Antimicrob Agents 2010; 35: 312–4. 
91. Yoon YK, Sim HS, Kim JY et al. Epidemiology and control of an outbreak of vancomycin-resistant enterococci 
in the intensive care units. Yonsei Med J 2009; 50: 637–43. 
Ana P. Tedim  Chapter 4 
 
162 
 
92. Zhu X, Zheng B, Wang S et al. Molecular characterisation of outbreak-related strains of vancomycin-resistant 
Enterococcus faecium from an intensive care unit in Beijing, China. J Hosp Infect 2009; 72: 147–54. 
93. Khan MA, Northwood JB, Loor RGJ et al. High prevalence of ST-78 infection-associated vancomycin-resistant 
Enterococcus faecium from hospitals in Asunción, Paraguay. Clin Microbiol Infect 2010; 16: 624–7. 
ϵϰ. KaǁaleĐ M, Pietƌas ), DaŶiłoǁiĐz E et al. Clonal structure of Enterococcus faecalis isolated from Polish 
hospitals: characterization of epidemic clones. J Clin Microbiol 2007; 45: 147–53. 
95. Werner G, Klare I, Witte W. The current MLVA typing scheme for Enterococcus faecium is less discriminatory 
than MLST and PFGE for epidemic-virulent, hospital-adapted clonal types. BMC Microbiol 2007; 7: 28. 
96. Schmidt-Hieber M, Blau IW, Schwartz S et al. Intensified strategies to control vancomycin-resistant 
enterococci in immunocompromised patients. Int J Hematol 2007; 86: 158–62. 
97. Ergani-Ozcan A, Naas T, Baysan BO et al. Nosocomial outbreak of vancomycin-resistant Enterococcus faecium 
in a paediatric unit at a Turkish university hospital. J Antimicrob Chemother 2008; 61: 1033–9. 
98. Comert FB, Kulah C, Aktas E et al. First isolation of vancomycin-resistant enteroccoci and spread of a single 
clone in a university hospital in northwestern Turkey. Eur J Clin Microbiol Infect Dis 2007; 26: 57–61. 
99. Montesinos I, Campos S, Ramos MJ et al. [Study of the first outbreak of vanA enterococcus faecium in the 
Canary Islands]. Enferm Infecc Microbiol Clin 28: 430–4. 
100. Souli M, Sakka V, Galani I et al. Colonisation with vancomycin- and linezolid-resistant Enterococcus faecium 
in a university hospital: molecular epidemiology and risk factor analysis. Int J Antimicrob Agents 2009; 33: 137–42. 
101. Ergaz Z, Arad I, Bar-Oz B et al. Elimination of vancomycin-resistant enterococci from a neonatal intensive 
care unit following an outbreak. J Hosp Infect 2010; 74: 370–6. 
102. Drews SJ, Richardson SE, Wray R et al. An outbreak of vancomycin-resistant Enterococcus faecium in an 
acute care pediatric hospital: Lessons from environmental screening and a case-control study. Can J Infect Dis Med 
Microbiol 2008; 19: 233–6. 
103. Lucet J-C, Armand-Lefevre L, Laurichesse J-J et al. Rapid control of an outbreak of vancomycin-resistant 
enterococci in a French university hospital. J Hosp Infect 2007; 67: 42–8. 
104. Yang K-S, Fong Y-T, Lee H-Y et al. Predictors of vancomycin-resistant enterococcus (VRE) carriage in the first 
major VRE outbreak in Singapore. Ann Acad Med Singapore 2007; 36: 379–83. 
105. López M, Hormazábal JC, Maldonado A et al. Clonal dissemination of Enterococcus faecalis ST201 and 
Enterococcus faecium CC17-ST64 containing Tn5382-vanB2 among 16 hospitals in Chile. Clin Microbiol Infect 2009; 
15: 586–8. 
106. Worth LJ, Thursky KA, Seymour JF et al. Vancomycin-resistant Enterococcus faecium infection in patients 
with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol 2007; 79: 226–
33. 
107. Aumeran C, Baud O, Lesens O et al. Successful control of a hospital-wide vancomycin-resistant Enterococcus 
faecium outbreak in France. Eur J Clin Microbiol Infect Dis 2008; 27: 1061–4. 
108. Nebreda T, Oteo J, Aldea C et al. Hospital dissemination of a clonal complex 17 vanB2-containing 
Enterococcus faecium. J Antimicrob Chemother 2007; 59: 806–7. 
109. Brossier F, Lefrançois S, Paute J et al. Decolonisation for early control of an outbreak of vancomycin-
resistant Enterococcus faecium in a geriatric rehabilitation care facility. J Hosp Infect 2010; 76: 368–9. 
110. Theilacker C, Jonas D, Huebner J et al. Outcomes of invasive infection due to vancomycin-resistant 
Enterococcus faecium during a recent outbreak. Infection 2009; 37: 540–3. 
111. Borgmann S, Schulte B, Wolz C et al. Discrimination between epidemic and non-epidemic glycopeptide-
resistant E. faecium in a post-outbreak situation. J Hosp Infect 2007; 67: 49–55. 
112. Deplano A, Denis O, Nonhoff C et al. Outbreak of hospital-adapted clonal complex-17 vancomycin-resistant 
Enterococcus faecium strain in a haematology unit: role of rapid typing for early control. J Antimicrob Chemother 
2007; 60: 849–54. 
113. Dobbs TE, Patel M, Waites KB et al. Nosocomial spread of Enterococcus faecium resistant to vancomycin 
and linezolid in a tertiary care medical center. J Clin Microbiol 2006; 44: 3368–70. 
114. Chlebicki MP, Ling ML, Koh TH et al. First outbreak of colonization and infection with vancomycin-resistant 
Enterococcus faecium in a tertiary care hospital in Singapore. Infect Control Hosp Epidemiol 2006; 27: 991–3. 
Ana P. Tedim  Chapter 4 
 
163 
 
115. Koh TH, Hsu L-Y, Chiu L-L et al. Emergence of epidemic clones of vancomycin-resistant Enterococcus faecium 
in Singapore. J Hosp Infect 2006; 63: 234–6. 
116. Libisch B, Lepsanovic Z, Top J et al. Molecular characterization of vancomycin-resistant Enterococcus spp. 
clinical isolates from Hungary and Serbia. Scand J Infect Dis 2008; 40: 778–84. 
117. Naas T, Fortineau N, Snanoudj R et al. First nosocomial outbreak of vancomycin-resistant Enterococcus 
faecium expressing a VanD-like phenotype associated with a vanA genotype. J Clin Microbiol 2005; 43: 3642–9. 
118. Böröcz K, Szilágyi E, Kurcz A et al. First vancomycin-resistant Enterococcus faecium outbreak reported in 
Hungary. Euro Surveill 2005; 10: E050127.1. 
119. Pendle S, Jelfs P, Olma T et al. Difficulties in detection and identification of Enterococcus faecium with low-
level inducible resistance to vancomycin, during a hospital outbreak. Clin Microbiol Infect 2008; 14: 853–7. 
120. Abbassi MS, Znazen A, Mahjoubi F et al. Emergence of vancomycin-resistant Enterococcus faecium in Sfax: 
clinical features and molecular typing. Médecine Mal Infect 2007; 37: 240–1. 
121. Zárate MS, Gales A, Jordá-Vargas L et al. [Environmental contamination during a vancomycin-resistant 
Enterococci outbreak at a hospital in Argentina]. Enferm Infecc Microbiol Clin 2007; 25: 508–12. 
122. Novais C, Sousa JC, Coque TM et al. Molecular characterization of glycopeptide-resistant Enterococcus 
faecium isolates from Portuguese hospitals. Antimicrob Agents Chemother 2005; 49: 3073–9. 
123. Khan MA, van der Wal M, Farrell DJ et al. Analysis of VanA vancomycin-resistant Enterococcus faecium 
isolates from Saudi Arabian hospitals reveals the presence of clonal cluster 17 and two new Tn1546 lineage types. J 
Antimicrob Chemother 2008; 62: 279–83. 
124. Stampone L, Del Grosso M, Boccia D et al. Clonal spread of a vancomycin-resistant Enterococcus faecium 
strain among bloodstream-infecting isolates in Italy. J Clin Microbiol 2005; 43: 1575–80. 
125. Oh HS, Kim EC, Oh MD et al. Outbreak of vancomycin resistant enterococcus in a hematology/oncology unit 
in a Korean University Hospital, and risk factors related to patients, staff, hospital care and facilities. Scand J Infect 
Dis 2004; 36: 790–4. 
126. Peta M, Carretto E, Barbarini D et al. Outbreak of vancomycin-resistant Enterococcus spp. in an Italian 
general intensive care unit. Clin Microbiol Infect 2006; 12: 163–9. 
127. Christiansen KJ, Tibbett PA, Beresford W et al. Eradication of a large outbreak of a single strain of vanB 
vancomycin-resistant Enterococcus faecium at a major Australian teaching hospital. Infect Control Hosp Epidemiol 
2004; 25: 384–90. 
128. McEvoy SP, Plant AJ, Pearman JW et al. Risk factors for the acquisition of vancomycin-resistant enterococci 
during a single-strain outbreak at a major Australian teaching hospital. J Hosp Infect 2006; 62: 256–8. 
129. Mascini EM, Jalink KP, Kamp-Hopmans TEM et al. Acquisition and duration of vancomycin-resistant 
enterococcal carriage in relation to strain type. J Clin Microbiol 2003; 41: 5377–83. 
130. Mascini EM, Troelstra A, Beitsma M et al. Genotyping and preemptive isolation to control an outbreak of 
vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2006; 42: 739–46. 
131. Camargo ILBC, Gilmore MS, Darini ALC. Multilocus sequence typing and analysis of putative virulence 
factors in vancomycin-resistant and vancomycin-sensitive Enterococcus faecium isolates from Brazil. Clin Microbiol 
Infect 2006; 12: 1123–30. 
132. Knoll M, Daeschlein G, Okpara-Hofmann J et al. Outbreak of vancomycin-resistant enterococci (VRE) in a 
hematological oncology ward and hygienic preventive measures. A long-term study. Onkologie 2005; 28: 187–92. 
133. Routsi C, Platsouka E, Willems RJL et al. Detection of enterococcal surface protein gene (esp) and amplified 
fragment length polymorphism typing of glycopeptide-resistant Enterococcus faecium during its emergence in a 
Greek intensive care unit. J Clin Microbiol 2003; 41: 5742–6. 
134. Corso AC, Gagetti PS, Rodríguez MM et al. Molecular epidemiology of vancomycin-resistant Enterococcus 
faecium in Argentina. Int J Infect Dis 2007; 11: 69–75. 
135. Kawalec M, Gniadkowski M, Hryniewicz W. Outbreak of vancomycin-resistant enterococci in a hospital in 
Gdask, Poland, due to horizontal transfer of different Tn1546-like transposon variants and clonal spread of several 
strains. J Clin Microbiol 2000; 38: 3317–22. 
136. Khan E, Sarwari A, Hasan R et al. Emergence of vancomycin-resistant Enterococcus faecium at a tertiary 
care hospital in Karachi, Pakistan. J Hosp Infect 2002; 52: 292–6. 
Ana P. Tedim  Chapter 4 
 
164 
 
137. van der Steen LF, Bonten MJ, van Kregten E et al. [Vancomycin-resistant Enterococcus faecium outbreak in 
a nephrology ward]. Ned Tijdschr Geneeskd 2000; 144: 2568–72. 
138. Kawalec M, Gniadkowski M, Kedzierska J et al. Selection of a teicoplanin-resistant Enterococcus faecium 
mutant during an outbreak caused by vancomycin-resistant enterococci with the vanB phenotype. J Clin Microbiol 
2001; 39: 4274–82. 
139. Ozorowski T, Kawalec M, Zaleska M et al. The effect of an antibiotic policy on the control of vancomycin-
resistant enterococci outbreak and on the resistance patterns of bacteria isolated from the blood of patients in a 
hematology unit. Pol AƌĐh Med WeǁŶętƌzŶej ϮϬϬ9; 119: 712–8. 
140. Chang C-M, Wang L-R, Lee H-C et al. Characterisation of vancomycin-resistant enterococci from hospitalised 
patients at a tertiary centre over a seven-year period. J Hosp Infect 2010; 74: 377–84. 
141. Granlund M, Carlsson C, Edebro H et al. Nosocomial outbreak of vanB2 vancomycin-resistant Enterococcus 
faecium in Sweden. J Hosp Infect 2006; 62: 254–6. 
142. McCarthy KM, Van Nierop W, Duse A et al. Control of an outbreak of vancomycin-resistant Enterococcus 
faecium in an oncology ward in South Africa: effective use of limited resources. J Hosp Infect 2000; 44: 294–300. 
143. Colak D, Naas T, Gunseren F et al. First outbreak of vancomycin-resistant enterococci in a tertiary hospital in 
Turkey. J Antimicrob Chemother 2002; 50: 397–401. 
144. Panesso D, Ospina S, Robledo J et al. First characterization of a cluster of VanA-type glycopeptide-resistant 
Enterococcus faecium, Colombia. Emerg Infect Dis 2002; 8: 961–5. 
145. Roger M, Faucher MC, Forest P et al. Evaluation of a vanA-specific PCR assay for detection of vancomycin-
resistant Enterococcus faecium during a hospital outbreak. J Clin Microbiol 1999; 37: 3348–9. 
146. Timmers GJ, van der Zwet WC, Simoons-Smit IM et al. Outbreak of vancomycin-resistant Enterococcus 
faecium in a haematology unit: risk factor assessment and successful control of the epidemic. Br J Haematol 2002; 
116: 826–33. 
147. Bartley PB, Schooneveldt JM, Looke DF et al. The relationship of a clonal outbreak of Enterococcus faecium 
vanA to methicillin-resistant Staphylococcus aureus incidence in an Australian hospital. J Hosp Infect 2001; 48: 43–
54. 
148. Zanella RC, Brandileone MCC, Bokermann S et al. Phenotypic and genotypic characterization of VanA 
Enterococcus isolated during the first nosocomial outbreak in Brazil. Microb Drug Resist 2003; 9: 283–91. 
149. Titze-de-Almeida R, Van Belkum A, Felipe MSS et al. Multilocus sequence typing of hospital-associated 
Enterococcus faecium from Brazil reveals their unique evolutionary history. Microb Drug Resist 2006; 12: 121. 
150. MacIntyre CR, Empson M, Boardman C et al. Risk factors for colonization with vancomycin-resistant 
enterococci in a Melbourne hospital. Infect Control Hosp Epidemiol 2001; 22: 624–9. 
151. Lee HK, Lee WG, Cho SR. Clinical and molecular biological analysis of a nosocomial outbreak of vancomycin-
resistant enterococci in a neonatal intensive care unit. Acta Paediatr 1999; 88: 651–4. 
152. Kirkpatrick BD, Harrington SM, Smith D et al. An outbreak of vancomycin-dependent Enterococcus faecium 
in a bone marrow transplant unit. Clin Infect Dis 1999; 29: 1268–73. 
153. Falk PS, Winnike J, Woodmansee C et al. Outbreak of vancomycin-resistant enterococci in a burn unit. Infect 
Control Hosp Epidemiol 2000; 21: 575–82. 
154. Hanna H, Umphrey J, Tarrand J et al. Management of an outbreak of vancomycin-resistant enterococci in 
the medical intensive care unit of a cancer center. Infect Control Hosp Epidemiol 2001; 22: 217–9. 
155. Schuster F, Graubner UB, Schmid I et al. Vancomycin-resistant-enterococci--colonization of 24 patients on a 
pediatric oncology unit. Klin Pädiatrie 210: 261–3. 
156. Elsner HA, Sobottka I, Feucht HH et al. Nosocomial outbreak of vancomycin-resistant Enterococcus faecium 
at a German university pediatric hospital. Int J Hyg Environ Health 2000; 203: 147–52. 
157. Donskey CJ, Schreiber JR, Jacobs MR et al. A polyclonal outbreak of predominantly VanB vancomycin-
resistant enterococci in northeast Ohio. Northeast Ohio Vancomycin-Resistant Enterococcus Surveillance Program. 
Clin Infect Dis 1999; 29: 573–9. 
158. Nourse C, Murphy H, Byrne C et al. Control of a nosocomial outbreak of vancomycin resistant Enterococcus 
faecium in a paediatric oncology unit: risk factors for colonisation. Eur J Pediatr 1998; 157: 20–7. 
159. Rizkalla EA, Moore JE, Marshall SA et al. Glycopeptide-resistant enterococci in Northern Ireland: first 
reported outbreak. J Antimicrob Chemother 1997; 40: 607–8. 
Ana P. Tedim  Chapter 4 
 
165 
 
160. Hwang YS, Brinton BG, Leonard RB et al. Investigation of an outbreak of vancomycin-resistant Enterococcus 
faecium in a low prevalence university hospital. J Investig Med 1998; 46: 435–43. 
161. Scagnelli M, Pellizer G, de Lalla F et al. Epidemiological analysis of vancomycin-resistant enterococci in a 
large tertiary-care hospital in Northern Italy. Eur J Clin Microbiol Infect Dis 2001; 20: 609–16. 
162. Bonten MJ, Hayden MK, Nathan C et al. Epidemiology of colonisation of patients and environment with 
vancomycin-resistant enterococci. Lancet (London, England) 1996; 348: 1615–9. 
163. Brown AR, Amyes SG, Paton R et al. Epidemiology and control of vancomycin-resistant enterococci (VRE) in 
a renal unit. J Hosp Infect 1998; 40: 115–24. 
164. Torell E, Fredlund H, Törnquist E et al. Intrahospital spread of vancomycin-resistant Enterococcus faecium in 
Sweden. Scand J Infect Dis 1997; 29: 259–63. 
165. Pegues DA, Pegues CF, Hibberd PL et al. Emergence and dissemination of a highly vancomycin-resistant 
vanA strain of Enterococcus faecium at a large teaching hospital. J Clin Microbiol 1997; 35: 1565–70. 
166. Pearce CL, Evans MK, Peters SM et al. Clonal diversity of vancomycin-resistant enterococci from an 
outbreak in a tertiary care university hospital. Am J Infect Control 1998; 26: 563–8. 
167. Chadwick PR, Oppenheim BA, Fox A et al. Epidemiology of an outbreak due to glycopeptide-resistant 
Enterococcus faecium on a leukaemia unit. J Hosp Infect 1996; 34: 171–82. 
168. Lavery A, Rossney AS, Morrison D et al. Incidence and detection of multi-drug-resistant enterococci in 
Dublin hospitals. J Med Microbiol 1997; 46: 150–6. 
169. Anglim AM, Klym B, Byers KE et al. Effect of a vancomycin restriction policy on ordering practices during an 
outbreak of vancomycin-resistant Enterococcus faecium. Arch Intern Med 1997; 157: 1132–6. 
170. Wells CL, Juni BA, Cameron SB et al. Stool carriage, clinical isolation, and mortality during an outbreak of 
vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995; 21: 45–50. 
171. Quale J, Landman D, Atwood E et al. Experience with a hospital-wide outbreak of vancomycin-resistant 
enterococci. Am J Infect Control 1996; 24: 372–9. 
172. Issack MI, Power EG, French GL. Investigation of an outbreak of vancomycin-resistant Enterococcus faecium 
by random amplified polymorphic DNA (RAPD) assay. J Hosp Infect 1996; 33: 191–200. 
173. Dominguez EA, Davis JC, Langnas AN et al. An outbreak of vancomycin-resistant Enterococcus faecium in 
liver transplant recipients. Liver Transpl Surg 1997; 3: 586–90. 
174. Edmond MB, Ober JF, Weinbaum DL et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk 
factors for infection. Clin Infect Dis 1995; 20: 1126–33. 
175. Jordens JZ, Bates J, Griffiths DT. Faecal carriage and nosocomial spread of vancomycin-resistant 
Enterococcus faecium. J Antimicrob Chemother 1994; 34: 515–28. 
176. Montecalvo MA, Horowitz H, Gedris C et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-
resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994; 38: 
1363–7. 
177. Boyce JM, Opal SM, Chow JW et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable 
vanB class vancomycin resistance. J Clin Microbiol 1994; 32: 1148–53. 
178. Boyle JF, Soumakis SA, Rendo A et al. Epidemiologic analysis and genotypic characterization of a 
nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993; 31: 1280–5. 
179. Livornese LL, Dias S, Samel C et al. Hospital-acquired infection with vancomycin-resistant Enterococcus 
faecium transmitted by electronic thermometers. Ann Intern Med 1992; 117: 112–6. 
180. Handwerger S, Raucher B, Altarac D et al. Nosocomial outbreak due to Enterococcus faecium highly 
resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993; 16: 750–5. 
 
 
  
Ana P. Tedim  Chapter 4 
 
166 
 
SUPPLEMENTARY MATERIAL 
Table S1. Clonal characteristics and epidemiological background of VREfm (n=71) and VSEfm (n=82) 
isolates included in this study. 
 
 
VREfm/VSEfm BAPS ST PFGE No. van Countryc City / Region Date Source
isolatesa subgroup type b gene esp hyl entA bac32 bac43 entB entP entQ entL
P575 3.1 280 VREF-55 1 A PER NI NI urine + + + +
H358 3.1 280 VREF-17 1 A PRT Porto, Viseu 2002-03 urine + + +
DB20546/OB19275 3.1 280 VREF-17 2 B SIN Singapore 2004 NI + +
E0161 3.3a2 16 VREF-26 1 A USA Chicago 1995 faeces +
PAO2 3.3a2 16 VREF-41 1 A AUS Brisbane 1997-1999 faeces; urine + +
E0481 3.3a2 16 VREF-8 1 A NLD Amsterdam 1999 NI + +
E0805 3.3a2 16 VREF-9** 1 A NLD Utrecht 2000 faeces + + +
E1132 3.3a2 16 VREF-9** 1 A USA Oregon 2001 faeces + + +
E1651 3.3a2 16 VREF-9** 1 A NLD Amersfoort 2002 wound + + +
2664 3.3a2 16 VREF-38 1 A ARG NI 2000 stool + + +
E2480 (C68) 3.3a2 16 VREF-27 1 B USA Cleveland 1996 faeces + + +
Ef82 3.3a2 17 VREF-32* 1 A USA New York 1992 NI + + +
2391 3.3a2 17 VREF-32* 1 A ARG Buenos Aires 1997-98 stool + +
232/09 3.3a2 17 VREF-56* 1 A ESP Granada 2009 blood + + +
E417 3.3a2 17 VREF-58 1 A ECU NI NI blood + +
VREII 3.3a2 17 VREF-55 1 A FIN Helsinki 1996-98 NI +
265859 3.3a2 17 VREF-18 1 A ESP Madrid 2003 organic fluid +
S13 3.3a2 17 VREF-52 1 A SAR Riyadh 2000-03 NI + + +
A437 3.3a2 17 VREF-53 1 A TUN Sfax 2003 NI + +
Vri16 3.3a2 17 VREF-34 1 A BRA NI NI NI + + + +
Ef80 3.3a2 17 VREF-31 1 B USA New York 1991-92 NI + + +
E0532 3.3a2 17 VREF-46 1 B AUS NI 1998 urine + +
361400 3.3a2 17 VREF-19 1 B ESP Madrid 2004 wound +
135487 3.3a2 17 VREF-19 1 B ESP Madrid 2005 blood + +
604/06 3.3a2 17 VREF-45 1 B ESP Burgos 2006 abdominal fluid + +
Ent35 3.3a2 17 VREF-45 1 B ESP Soria 2004-06 NI + +
E1438 3.3a2 65 VREF-7 1 A GRC Athens 1999 blood + + +
2219/05 3.3a2 202 VREF-36 1 A POL Krakow 2005 wound + + +
UW6511 3.3a2 202 VREF-24 1 A DEU Berlin 2006 blood + + +
AE12 3.3a2 209 VREF-15 1 B ITA Northern Italy 2002 blood + +
E0013 3.3a1 18 VREF-3 1 A GBR Oxford 1992 urine + +
S30 3.3a1 18 VREF-NI 1 A SAR Riyadh 2000-03 NI + +
E2373 3.3a1 18 VREF-22 1 A SER Belgrade 2005 coproculture + + +
H182 3.3a1 18 VREF-13 1 A PRT Porto, Coimbra 2002-03 blood, hepatic fluid +
48311 3.3a1 18 VREF-14 1 A PRT Coimbra NI NI + +
VRE101 3.3a1 18 VREF-49 1 A DNK NI 2005-08 NI
2227/05 3.3a1 18 VREF-43 1 A POL Krakow 2005 rectal swab + + +
C497 3.3a1 18 VREF-48 1 A COL NI NI blood + +
E144 3.3a1 64 VREF-39 1 B CHI Santiago 2003 urine + +
E76 3.3a1 64 VREF-40 1 B CHI Santiago 2004 urine + +
H74 3.3a1 132 VREF-10 1 A PRT Porto, Coimbra 1999-2001 organic fluid, blood +
H311 3.3a1 132 VREF-54 1 A PRT Porto 2002 urine + +
VRE100 3.3a1 173 VREF-42 1 B AUS Perth 2001 NI + + +
2348 2.1a 78 VREF-37 1 A ARG NI 1998 stool + + +
AE01 2.1a 78 VREF-11 1 A ITA Several cities 2001-03 blood + +
E1644 2.1a 78 VREF-11 1 A DEU Freiburg 2002 catheter + +
C853 2.1a 78 VREF-11 1 A ESP Barcelona 2006 NI + +
P1 2.1a 78 VREF-51 1 A PRG Asunción 2005 NI + + +
E2365 2.1a 80 VREF-20 1 B HUN Budapest 2004 blood + + +
UW1806 2.1a 117 VREF-5 1 A DEU Berlin 1998 tracheal secretion + +
VnR16 2.1a 117 VREF-28 1 A ESP Madrid 2008 Wound + + +
UW5905 2.1a 192 VREF-16 1 A DEU Freiburg 2004 blood + + +
Lin1 2.1a 203 VREF-30 1 A USA Alabama 2004-05 NI + +
UW6337 2.1a 203 VREF-23 1 A DEU Tübingen 2005 tracheal secretion + + +
E422 2.1a 203 VREF-57 1 A ECU NI NI urine + +
VRE2 2.1a 203 VREF-48 1 B DNK NI 2005-08 NI +
S1 2.1a 358 VREF-44 1 A SAR Riyadh 2000-03 NI +
Efm Canada 2.1a 412 VREF-50 1 A CAN Ontario 2005 NI + + + +
V689 2.1a 412 VREF-50 1 A VEN NI NI wound + +
P1123 2.1a 412 VREF-56 1 A PER NI NI blood + +
P118 2.1a 438 VREF-51 1 A PRG Asunción 2006 NI + + +
Virulence 
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VREfm/VSEfm BAPS ST PFGE No. van Countryc City / Region Date Source
isolatesa subgroup type b gene esp hyl entA bac32 bac43 entB entP entQ entL
H305 2.1b 5 VREF-12 1 A PRT Porto 2002 wound
Vri22 2.1b 50 VREF-35 1 A BRA NI NI NI + +
BM4147 (E0005) 2.3a 25 VREF-1 1 A FRA NI 1986 faeces
BM4165 2.3a 25 VREF-2 1 A FRA Nancy 1987 faeces
E1686 2.3a 114 VREF-33 1 A BRA S. Paulo 1998 faeces + +
71689 2.3b 265 VREF-4 1 B ESP Madrid 1998 urine + +
VREI 5 484 VREF-47 1 B FIN Helsinki 1996-98 NI
E0292 7 20 VREF-25 1 A USA Detroit 1992-94 urine + +
Texas 7 182 VREF-29 1 B USA Texas 1992 NI + + +
EFM4s 3.1 22 ASEF-2 1 - ESP Madrid 1995 blood + +
EFM28s 3.1 22 ASEF-22 1 - ESP Madrid 1999 blood + + +
EFM22s 3.1 32 ASEF-5 1 - ESP Madrid 1995 blood + +
EFM48 3.1 125 AREF-Q 1 - ESP Madrid 2000 blood + + +
EFM11s 3.1 214 ASEF-36 1 - ESP Madrid 2006 blood + + +
EFM12s 3.1 214 ASEF-37 1 - ESP Madrid 2006 blood + +
EFM20s 3.1 533 ASEF-41 1 - ESP Madrid 2006 blood + + +
EFM5s 3.2 29 ASEF-34 1 - ESP Madrid 2007 blood +
EFM1s 3.2 97 ASEF-31 1 - ESP Madrid 2001 blood
EFM39-42 3.3a2 16 AREF-T** 4 - ESP Madrid 2001-04 blood + + + 1
E1718 3.3a2 17 AREF-1 1 - DNK Aarhus 1999-2000 NI +
E1340 3.3a2 17 AREF-6 1 - NOR Bergen 1999 wound +
EFM34 3.3a2 17 AREF-P 1 - ESP Madrid 1995 blood + +
EFM35 3.3a2 17 AREF-B 1 - ESP Madrid 1996 blood + +
EFM38 3.3a2 17 AREF-8 1 - ESP Madrid 2008 blood + + +
EFM44 3.3a2 63 AREF-W.2 1 - ESP Madrid 2000 blood + + +
EFM46 3.3a2 103 AREF-W 1 - ESP Madrid 2001 blood + + +
EFM47 3.3a2 103 AREF-W.3 1 - ESP Madrid 2001 blood + + + +
EFM1 3.3a1 18 AREF-A 1 - ESP Madrid 1995 blood + +
EFM2 3.3a1 18 AREF-C 1 - ESP Madrid 1996 blood + +
EFM3-29 3.3a1 18 AREF-D 13 - ESP Madrid 1997-2005 blood 8 1 + 1 7
EFM23 3.3a1 18 AREF-D.1 1 - ESP Madrid 2002 blood + + +
EFM8 3.3a1 18 AREF-E 1 - ESP Madrid 1997 blood + +
EFM13 3.3a1 18 AREF-G 1 - ESP Madrid 1998 blood + +
EFM14 3.3a1 18 AREF-Z 1 - ESP Madrid 1998 blood + +
EFM15 3.3a1 18 AREF-J 1 - ESP Madrid 1999 blood +
EFM17,19 3.3a1 18 AREF-N 2 - ESP Madrid 2000 blood 1 +
EFM18 3.3a1 18 AREF-M 1 - ESP Madrid 2000 blood + +
EFM20 3.3a1 18 AREF-Y 1 - ESP Madrid 2001 blood + + + +
EFM24 3.3a1 18 AREF-U 1 - ESP Madrid 2002 blood +
EFM25 3.3a1 18 AREF-1 1 - ESP Madrid 2003 blood +
EFM26,28 3.3a1 18 AREF-2 2 - ESP Madrid 2004 blood 1 1 +
EFM27 3.3a1 18 AREF-3 1 - ESP Madrid 2004 blood + +
EFM30 3.3a1 18 AREF-4 1 - ESP Madrid 2006 blood + + +
EFM31 3.3a1 18 AREF-5 1 - ESP Madrid 2006 blood + + +
EFM32 3.3a1 18 AREF-6 1 - ESP Madrid 2007 blood +
EFM33 3.3a1 18 AREF-7 1 - ESP Madrid 2008 blood +
EFM2s 3.3a1 18 ASEF-9 1 - ESP Madrid 1996 blood +
EFM25s 3.3a1 18 ASEF-12 1 - ESP Madrid 1997 blood + +
EFM3s 3.3a1 18 ASEF-24 1 - ESP Madrid 2000 blood
EFM32s 3.3b 102 ASEF-29 1 - ESP Madrid 2001 blood + + +
EFM45 3.3b 102 AREF-S 1 - ESP Madrid 2001 blood + + +
EFM27s 3.3b 888 ASEF-20 1 - ESP Madrid 1999 blood + + + + +
EFM49 2.1a 203 AREF-9 1 - ESP Madrid 2006 blood + + +
EFM50 2.1a 203 AREF-9.3 1 - ESP Madrid 2006 blood +
EFM51 2.1a 203 AREF-9.1 1 - ESP Madrid 2007 blood + +
EFM52 2.1a 266 AREF-10 1 - ESP Madrid 2004 blood + +
EFM17s 2.1a 442 ASEF-39 1 - ESP Madrid 2005 blood + +
EFM33s 2.1b 46 ASEF-30 1 - ESP Madrid 2001 blood + +
EFM7s 2.1b 69 ASEF-35 1 - ESP Madrid 2003 blood + +
EFM8s 2.1b 69 ASEF-44 1 - ESP Madrid 2005 blood + + +
EFM26s 2.3a 21 ASEF-13 1 - ESP Madrid 1997 blood + +
EFM30s 2.3a 25 ASEF-26 1 - ESP Madrid 2000 blood +
EFM21s 2.3a 71 ASEF-3 1 - ESP Madrid 1995 blood + +
EFM13s 2.3a 420 ASEF-38 1 - ESP Madrid 2007 blood + +
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Abbreviations: BAPS, Bayesian analysis of Population Structure; CC, clonal complex; ST, sequence type;  VSEF, vancomycin-
susceptible Enterococcus faecium; AREF, ampicillin-resistant Enterococcus faecium; ASEF, ampicillin-susceptible Enterococcus 
faecium; NI, not identified. aThe original references describing the isolates included in this study can be found in Table 1. bPFGE 
types were arbitrarily designated by main phenotype (VREF, ASEF or AREF) followed by a number or capital letter. *The PFGE 
patterns VREF-32 and VREF-56 share common bands (< 8 bands difference). **VREF-9 and AREF-T are the same PFGE pattern (< 6 
bands difference). cARG, Argentina; AUS, Australia; BRA, Brazil; CAN, Canada; CHI, Chile; COL, Colombia; DEU, Germany; DNK, 
Denmark; ECU, Ecuador; ESP, Spain; FIN, Finland; FRA, France; GBR, Great Britain; GRC, Greece; HUN, Hungary; ITA, Italy; NLD, The 
Netherlands; NOR, Norway ; PER, Peru; POL, Poland; PRG, Paraguay; PRT, Portugal; SAR, Saudi Arabia; SER, Serbia; SIN, Singapore; 
TUN, Tunisia; USA, United States of America; VEN, Venezuela. dPositive virulence (esp, hyl) and bacteriocin (entA, entB, entP, entQ, 
entL, bac32, bac43) genes appear with a (+).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VREfm/VSEfm BAPS ST PFGE No. van Countryc City / Region Date Source
isolatesa subgroup typeb gene esp hyl entA bac32 bac43 entB entP entQ entL
EFM29s 2.3b 247 ASEF-25 1 - ESP Madrid 2000 blood + +
EFM15s 1.1 474 ASEF-42 1 - ESP Madrid 2004 blood + + +
EFM31s 1.2 74 ASEF-28 1 - ESP Madrid 2001 blood + +
EFM9s 1.2 85 ASEF-17 1 - ESP Madrid 1997 blood + +
EFM6s 1.2 96 ASEF-32 1 - ESP Madrid 2002 blood + + +
EFM10s 1.2 178 ASEF-18 1 - ESP Madrid 1997 blood + + + + +
EFM14s 1.2 178 ASEF-19 1 - ESP Madrid 1999 blood + + +
EFM24s 1.2 674 ASEF-15 1 - ESP Madrid 1997 blood +
EFM54 6 419 AREF-11 1 - ESP Madrid 2005 blood + + +
EFM34s 7 675 ASEF-40 1 - ESP Madrid 2007 blood + +
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Figure S3. Tn1546 diversity of vanA E. faecium isolates. 
Abbreviations: IS, insertion sequence; MLST, multilocus sequence typing; CC, clonal complex; ST, sequence type; ARG, Argentina; 
AUS, Australia; BRA, Brazil; COL, Colombia; DEU, Germany; DNK, Denmark; ECU, Ecuador; ESP, Spain; FIN, Finland; FRA, France; 
GBR, Great Britain; GRC, Greece; ITA, Italy; NLD, The Netherlands; PER, Peru; POL, Poland; PRT, Portugal; SER, Serbia; TUN, Tunisia; 
USA, United States of America; VEN, Venezuela; P, plasmid; C, chromosome. *(+) amplification; (-) no amplification; (++) 
amplification of sequences larger than those of the expected sizes. aTn1546 types A, D, G, M, T and X were designated as 
previously described by Woodford et al. 164. bTn1546 variants similar to "type F" were previously described as F1/F2 types 165 or the 
Greek type II 166. In this study we assigned six subvariants of "type F" designated as F1, F2, F3, F4, F5 and F6. cFor those variants 
that did not have a specific previously described type, we used designations similar to previous ones that have similar profiles: 
tǇpes ͞B.ϭ͟ aŶd ͞E.ϭ͟ fƌoŵ “outh AŵeƌiĐa aƌe siŵilaƌ to tǇpes ͞B͟ aŶd ͞E͟, respectively, described by Woodford et al; or used new 
desigŶatioŶs as tǇpe ͞Y͟ folloǁiŶg the letteƌ ŶuŵďeƌiŶg Đƌiteƌia of Woodfoƌd et al. 164. dTn1546 types "PP-4", "PP-5", "PP-13", "PP-
ϭϲ" aŶd ͞PP-Ϯϯ͟ ǁeƌe Đlassified as described 167, being types "PP-4" and "PP-5" widely disseminated in Portuguese hospitals. PP-16 
has been also designated as "type A3" 168. eTn1546 types B, H* and J* were recently described by Khan MA et al. 65. fTn1546 type C 
was previously described by Werner et al. 168. gIS1251 was identified after sequencing the vanS-vanH amplicon or the fragment 
resulting of the amplification using IS1251-F and p11 165,166. hThe presence of IS1216 within vanX-vanY region was determined after 
sequencing the vanX-vanY amplicon or IS1216-R and p15 when first amplification was negative. iPositive amplification using ISEf1-
F and p18 as described 167. i*The Spanish isolate VnR16  had  single copies of ISEf1,and IS1216 within vanY-vanZ region. jIS1485 was 
identified after sequencing p1-p2 amplicon fragment 65. 
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Figure S4. Plasmid diversity among VanA and VanB E. faecium isolates from different countries (1986-
2012) (Due to the size of the table it will be provided only in digital format) 
Abbreviations: ST, sequence type; Tn, transposon; IS, insertion sequence; Rep (replicases); Rel (relaxases). aThe isolates were 
organized in the table according the family of the plasmid that carry the van genes. Isolates marked with (*) carry plasmids which 
size is increased after conjugation. bVariants of Tn1546 and Tn1547/Tn1549/Tn5382 were designated by capital letters as 
described in Fig. S2 and S3. The backbone of VanB transposons was also designated according the RFLP profile of the vanRSYWHBX 
cluster by numbers (e.g. RFLP1-RFLP3)6. cThe diversity of the plasmids present in each isolate is organized according their size and 
the modules Rep, Rel and TA: Rep (plain cells), rel (cells filled with dots) and TA (cells with diagonal stripes). Genes belonging to 
the same plasmid are represented with the same colour and those belonging to the same plasmid family with the same range of 
colours. The Rep/Rel/TA genes nomenclature has been previously described.11,25,26 Plasmid families are represented in different 
colours. They include green (Rolling-Circle; rep14/pRI1-like, rel1/pRI1), violet (small-theta replicating plasmids; rep18a/pEF418, 
rep18b/pB82, rep18c/pCIZ2, rel2/pCIZ2), red (Inc18; rep1/pIP501, rep2/pRE25/pEF1, rel6/pEF1, rel7/pIP501, TA-Inc18-ω-Ȝ-ȝ); 
different blue tones for RepA_N subfamilies, dark blue (pRUM; rep17/pRUM, rel3/pRUM, TA-pRUM-Axe-Txe), turquoise (pLG1, 
rep20/pLG1), and light blue (pheromone-responsive, rel5/pAD1); grey (pHTß/pMG1, rep22/pHTß, rel8/pHTß) and yellow (pK214 
from the Rep_3 family of Lactococcus lactis rep7/pK214). Toxin-antitoxin systems and virulence/bacteriocins genes located on 
plasmids included Axe-Txe from pRUM and Ȝ-ȝ from Inc18 plasmids, and hyl/bac32/bac43/entP, respectively. Genes hybridizing 
in the same band as vanA/B plasmids appear in bold cells. In a few cases, hybridization of specific probes was not achieved and 
amplified genes by PCR appear in dot cells.  
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Figure S6. Plasmid number of the VREfm and VSEfm included in this study.  
The number of plasmids was inferred by visualization of PFGE pattern of S1-digested genomic DNA. The VREfm (coloured cells, 
n=71) and VSEfm (dot coloured cells, n=82) isolates analysed were organized according phylogenomic groups inferred by BAPS.  
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ABSTRACT 
Vancomycin-resistance in enterococci (VRE) is associated with isolates within ST18, ST17, ST78 
Enterococcus faecium (Efm) and ST6 Enterococcus faecalis (Efs) human adapted lineages. Despite of its 
global spread, vancomycin resistance rates in enterococcal populations greatly vary temporally and 
geographically. Portugal is one of the European countries where Tn1546 (vanA) is consistently found in a 
variety of environments. A comprehensive multi-hierarchical analysis of VRE isolates (75 Efm and 29 Efs) 
from Portuguese hospitals and aquatic surroundings (1996–2008) was performed to clarify the local 
dynamics of VRE. Clonal relatedness was established by PFGE and MLST while plasmid characterization 
comprised the analysis of known relaxases, rep initiator proteins and toxin-antitoxin systems (TA) by 
PCR-based typing schemes, RFLP comparison, hybridization and sequencing. Tn1546 variants were 
characterized by PCR overlapping/sequencing. Intra- and inter-hospital dissemination of Efm ST18, 
ST132 and ST280 and Efs ST6 clones, carrying rolling-circle (pEFNP1/pRI1) and theta-replicating (pCIZ2-
like, IŶĐϭϴ, pHTβ-like, two pRUM-variants, pLG1-like, and pheromone-responsive) plasmids was 
documented. Tn1546 variants, mostly containing ISEf1 or IS1216, were located on plasmids (30–150 kb) 
with a high degree of mosaicism and heterogeneous RFLP patterns that seem to have resulted from the 
interplay between broad host Inc18 plasmids (pIP501, pRE25, pEF1), and narrow host RepA_N plasmids 
(pRUM, pAD1-likeͿ. TAs of IŶĐϭϴ ;ω-ε-ζͿ aŶd p‘UM ;Aǆe-Txe) plasmids were infrequently detected. Some 
plasmid chimeras were persistently recovered over years from different clonal lineages. This work 
represents the first multi-hierarchical analysis of VRE, revealing a frequent recombinatorial 
diversification of a limited number of interacting clonal backgrounds, plasmids and transposons at local 
scale. These interactions provide a continuous process of parapatric clonalization driving a full 
exploration of the local adaptive landscape, which might assure long-term maintenance of resistant 
clones and eventually fixation of Tn1546 in particular geographic areas. 
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INTRODUCTION 
“iŶĐe its fiƌst desĐƌiptioŶ iŶ the late ϴϬ͛s, ǀaŶĐoŵǇĐiŶ-resistant enterococci (VRE) have been increasingly 
reported worldwide, but presenting remarkable geographical and temporal differences in local rates 
(http://www.cddep.org/ResistanceMap/bug-drug/EFa-VC) [1–3]. Vancomycin-resistant Enterococcus 
faecium (VREfm) became endemic in most Noƌth AŵeƌiĐaŶ hospitals siŶĐe the ŵid ϵϬ′s [1,2,4–6] while 
their overall occurrence in Europe remained low until recently, when VRE nosocomial outbreaks started 
to be increasingly reported in some European countries (Annual Report of the European Antimicrobial 
Resistance Surveillance Network, EARS-Net, 2009)[1,3,7,8]. Despite E. faecium (Efm) being less 
frequently found than Enterococcus faecalis (Efs) in clinical isolates, it is far more frequently resistant to 
vancomycin, one of the last-line intravenous antibiotic resources for therapy. However, although the 
rate of vancomycin-resistant E. faecalis (VREfs) has remained low, they are steadily increasing in both 
the US and in EU countries (http://www.cddep.org/ResistanceMap/bug-drug/EFe-VC) [3]. 
Vancomycin resistance among enterococci is mostly due to the spread of Tn1546 (vanA genotype) and 
Tn1549 (vanB genotype), which are generally identified on plasmids and chromosome, respectively [3]. 
The few studies in which plasmids carrying Tn1546 from human or animal isolates were characterized 
revealed they belong to plasmid families RepA_N (pheromone-responsive plasmids and derivatives of 
p‘UM aŶd pLGϭͿ, IŶĐϭϴ aŶd pHTβ [9–18] suggesting an apparent plasmid promiscuity of this transposon 
influencing its dissemination among enterococcal populations. 
Recent analysis of enterococcal populations in the clinical setting depicts a rugged epidemiological 
profile, with successive waves of isolates causing infections, which belong to specific lineages of E. 
faecium [ST17, ST18 and ST78, previously considered within the same clonal complex (CC) 17], and E. 
faecalis (ST6, ST40) [19–21]. However, regional differences in the rates of VRE cannot be only explained 
by clonal replacement dynamics as suggested for other pathogens [22–24]. 
The aim of this study was to address the dynamics of vancomycin resistance among enterococci in 
Portugal, one of the developed countries with higher rates of both VREfm (21–23%) and VREfs (1.8–
4.1%) (www.earss.rivm.nl; http://www.cddep.org/ResistanceMap/bug-drug/EFe-VC), and where VanA is 
prevalent over VanB [3,25–27], by analyzing the clonal and plasmid backgrounds influencing the spread 
and persistence of Tn1546. Our study suggests that clonalization, the local selection of distinct clonal 
variants giving rise to durable bacterial lineages, might result and be modified by the local spread and 
recombinatorial dynamics of mobile genetic elements, thus providing new clues about the local multi-
hierarchical evolutionary biology of vancomycin resistance. 
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RESULTS 
Local dynamic landscape drives the spread and fixation of vancomycin resistance in 
Portuguese hospitals 
We have determined that the enterococcal population from the Portuguese hospitals is formed by an 
ensemble of MLST/PFGE clones. Efm isolates fit in three out of six phylogenomic groups recently 
established by using Bayesian Analysis of Population Structure (BAPS), namely BAPS groups 2, 3 and 5 
[19] (Figure 1). Most of the isolates cluster into the predominant BAPS group 3 [subgroup 3–3 
comprising main human lineages ST18 (ST18 and ST132) and ST17 (ST16); and subgroup 3–1 comprising 
ST280], and the BAPS group 2 (including ST80 and ST656/ST78 lineage, ST5/CC5, ST190/CC9), which 
have been previously associated with isolates from humans and both animals and humans, respectively 
[10,19,25,28–30][10]. A number of clones cluster in the small Efm BAPS group 5 (ST366, ST367, ST369), 
which seems to comprise mosaic genomes [19]. Isolates of Efs belong to ST6/CC2, ST30, ST55, ST117, 
and ST159 lineages although, to the date of this publication, Efs population has not been clustered in 
different BAPS groups. Among all them, isolates within ST18 Efm and ST6 Efs lineages were 
predominant, in line with the intra- and interhospital spread of particular highly transmissible Efm and 
Efs clones recovered in Portuguese hospitals since the late 90s [22,25,31,32]. While ST6 Efs was widely 
disseminated in all hospitals analyzed in this country [26], specific Efm lineages were overrepresented in 
Coimbra (ST18) and Oporto (ST132, a single locus variant, SLV, of ST18). Strains belonging to ST18 
(showing PFGE types H70 and H78), ST132 (PFGE type H88) and ST280 (with PFGE types 71 and H100) 
were spread in different hospitals (Figure 1 and Figure 2).  
It is worthwhile to note the possible relatedness between isolates of different STs (Figure 1 and 2). They 
include some isolates linked to BAPS 3–3 subgroup as ST18, ST80, ST125, ST132, ST368, ST369, all SLVs 
of each other, with PFGE patterns differing in less than 8 bands difference. Similarly, strains identified as 
ST280 and ST391, both linked to BAPS group 3–1, showed related PFGE patterns despite being trilocus 
ǀaƌiaŶts ;ч ϴ ďaŶds diffeƌeŶĐeͿ. 
vanA-Tn1546 is located on highly transferable mosaic plasmids involving narrow host pRUM 
and pAD1 derivatives 
The plasmid content of the isolates studied appears in Figure 2. Efm isolates carried a variable number 
of plasmids (n=1–6) which contained specific sequences of different families including rolling-circle 
plasmids (RCR) related to pRI1 and small theta plasmids related to pCIZ2, RepA_N (pRUM-like, pLG1), 
pHTβ ;pƌeseŶt iŶ all ST132 isolates), and Inc18 (pRE25 and pEF1-related). All Efs contained RCR plasmids 
and pheromone responsive-plasmids. 
vanA-Tn1546 was located on plasmids ranging from 30 to 150 kb, successfully transferred by 
conjugation in 95% (n=71/75) of Efm and 97% (n=28/29) of Efs, with a variable frequency (10
−1–10−8). 
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Transferable plasmids were identified as members of pRUM and Inc18 families or were mosaic plasmids 
of pRUM, Inc18 and pheromone plasmids (see sections below). Although some of these mosaic plasmids 
were detected in both Efm and Efs hosts, species-specific plasmid variants were predominant. 
We have classified the enterococcal plasmids according to the content in rep/rel/TA systems, and RFLP 
profiles (Table 1, Figure 2). For the better interpretation of the results, we should keep in mind that 
members of the most common plasmid families classified in this and other studies as Inc18-like (pRE25, 
pIP501, pVEF1, pVEF2, pVEF3, pIP816, pEF1, pWZ909) or pRUM-like (pRUM, p5753cB, pS177) exhibit a 
high degree of modular dissociability or propensity for independent variation and shuffling, and may 
contain multiple replicons or be devoid of conjugation systems, thus making it very difficult to establish 
an accurate classification and to trace the origin of certain elements [9,35–42]. See Clewell et al. for a 
comprehensive updated revision of enterococcal plasmids [9]. In the following sections we will describe 
vancomycin resistant plasmids of Efm and Efs. 
 
Figure 1. Population of vancomycin resistant E. faecium. 
Abbreviations: ST, sequence types; CC, clonal complex; BAPS, Bayesian Analysis of Population Structure; HUC, Hospital 
Universitário de Coimbra; HSA, Hospital Santo António; HSJ, Hospital São João; HST, Hospital São Teotónio; HPH, Hospital Pedro 
Hispano; CHCB, Centro Hospitalar da Cova da Beira; HVR, Hospital S. Pedro. A colored circle represents each PFGE type (white 
numbers/letters; H for hospital, SW for sewage, R for river and S for swine clones) and each PFGE type is associated with the 
corresponding sequence type (STs are represented in black letter and in colored elipses grouping different PFGE types) and BAPS 
group (in colored elipses grouping different STs). The size of the colored circles corresponds to the number of isolates. CC17 (in 
light blue), CC5 (in light green), CC9 (in light red) and the singletons ST366, ST367 and ST391 (light yellow) are represented 
according to the eBURST algorithm (download on 26th January 2012) with black lines joining single locus variants (SLV). STs that 
were not identified in this study are represented as light grey nodes to link the sequence types identified in this study accordingly 
to eBURST. ST18 strains (H70, H78, H87, H93, H108, H125) and most ST132 strains (H86, H88, H106, SWC) were clonally related by 
PFGE (<7 bands difference). Remarkable relationships among PFGE banding patterns of strains belonging to different STs were 
observed (H125/ST18 and H126/ST125; H124/ST391 and H71/ST280, SWM/ST80 and H86/H88/H106/H119/SWC/ST132, and 
isolates “WA/“Tϭϴ aŶd “WC/“TϭϯϮ ;<ϴ ďaŶds diffeƌeŶĐeͿ. This figuƌe dƌaǁŶ up ǁas peƌfoƌŵed iŶ the ͞OpeŶ “ouƌĐe vector 
gƌaphiĐs editoƌ IŶksĐape͟ ;ǀeƌsioŶ IŶksĐape-0.48.2–1). 
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Figure 2. Clonal and plasmid diversity among VREfm and VREFs from Portugal. 
Abbreviations: IS, insertion sequence; Efm, Enterococcus faecium; Efs, Enterococcus faecalis; kb, kilobases; BAPS, Bayesian 
Analysis of Population Structure; ST, sequence type; CC, clonal complex; rep (replicases); rel (relaxases); TA (toxin-antitoxin 
system); HUC, Hospital Universitário de Coimbra; HSA, Hospital Santo António; HSJ, Hospital São João; HST, Hospital São Teotónio; 
HPH, Hospital Pedro Hispano; CHCB, Centro Hospitalar da Cova da Beira; HVR, Hospital S. Pedro; SW, sewage wastewaters; UW, 
urban wastewaters; R, river; ND, not determined; NI, not identified; UK, unknown. aThe distribution of the different isolates is 
shown by BAPS subgroups as described [19]. bPFGE types shown in bold represented widespread clones in Portuguese hospitals 
and/or aquatic surroundings over years. cMost Efm isolates expressed resistance to vancomycin, teicoplanin, erythromycin, 
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ampicillin, ciprofloxacin (92–100%) and to a lesser extent to high levels of kanamycin (65%), gentamicin (41%), streptomycin and 
tetracycline (28% each). While acm was identified in different CC17 and non-CC17 lineages (76%), esp was detected in CC17 
isolates (35%, ST132 and its SLVs ST368, ST369) and hyl was sporadically found (9%, ST18, ST125, ST132, SLVs of each other, and 
ST280 isolates) [25]. Efs isolates (mostly ST6) showed resistance to vancomycin, teicoplanin, erythromycin, ciprofloxacin, high 
levels of gentamicin and kanamycin (82–100%), tetracycline and chloramphenicol (65% each) and high levels of streptomycin 
(46%), and mostly contained gelE and agg (>90%), cyl (82%) and esp (46%) [26]. dTn1546 designation is based on the results 
obtained by a PCR assay described by Woodford et al. consisting on the amplification of overlapped fragments covering the whole 
Tn1546 [33]. Fragments of unexpected length were further analysed by sequencing (this study) [27]. eThe total rep/rel/TA content 
of isolates is represented according to its location on plasmids of different size ranges. Rep (normal cells), rel (cells with dots) and 
TA (cells with diagonal stripes) genes belonging to the same plasmid are represented with the same color and that belonging to 
the same plasmid family with the same range of colors. The content of VanA plasmids including rep, rel, and TA genes is indicated 
according to the plasmid type in which they were identified, as well as by the numeric nomenclature used by Jensen et al. [34] for 
replicases (rep1, rep2, rep9, rep14, rep17, rep18a), given new and consistent designations to replicases non described in reference 34 
(rep18b, rep18c, rep20, rep22). Relaxases were designated per numerical order as designed by M. V. Francia (unpublished data). 
Rolling-Circle plasmids are represented in green (rep14/pRI1-like, rel1/pRI1), small-theta replicating plasmids in violet (rep18a/pEF418, 
rep18b/pB82, rep18c/pCIZ2, rel2/pCIZ2), Inc18-like plasmids in different red tones (rep1/pIP501, rep2/pRE25/pEF1, rel6/pEF1, TAInc18-ω-ε-ζ), RepA_N 
plasmids in different blue tones, pRUM in dark blue (rep17/pRUM, rel3/pRUM, TApRUM-Axe-Txe), pLG1 in turquoise (rep20/pLG1), pheromone-
responsive plasmids in light blue (rep9/pAD1, rel5/pAD1, rel9/pCF10, parpAD1Ϳ, aŶd pHTβ/pMGϭ plasŵids iŶ gƌeǇ ;ƌepϮϮ/pHTβ, rel8/pHTβ). Rep 
families are named Rep ˝Ŷ˝ ǁheƌe ˝Ŷ˝ iŶdiĐates the Ŷuŵďeƌ assigŶed to diffeƌeŶt ƌep-families according to Jensen et al. [34]. The 
name of the most representative plasmid of the family is also represented for a better follow-up of the results (e.g. rep17/pRUM, 
rep17 from pRUM and related plasmids p5753cB and pS177; rep1/pIP501 rep1 linked to Inc18 plasmids as pIP501, pIP816 and pRE25; 
rep9/pAD1, rep9 linked to pCF10, pAD1, pTEF1, pTEF2, pBEE99, pMG2200; rep14/pRI1-like, rep14 associated with RCR plasmids pEFNP1, 
pJS42 and/or pRI1; rep18a/pEF418, rep18 from pEF418; and repϮϮ/pHTβ, ƌep of ďoth pHTβ aŶd pMGϭ plasŵidsͿ. We fuƌtheƌ speĐified the 
name of different plasmids associated with a given group if necessary. For example, it results helpful for Inc18 family given the 
number of plasmids containing the same rep gene. These plasmids are increasingly identified among isolates of different origins 
(e.g. rep2/pRE25/pEF1 for designing rep2, as rep and rel modules of pEF1, a plasmid originally identified in olives [35], seems to be 
widely present in all Efm clinical isolates).Sequencing identified the different variants within these families (see text). Rep18b, rep18c 
and rep20 were not included in Jensen's scheme [34] and the numbers were assigned in this paper following that numeration 
(rep18b/pB82, rep from pB82; rep18c/pCIZ2, rep from pCIZ2; rep20/pLG1, rep from pLG1). Rel genes were arbitrarily designated with 
numbers corresponding to different plasmid types [9] (Francia et al, unpublished data): Rel1, pJS42, pRI1; Rel2, rel from p200B, 
pCIZ2 and/or pB82 plasmids; Rel3, pRUM; Rel5, rel from pAD1, pTEF1, pAM373 and the pathogenicity island of V583; Rel6, pEF1; 
Rel8, pHTβ aŶd pMGϭ; ‘el9, pCF10. Toxin-antitoxin systems included Axe-Tǆe fƌoŵ p‘UM, ω-ε-ζ fƌoŵ IŶĐϭϴ plasŵids aŶd par from 
pAD1. Genes hybridizing in the same band as vanA plasmids appear in bold rectangles 
vanA plasmids of E. faecium 
They were classified in two broad groups according to the plasmid replication modules and the 
background epidemiological context, i) pRUM-like variants (Rep17.2/pRUM-like+ Rel6/pEF1±Rep1/pIP501± 
Rep2/pRE25/pEF1/TAInc18), ii) mosaics of Inc18-pRUM-like (Rep2/pRE25/pEF1 ± Rep17.2/pRUM/TAAxe-Txe). Highly 
transmissible pAD1-Inc18 mosaic plasmids from major Efs clones were also identified among Efm but 
they will be described in the next section. 
i. pRUM derivatives (Rep17.2/pRUM-like+Rel6/pEF1) of variable size (30–120 kb) were detected since 
the mid 90 s from a diversity of clonal backgrounds. pRUM plasmids showing different ClaI-
digested DNA RFLP patterns were identified carrying a whole copy of Tn1546 (RFLP_1, RFLP_2, 
RFLP_20, 30–80 kb), IS1216::Tn1546 (RFLP_8–12, 40–120 kb) or ISEf1::Tn1546 (RFLP_3–7, 
RFLP_13, 50–95 kb). Despite the heterogeneity of plasmid profiles, RFLP_3–6 or RFLP_8–10 
shared a variable number of common bands that suggest a relationship among them (see Table 
1 and Figure 3 for details about relationships among plasmids). pRUM-like plasmids exhibiting 
distinct RFLP profiles and carrying different transposon variants were isolated in early and 
recent isolates of different clonal backgrounds (Figure 2). They include ST190, carrying a 60 kb 
plasmid RFLP_1 type; ST670 carrying a 85 kb exhibiting a RFLP_4 plasmid type; ST656 carrying a 
30 kb plasmid designated as RFLP_20, and ST18, ST132, ST280, carrying different transposon 
variants. These results suggest multiple independent acquisitions of pRUM-like plasmids and 
further rearrangements with other elements, some plasmid variants being efficiently 
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transferred among a diversity of different clones. It is of interest to highlight that epidemic 
ST18 PFGE types H83 (1996) and H92 (2000) harboured two pRUM-like plasmids. One was the 
rep17.2/pRUM-like::rel6/pEF1 vancomycin resistant plasmid showing RFLP_2 and RFLP_12 and the 
other was a 25kb carrying a rep17.1/pRUM gene and a copy of the Axe-Txe toxin-antitoxin system 
(Rep17.1/pRUM+TAAxe-Txe) identical to the pRUM derivatives described to date (pRUM, p5753cB and 
pS177) (GenBank accession number GQ900487; Figure 2) [12,40,41] and other vancomycin 
resistant plasmids circulating at international level (Freitas et al., unpublished data). 
Diversification in the Rep sequences of these pRUM-like plasmids (homology of 96% at 
nucleotide level and 95% at protein level) might have resulted in the compatibility with similar 
(but not identical) plasmids in the same clonal background along extended periods of time. 
ii. Inc18 plasmids and mosaic Inc18-pRUM plasmids. Clonally related ST132 and ST18 Efm isolates 
from Oporto contained Inc18 plasmids (Rep1/pIP501±Rep2/pRE25/pEF1, RFLP_14–15) or mosaic 
plasmids of Inc18 and pRUM (Rep2/pRE25/pEF1+Rep1/pIP501+TAInc18+Rep17.2/pRUM-like+RelpEF1, RFLP_16–
19), all carrying IS1216-Tn1546 variants. Plasmids showing RFLP types 16–19 were highly similar 
(5 bands/12 bands in common), RFLP_19 being persistently recovered from clonally related 
ST132, ST368 and ST369 isolates, collected from hospitalized patients of HSA nearby sewage 
plant and the river Douro from 2001 to 2003. This RFLP_19 has been also identified in a VREfm 
isolate recovered from swine in 2007 (Tn1546 tǇpe ͞PP-3ϭ͟, ‘FLP_ϭϵ.ϭͿ, highlightiŶg the 
remarkable stability of particular VanA Inc18 plasmids in ensembles of related clones able to 
spread in different hosts [10]. A diversity of Tn1546::IS1216 variants (PP-13, PP-17, PP-20, PP-
23, PP-31 and X) which differed in the number of IS1216 copies, the presence of insertions 
identified as short regions of Inc18-like plasmids or duplicated Tn1546 sequence fragments in 
different orientations, were identified among related plasmids showing the RFLP_19 pattern 
(Table 1, Figure 4). These results illustrate the possibility of efficient intraclonal and 
intraplasmid diversification of Tn1546::IS1216 variants. Acquisition of a vanA-Inc18 
(Rep2/pRE25/pEF1+Rep1/pIP501+ω-ε-ζͿ plasŵid ĐaƌƌǇiŶg a TŶ1546::IS1216 ͞ǀaƌiaŶt͟, pƌedoŵiŶaŶt 
among poultry from Europe [43] by Portuguese strains containing VanA-pRUM (Rep17.2/pRUM-
like+Rel6/pEF1) plasmids cannot be excluded. Recombination between pRUM::Tn1546 and 
Inc18::Tn1546 would explain duplicated Tn1546 regions. 
iii. Megaplasmids. Tn1546 tǇpe ͞D͟ ǁas loĐated on a megaplasmid carrying Rep20/pLG1 and Rel6/pEF1 
from isolates of a CC5 Efm clone spreading among swine and humans of different continents. 
This transposon has been previously associated with isolates from swine which frequently 
exhibit the G8234T mutation. The variable size (150–190 kb) of vanA megaplasmids linked to 
CC5 lineage has been previously reported [10]. 
 
 
Ana P. Tedim  Chapter 5 
 
195 
 
Table 1. Plasmids identified in this study. 
 
Abbreviations: RFLP, restriction fragment length polymorphism; ST, sequence type; NI, not identified. 
aPlasmid type RFLP_12 (Rep17.1pRUM-like+Rep2+RelpEF1) contains a partial sequence of the replication gene of the RCR plasmid pEFNP1 
(GenBank accession number AB038522), suggesting the integration of this RCR plasmid on the mobile element carrying Tn1546 
involving truncation of the rep14/pRI1/pEFNP1. 
bPlasmid types RFLP_3, _4, _5 _6 and _13 (Rep17.1+Rel6/pEF1 and eventually containing Rep1/pIP501 or Rep2/pRE25/pEF1 or TAInc18) shared 
common bands and were identified in the same or different clonal backgrounds in different cities for extended periods of time. 
cPlasmids types RFLP 8, _9 and _10 also shared a variable number of common bands.  
dPlasmids showing patterns related to RFLP_27 (75-85kb; rep9/pAD1+relpAD1+rep1/pIP501+par and/or rep2/pRE25/pEF1) initially recovered 
from the widespread ST6-CC2 Efs clone in Coimbra in 1996 and other Efs (ST55 and ST159) and Efm clones contained similar ISEf1-
Tn1546 variants (PP-2a, PP-4, PP-9). Other highly related mosaic Inc18-pAD1-related plasmids carrying IS1216-Tn1546 were 
ƌeĐoǀeƌed fƌoŵ “Tϲ V‘Efs aŶd “TϴϬ V‘Efŵ isolates ;tǇpe ˝IIEfs˝, ƌep9/pAD1+relpAD1+parpAD1+rep2/pRE25/pEF1 versus tǇpe ˝IIEfm˝, 
rep9/pAD1+rep2/pRE25/pEF1).  
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Figure 3. Restriction fragment length polymorphism patterns of plasmids showing RFLP_5 profiles 
after digestion with ClaI (I) and EcoRI (II) restriction enzymes (New England Biolabs Inc, UK). 
Lane 1, RFLP_5 (PFGE H78, ST18 Efm,); lane 2, RFLP_5 (PFGE H72, ST18 Efm); lane 3, RFLP 5.2 (PFGE H100, ST280 Efm), lane 4, RFLP 
5 (PFGE H78, ST18 Efm); laŶe ϱ, ‘FLP_ϱ ;PFGE Hϳϴ, “Tϭϴ EfŵͿ; laŶe ϲ, ‘FLP_ϱ.Ϯ͛ ;PFGE HϭϯϮ, “TϭϯϮ EfŵͿ. 
E. faecalis vanA plasmids 
The vanA Efs plasmids were Inc18-pheromone-responsive mosaics, further classified in four main types 
on the basis of their RFLP patterns (RFLP_27–30), rep-rel/TA content, and replicase sequences. These 
plasmids have been documented in different Portuguese hospitals since the mid 90s [26]. 
Plasmids showing highly related patterns designated as RFLP_27 (carrying ISEf1-Tn1546) or RFLP_28 
(carrying IS1216-Tn1546) were recovered from both Efs (ST6, ST55, ST159) and Efm (ST80, ST132). 
However, despite the similarity of their RFLP patterns, they differed in the rep/rel/TA content and 
transposon variant content (Table 1). Conversely, the finding of an ST117 Efs isolate from Oporto with 
two different vanA plasmids of 150 kb and 300 kb indicates acquisition and further recombination of 
widespread pRUM-vanA plasmids from Efm with narrow host pheromone responsive plasmids of Efs. 
The observed differences in transposon variants and plasmid modules reflect frequent rearrangements 
during transfer of plasmids between Efs and/or Efm clonal backgrounds and also highlight the 
connectivity of these enterococcal populations resulting in the acquisition and generation of plasmids 
with enhanced host range. 
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Figure 4. Genetic maps of Tn1546 variants. 
Tn1546 variants are represented as previously described by Novais et al. [27] although grouped differently and specific types have 
been further explored (PP10, PP30): Tn1546 prototype A corresponds to the original sequence described by Arthur et al. [44] and 
D corresponds to Tn1546 variants from animals. Tn1546 variants with ISEf1 within vanX-vanY intergenic region (PP2a, PP4, PP5, 
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PP9, PP24) and Tn1546 variants with IS1216 insertions at different positions (PP10, PP2b, PP13, PP15, PP16, PP17, PP20, PP23, 
PP27, PP30, X) are represented. The positions of genes and open reading frames and the direction of transcription are depicted 
with open arrows. IS elements are represented by triangles; other sequences are designated by rectangles. DNA insertions are 
represented highlighting the first nucleotide upstream and downstream from the insertion sites whenever known. Deletions are 
indicated by dots and discontinuous lines indicate sequences that were not characterized. (a) DNA sequence with homology to 
ORF3 (unknown protein product) and ORF1 (replication protein) of pEFNP1 plasmid (GenBank accession number AB038522). (b) 
DNA sequence with no match to any sequence available in GenBank. (*) PP23 was identified in an isolate susceptible to 
teicoplanin; this variant contained an insertion in the vanY gene that would affect the transcription ofvanZ and it might explain the 
susceptibility to this glycopeptide as previously reported [27]. (**) PP30 was identified in an ST78 isolate susceptible to both 
glycopeptides (MIC against vancomycin and teicoplanin of 4 mg/L) carrying vanA-Tn1546. This variant contained alterations within 
the vanS-vanH intergenic region (an IS1216 insertion), which is involved in the expression and regulation of the resistance to 
vancomycin, and it constitutes the first description of a vanA isolate phenotypically susceptible to vancomycin in Portugal. 
Fixation of vanA-Tn1546 variants is associated with plasmid connectivity 
Tn1546 backbones were classified in three main groups corresponding to Tn1546 with no insertion 
seƋueŶĐes ;͞tǇpe A͟ aŶd ͞tǇpe D͟Ϳ aŶd ǀaƌiaŶts ĐoŶtaiŶiŶg I“Ef1 (5 types) or IS1216 (11 types) at 
different locations of the Tn1546 backbone (Figure 4). Variants with a single copy of ISEf1 within the 
vanX-vanY region at nt 9044 were located on early (1996–1997) Efm plasmids identified as Inc18 and 
pRUM lacking Axe-Txe, and also on early (1996) Efs Inc18-pAD1 mosaics. Some of them were isolated 
from strains for more than one decade, which can be explained by their successful long-term recovered 
clonal and plasmid backgrounds. 
Variants containing IS1216 were mostly located on Inc18 plasmids or on mosaic plasmids Inc18-pRUM or 
Inc18-pAD1. Most variants contained the IS1216 at 8839nt of the transposon (PP13, PP17, PP20, PP23, 
PP30) similarly to other Tn1546 variants previously described in Europe [45]. Some of them also 
harboured different insertions corresponding to unknown sequences (X, PP23) or RCR plasmid 
sequences (PP10) [46] suggesting frequent recombination between acquired genes/plasmids and 
housekeeping Efm and Efs plasmids (Figure 4). Tn1546 type D was specifically linked to megaplasmids 
from CC5 Efm from swine of different continents (Figure 2, Figure 4). 
The presence of early plasmids carrying Tn1546 belonging to different families suggests independent 
acquisitions of the transposon by pRUM and Inc18 plasmids, which would have been acquired by diverse 
Efm and Efs populations. Local fixation would be influenced by connectivity of plasmid and population 
backgrounds enabling further evolvability of transposon variants. 
DISCUSSION 
This paper shows the local dynamics of Tn1546-vanA among Enterococci is shaped by horizontal genetic 
transfer of pRUM and Inc18 plasmids and by recombination-driven evolution of them within and 
between Efs and Efm clones. The clonal diversity reported in this study has also been observed in areas 
where the spread of VRE has been documented [47]. Recent retrospective analysis of enterococcal 
populations suggests that the temporal evolution of the population biology of Enterococci is driven by a 
succession of epidemic waves of enterococcal human specific lineages, Efm ST78 and Efs ST6 emerging 
in the last decade at global scale similarly to that reported for other pathogens [19,23,24]. In Portugal, 
the population structure of VRE analysed in this study comprises isolates of main human Efm lineages, 
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ST18 (ST18, ST132) being much more abundant than ST17 (represented by a single isolate of early ST16 
lineage) [31], or ST78 (represented by sporadic ST80 and ST656, the first one linked to early VRE 
outbreaks) [25,29]. It is worthwhile highlighting the recent detection of isolates of another Efm lineage 
in hospitals of the Oporto area (http://www.mlst.net) as ST117 Efm (ST78 lineage), which would reflect 
the increasing trend of isolates belonging to the ST78 lineage at international level. However, regional 
differences in the rates of VRE cannot be fully explained by clonal replacement dynamics since similar 
enterococcal clones appear widely distributed in areas with high and low rates of VRE (Tedim AP et al., 
unpublished data). Instead, local conditions, including type and density of hosts, antibiotic usage, and 
transmission facilities, may influence regional differences in the proportions of VRE, as suggested by 
mathematical modelling studies on local trends of antibiotic resistance [48,49]. Clones can locally evolve 
by variation, drift and short-distance migration, leading to changes in colonization ability, pathogenicity 
or even host range, the fittest clonal variants being able to facilitate the spread of antibiotic resistance 
[23,50–53]. The observed clonal heterogeneity of the predominant ST18 lineage which comprises 
particular ST18 and ST132 strains widespread in different cities, highlights the role of certain efficiently 
transmissible clones in the dissemination of antibiotic resistance. Successful clones can eventually be 
able to disseminate at international level as strains of ST6 Efs or ST280 Efm within main Efm human 
lineages driving or contributing the spread of different traits as Tn1546 or Tn1549 [54]. One remarkable 
fact is the similarity among PFGE patterns of isolates with different STs. Given the high content of 
plasmids and transposons of the isolates studied, and the frequent rearrangements identified among 
Efm and/or Efs isolates [21], chromosomal transfer cannot be discarded. Recent phylogenomic analysis 
based on the degree of admixture among a diversity of isolates studied suggests that recombination is 
restricted to isolates within specific BAPS groups [19]. Most plasmids coding for vancomycin resistance 
are found in similar clonal backgrounds. This observation suggests that recombination does occur within 
isolates of similar BAPS groups as recently described [19]. However, the observed mosaicism and 
enhanced host range of particular plasmid variants indicates the existence of an unexpectedly high 
degree of connectivity between phylogenetically distant enterococcal populations and/or in bacterial 
genetic exchange communities integrating enterococci. 
Bƌoad host aŶd Ŷaƌƌoǁ host plasŵids ĐaƌƌǇiŶg ǀaŶĐoŵǇĐiŶ ƌesistaŶĐe ǁould haǀe a high ͞betweenness 
ĐeŶtƌality͟, which is a pivotal index in network theory useful for measuring the load placed on the given 
node in the network as well as the node's importance to the network than just connectivity [55]. A 
recent in silico network analysis of all plasmid sequences available at the GenBank databases confirms 
very high betweenness values for some Inc18 plasmids as pVEF3 (an Inc18 derivative highly spread 
among Efm from animals in Europe) [13,39], and also for a pheromone-responsive plasmid pTEF1 (a 
plasmid recovered from ST6_Efs strain V583, highly related to the ST6 described in this work) [56] 
(unpublished data). Other plasmids with a high degree of modular dissociability, would be pRUM-like 
elements, which may enhance their complexity resulting in new configurations with enhanced 
betweenness. It is tempting to suggest that plasmid variability has contributed to intra-clonal 
diversification both in Efm and Efs, giving rise to a local wealth of clonal variants able to fully explore the 
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local adaptive landscape. In fact, this and other studies demonstrate that selected variants of Inc18, 
pAD1, and pRUM plasmids can determine differences in the dynamics of VRE in different areas, further 
influencing the plasmid host range and the selection of specific clones within human adapted lineages. 
Examples of widespread plasmid variants of Inc18 or pRUM plasmids coding for vancomycin resistance 
have been reported recently. They included Inc18 widespread among Efm poultry isolates from Europe 
[13] or among Efs clinical isolates from the USA, the last one being able to transfer Tn1546 to S. aureus 
[15]; and mosaics of pRUM variants containing Axe-Txe and Inc18 from humans in different continents 
(Freitas AR et al. unpublished data). The identification of chimeric pRUM-Inc18 plasmids containing 
rep/rel/TA of Inc18 sequences and Tn1546 variants widely observed in poultry, hospitals and hospital 
sewage in the Oporto area reflects genetic exchanges between enterococci from different origins and 
highlights the need to enforce barriers to avoid the spread of multi-drug resistance human pathogens to 
the environment and vice-versa. 
In this scenario, the genetic context of Tn1546 seems to greatly influence the evolvability of the 
transposon and explains the high diversity of variants found in this and other studies [1,27,45,57]. The 
frequent presence of insertions in the backbone of Tn1546 and the abundance of IS1216 and ISEf1 in 
enterococcal genomes [9,58] makes homoplasic evolution of Tn1546 in different backgrounds possible. 
However, other IS (IS1251, IS1542, IS1476, IS19 and IS1485) linked to different plasmid and clonal 
backgrounds [9,42] have been identified at different sites of Tn1546, thus suggesting that chance and 
selection are responsible to differences in variants collected in different areas. The widespread of Inc18 
plasmids with a common origin in Europe [13,59] indicates local fixation of Tn1546 influenced by a 
founder effect and further connectivity of plasmid and population backgrounds enabling further 
evolvability of transposon variants as reported in this study. 
Our results suggest that VRE spread is facilitated by selected clones of different lineages through strong 
interactive processes of clonalization and plasmid diversification that might occur at local scales. Despite 
the maintenance of significant gene flow, a sympatric, or more probably, parapatric bacterial 
clonalization process (when diverging populations share a common or neighbouring environment), 
might contribute to the formation of temporary genetic mosaics and the preservation of ecologically 
important genomic traits [60]. Such micro-evolutionary process will result in an array of clonal 
complexes forming a population structure able to exploit the local spatio-temporal patch 
heterogeneities [61]. Note that exploitation of connected microenvironments should accelerate 
evolution of antibiotic resistance [62]. The expected result of such a successful population structure is 
the local persistence of antibiotic resistant clones, and eventually the local fixation [63] of vancomycin-
resistance [49]. 
In summary, this study highlights the relevance of studying the local microecology of genes, elements, 
lineages and populations to decipher the robustness of the trans-hierarchical networks connecting these 
evolutionary elements in order to describe and predict the local evolvability of vancomycin-resistance 
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[64]. Traditional surveillance studies are one-off cross sectional surveys focused on single traits as 
epidemic strains, genes or mobile genetic elements over limited periods of time which only gives one 
shot view that precludes addressing the long-term dynamics of antibiotic resistance. The more 
comprehensive approach described in this study is needed for understanding in depth the evolution of 
complexity in multi-hierarchical systems as those involved in the spread of antibiotic resistance among 
the populations of bacterial human pathogens. 
MATERIALS AND METHODS 
Bacterial strains and epidemiological background 
One hundred four VRE clinical isolates carrying Tn1546 from different regions of Portugal, 75 VREfm and 
29 VREfs, were analyzed in this study. They included: i) clinical isolates from hospitals of Coimbra 
(Hospital Universitário de Coimbra, HUC), Oporto (Hospital Santo António, HSA), Viseu (Hospital de São 
Teotónio, HST); Matosinhos (Hospital Pedro Hispano, HPH), Vila Real (Hospital S. Pedro, HVR) and 
Covilhã (Centro Hospitalar da Cova da Beira, CHCB) located in Northern and Central Portugal (62 Efm 
and 26 Efs; 1996–2008); ii) isolates from waste waters of hospitals (HSA and Hospital de São João, HSJ) 
(10 Efm and 3 Efs), and iii) isolates from the estuary of the River Douro (3 Efm) recovered in the Oporto 
area during 2001–2003. Part of the isolates analyzed in this work corresponds to strains from previous 
surveillance studies [25–27,65]; this paper constitutes the first description of isolates obtained during 
2007 and 2008. Contemporary Portuguese VRE isolates of animal origin were used for comparative 
analysis of lateral transfer events [10]. 
Susceptibility against 15 antibiotics was determined by the agar dilution method following CLSI standard 
guidelines. Clonal relatedness was established by pulsed-field gel electrophoresis (PFGE), banding 
patterns were interpreted according to criteria previously suggested for long-term studies, and 
multilocus sequence typing (MLST) as described elsewhere (http://efaecium.mlst.net) [25,66–68]. 
The presence of putative virulence traits [collagen-binding adhesin (acm), enterococcal surface protein 
(esp), hyaluronidase (hylE. faecium), cytolysin/hemolysin (cyl), gelatinase (gelE) and aggregation substance 
(agg)] was searched by using PCR as described [69,70]. 
Genetic context of Tn1546 
Characterization of Tn1546 backbone was determined by amplification of overlapping transposon 
fragments and further sequencing of PCR products [27,33]. We have accomplished the analysis for the 
isolates not studied in previous surveys and have interpreted the resulting transposon diversity (this 
study) [27], under the light of the plasmid and clonal backgrounds identified in this geographical area. 
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Plasmid analysis 
Isolates (n=62 Efm and n=13 Efs) representing the clonal diversity observed in both species were 
selected for plasmid characterization (Table 1, Figure 2). The content and size of plasmids from 
transconjugants obtained by filter mating were determined by using either the technique described by 
Barton et al. (plasmids >10 kb) or the alkaline lysis extraction method of Kado & Liu (plasmids <10 kb) 
[54,71,72]. Classification of E. faecium plasmids was based on the presence of specific modules for 
replication (rep-initiator proteins), mobilization (relaxases) and stability (toxin-antitoxin systems). 
Relaxases (rel) were sought by a multiplex-PCR-based relaxase typing method which differentiates 
relaxases of the MOBQ, MOBP, MOBC and MOBV families related to 27 known plasmids [9,73] (Francia 
MV, unpublished data). Replication initiator proteins (rep) were investigated by amplification of 24 
replicons, which allows discriminating among DNA sequences from more than 100 published Gram-
positive plasmids [9,34]. Designation of rep sequences pointed out the plasmid type in which they were 
initially identified, as well as the numeric nomenclature originally used by Jensen et al. (Figure 2͛s 
footnote) [34]. Toxin-antitoxin systems (TA) previously identified among streptococci and enterococci 
(Axe-Tǆe, ω-ε-ζ, par, mazEF) or Gram-negative bacteria (relBE) were detected by PCR [74]. PCR products 
were sequenced in order to confirm the specificity of the method and to analyze similarities with other 
well-characterized plasmids. Genomic location of the Tn1546 and the rel/rep/TA sequences was 
determined by hybridization of vanA and rel/rep/TA specific probes obtained by PCR from DNA from 
reference plasmids with S1 or I-CeuI digested genomic DNA from representative strains [54,71]. 
Structural relationship between plasmids of similar size was established by comparison of their RFLP 
patterns obtained after digestion with different restriction enzymes (EcoRI, HindIII and ClaI; see Figure 
3). Plasmid DNA was obtained by using a modified protocol based on the alkaline lysis method described 
by Handwerger et al. [75] consisting of increasing two-fold the volume of lysozyme, SDS/NaOH and 
acetate potassium solutions, extending the incubation period in potassium acetate solution for at least 
three hours, precipitating the supernatant obtained after extraction with phenol-chloroform using 
ethanol-acetate potassium solution (2:0.1 vol/vol) at 25°C for at least 2 hours, and resuspending final 
DNA pellets in 30 µl of water for further enzyme digestion analysis. 
Molecular techniques 
Southern blot DNA transfer and hybridization were performed by standard procedures [76]. The vanA 
and rep/rel/TA/bac probes used in the hybridization assays were generated by PCR using well known 
positive controls as template DNA. Labelling and detection were carried out using Gene Images Alkphos 
Direct Labelling system kit, following the manufacturer's instructions (Amersham GB/GE Healthcare Life 
Sciences UK Limited). PFGE was performed as described previously [77] using the following conditions: 
switch time of 5 s to 25 s for 6 h, followed by 30 s to 45 s for 18 h (S1 nuclease); 5 s to 30 s for 22 h, 
14°C, and 6 V/cm2 (I-CeuI) and 1 s to 20 s for 26 h, 14°C, and 6 V/cm2 (SmaI). 
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Plasmid sequences 
Analysis of nucleotide and amino acid sequences revealed two types of sequences amplified with 
primers used for identification of rep17/pRUM. They were 100% (designated as Rep17.1/pRUM) or 97% (96% 
identity at amino acid level; designated as Rep17.2/pRUM-like) homologous to that of RepA_pRUM (GenBank 
accession number AF507977). Most Rep1/pIP501 amino acid sequences were 98%–100% identical to 
RepE_pIP816, a member of the Inc18 family (GenBank accession number AM932524), and to a lesser 
degree to pRE25, pTEF1 or pSM19035; and Rep2/pRE25/pEF1 showed 96%–100% amino acid identity to that 
of pEF1 (GenBank acc. no. DQ198088). Sequences identified as Rel6/pEF1 showed 98%–100% homology to 
orf34_pEF1. Relaxases of the E. faecalis pheromone-responsive plasmids identified in this study 
displayed a high homology with those of known enterococcal pheromone plasmids pAD1, pAM373 and 
pTEF1 (orf57_pAD1, GenBank acc. no. AAL59457; EFA0025_pTEF1, GenBank AE016833; and 
EP0019_pAM373, GenBank acc. no. NC_002630). That of plasmid showing RFLP_27 showed a 67–84% 
homology with the above mentioned pheromone enterococcal plasmids but 94% identity with a MobC 
relaxase (annotated as a hypothetical protein) from a vancomycin-resistant S. aureus strain (GenBank 
acc. no. EIK35827). 
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I don't pretend we have all the answers. But the questions are certainly worth thinking 
about.  
Arthur C. Clarke 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
 
 
 
 
 
 210 
 
 
  
Ana P. Tedim  Chapter 6 
 
211 
 
 
 
 
 
Co-diversification of transferable ampicillin-resistant PBP5 
and Enterococcus faecium phylogenomic groups 
 
Carla Novais1, Ana P. Tedim2,3,4 , Val F. Lanza2,3,4, Ana R. Freitas1,2, Eduarda Silveira1, Ricardo 
Escada1,5, Adam P. Roberts6, Mohammed Al-Haroni6, Fernando Baquero2,3,4, Luísa Peixe1, 
Teresa M. Coque 2,3,4 * 
  
1
UCIBIO/REQUIMTE. Departamento de Ciências Biológicas. Laboratório de Microbiologia, Faculdade 
Farmácia, Universidade do Porto, Porto, Portugal. 
2
Servicio de Microbiología, Instituto Ramón y Cajal de 
Investigación Sanitaria (IRYCIS), Madrid, Spain. 
3
Unidad de Resistencia a Antibióticos y Virulencia 
Bacteriana (RYC-CSIC), Madrid, Spain. 
4
CIBER en Epidemiología y Salud Pública (CIBER-ESP), Barcelona, 
Spain. 
5
Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Porto, Portugal. 
6
Division of 
Microbial Diseases, UCL Eastman Dental Institute, University College London, London, United Kingdom. 
 
Authors contribution: 
C.N., L.P. and T.M.C. design the study. C.N., A.R.F., A.P.R. M.H.A, E.S. and R.E. performed wet lab 
experiments and participated in the analysis of the data. A.P.T. and V.F.L. performed bioinformatic 
analysis. F.B., A.P.R. and L.P. provided expertise, participated in the analysis of data, and in the revision 
of the manuscript. C.N., A.P.T and T.M.C. performed the analysis of data and wrote the manuscript. All 
authors approved the final version of the manuscript.  
 
Frontiers in Microbiology in review 
 
 
Ana P. Tedim  Chapter 6 
 
212 
 
 
 
 
 
ABSTRACT 
Ampicillin-resistance is probably a major cause of the recent dramatic increase of a cluster of human 
adapted Enterococcus faecium lineages (ST17, ST18 and ST78) in hospital-based infections. Different 
levels of ampicillin-susceptibility were associated with changes in the pbp5 gene, leading to protein 
variants (here designated as PBP5 C-types) with diverse degrees of reduction in penicillin affinity. The 
analyses of 78 E. faecium strains, as well as published E. faecium genomes, suggests that the diversity of 
pbp5 mirrors the phylogenomic diversification of E. faecium. The presence of identical PBP5 C-types as 
well as similar pbp5 genetic milieu in different E. faecium lineages and clones from quite different 
geographical and environmental origin was also documented and would indicate their horizontal gene 
transfer among E. faecium populations. This was supported by experimental assays showing transfer of 
laƌge ;≈ϭϴϬ-280 kb) chromosomal genetic platforms containing pbp5 alleles, ponA (transglycosilase) and 
other metabolic and adaptive features, from E. faecium donor isolates to suitable E. faecium recipient 
strains (10
-11
-10
-12
 UFC/recipient). Mutation profile analysis of PBP5 from available genomes and strains 
from this study suggests that the spread of PBP5 C-types might have occurred even in the absence of a 
significant ampicillin-resistance phenotype, but changes would have been facilitated by ampicillin 
exposure and, eventually, by compensatory evolution. In summary, genetic platforms containing 
polymorphic pbp5 sequences were able to be stably maintained in particular E. faecium lineages, but 
were also able to be transferred among E. faecium clones of different origins, emphasizing the growing 
risk of further spread of ampicillin-resistance in this nosocomial pathogen. 
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INTRODUCTION 
Infections caused by Enterococcus faecium haǀe iŶĐƌeasiŶglǇ ďeeŶ ƌepoƌted siŶĐe the eaƌlǇ ϭϵϴϬs͛ (Top 
et al., 2007). Currently, most clinical isolates of E. faecium are ampicillin resistant (AmpR) which are 
stably maintained for long periods in the hospital setting, serving as substrate for the acquisition of 
genetic elements including transposons coding for resistance to vancomycin (Arias and Murray, 2012; 
Wagenvoort et al., 2015). Multidrug resistant E. faecium isolates frequently cause infections associated 
with treatment failure and high mortality rates (Arias et al., 2010; Centers for Disease Control and 
Prevention, 2013)  
E. faecium is intrinsically resistant to cephalosporins and exhibits reduced susceptibility to penicillins due 
to the low affinity class B penicillin binding protein (PBP) 5, a transpeptidase that requires the 
participation of class A PBPs with glycosyltransferase activity (PonA, PbpF) to synthesize the cell wall in 
the presence of cephalosporins (Rice et al., 2009; Williamson et al., 1983). Acquired high level of AmpR 
in E. faecium was initially linked to either the enhanced production of PBP5 or polymorphisms in the 
beta subunit of this protein (Fontana et al., 1996). Soon after, it was demonstrated that single point 
mutations (Sifaoui et al., 2001), the levels of pbp5 mRNA expression (Belhaj et al., 2016), or the 
quantities of relative pbp5 transcripts were frequently strain specific and did not necessarily correlate 
with differences in the MIC values (Fontana et al., 1996; Rice et al., 2001, 2004; Rybkine et al., 1998; 
Zorzi et al., 1996). Further analysis of the PBP5 sequences of E. faecium isolates with different ampicillin 
susceptibility levels (0,5->128 mg/L) revealed that the highest variability of PBP5 sequences occurred in 
21 specific positions of the protein and suggested that a sequential acquisition of mutations could have 
resulted in the progressive tolerance to ampicillin from the early 1980s onwards (Galloway-Peña et al., 
2011; Pietta et al., 2014). Additional AmpR mechanisms described in E. faecium included mutations in 
genes encoding other species-specific proteins that participate in the cell wall synthesis as D,D-
carboxypeptidases (Ddcp and DdcY), L,D-transpeptidases (Ldtfm), glycosiltransferases (PgtA) and 
acetylmuramoyl-L-alanine amidase (LytG) resulting in slightly increased MICs values for ampicillin 
(Kristich et al., 2014; Rice et al., 2007; Zhang et al., 2012), even in the absence of PBP5 (Sacco et al., 
2014). Also, the occurrence of β-lactamases has been documented in E. faecium, although -lactamase 
producers still remain rare in this species (Coudron et al., 1992; Hendrickx et al., 2013; Klare et al., 1992; 
Zhang et al., 2012). A particularly relevant observation was the transferability of a large 60kb 
chromosomal region comprising the pbp5 gene and a transposon that confers resistance to 
glycopeptides (vanB2-CTn5386) (Carias et al., 1998; Rice et al., 2005b).  
Most AmpR E. faecium isolates belong to one of the two phylogenomic groups or sub-populations, 
ŶaŵelǇ ͞Đlade A͟ oƌ hospital-associated clade, which mainly comprises isolates from hospitalized 
patients (Galloway-Peña et al., 2012; Lebreton et al., 2013; Palmer et al., 2012). Clonal groups within a 
suďgƌoup of ͞Đlade A͟, ŶaŵelǇ ͞Đlade Aϭ͟, aƌe eŶƌiĐhed iŶ ŵoďile genetic elements and have enhanced 
ability to colonize and persist in human hosts due to the presence of adhesins and specific metabolic 
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traits (Freitas et al., 2010a, 2010b; Heikens et al., 2007; Top et al., 2008; Willems et al., 2005; Zhang et 
al., 2012). IŶ ĐoŶtƌast, ͞Đlade B͟, the ĐoŵŵuŶity-associated E. faecium subpopulation, mostly comprises 
ampicillin susceptible (AmpS) isolates from healthy non-hospitalized persons (Lebreton et al., 2013; 
Tedim et al., 2015). The increasing detection of AmpR among isolates from hosts and environments not 
associated with the hospital setting (Gonçalves et al., 2011; Novais et al., 2013; de Regt et al., 2012; 
Santos et al., 2013; Tremblay et al., 2013) is of concern, as the acquisition of transferable genes 
encoding AmpR might facilitate its further spread into other AmpS E. faecium populations or to other 
less frequently recovered enterococcal species for which AmpR has been exceptionally documented 
(Raze et al., 1998). 
Available knowledge about the diversity of AmpR genotypes in E. faecium is fractionated, and mainly 
focused on the PBP5 polymorphisms in a limited number of strains (Galloway-Peña et al., 2011). 
Similarly, data related to pbp5 transferability describe conjugative processes mediated by Tn916-like 
elements (CTn5382 or the interaction of CTn916 and CTn5386) in a few E. faecium strains (Carias et al., 
1998; Rice et al., 2005a, 2005b). Here, we report a comprehensive analysis of PBP5 diversity and 
evaluate pbp5 transfer ability among diverse E. faecium lineages to enhance the understanding of the 
impact of resistance to penicillins in the evolvability of this species. By comparative genomics of the 
transferable chromosomal regions containing pbp5 in available E. faecium genomes, we document a 
relationship between the diversity of pbp5 and the differentiation of clonal lineages, which suggests that 
AmpR should be considered from a population biology perspective. 
MATERIAL AND METHODS 
Bacterial strains.  
Seventy-eight AmpR E. faecium isolates from a collection of 1,700 enterococci recovered in Portugal 
from the last decade were analyzed (Novais et al., 2005a, 2005b, 2005c, 2006, 2013). They were 
selected on the basis of their resistance phenotype to ampicilliŶ ;шϭϲŵg/LͿ aŶd otheƌ aŶtiďiotiĐs, oƌigiŶ 
(39 from different patients admitted in five hospitals from different cities, 18 from swine feces and 
piggeries, 4 from retail poultry carcasses, 2 from healthy human feces and 15 from hospital wastewater) 
and date of isolation. Antibiotic susceptibility to ampicillin and another 10 antibiotics of different classes 
was evaluated by disk diffusion and/or agar dilution method (Clinical and Laboratory Standards Institute, 
2012). ß-lactamase production was tested in AmpR E. faecium isolates by the nitrocefin test (5μl were 
directly placed in bacteria growing around the ampicillin disc) and amplification of blaZ by PCR using 
primers based on the GenBank sequence no. M25257.1 (blaZF-ϯ͛-TTGCCTATGCTTCGACTTCA-ϱ͛, blaZR- 
ϯ͛-AGTGAAACCGCCAAGAGTGT-ϱ͛Ϳ. Clonal relatedness was established by Pulsed-Field Gel 
Electrophoresis (PFGE) and Multilocus Sequence Typing (MLST) as previously described (Freitas et al., 
2013; Homan et al., 2002; Tenover et al., 1995) (http://pubmlst.org/). Population genetic analysis was 
performed using BAPS software as previously described (Tedim et al., 2015; Willems et al., 2012). 
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Transferability of ampicillin resistance.  
Filter mating assays were performed in Brain Heart Infusion (BHI) at 37ºC overnight, using a 
donor/recipient ratio of 1:1 (1-3 experiments per isolate) using E. faecium GE1 as the recipient. Those 
donor strains transferring pbp5 to E. faecium GE1 were also included in additional filter mating assays 
using E. faecium BM4105RF and E. faecium 64/4 using the same conditions. These laboratory recipient 
strains differed in the susceptibility against ampicillin and the presence of pbp5: GE1 (pbp5; 
MICAmp<0.016mg/L; tetracycline, rifampicin and fusidic acid resistant; ST515/BAPS 2.3b), BM4105RF 
(pbp5; rifampicin and fusidic acid resistant; MICAmp=0.5mg/L; ST172/BAPS 1.3) and 64/3 (pbp5; 
rifampicin and fusidic acid resistant; MICAmp=1mg/L; ST21/BAPS 2.3a). Transconjugants were selected in 
BHI agar supplemented with antibiotics (ampicillin-10mg/L, fusidic acid-25mg/L; rifampicin-30mg/L) and 
incubated for 24-96h at 37ºC. Transconjugants were confirmed by comparison of their antibiotic 
resistance phenotype and PFGE profile with those of the wild type and the recipient strains. Conjugation 
frequency was calculated as the number of transconjugants by E. faecium GE1 recipient cell. Stability of 
acquired pbp5 platforms after serial daily passages (x30) on antibiotic free BHI agar was evaluated in 
both wild type strains and transconjugants. Colonies from each passage were inoculated on plates 
containing the same agar medium and tested for antibiotic susceptibility by disc diffusion (Clinical and 
Laboratory Standards Institute, 2012).  
Characterization of the region conferring AmpR.  
Genomes of the donor (AmpR E. faecium clinical isolate HPH-2), the recipient strain (AmpS E. faecium 
GE1) and the resulting GE1 transconjugant (AmpR E. faecium TC_GEHPH2.1) were sequenced. Total DNA 
from these strains was extracted from 2mL overnight cultures using PureElute
TM
 Bacterial Genomic Kit 
(EdgeBio, Gaithersburg, MD, USA) and DNA concentration was measured with a Nanodrop 2000 
(Thermo Scientific, Waltham, MA, USA). A total of 250-350ng of genomic DNA was sequenced using the 
Illumina MiSeq platform. MiSeq reagent kit was applied to prepare a library of Pair end DNA fragments 
according the manufacturer instructions (Illumina, San Diego, USA). Sequencing was carried out using a 
standard 2 x 71 base protocol (300-400 bp insert size) in a Genome Analyzer IIx (Illumina, San Diego, CA) 
at the sequencing facility of the University of Newcastle (United Kingdom). The main statistics for the 
three sequence datasets (number of reads and coverage) analyzed are shown in Table S1. Assembly of 
sequence data was done using Newbler software (454 life sciences, Roche, Connecticut, USA). Table S2 
shows the final assembly results. 
Prediction of ORFs was performed using GeneMark 3.05 (Besemer et al., 2001) and gene annotation was 
carried out by the Best Blast Hit approach using the UniRef100 database (Table S3). The characterization 
of the transferred region containing the pbp5 gene was done based on a gene-by-gene comparison 
approach using blastn [genes present in transconjugant (TCGEHPH2.1) and donor (HPH2) strain but not 
in recipient (GE1)]. The results are summarized in supplementary Table S4 where the presence/absence 
of each transconjugant gene in the donor and/or receptor is shown. The region characterized as 
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͞tƌaŶsfeƌƌed ƌegioŶ͟ ǁas Đoŵpaƌed agaiŶst the geŶoŵe of the E. faecium strain DO (RefSeq Accession: 
NC_017960) using Easyfig 1.2 software (Sullivan et al., 2011). The functional annotation of such 
transferred region was performed according to that one of E. faecium DO using the KEGG database 
(http://www.genome.jp/kegg/genome.html). Besides E. faecium DO, the ͞tƌaŶsfeƌƌed ƌegioŶ͟ ǁas also 
aligned against fully sequenced and closed genomes of E. faecium Aus0004, E. faecium NRRL B-2354 and 
E. faecium Aus0085 strains (RefSeq accessions numbers: NC_017022, NC_020207 and NC_021994, 
respectively) using Mauve (Darling et al., 2004). 
Analysis of the pbp5 genetic milieu.  
An 8-10kb region comprising pbp5 of 15 transconjugants and 21 wild type strains (Table 1) was 
characterized by an overlapping PCR assay. PCR conditions were adapted according to amplicon size 
(<3kb/>3kb): 0.5/1mM of each primer, 2/2.5mM MgCl2, 1x of reaction buffer, 0.2/0.4 mM of each 
deoxynucleoside triphosphate, 1,25U GoTaq® Flexi DNA Polymerase [Promega Corporation, Madison, 
U“AͿ]/Ϯ.ϱU Takaƌa LA TaƋ polǇŵeƌase ;Takaƌa™ Bio IŶĐ., “higa, JapaŶͿ. The aŵplifiĐatioŶ pƌogƌaŵ ǁas 
25 cycles of 30s at 94ºC, 30s at 55ºC, 30s at 72ºC; 1 cycle 10 min at 72ºC (for fragments <3kb) or 35 
cycles of 30s at 96ºC, 1 min at 55ºC, 7 min at 72ºC; 1 cycle 10 min at 72ºC (for fragments >3kb). 
Differences between regions were established by comparing the RFLP patterns of the corresponding 
amplicons after digestion with DdeI or ApaI, which were further sequenced. Genomic location of pbp5 
was identified by hybridization of I-CeuI and SmaI -digested genomic DNA using 23S rDNA and/or pbp5 
probes (Freitas et al., 2013; Liu et al., 1993). Labeling and detection were carried out using the Gene 
Images Alkphos direct labeling system kit following the ŵaŶufaĐtuƌeƌ͛s iŶstƌuĐtioŶs ;Aŵeƌshaŵ GB/GE 
Healthcare Life Sciences UK limited). The presumptive presence of integrative conjugative elements 
previously associated with transference of AmpR was searched by analyzing the presence of integrases 
and excisionases of CTn916 and CTn5386 as well as the non-integrase left region of CTn5382, as 
described (Carias et al., 1998; Novais et al., 2009). The transferred 8-10kb regions carrying pbp5 
characterized in this study were compared with those of all E. faecium available genomes at the 
National Center for Biotechnology Information (NCBI) database (Table S5). 
Phylogenetic analysis of PBP5. 
Comparative analysis of all PBP5 protein sequences available in the GenBank database with those 
identified in this study was performed using the searching basic local sequence alignment (nBLAST) tool 
(Altschul et al., 1997) and the ClustalW2 algorithm for multiple sequence alignment (Goujon et al., 2010; 
Larkin et al., 2007) which are provided by the NCBI and the European Bioinformatic Centre (EBI), 
respectively. The PBPϱ aŵiŶo aĐid seƋueŶĐes ǁeƌe desigŶated ďǇ a ͞C͟ folloǁed ďǇ a Ŷuŵďeƌ ;Taďle “ϲͿ. 
Phylogenetic analysis of all PBP5 sequences was performed using a Neighbor-Joining algorithm with 
bootstrap analysis based in 1000 permutations and a cut-off of ш ϳϬ% thƌough MEGA ϱ.Ϭϱ software 
(www.megasoftware.net).  
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Comparative analysis of the phylogenetic trees of pbp5 sequences and core genomes was performed to 
analyze the congruence between the pbp5 and the rest of the genome. The core genome phylogeny was 
built using 233 E. faecium (Table S5) draft genome sequences downloaded from NCBI Trace Database 
(last updated on February 2014). ORF prediction was performed for each strain by GeneMark (Besemer 
et al., 2001). The core genome was defined as genes present in all strains, non-repeated and with at 
least 80% of identity and 80% of coverage. The core genome search was performed by CD-HIT (Li and 
Godzik, 2006) and parsed by homemade Perl script. The core genome alignment is the result of the 
concatenation of all individual gene alignment. The multiple alignment of each core gene was 
performed by MAFFT (Katoh and Toh, 2010). The phylogenetic tree was built by FastTree2 (Price et al., 
2010). Tree comparison was carried out by cophyloplot command of APE (Analyses of Phylogenetics and 
Evolution) (Paradis et al., 2004) from R software. 
RESULTS 
Transferability of AmpR (pbp5).  
Twelve clinical isolates (n=12/78; 15%; Table 1) were able to transfer a region containing pbp5 to E. 
faecium strain GE1 at a frequency of 10
-11 
to 10
-12
 CFU/mL per recipient. Five of them were also able to 
transfer the pbp5 (AmpR) region to E. faecium BM4105RF and two, to the E. faecium 64/3. All donor 
strains belonged to major human lineages associated with clinical isolates causing hospital infections, 
namely BAPS subgroups 3.3a (ST670, ST132, ST280), 3.1 (ST280, ST125), and 2.1a (ST393). β-lactamase 
production was not detected in any of the isolates. 
 
Figure 1. Clonality and hybridization assays with pbp5 probes of wild type, recipients and 
transconjugants  strains.  
A-PFGE SmaI digested DNA of recipient strains (1-E. faecium GE1, 25-E. faecium 64/3, 28-E. faecium BM4105RF), wild type (2-
VD79C1, 4-SN71, 6-SN133, 8-HPH2, 10-H323, 12-70411, 14-H207, 16-E49, 18-E233, 20-E169, 22-E4) and transconjugants (3-
GEVD79C1.5, 5-GESN71.1, 7-GESN133.1, 9-GEHPH2.1, 11-GEH323.3, 13-GE70411.2, 15-GE207.1, 17-GEE49.1, 19-GEE233.1, 21-
GEE169.3, 23-GE28798.1, 24-GEE4.1, 26- 64SN71.1, 27- 64HPH2.1, 29- BMSN71.1, 30- BMH207.3, 31- BM70411.5, 32- BME169.3, 
33- BMVD79C1.6). B- Hybridization assays with a pbp5 probe (primers P1 and P2-Figure 4). M- Low Range PGE Marker, kb (New 
England, BioLabs). Abbreviations: TCEfm- Transconjugant E. faecium  
Ana P. Tedim  Chapter 6 
 
220 
 
All transconjugants had similar PFGE profiles to recipient strains (Figure 1), were resistant to rifampicin 
and fusidic acid and exhibited ampicillin MICs=8-128mg/L lower than their corresponding wild types in 
some cases (8mg/L or 16 vs 32mg/L to >256mg/L). Besides the AmpR phenotype, some transconjugants 
also exhibited resistance to vancomycin (n=8), teicoplanin (n=8), erythromycin (n=6), tetracycline (n=1; 
corresponding only to non-E. faecium GE1 transconjugants; as GE1 strain is resistant to this antibiotic), 
streptomycin (n=1) and/or gentamicin (n=1). Transference of the pbp5 platform either alone or with 
plasmids that carry genes encoding resistance to different antibiotics only occurred when plates were 
supplemented with ampicillin (data not shown).  
The pbp5 gene of AmpR isolates is located on large and transferable chromosomal platforms 
containing metabolic traits. 
Hybridization of pbp5 and 23S rDNA probes was observed in the same high band of digested I-CeuI DNA, 
thus indicating its chromosomal location. Further hybridization of SmaI-digested genomic DNA with the 
pbp5 probe showed signals in fragments of ~210kb in all but one GE1 transconjugants, for which the 
pbp5 was detected in a band of ~180kb (Figure 1). Hybridization of the same probe with fragments of 
SmaI-digested genomic DNA of E. faecium BM4105RF and 64/3 transconjugants of different size 
suggests the occurrence of independent transfer events that seem to occur in a particular region of the  
genome based on the similarity of PFGE patterns of the transconjugants obtained using different donors 
(Figure 1). The donor strains lack integrases/excisionases of Tn916-like transposons (Tn916, Tn5386, 
Tn5382) suggesting a different mechanism of movement than that previously reported (Rice et al., 
2005a, 2005b). 
Sequencing of the recipient (E. faecium strain GE1), the donor (E. faecium HPH2) and the transconjugant 
(E. faecium strain TCGEHPH2.1) allowed us to identify 7 contigs containing genes present in the donor 
and its transconjugant but absent in the recipient strain. They were considered to correspond to the 
͞tƌaŶsfeƌƌed ƌegioŶ͟, ǁhiĐh Đoŵpƌised the pbp5 gene and had a size of approximately 280kb, slightly 
larger than that inferred from the SmaI-PFGE gels. A more detailed analysis of the contigs revealed that 
two of them (contg00158 and contig00068), particularly contig00158, contained genes present in the 
recipient and transconjugants but not in the donor strain, which could be explained either by the partial 
transfer of the platform and/or by post-transfer recombination events (Figure 2). The comparative 
analysis of the genomes sequenced in this work with the four closed E. faecium genomes (DO, NRRL B-
2354, Aus0004, Aus0085 strains) available at the NCBI database at the time of writing this manuscript, 
revealed a common region among our donor/transconjugant strains and the four genomes of 153kb 
containing the pbp5 gene, which is absent in the recipient E. faecium GE1 genome (Figure 3). The 
remaining region of the transferable platform was variably present at different chromosomal positions 
in different strains (Figure 3). 
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Figure 2. Representation of the transferable chromosomal region containing pbp5. 
Mapping and annotation (using KEGG database) of transferable region of transconjugant TCGEHPH2.1 (represented by black line) 
using E. faecium DO as reference genome. Lines above E. faecium DO genetic structure represent the transferable genetic 
platform observed in wild type and transconjugant isolates (pink) and genomic regions of E. faecium GE1 recipient and 
transconjugant (green). GC content was calculated using seqinr in Rstudio. The window used to calculate the GC content was 
200bp, represented in the figure by each vertices of the graph. Abbreviations: WT, wild type. 
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Figure 2 shows a detailed characterization of the region transferred containing ORFs with a G+C content 
ranging from 24 to 41%. Beside pbp5-related resistance to β-lactams, genes contained in this transferred 
region are involved in different cell functions such as transport of some amino acids and carbohydrates, 
redox processes and survival under stressful conditions in the intestinal environment (e.g. acid and bile 
tolerance). Among genes related to β-lactam resistance we detected a gene encoding a bifunctional 
class A PBP with a transpeptidase and transglycosylase activity named ponA, which is involved in the 
synthesis of the peptidoglycan, allowing the survival of the cell in the presence of cell wall inhibitory 
compounds (Rice et al., 2009). A copy of the CiaRH operon, a two component and cell envelope stress 
response, a system that was restricted to the genus Streptococcus to date, was also detected. In this 
species, the CiaRH operon is weakly induced by prolonged incubation with sub-lethal amounts of cell 
wall active antibiotics and it seems to mediate resistance to lysis induced by these compounds. The 
CiaRH-dependent regulation has been said to influence the virulence of Streptococcus pneumoniae but 
its role in enterococci has not yet been elucidated (Jordan et al., 2008; Krawczyk-Balska and Markiewicz, 
2016). The transferable chromosomal region containing pbp5 in Enterococcus has also genes with 
presumed influence on the microbe-host interaction. Among them, some involved in the transport and 
use of different substrates generated by the host, including three phosphotransferase systems (PTS, 
namely glucitol/sorbitol, L-ascorbate and mannose/fructose/sorbose), the ABC transport and 
transformation system of maltodextrines (malACDX) and the N-acetylmannosamine-6-phosphate 
epimerase (NanE; part of a pathway that allows the usage of sialic acids, major components of 
glycoproteins, gangliosides, and other sialoglycoconjugates). Other metabolic genes in the platform 
could be involved in tolerance to intestinal acid environment, including glyceraldehyde-3-phosphate 
dehydrogenase, ATP synthase subunit α, NADH dehydrogenase, glutaminase and genes encoded 
enzymes that favored the production of ammonia from glutamine, and deamination or transport of 
branched/nitrogenated amino acids. The region also contains five stress response proteins including two 
belonging to the Csp (cold shock proteins) system (CspA and CspC) and the small chaperone Hsp20, and 
Gls33, which are also present in E. faecium genomes available in the GenBank databases. They have 
been involved in stress response to salts, pH and ethanol exposure in Clostridium; Hsp20 is an small 
chaperone protein involved in the survival at different abiotic stress conditions as heat (55ºC) and salt 
(5mM) in Bifidobacterium longum (Khaskheli et al., 2015). 
The large and transferable chromosomal platforms exhibit hotspots for insertions. 
The occurrence of different insertion sequences (Figure 4) in the boundaries of the pbp5 gene and the 
presence of a >3027 bp psr-pbp5 fragment in E. hirae (99.9% identical to that found on E. faecium) 
suggest the occurrence of hot spots that could facilitate recombination of certain regions. To test this 
possibility we further analyzed the 8-10Kb genetic context of pbp5 genes from 21 wild type and 15 
transconjugants isolates included in this study as well as in available enterococcal genomes. RFLP 
amplicons corresponding to ftsW to pbp5 region as well as pbp5 to ion efflux gene showed an identical 
pattern both in donor and transconjugants, but were different from the same regions of pbp5 carrying 
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recipient strains E. faecium BM4105RF and 64/3 (Figure 4). Sequencing of fragments representing 
distinct RFLP patterns and comparative analysis with similar regions of GenBank available genomes, 
revealed 21 variants of such 8-10kb-chromosomal fragment (designed by roman numerals), which 
differed in the number and type of insertions sequences (Figure 4). Three variants (types I, II, III) 
correspond to transferable platforms described in this study (Figure 4; Table 1).  
The predominant 8-10kb fragment identified in both AmpR and AmpS E. faecium analyzed in this study 
did not contain indels and was considered the prototype chromosomal region arbitrarily named Type I 
(Table S5, Figure 4, Figure 5). The pbp5 or other genes (e.g. psr, ftsw, ion efflux genes) were flanked by 
one or two insertions sequences of the IS256, ISL3 of IS30 families (ISEf1, ISEfm1, ISEfm2, IS1542, IS256-
like, ISEfa11, or IS1251-like) in isolates carrying types II to XXI, with the exception of type VIII that had 
CTn5382 (vanB2) inserted just after pbp5 gene. The identifiable boundaries of ISs detected in most 
platforms as well as the common nucleotide positions at which insertions occurred, suggested recent 
acquisition events at the platform hot spots (Figure 4). Also, some types can represent evolved 
platforms from others by insertion of additional IS or occurrence of recombination events. That could be 
the case for example of types III, XIV, XV and XVII evolving from type II or XI and XII from type V, 
respectively. Despite of predominance of type I, some types seem to be more associated with specific 
hosts as the case of type V to pigs and type II/II-like, III or type XIV-like to the clinical setting. 
Epidemiological distribution of isolates appears in Table S5.  
Diversity of PBP5 sequences reflects the phylogenomic diversification of E. faecium.   
We identified 75 PBP5 protein variants (Table S5 and S6) corresponding to AmpR and AmpS strains 
which comprise 20 of the previously described variants C4, C7, C9, C11, C15-C18, C21, C24, C46-C48, 
C50, C51, C61, C63, C65, C67, C71 (Galloway-Peña et al., 2011; López et al., 2009; Rybkine et al., 1998). 
The other 55 variants were firstly detected in this study either in strains from Portugal (n=11) or from 
available genomes at NCBI database (n=44). The C4, C7, C8, C9, C12, C19, and C20 sequences are linked 
to isolates able to transfer a region containing pbp5 (Table 1 and S6, Figure 5), which belong mostly to 
ST18, its SLV ST125, and the ST280 and ST670 (BAPS 3.3a, 3.1 and 2.1a, respectively) (Table 1).  
Figure 5 shows the phylogenetic tree constructed with all known PBP5 protein sequences (this study and 
those available at GenBank databases). The tree is split in two major clades arbitrarily named B and A, 
mirroring the clades associated with populations of non-hospitalized persons and hospital isolates 
respectively, in agreement with what was previously inferred from phylogenomic studies of E. faecium 
(Lebreton et al., 2013). Clade B comprises PBP5 of AmpS isolates (PBP5-S) mainly belonging to BAPS 1.2 
and 1.5. Some are similar to the prototype PBP5-S C46 sequence from E. faecium BM4107 strain (Sifaoui 
et al., 2001) but most of them also exhibit mutations at positions T25A, S39T and D644N, which are also 
common to PBP5 sequences of clade A isolates (Table S6). Two strains, isolated in 1964 and 2006, 
further showed changes at S27G+T324A and S27G, respectively, such mutations corresponding to the  
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Figure 4. Characterization of E. faecium pbp5 genetic environment by PCR and sequencing.  
The Roman numbers I, II, III, and V represent the different genetic platforms detected in E. faecium from this study. The numbers 
IV, VI to XXI were detected in available genomes from GenBank database. The different types were named according to diversity 
of insertions sequences, genomic fragments or conjugative transposons within genes or intergenic regions. Mutations or 
recombinations within genes or intergenic regions were not considered for type classification. The Table indicates the primers 
used (designed for this study; P1/P2 described by Dahl et al, 2000) and the size of PCR amplicons from genetic environment of 
types I-III and V. The  A, B, C and D lines of the bottom right side figure represent RFLP patterns of amplicon P3-P2 of mobile 
platforms I (pattern C) and II/III (pattern D) of isolates included in this study, when digested with DdeI restriction enzyme. The 
patterns A and B correspond to the amplicons of the recipient strains E. faecium BM4105RF and 64/3, respectively. a These gene 
has an extra stop codon within its sequence. Abbreviations: N-acyl, (N-acyl-glucosamine-6-phosphate-2-epimerase); HP 
(hypothetical protein); ftsW (cell cycle protein); psr, (pbp5 synthesis repressor); pbp5 (gene encoding penicillin binding protein 5); 
AceT (acetiltransferase); HisPh (Histidinol Phosphate Phosphatase). 
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PBP5-R consensus sequence (Pietta et al., 2014). The type I chromosomal region above mentioned was 
observed in all available isolates from this group (Figure 5; Table S5). 
 
Figure 5. Phylogenetic analysis of PBP5 protein sequences from E. faecium isolates of this study and 
available in Genbank database (until February 2014).  
The Maximum Likelihood tree was obtained using Mega 7 based on the JTT method. The tree with the highest log likelihood (-
2000.3736) is shown. Initial tree(s) for the heuristic search were obtained automatically by applying Neighbor-Join and BioNJ 
algorithms to a matrix of pairwise distances estimated using a JTT model, and then selecting the topology with superior log 
likelihood value. The analysis involved 75 amino acid sequences. All positions containing gaps and missing data were eliminated. 
There were a total of 445 positions in the final dataset. Evolutionary analyses were conducted in MEGA7. Bootstrap values are 
indicated and are based in 1000 permutations. The cut-off used ǁas ш ϳϬ%.  ͞C͟ folloǁed ďǇ a Ŷuŵďeƌ ƌepƌeseŶt PBPϱ aŵiŶo aĐid 
combinations described in Table S6. Only one E. faecium isolate ĐaƌƌǇiŶg ƌepƌeseŶtatiǀe PBPϱ seƋueŶĐes ;eaĐh tǇpe of ͞C͟Ϳ ǁas 
included in the tree. The pbp5 genetic environments types described in Figure 4 are indicated by colored circles and, when more 
thaŶ oŶe tǇpe is pƌeseŶt iŶ isolates ĐaƌƌǇiŶg the saŵe ͞C͟, ďǇ Đoloƌed sƋuaƌes. If Ŷo sǇŵďol is pƌeseŶt, the geŶetiĐ eŶǀiƌoŶŵent 
was undetermined. Abbreviations: NA, not applicable 
Clade A includes PBP5 variants grouped in two main clusters arbitrarily designed here A0 and A1, with 
most isolates sharing mutations at positions V24A, S27G, E100Q, K144Q, T172A, T324A, N496K, A499T 
and E525D (7 of the 21 positions used to establish sequence diversity of this protein) (Pietta et al., 
2014). The Clade A0, represented by C30, C31, C37, C52, C53 and C54 PBP5 sequences, corresponds to 
AmpS isolates of different BAPS groups (BAPS 1.2, BAPS 2.3a and BAPS 3.3b), hosts (animals and 
humans), countries and were collected from 1995 to 2001 (Figure 5, Table S6). Most isolates carrying 
pbp5 within a type I fragment. Sequences within the Clade A1 were divided in three subclusters that 
parallels E. faecium populations of BAPS groups 2 and 3 (Tedim et al., 2015; Willems et al., 2012). They 
were designated as A1S, comprising a subset of PBP5-AmpS variants (mainly associated with human and 
animal isolates of BAPS subgroup 2.1b); A1M, comprising a subset of PBP5-AmpS and PBP5-AmpR 
(mostly associated with animal isolates of diverse BAPS subgroups 2.1b, 2.3a, 2.3b, 3.1, 3.2 and 3.3b); 
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and A1R, including almost all PBP5-AmpR (mostly associated with the clinical setting and BAPS 
subgroups 3.1, 3.3a and 2.1a, with the latter two only observed in this group). 
All isolates from Clades A1S, A1M and A1R share mutations R34Q, G66E, L177I and A216S but also 
present some differences. Mutations S39N and A401S plus A499I were specific for subclades A1S and 
A1M, respectively. The last two polymorphisms were previously documented in two AmpR strains 
(Pietta et al., 2014) but this study suggests that they are fixed in certain populations despite they were 
not previously considered within the PBP5 relevant changes. One of the A1M strains had also variations 
at specific positions linked to the A1R group (A68T, E85D, M485T, V586L, E629V and P667S). Of note is 
the PBP5 variant C23 within this cluster, which is here overrepresented (n=44).  
PBP5 variants within the A1R group exhibited six mutations (A68T, E85D, S204G, 466´S/D, M485A/T, 
E629V, P667S) predominant in this group, some of them located at the active site of the protein 
(466´S/466´D, M485A/T) and at the end of a turn between the β1 and β2 strands (E629V; P667S) 
(Fontana et al., 1996; Rice et al., 2004). It is of note that some AmpS isolates (BAPS subgroups 3.1, 2.3a 
and 3.2) with PBP5 clustering in the A1R subgroup (including the PBP5 of the recipient E. faecium 64/3) 
lack the mutation M485A and E629V, which suggest that such mutations might be necessary for AmpR 
phenotype, as reported (Rice et al., 2004). Changes A68T, E85D and S204G were shared by AmpS and 
AmpR isolates of A1R group (Table S6). Some strains exhibited the particular pattern of mutations 
Q408H, A558T, G582S, K632Q and, eventually, V462A, N546T and P642L. They have not previously been 
associated with AmpR. The pbp5 genetic environment type I was distributed in all clade A1, although the 
subgroups A1M and A1R included isolates with the most types variety. Of note, most isolates carrying 
types V and XI grouped in A1M and all carrying the similar types II, III, XIV, XV and XVII grouping in A1R 
(Figure 5, Table S5). 
We also analyzed, in available genomes, other genes that have previously been associated with AmpR 
(ddcP, ddcY, ldtEfm, pgtA, lytG) and considered representative protein sequence per UniRef100 
available at Uniprot using as reference E. faecium strain Aus0004. Single-locus phylogenetic tree of PBP5 
was congruent with those of proteins codified by ldtEfm and ddcY but was non-congruent with those of 
ddcP, pgtA and lytG (data not shown). 
Analysis of the topology of the phylogenetic tree of the available E. faecium core genomes and the 
phylogenetic trees of E. faecium pbp5 genes analyzed in this study revealed branches in both trees with 
the same and different topologies. Such discrepancies further suggested that the pbp5 gene could be 
transferred within E. faecium populations (Figure 6) potentially explaining the occurrence of the same 
PBP5 variants in isolates of different clonal lineages and phylogenomic groups containing different PBP5 
variants (Figure 5, Table S5). As examples, isolates of BAPS 1.2 (PBP5 variants of clades A0 and B), BAPS 
4 (clades A1R and B) or BAPS 7 (clades A1S, A1R and B). 
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Figure 6. Comparison between 233 E. faecium Core Genome phylogeny and pbp5 phylogeny. 
Strains in blue belong to Clade B, strains in red belong to Clade A1, strains in green belong to Clade A2. The edges join the core 
genome and the corresponding pbp5 of each strain. Both trees were made by ML using GTR-CAT. Tress and edges was made with 
APE packages. The result of Mantel test (r=-0.03 and significance of 0.761) show the rearrangement of the pbp5 in comparison 
with the core genome. The Mantel test (APE package) was made using the distance matrix calculated from nucleotide alignments. 
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Ampicillin resistance was maintained without selective pressure. 
AmpR was maintained in the wild type strains and respective E. faecium GE1 transconjugants over 200 
generations in antibiotic free BHI indicating that the acquired genetic platforms containing pbp5 may 
persist in absence of selective pressure in different genetic backgrounds.  
DISCUSSION 
This study documents the transferability of pbp5 within a large chromosomal region not associated with 
CTn (Tn5282, Tn916, Tn5386) previously described to be involved with this event and shows a trend 
between the PBP5 diversity and the phylogeny of this species. 
The evolution of the PBP5 remains elusive despite of its role in the resistance to cephalosporins and 
penicillins in E. faecium and the emergence of AmpR E. faecium on a global level. This PBP is a member 
of the Mec family, which comprises proteins with natural low affinity for β-lactams as PBP2r (mecA) of 
Staphylococcus aureus, and shows a 99% identity with PBP3r of Enterococcus hirae (suggesting a 
common origin) (Hiramatsu et al., 2013; Raze et al., 1998). Hiramatsu et al. hypothesized that proteins 
of the Mec family such as MecA (PBP2r) would have been essential for the survival of ancestral 
members of staphylococci in the presence of ß-lactam antibiotics produced by fungi and Actinobacteria 
and further lost in the Devonian period with the emergence of mammals (more than 400 million of years 
ago) coincidental with the separation and adaptation of staphylococcal species to different hosts 
(Hiramatsu et al., 2013). It is tempting to suggest a similar scenario for the PBP5 of E. faecium. This 
species has traditionally been classified within the enterococcal groups established by Carvalho et al. 
(Carvalho et al., 1998) ďased oŶ ŵetaďoliĐ pƌofiles, ŶaŵelǇ ͞gƌoup II͟ ƌestƌiĐted to huŵaŶs aŶd oŶlǇ 
comprising E. faecalis and E. faecium. Some E. faecium ǀaƌiaŶts liŶked to the ͞gƌoup III͟ ;assoĐiated ǁith 
water and plants; also grouping Enterococcus hirae) could be the origin of pbp5 and psr genes (G+C 
content of 38.9% compatible with an enterococcal origin). Based on the apparent universal presence of 
pbp5 gene in E. faecium populations, we could speculate that acquisition might have predated the 
evolutionary split among mammals, reptiles, birds, and insects, with further multiple acquisition events 
to shape the contemporary platform if we consider the variable G+C content of this set of genes. 
However, the low number of non-mammals isolates in databases might mask a more recent acquisition. 
The full characterization of the 153kb chromosomal region that contains not only the pbp5 gene but also 
genes codifying for traits that might facilitate the survival in the gastrointestinal tract (e.g. resistance to 
stress by acids and bile; substrates produced by the host as maltodextrines, sialic acids) in almost all 
available E. faecium genomes suggest a contribution of this region to the adaptation to the mammalian 
intestine and persistence in abiotic environments. To date, only two E. faecium strains lacking pbp5 have 
been documented, strains GE1 and D344S, which derived from AmpS and AmpR isolates, respectively. 
The D344S strain is susceptible to cephalosporin and ampicillin due to the spontaneous deletion of a 170 
kb genome fragment that included pbp5 and other pbp genes. This deletion occurred by the interaction 
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of CTn5386 (a 60kb element that comprises pbp5 and vanB2) with Tn916 (Rice et al., 2007). The GE1 
strain does not harbor Tn916 and the causes for the loss of the region in which pbp5 is located are 
unknown.  
Polymorphisms in the PBP5 protein sequences allowed us to group the variants in clusters that parallel 
phylogenomic diversification of E. faecium (Lebreton et al., 2013). Lebreton et al suggested a model for 
eǀolǀaďilitǇ of this eŶteƌoĐoĐĐal speĐies ĐoŶsistiŶg oŶ a fiƌst split of ͞Đlade B͟ aŶd ͞Đlade A͟ ĐoiŶĐideŶtal 
ǁith huŵaŶ aŶd aŶiŵal iŶsulatioŶ oĐĐuƌƌiŶg ϯϬϬϬǇ ago, aŶd a fuƌtheƌ split of ͞Đlade A͟ iŶ suďĐlades ͞Aϭ͟ 
aŶd ͞AϮ͟ afteƌ the iŶtƌoduĐtioŶ of antibiotics in the therapeutical arsenal in late 1940s (Lebreton et al., 
2013). Tǁo ŵaiŶ Đlusteƌs of PBPϱ ǀaƌiaŶts ǁeƌe also ideŶtified iŶ this studǇ, desigŶated as ͞B͟ 
(associated with the E. faecium ͞Đlade B͟Ϳ, aŶd ͞A͟ that fuƌtheƌ split iŶ suďgƌoups AϬ ;iŶĐludiŶg oŶlǇ 
AmpS isolates) and A1 comprising three small groups linked to different E. faecium populations differing 
in the susceptibility to ampicillin; A1S (AmpS from healthy humans of different BAPS groups), A1M  
(AmpS and AmpR from humans and animals), and A1R (AmpR from clinical isolates). Although some 
authors have suggested sequential acquisition of amino acid changes (Galloway-Peña et al., 2011; Pietta 
et al., 2014), such diversification may also indicate different evolvability routes for AmpR in response to 
distinct selective pressures in different hosts similarly to what has been observed for different β-
lactamase enzymes of Gram negative organisms (Novais et al., 2010). Nonetheless, transfer events could 
also have contributed to the diversification of the PBP5-A1 group.  
The transfer of platforms carrying pbp5 gene in E. faecium resulting from the interaction between 
transposons as Tn5382 or Tn916 plus Tn5386 (Rice et al., 2005a) was demonstrated for a few isolates. 
This was not the case of any of the strains included in our study lacking Tn916-like elements, thus 
opening the possibility of the involvement of different mechanisms responsible for intercellular transfer 
or mobilization (Manson et al., 2010). It is of note that disparate topologies of the phylogenetic trees of 
E. faecium core genomes and E. faecium PBP5 would further reflect how frequent the transference of 
pbp5 genetic platforms under natural circumstances may occur. However, such horizontal gene transfer 
(HGT) events preferentially occur or are fixed in diverse populations prone to mutation (the subclade A1 
that is characterized by a higher mutation rate that clade B) that would further facilitate their clonal 
expansion under ampicillin seleĐtiǀe pƌessuƌe, ƌefleĐtiŶg the ͞ex unibus plurum͟ eǀolutioŶaƌǇ dǇŶaŵiĐs 
(Baquero, 2011). HeteƌogeŶeitǇ of populatioŶs that ĐoloŶize huŵaŶs, desigŶated as ͞Đlouds͟ elseǁheƌe 
(Stanczak-Mrozek et al., 2015), leads to a possible global adaptive benefit for certain clones and finally 
for the overall species, that is enhanced by HGT.  
The progressive increase in the number of isolates with reduced susceptibility to ampicillin paralleled 
the number of infections caused by E. faecium throughout the last decades (Grayson et al., 1991; 
National Nosocomial Infections Surveillance System, 2004; Treitman et al., 2005). While AmpR isolates 
recovered from humans are in low numbers and are always recovered under selective pressure, AmpR 
from pet animals have frequently been detected and are often associated with PBP5 variants commonly 
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found in these hosts (de Regt et al., 2012; Tedim et al., 2015). The specific causes associated with this 
AmpR-E.faecium emergence in different hosts remains unknown. Besides the increase in intestinal E. 
faecium population size following selective events in humans and the possible transmission events 
between animals and humans (Sánchez-Díaz et al., 2015; Ubeda et al., 2010), other factors could be 
responsible for bloomings or a more frequent representation of AmpR populations in the normal flora of 
another non-human hosts (Stecher et al., 2013). 
The necessary contribution of different genes for the expression of AmpR phenotype is suggested by the 
lower MIC values of the transconjugants in comparison with the wild type strains in this and in previous 
studies (Rice et al., 2005b; Zhang et al., 2012). The transferable genetic region identified here contained 
the pbp5 and ponA but also other genes (ciaRH operon) previously associated with β-lactam resistance 
in Streptococcus pneumoniae, but still unexplored in enterococci (Guenzi et al., 1994). Outside this 
region, only ldtEfm and ddcY showed a similar non-congruent topology with that of pbp5 indicating that 
these genes are also under accelerated evolution, which could explain eventual AmpR phenotypes with 
a lack of correlation with PBP5 sequences in some cases (Zhang et al., 2012). The variable ampicillin-
susceptibility phenotypes observed in different transconjugants even when using the same recipient 
strain suggested either a partial transfer of the platform or occurrence of recombination events leading 
to variation in MICs, which seem to occur frequently in commensal bacteria (Levine et al., 2016).  
In summary, the characterization of a chromosomal region containing the pbp5 carrying different 
adaptive traits suggests its possible involvement in the adaptation of E. faecium to the gastrointestinal 
tract of mammals and the evolution of this species. The apparent frequent transfer events of an 
adaptiǀe Đhƌoŵosoŵal ƌegioŶ aŵoŶg ͞Đlouds͟ of ĐloselǇ ƌelated populations, indicates the relevance of 
bacterial shifts in the evolution of pathogenicity and antibiotic resistance. Such adaptations probably 
reflect changes in patients` demographics and medical strategies and interventions, within the paradigm 
of the ͞HaŵiltoŶiaŶ ŵediĐiŶe͟ (Fraser et al., 2005) and highlight the increasing need for evolutionary 
biology be aligned with medical challenges (Nesse et al., 2010). 
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NUCLEOTIDE SEQUENCE GENBANK ACCESSION NUMBERS.  
The sequences corresponding to representative pbp5 genetic platforms (Types I-IV) were assigned 
Genbank accession numbers JN208885, JN208888, JN208884 and JN208886, respectively.  PBP5 amino 
aĐid ǁeƌe aŶalǇzed aŶd desigŶated ďǇ a ͞C͟ folloǁed ďǇ a Ŷuŵďeƌ ;Taďle “ϲͿ. Neǁ seƋueŶĐes 
correspond to Genbank accession numbers JN208883 (C6 amino acid combination), JN208889 (C19 
amino acid combination); JN208887 (C8 amino acid combination); JN208886 (C3 amino acid 
combination), JN208882 (C2 amino acid combination), KC479673 (C1 amino acid combination), 
KC479675 (C5 amino acid combination), KC479676 (C10 amino acid combination) and KC479674 (C12 
amino acid combination). 
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SUPLEMENTARY MATERIAL 
Table S1. Number of reads and coverage of the bacterial genomes analyzed 
 
 
Table S2. Statistics of the sequence datasets. 
 
 
Table S3 - Best BLAST Hit annotation of E. faecium HPH2, GE1 and GEHPH2.1. 
 
Due to the size of the table it will be provided only in digital format.  
E. faecium  GE1 (recipient strain) 1169494 416713283
E. faecium  HPH2 (wild strain) 1120024 394271010
E. faecium  TCHPH2-1(transconjugant) 1123087 414888338
Number of sequenced reads (Genome coverage)Genome DNA bases (Genome coverage)
Bacterial sample Aligned reads Aligned bases Number of contigs N50 contig size
E. faecium  GE1 (recipient strain) 1133856 (96.95%) 401958556 (96.46%) 313 7.4 K
E. faecium  HPH2 (wild strain) 109511 (97.78%) 384306935 (97.47%) 421 3.7 K
E. faecium  TCHPH2-1(transconjugant) 1082923 (96.42%) 397931731 (95.91%) 157 6.7 K
Efm  GEHPH2.1  Efm  HPH2  Efm  GE1 Best BLAST Hit Annotation 
contig00001|1 0 1 UniRef100_D4SNG0 Zeta toxin family protein n=7 Tax=Enterococcus faecium RepID=D4SNG0_ENTFC
contig00001|2 0 1 UniRef100_L2IE87 DJ-1/PfpI family protein n=5 Tax=Enterococcus faecium RepID=L2IE87_ENTFC
contig00001|3 0 1 UniRef100_K0ZNC5 Uncharacterized protein n=22 Tax=Enterococcus RepID=K0ZNC5_9ENTE
contig00001|4 0 1 UniRef100_D4QSL9 LD-carboxypeptidase superfamily n=39 Tax=Enterococcus RepID=D4QSL9_ENTFC
contig00001|5 1 1 UniRef100_H8L917 YbaK/prolyl-tRNA synthetase-associated domain protein n=146 Tax=Firmicutes RepID=H8L917_ENTFU
contig00001|6 0 1 UniRef100_H8L918 Uncharacterized protein n=199 Tax=Firmicutes RepID=H8L918_ENTFU
contig00001|7 0 1 UniRef100_D4SNF2 DNA binding domain, excisionase family protein n=67 Tax=Enterococcus RepID=D4SNF2_ENTFC
contig00001|8 0 1 UniRef100_H8L920 Sugar transport protein n=198 Tax=Firmicutes RepID=H8L920_ENTFU
contig00001|9 0 1 UniRef100_J6AI78 Glucose 1-dehydrogenase n=87 Tax=Enterococcus RepID=J6AI78_ENTFC
contig00001|10 0 1 UniRef100_H8L922 Riboflavin biosynthesis protein RibF n=130 Tax=Firmicutes RepID=H8L922_ENTFU
contig00001|11 0 1 UniRef100_J6RB01 tRNA pseudouridine synthase B n=58 Tax=Enterococcus faecium RepID=J6RB01_ENTFC
contig00001|12 0 1 UniRef100_S4F5X4 D-xylulose 5-phosphate/D-fructose 6-phosphate phosphoketolase n=3 Tax=Enterococcus faecium RepID=S4F5X4_ENTFC
contig00001|13 0 1 UniRef100_C9B4V5 Ribosome-binding factor A n=145 Tax=Enterococcus RepID=C9B4V5_ENTFC
contig00001|14 0 1 UniRef100_C9BZ75 Translation initiation factor IF-2 n=92 Tax=Enterococcus RepID=C9BZ75_ENTFC
contig00001|15 1 1 UniRef100_H8L928 50S ribosomal protein L7Ae n=203 Tax=Firmicutes RepID=H8L928_ENTFU
contig00001|16 1 1 UniRef100_H8L929 Cytosolic protein YlxR n=231 Tax=Firmicutes RepID=H8L929_ENTFU
contig00001|17 0 1 UniRef100_D4SNE1 Transcription termination factor NusA n=36 Tax=Enterococcus faecium RepID=D4SNE1_ENTFC
contig00001|18 1 1 UniRef100_H8L931 Ribosome maturation factor RimP n=124 Tax=Firmicutes RepID=H8L931_ENTFU
contig00001|19 0 1 UniRef100_D4SND9 DNA polymerase III polC-type n=36 Tax=Enterococcus faecium RepID=D4SND9_ENTFC
contig00001|20 0 1 UniRef100_D4SND8 Proline--tRNA ligase n=35 Tax=Enterococcus faecium RepID=D4SND8_ENTFC
contig00001|21 0 1 UniRef100_J6KDD3 RIP metalloprotease RseP n=29 Tax=Enterococcus faecium RepID=J6KDD3_ENTFC
contig00001|22 0 1 UniRef100_D4SND6 Phosphatidate cytidylyltransferase n=13 Tax=Enterococcus faecium RepID=D4SND6_ENTFC
contig00001|23 0 1 UniRef100_H8L936 Isoprenyl transferase n=194 Tax=Firmicutes RepID=H8L936_ENTFU
contig00001|24 1 1 UniRef100_H8L937 Ribosome-recycling factor n=227 Tax=Firmicutes RepID=H8L937_ENTFU
contig00001|25 1 1 UniRef100_S4E7P4 Uridylate kinase n=1 Tax=Enterococcus faecium SD3B-2 RepID=S4E7P4_ENTFC
contig00001|26 0 1 UniRef100_J6KDE7 Elongation factor Ts n=7 Tax=Enterococcus faecium RepID=J6KDE7_ENTFC
contig00001|27 1 1 UniRef100_E4I4V0 30S ribosomal protein S2 n=48 Tax=Enterococcus faecium RepID=E4I4V0_ENTFC
contig00001|28 1 1 UniRef100_H8L941 Arginine repressor n=179 Tax=Firmicutes RepID=H8L941_ENTFU
contig00001|29 0 1 UniRef100_S4EV59 2-aminoethylphosphonate--pyruvate transaminase domain protein n=5 Tax=Enterococcus faecium RepID=S4EV59_ENTFC
contig00001|30 0 1 UniRef100_D4SNC8 2-aminoethylphosphonate:pyruvate transaminase n=1 Tax=Enterococcus faecium E1039 RepID=D4SNC8_ENTFC
contig00001|31 0 1 UniRef100_D4SNC7 Phosphonoacetaldehyde hydrolase n=6 Tax=Enterococcus faecium RepID=D4SNC7_ENTFC
contig00001|32 0 1 UniRef100_D4SLK2 Arginine--tRNA ligase n=3 Tax=Enterococcus faecium RepID=D4SLK2_ENTFC
contig00001|33 0 1 UniRef100_H8L946 Carbamate kinase n=194 Tax=Firmicutes RepID=H8L946_ENTFU
contig00001|34 0 1 UniRef100_H8L947 Ornithine carbamoyltransferase n=231 Tax=Firmicutes RepID=H8L947_ENTFU
contig00001|35 0 1 UniRef100_H8L948 Arginine deiminase n=201 Tax=Firmicutes RepID=H8L948_ENTFU
contig00001|36 0 1 UniRef100_H8L949 Cyclic nucleotide-binding domain protein n=176 Tax=Enterococcus RepID=H8L949_ENTFU
contig00001|37 0 1 UniRef100_D4QQM9 tRNA N6-adenosine threonylcarbamoyltransferase n=78 Tax=Enterococcus RepID=D4QQM9_ENTFC
contig00001|38 0 0 UniRef100_D4QQN0 Ribosomal-protein-alanine acetyltransferase n=79 Tax=Enterococcus RepID=D4QQN0_ENTFC
contig00001|39 0 1 UniRef100_L2JDN6 Ribosomal-protein-alanine acetyltransferase n=84 Tax=Enterococcus RepID=L2JDN6_ENTFC
contig00001|40 0 1 UniRef100_S4F5Z1 Universal bacterial protein YeaZ n=30 Tax=Enterococcus faecium RepID=S4F5Z1_ENTFC
contig00001|41 0 1 UniRef100_L2IC58 LacI family transcriptional regulator n=5 Tax=Enterococcus faecium RepID=L2IC58_ENTFC
contig00001|42 0 1 UniRef100_H8L955 Galactose-1-phosphate uridylyltransferase n=145 Tax=Firmicutes RepID=H8L955_ENTFU
contig00001|43 0 1 UniRef100_S4EXE0 UDP-glucose 4-epimerase n=1 Tax=Enterococcus faecium OC2A-1 RepID=S4EXE0_ENTFC
contig00001|44 1 1 UniRef100_H8L957 Uncharacterized protein n=230 Tax=Firmicutes RepID=H8L957_ENTFU
contig00001|45 0 1 UniRef100_C9BQG2 FAD(NAD)-dependent oxidoreductase n=14 Tax=Firmicutes RepID=C9BQG2_ENTFC
contig00001|46 1 1 UniRef100_H8L959 Uncharacterized protein n=196 Tax=Firmicutes RepID=H8L959_ENTFU
contig00001|47 1 1 UniRef100_H8L9W4 Rhodanese family protein n=150 Tax=Firmicutes RepID=H8L9W4_ENTFU
contig00001|48 0 1 UniRef100_H8L9W5 Glucokinase n=152 Tax=Firmicutes RepID=H8L9W5_ENTFU
contig00001|49 1 1 UniRef100_H8L9W6 Uncharacterized protein n=233 Tax=Firmicutes RepID=H8L9W6_ENTFU
contig00001|50 1 1 UniRef100_S4FX86 Peptidase, S54 family n=6 Tax=Enterococcus faecium RepID=S4FX86_ENTFC
contig00001|51 1 1 UniRef100_H8L9W8 5-formyltetrahydrofolate cyclo-ligase family protein n=198 Tax=Firmicutes RepID=H8L9W8_ENTFU
contig00001|52 0 1 UniRef100_D3LGD5 Uncharacterized protein n=51 Tax=Enterococcus faecium RepID=D3LGD5_ENTFC
contig00001|53 0 1 UniRef100_C9BQH0 Iron-hydroxamate transporter permease subunit n=147 Tax=Firmicutes RepID=C9BQH0_ENTFC
contig00001|54 0 1 UniRef100_S4F5Z8 Ferrichrome ABC transporter, ATP-binding protein FhuC n=5 Tax=Enterococcus faecium RepID=S4F5Z8_ENTFC
contig00001|55 0 1 UniRef100_J6PNA8 Periplasmic binding protein n=13 Tax=Enterococcus faecium RepID=J6PNA8_ENTFC
contig00001|56 0 1 UniRef100_H8L9X3 Dihydrofolate reductase n=178 Tax=Firmicutes RepID=H8L9X3_ENTFU
contig00001|57 1 1 UniRef100_D0AG91 Uncharacterized protein n=156 Tax=Firmicutes RepID=D0AG91_ENTFC
contig00001|58 0 1 UniRef100_C9B4Q9 Asparagine synthetase n=104 Tax=Enterococcus RepID=C9B4Q9_ENTFC
contig00001|59 0 1 UniRef100_D0AG93 Uncharacterized protein n=46 Tax=Enterococcus faecium RepID=D0AG93_ENTFC
contig00001|60 1 1 UniRef100_G9SRP3 Putative uncharacterized protein n=1 Tax=Enterococcus faecium E4453 RepID=G9SRP3_ENTFC
contig00001|61 1 1 UniRef100_H8L9Y3 Transcriptional regulator, TetR family n=142 Tax=Firmicutes RepID=H8L9Y3_ENTFU
contig00001|62 0 1 UniRef100_L2HZF2 Uncharacterized protein n=4 Tax=Enterococcus faecium RepID=L2HZF2_ENTFC
contig00001|63 0 1 UniRef100_H8L9Y5 Uncharacterized protein n=150 Tax=Firmicutes RepID=H8L9Y5_ENTFU
contig00001|64 0 1 UniRef100_D0ADQ9 Uncharacterized protein n=62 Tax=Enterococcus RepID=D0ADQ9_ENTFC
contig00001|65 0 1 UniRef100_L2HZQ9 Carboxymuconolactone decarboxylase n=7 Tax=Enterococcus faecium RepID=L2HZQ9_ENTFC
contig00001|66 1 1 UniRef100_H8L9Y9 Uncharacterized protein n=180 Tax=Firmicutes RepID=H8L9Y9_ENTFU
Ana P. Tedim  Chapter 6 
 
238 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 E
. 
F
a
e
c
iu
m
 E
. 
fa
e
c
iu
m
 
 E
. 
fa
e
c
iu
m
 
E
. 
fa
e
c
iu
m
 D
O
 
G
C
 
G
E
H
P
H
2
.1
H
P
H
2
G
E
1
G
e
n
B
a
n
k
 a
c
c
e
ss
io
n
 n
o
.
c
o
n
te
n
t 
(%
)
co
n
ti
g0
0
1
5
8
|9
4
1
0
U
n
iR
e
f1
0
0
_H
8
LE
C
1
 X
-P
ro
 d
ip
e
p
ti
d
yl
-p
e
p
ti
d
a
se
 n
=1
7
1
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
C
1
_E
N
TF
U
S9
 fa
m
il
y 
p
e
p
ti
d
a
se
 (C
h
) C
D
S 
7
4
7
YP
_0
0
6
3
7
5
9
0
5
3
9
.9
co
n
ti
g0
0
1
5
8
|9
3
1
0
U
n
iR
e
f1
0
0
_S
4
EM
S2
 G
ly
ce
ra
ld
e
h
yd
e
-3
-p
h
o
sp
h
a
te
 d
e
h
yd
ro
ge
n
a
se
, t
yp
e
 I 
n
=4
1
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=S
4
EM
S2
_E
N
TF
C
ga
p
A
 (c
h
)
YP
_0
0
6
3
7
5
9
0
6
4
0
.5
co
n
ti
g0
0
1
5
8
|9
2
1
0
U
n
iR
e
f1
0
0
_H
8
LE
B
9
 G
TP
a
se
 o
b
g 
n
=1
3
8
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
B
9
_E
N
TF
U
cg
tA
 (C
h
)
YP
_0
0
6
3
7
5
9
0
7
4
5
.1
co
n
ti
g0
0
1
5
8
|9
1
1
0
U
n
iR
e
f1
0
0
_H
8
LE
B
8
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=2
0
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
B
8
_E
N
TF
U
H
P
 (C
h
) C
D
S 
7
4
8
YP
_0
0
6
3
7
5
9
0
8
4
0
.1
co
n
ti
g0
0
1
5
8
|8
9
1
0
U
n
iR
e
f1
0
0
_H
8
LE
B
7
 R
ib
o
n
u
cl
e
a
se
 Z
 n
=2
0
0
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
B
7
_E
N
TF
U
rn
z 
(C
h
)
YP
_0
0
6
3
7
5
9
0
9
4
0
.6
co
n
ti
g0
0
1
5
8
|8
8
1
0
U
n
iR
e
f1
0
0
_C
9
B
5
V
5
 S
h
o
rt
 c
h
a
in
 d
e
h
yd
ro
ge
n
a
se
/r
e
d
u
ct
a
se
 n
=4
9
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=C
9
B
5
V
5
_E
N
TF
C
D
e
h
yd
ro
ge
n
a
se
 (C
h
) C
D
S 
7
4
9
YP
_0
0
6
3
7
5
9
1
0
4
1
.4
co
n
ti
g0
0
1
5
8
|8
7
1
0
U
n
iR
e
f1
0
0
_C
9
B
5
V
4
 P
re
d
ic
te
d
 p
ro
te
in
 n
=5
5
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=C
9
B
5
V
4
_E
N
TF
C
H
P
 (C
h
) C
D
S 
7
5
0
YP
_0
0
6
3
7
5
9
1
1
3
8
.3
co
n
ti
g0
0
1
5
8
|8
6
1
0
U
n
iR
e
f1
0
0
_L
2
N
Q
R
6
 S
in
gl
e
-s
tr
a
n
d
e
d
-D
N
A
-s
p
e
ci
fi
c 
e
xo
n
u
cl
e
a
se
 R
e
cJ
 n
=2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=L
2
N
Q
R
6
_E
N
TF
C
re
cJ
 (C
h
)
YP
_0
0
6
3
7
5
9
1
2
4
0
.8
co
n
ti
g0
0
1
5
8
|8
5
1
0
U
n
iR
e
f1
0
0
_H
8
LE
B
3
 A
d
e
n
in
e
 p
h
o
sp
h
o
ri
b
o
sy
lt
ra
n
sf
e
ra
se
 n
=2
2
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
B
3
_E
N
TF
U
a
p
t 
(C
h
)
YP
_0
0
6
3
7
5
9
1
3
4
1
.9
co
n
ti
g0
0
1
5
8
|8
4
1
0
U
n
iR
e
f1
0
0
_E
4
J2
D
5
 L
e
xA
 r
e
p
re
ss
o
r 
n
=2
1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=E
4
J2
D
5
_E
N
TF
C
le
xA
 (C
h
)
YP
_0
0
6
3
7
5
9
1
5
4
2
.7
co
n
ti
g0
0
1
5
8
|8
3
1
0
U
n
iR
e
f1
0
0
_H
8
LE
B
0
 U
P
F0
2
9
1
 p
ro
te
in
 E
FA
U
0
0
4
_0
1
0
1
0
 n
=1
7
8
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
B
0
_E
N
TF
U
H
P
 (C
h
) C
D
S 
7
5
2
YP
_0
0
6
3
7
5
9
1
6
3
9
.3
co
n
ti
g0
0
1
5
8
|8
2
1
0
U
n
iR
e
f1
0
0
_J
6
Z7
1
8
 T
ra
n
sk
e
to
la
se
 n
=8
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=J
6
Z7
1
8
_E
N
TF
C
tk
tA
 (C
h
)
YP
_0
0
6
3
7
5
9
1
7
4
2
.5
co
n
ti
g0
0
1
5
8
|8
1
0
0
U
n
iR
e
f1
0
0
_C
9
B
ZP
1
 T
ra
n
sp
o
sa
se
 n
=1
1
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=C
9
B
ZP
1
_E
N
TF
C
IS
Ef
a
4
 (I
S2
0
0
/I
S6
0
5
 fa
m
il
y)
YP
_0
0
6
3
7
7
7
1
6
3
2
.6
co
n
ti
g0
0
1
5
8
|7
9
0
0
U
n
iR
e
f1
0
0
_L
2
M
TX
1
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 E
n
G
e
n
0
0
2
5
 R
e
p
ID
=L
2
M
TX
1
_E
N
TF
C
Δa
ŵi
C ;C
hͿ
YP
_0
0
6
3
7
5
9
1
8
4
1
co
n
ti
g0
0
1
5
8
|7
7
1
0
U
n
iR
e
f1
0
0
_S
5
V
6
G
7
 C
ys
te
in
e
 s
yn
th
a
se
 A
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 A
u
s0
0
8
5
 R
e
p
ID
=S
5
V
6
G
7
_E
N
TF
C
cy
st
e
in
e
 s
yn
th
a
se
 A
 (C
h
) (
Lo
w
 h
o
m
o
lo
gy
 p
ro
b
a
b
ly
)
YP
_0
0
6
3
7
5
9
2
0
/1
9
4
1
.1
co
n
ti
g0
0
1
5
8
|7
6
1
1
U
n
iR
e
f1
0
0
_H
8
LE
A
5
 T
ra
n
sc
ri
p
ti
o
n
a
l r
e
gu
la
to
r,
 F
u
r 
fa
m
il
y 
n
=2
2
0
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
A
5
_E
N
TF
U
fu
r2
 (C
h
)
YP
_0
0
6
3
7
5
9
2
1
3
7
.6
co
n
ti
g0
0
1
5
8
|7
5
1
0
U
n
iR
e
f1
0
0
_L
2
M
TW
4
 N
A
D
H
 o
xi
d
a
se
 n
=3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=L
2
M
TW
4
_E
N
TF
C
n
o
x 
(C
h
)
YP
_0
0
6
3
7
5
9
2
2
3
8
.7
co
n
ti
g0
0
1
5
8
|7
4
1
0
U
n
iR
e
f1
0
0
_H
8
LE
A
3
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
0
3
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
A
3
_E
N
TF
U
H
P
 (C
h
) C
D
S 
7
5
4
YP
_0
0
6
3
7
5
9
2
3
3
5
.7
co
n
ti
g0
0
1
5
8
|7
3
1
0
U
n
iR
e
f1
0
0
_E
4
IA
X
4
 T
ra
n
sc
ri
p
ti
o
n
a
l r
e
gu
la
to
r,
 M
a
rR
 fa
m
il
y 
n
=3
4
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=E
4
IA
X
4
_E
N
TF
C
m
a
rR
 (C
h
)
YP
_0
0
6
3
7
5
9
2
4
3
2
.6
co
n
ti
g0
0
1
5
8
|7
2
1
0
U
n
iR
e
f1
0
0
_H
8
LE
A
1
 M
a
jo
r 
fa
ci
li
ta
to
r 
su
p
e
rf
a
m
il
y 
tr
a
n
sp
o
rt
e
r 
n
=9
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
A
1
_E
N
TF
U
M
FS
 t
ra
n
sp
o
rt
e
r 
(C
h
) C
D
S 
7
5
5
YP
_0
0
6
3
7
5
9
2
5
3
9
.2
co
n
ti
g0
0
1
5
8
|7
1
1
0
U
n
iR
e
f1
0
0
_H
8
LE
A
0
 D
n
a
D
 a
n
d
 p
h
a
ge
-a
ss
o
ci
a
te
d
 d
o
m
a
in
 p
ro
te
in
 n
=1
9
8
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
A
0
_E
N
TF
U
d
n
a
D
 (C
h
)
YP
_0
0
6
3
7
5
9
2
6
3
6
.2
co
n
ti
g0
0
1
5
8
|7
0
1
0
U
n
iR
e
f1
0
0
_H
8
LE
9
9
 E
n
d
o
n
u
cl
e
a
se
 II
I n
=1
2
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
9
9
_E
N
TF
U
n
th
 (h
)
YP
_0
0
6
3
7
5
9
2
7
4
1
.9
co
n
ti
g0
0
1
5
8
|6
9
1
0
U
n
iR
e
f1
0
0
_E
4
IA
X
0
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=5
2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=E
4
IA
X
0
_E
N
TF
C
H
P
 (C
h
) C
D
S 
7
5
6
YP
_0
0
6
3
7
5
9
2
8
2
6
.4
co
n
ti
g0
0
1
5
8
|6
8
1
0
U
n
iR
e
f1
0
0
_H
8
LE
9
7
 P
e
n
ic
il
li
n
-b
in
d
in
g 
p
ro
te
in
 1
A
 n
=1
0
7
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
9
7
_E
N
TF
U
p
o
n
A
YP
_0
0
6
3
7
5
9
2
9
4
2
.1
co
n
ti
g0
0
1
5
8
|6
7
1
1
U
n
iR
e
f1
0
0
_H
8
LE
9
6
 H
o
ll
id
a
y 
ju
n
ct
io
n
 r
e
so
lv
a
se
 R
e
cU
 n
=1
4
1
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
9
6
_E
N
TF
U
re
cU
 (C
h
)
YP
_0
0
6
3
7
5
9
3
0
3
9
.5
co
n
ti
g0
0
1
5
8
|6
5
1
1
U
n
iR
e
f1
0
0
_J
8
ZL
2
3
 C
e
ll
 c
yc
le
 p
ro
te
in
 G
p
sB
 n
=7
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=J
8
ZL
2
3
_E
N
TF
C
d
iv
IV
A
2
 (C
H
)
YP
_0
0
6
3
7
5
9
3
2
3
6
.1
co
n
ti
g0
0
1
5
8
|6
4
0
1
U
n
iR
e
f1
0
0
_D
4
SK
7
2
 M
e
th
yl
tr
a
n
sf
e
ra
se
 n
=3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
SK
7
2
_E
N
TF
C
m
e
th
yl
tr
a
n
sf
e
ra
se
 (C
h
) C
D
S 
7
5
8
YP
_0
0
6
3
7
5
9
3
3
4
1
co
n
ti
g0
0
1
5
8
|6
3
0
1
U
n
iR
e
f1
0
0
_H
8
LE
9
2
 C
a
rb
o
xy
p
e
p
ti
d
a
se
 T
a
q
 m
e
ta
ll
o
p
e
p
ti
d
a
se
 n
=1
6
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
9
2
_E
N
TF
U
p
e
p
ti
d
a
se
 (C
h
) C
D
S 
7
5
9
YP
_0
0
6
3
7
5
9
3
4
3
7
co
n
ti
g0
0
1
5
8
|6
2
0
1
U
n
iR
e
f1
0
0
_H
8
LE
9
1
 H
D
 d
o
m
a
in
-c
o
n
ta
in
in
g 
p
ro
te
in
 n
=2
0
0
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
9
1
_E
N
TF
U
p
h
o
sp
h
o
h
yd
ro
la
se
 (C
h
) C
D
S 
7
6
0
YP
_0
0
6
3
7
5
9
3
5
3
9
.8
co
n
ti
g0
0
1
5
8
|6
1
0
1
U
n
iR
e
f1
0
0
_J
6
ED
E4
 P
u
ta
ti
ve
 8
-a
m
in
o
-7
-o
xo
n
o
n
a
n
o
a
te
 s
yn
th
a
se
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 E
R
V
1
6
1
 R
e
p
ID
=J
6
ED
E4
_E
N
TF
C
kb
l (
C
h
)
YP
_0
0
6
3
7
5
9
3
6
3
9
.2
co
n
ti
g0
0
1
5
8
|6
0
0
1
U
n
iR
e
f1
0
0
_D
4
SK
7
6
 E
p
im
e
ra
se
/r
e
d
u
ct
a
se
, p
u
ta
ti
ve
 n
=3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
SK
7
6
_E
N
TF
C
ga
lE
2
 (C
h
)
YP
_0
0
6
3
7
5
9
3
7
4
0
.8
co
n
ti
g0
0
1
5
8
|5
9
0
1
U
n
iR
e
f1
0
0
_S
4
EF
C
0
 P
u
ta
ti
ve
 s
e
ri
n
e
/t
h
re
o
n
in
e
 e
xc
h
a
n
ge
r 
St
e
T 
n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 S
D
1
C
-2
 R
e
p
ID
=S
4
EF
C
0
_E
N
TF
C
A
P
C
tr
a
n
sp
o
rt
e
r 
(C
h
) C
D
S 
7
6
1
YP
_0
0
6
3
7
5
9
3
8
4
1
.2
co
n
ti
g0
0
1
5
8
|5
8
0
1
U
n
iR
e
f1
0
0
_L
2
H
C
D
9
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=L
2
H
C
D
9
_E
N
TF
C
M
P
 (C
h
) C
D
S 
7
6
2
YP
_0
0
6
3
7
5
9
3
9
3
5
.8
co
n
ti
g0
0
1
5
8
|5
7
0
1
U
n
iR
e
f1
0
0
_D
4
R
G
0
9
 P
e
rm
e
a
se
 n
=2
3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
R
G
0
9
_E
N
TF
C
p
e
rm
e
a
se
 (v
a
n
Z 
fa
m
il
y)
 (C
h
) C
D
S 
7
6
3
YP
_0
0
6
3
7
5
9
4
0
3
6
.9
co
n
ti
g0
0
1
5
8
|5
6
0
1
U
n
iR
e
f1
0
0
_H
8
LE
8
4
 D
EA
D
-b
o
x 
A
TP
 d
e
p
e
n
d
e
n
t 
D
N
A
 h
e
li
ca
se
 n
=1
7
6
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
8
4
_E
N
TF
U
rh
lB
 (C
h
)
YP
_0
0
6
3
7
5
9
4
1
3
8
.1
co
n
ti
g0
0
1
5
8
|5
5
0
1
U
n
iR
e
f1
0
0
_J
6
L2
G
7
 A
ce
ty
lt
ra
n
sf
e
ra
se
, G
N
A
T 
fa
m
il
y 
n
=1
0
1
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=J
6
L2
G
7
_E
N
TF
C
e
la
A
 (C
h
)
YP
_0
0
6
3
7
5
9
4
2
3
8
.9
co
n
ti
g0
0
1
5
8
|5
3
0
1
U
n
iR
e
f1
0
0
_D
4
SK
8
2
 A
la
n
in
e
--
tR
N
A
 li
ga
se
 n
=5
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
SK
8
2
_E
N
TF
C
a
la
S 
(C
h
)
YP
_0
0
6
3
7
5
9
4
3
3
9
.9
co
n
ti
g0
0
1
5
8
|5
2
0
1
U
n
iR
e
f1
0
0
_H
8
LE
8
1
 In
te
gr
a
l m
e
m
b
ra
n
e
 p
ro
te
in
 n
=1
9
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
8
1
_E
N
TF
U
M
P
 (C
h
) C
D
S 
7
6
4
YP
_0
0
6
3
7
5
9
4
4
4
0
.9
co
n
ti
g0
0
1
5
8
|5
1
0
1
U
n
iR
e
f1
0
0
_R
3
Y9
F4
 C
a
ti
o
n
 d
if
fu
si
o
n
 fa
ci
li
ta
to
r 
fa
m
il
y 
tr
a
n
sp
o
rt
e
r 
n
=2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=R
3
Y9
F4
_E
N
TF
C
H
P
 (C
h
) C
D
S 
7
6
5
YP
_0
0
6
3
7
5
9
4
5
3
6
.3
co
n
ti
g0
0
1
5
8
|5
0
0
1
U
n
iR
e
f1
0
0
_C
9
B
5
R
7
 R
N
a
se
 H
 n
=1
3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=C
9
B
5
R
7
_E
N
TF
C
rn
h
A
 (C
h
)
YP
_0
0
6
3
7
5
9
4
6
3
7
.2
co
n
ti
g0
0
1
5
8
|4
9
0
1
U
n
iR
e
f1
0
0
_H
8
LE
7
8
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=2
0
1
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
7
8
_E
N
TF
U
e
b
sA
 (C
h
)
YP
_0
0
6
3
7
5
9
4
7
3
4
co
n
ti
g0
0
1
5
8
|4
8
1
1
U
n
iR
e
f1
0
0
_D
4
Q
W
T8
 C
o
ld
-s
h
o
ck
 p
ro
te
in
 n
=5
9
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=D
4
Q
W
T8
_E
N
TF
C
cs
p
C
 (C
h
)
YP
_0
0
6
3
7
5
9
4
8
3
8
.7
co
n
ti
g0
0
1
5
8
|4
6
0
1
U
n
iR
e
f1
0
0
_J
6
YW
S9
 F
o
rm
a
te
--
te
tr
a
h
yd
ro
fo
la
te
 li
ga
se
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 5
0
9
 R
e
p
ID
=J
6
YW
S9
_E
N
TF
C
fh
s 
(C
h
)
YP
_0
0
6
3
7
5
9
4
9
4
1
.9
co
n
ti
g0
0
1
5
8
|4
5
1
0
U
n
iR
e
f1
0
0
_C
9
B
5
R
3
 P
re
d
ic
te
d
 p
ro
te
in
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 1
,2
3
1
,5
0
1
 R
e
p
ID
=C
9
B
5
R
3
_E
N
TF
C
H
P
 (C
h
) C
D
S 
7
6
6
YP
_0
0
6
3
7
5
9
5
0
3
6
.4
co
n
ti
g0
0
1
5
8
|4
4
0
1
U
n
iR
e
f1
0
0
_H
8
LE
7
4
 C
B
S 
d
o
m
a
in
 p
a
ir
 p
ro
te
in
 n
=1
9
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
7
4
_E
N
TF
U
H
P
 (C
h
) C
D
S 
7
6
7
YP
_0
0
6
3
7
5
9
5
1
3
8
.3
co
n
ti
g0
0
1
5
8
|4
3
0
1
U
n
iR
e
f1
0
0
_J
6
YF
W
6
 L
ip
o
p
ro
te
in
 s
ig
n
a
l p
e
p
ti
d
a
se
 n
=6
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=J
6
YF
W
6
_E
N
TF
C
lp
sA
 (C
h
)
YP
_0
0
6
3
7
5
9
5
2
3
6
.1
co
n
ti
g0
0
1
5
8
|4
2
0
1
U
n
iR
e
f1
0
0
_J
7
C
ZX
4
 P
se
u
d
o
u
ri
d
in
e
 s
yn
th
a
se
 n
=3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=J
7
C
ZX
4
_E
N
TF
C
rl
u
D
 (C
h
)
YP
_0
0
6
3
7
5
9
5
3
4
1
.6
co
n
ti
g0
0
1
5
8
|4
1
0
1
U
n
iR
e
f1
0
0
_J
6
Z6
Y5
 B
if
u
n
ct
io
n
a
l p
ro
te
in
 P
yr
R
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 5
0
4
 R
e
p
ID
=J
6
Z6
Y5
_E
N
TF
C
p
yr
R
(C
h
)
YP
_0
0
6
3
7
5
9
5
4
4
0
.1
co
n
ti
g0
0
1
5
8
|4
0
0
1
U
n
iR
e
f1
0
0
_D
4
SK
9
4
 U
ra
ci
l p
e
rm
e
a
se
 n
=6
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
SK
9
4
_E
N
TF
C
p
yr
P
 (C
h
)
YP
_0
0
6
3
7
5
9
5
5
4
1
.5
co
n
ti
g0
0
1
5
8
|3
9
0
1
U
n
iR
e
f1
0
0
_H
8
LE
6
9
 A
sp
a
rt
a
te
 c
a
rb
a
m
o
yl
tr
a
n
sf
e
ra
se
 n
=2
0
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
6
9
_E
N
TF
U
p
yr
B
 (C
h
)
YP
_0
0
6
3
7
5
9
5
6
4
2
.4
co
n
ti
g0
0
1
5
8
|3
8
0
1
U
n
iR
e
f1
0
0
_J
6
YF
W
2
 D
ih
yd
ro
o
ro
ta
se
 n
=4
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=J
6
YF
W
2
_E
N
TF
C
p
yr
C
 (C
h
)
YP
_0
0
6
3
7
5
9
5
7
4
2
.8
co
n
ti
g0
0
1
5
8
|3
7
0
1
U
n
iR
e
f1
0
0
_H
8
LE
6
7
 C
a
rb
a
m
o
yl
-p
h
o
sp
h
a
te
 s
yn
th
a
se
 s
m
a
ll
 c
h
a
in
 n
=1
7
6
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
6
7
_E
N
TF
U
ca
rA
 (C
h
)
YP
_0
0
6
3
7
5
9
5
8
4
0
.7
co
n
ti
g0
0
1
5
8
|3
6
0
1
U
n
iR
e
f1
0
0
_D
4
SK
9
8
 C
a
rb
a
m
o
yl
-p
h
o
sp
h
a
te
 s
yn
th
a
se
 la
rg
e
 c
h
a
in
 n
=4
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
SK
9
8
_E
N
TF
C
ca
rB
 (C
h
)
YP
_0
0
6
3
7
5
9
5
9
4
0
.9
co
n
ti
g0
0
1
5
8
|3
5
0
1
U
n
iR
e
f1
0
0
_L
2
IB
E1
 D
ih
yd
ro
o
ro
ta
te
 d
e
h
yd
ro
ge
n
a
se
 B
 (N
A
D
(+
))
, e
le
ct
ro
n
 t
ra
n
sf
e
r 
su
b
u
n
it
 n
=4
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=L
2
IB
E1
_E
N
TF
C
p
yr
K
 (C
h
)
YP
_0
0
6
3
7
5
9
6
0
4
0
.7
co
n
ti
g0
0
1
5
8
|3
4
0
1
U
n
iR
e
f1
0
0
_D
4
SK
A
0
 D
ih
yd
ro
o
ro
ta
te
 d
e
h
yd
ro
ge
n
a
se
 n
=1
5
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
SK
A
0
_E
N
TF
C
p
yr
D
 (C
h
)
YP
_0
0
6
3
7
5
9
6
1
4
3
.9
B
e
st
 B
L
A
S
T
 H
it
 A
n
n
o
ta
ti
o
n
 
E
. 
fa
e
c
iu
m
 D
O
 A
n
n
o
ta
ti
o
n
T
a
b
le
 S
4
 -
 A
n
n
o
ta
ti
o
n
 o
f 
tr
a
n
sf
e
ra
b
le
 r
e
g
io
n
 o
f 
E
. 
fa
e
ci
u
m
 G
E
H
P
H
2
.1
 u
si
n
g
 B
e
st
 B
LA
S
T
 H
it
 a
n
d
 E
. 
fa
e
ci
u
m
 D
O
 a
s 
a
 r
e
fe
re
n
ce
 s
tr
a
in
 
Ana P. Tedim  Chapter 6 
 
239 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
a
b
le
 S
4
 -
 A
n
n
o
ta
ti
o
n
 o
f 
tr
a
n
sf
e
ra
b
le
 r
e
g
io
n
 o
f 
E
. 
fa
e
ci
u
m
 G
E
H
P
H
2
.1
 u
si
n
g
 B
e
st
 B
LA
S
T
 H
it
 a
n
d
 E
. 
fa
e
ci
u
m
 D
O
 a
s 
a
 r
e
fe
re
n
ce
 s
tr
a
in
 (
co
n
t.
) 
 E
. 
F
a
e
c
iu
m
 E
. 
fa
e
c
iu
m
 
 E
. 
fa
e
c
iu
m
 
E
. 
fa
e
c
iu
m
 D
O
 
G
C
 
G
E
H
P
H
2
.1
H
P
H
2
G
E
1
G
e
n
B
a
n
k
 a
c
c
e
ss
io
n
 n
o
.
c
o
n
te
n
t 
(%
)
co
n
ti
g0
0
1
5
8
|3
3
0
1
U
n
iR
e
f1
0
0
_L
2
N
C
L3
 O
ro
ti
d
in
e
 5
'-p
h
o
sp
h
a
te
 d
e
ca
rb
o
xy
la
se
 n
=1
0
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=L
2
N
C
L3
_E
N
TF
C
p
yr
F 
(C
h
)
YP
_0
0
6
3
7
5
9
6
2
4
1
.3
co
n
ti
g0
0
1
5
8
|3
2
0
1
U
n
iR
e
f1
0
0
_H
8
LE
6
2
 O
ro
ta
te
 p
h
o
sp
h
o
ri
b
o
sy
lt
ra
n
sf
e
ra
se
 n
=2
0
3
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
6
2
_E
N
TF
U
p
yr
E 
(C
h
)
YP
_0
0
6
3
7
5
9
6
3
3
9
.2
co
n
ti
g0
0
1
5
8
|3
1
1
1
U
n
iR
e
f1
0
0
_E
4
IA
Y5
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=5
6
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=E
4
IA
Y5
_E
N
TF
C
H
P
 (C
h
) C
D
S 
7
6
8
YP
_0
0
6
3
7
5
9
6
4
3
1
.4
co
n
ti
g0
0
1
5
8
|3
0
0
1
U
n
iR
e
f1
0
0
_H
8
LE
6
1
 H
D
 d
o
m
a
in
 p
ro
te
in
 n
=2
1
7
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LE
6
1
_E
N
TF
U
p
h
o
sp
h
o
h
yd
ro
la
se
 (C
h
) C
D
S 
7
6
9
YP
_0
0
6
3
7
5
9
6
5
3
7
.5
co
n
ti
g0
0
1
5
8
|2
9
0
1
U
n
iR
e
f1
0
0
_D
4
SK
A
4
 C
a
rb
o
n
ic
 a
n
h
yd
ra
se
 n
=1
3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
SK
A
4
_E
N
TF
C
C
a
rb
o
n
ic
 a
n
h
yd
ra
se
 (C
h
) C
D
S 
7
7
0
YP
_0
0
6
3
7
5
9
6
6
4
0
.3
co
n
ti
g0
0
1
5
8
|2
8
0
1
U
n
iR
e
f1
0
0
_L
2
ID
J2
 L
ys
R
 fa
m
il
y 
tr
a
n
sc
ri
p
ti
o
n
a
l r
e
gu
la
to
r 
n
=1
1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=L
2
ID
J2
_E
N
TF
C
Ly
sR
 t
ra
n
sr
ip
ti
o
n
a
l r
e
gu
la
to
r 
(C
h
) C
D
S 
7
7
1
YP
_0
0
6
3
7
5
9
6
7
4
1
.1
co
n
ti
g0
0
1
5
8
|2
7
0
1
U
n
iR
e
f1
0
0
_J
6
L2
A
0
 F
ib
ro
n
e
ct
in
-b
in
d
in
g 
p
ro
te
in
 A
 n
=5
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=J
6
L2
A
0
_E
N
TF
C
p
a
vA
 (C
h
)
YP
_0
0
6
3
7
5
9
6
9
3
9
.3
co
n
ti
g0
0
1
5
8
|2
6
0
1
U
n
iR
e
f1
0
0
_L
2
IB
5
3
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=L
2
IB
5
3
_E
N
TF
C
H
P
 (C
h
) C
D
S 
7
7
4
YP
_0
0
6
3
7
5
9
7
1
3
7
co
n
ti
g0
0
1
5
8
|2
5
0
1
U
n
iR
e
f1
0
0
_D
0
A
F9
3
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=4
2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
0
A
F9
3
_E
N
TF
C
A
B
C
 t
ra
n
sp
o
rt
e
r 
(C
h
) C
D
S 
7
7
5
YP
_0
0
6
3
7
5
9
7
2
4
0
.6
co
n
ti
g0
0
1
5
8
|2
4
1
1
U
n
iR
e
f1
0
0
_H
8
LE
5
4
 A
m
in
o
 a
ci
d
 o
r 
su
ga
r 
A
B
C
 t
ra
n
sp
o
rt
 s
ys
te
m
, p
e
rm
e
a
se
 p
ro
te
in
 n
=1
6
8
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
5
4
_E
N
TF
U
H
P
 (C
h
) C
D
S 
7
7
6
YP
_0
0
6
3
7
5
9
7
3
4
1
.6
co
n
ti
g0
0
1
5
8
|2
3
0
1
U
n
iR
e
f1
0
0
_D
4
R
G
T0
 A
B
C
 t
ra
n
sp
o
rt
e
r,
 A
TP
-b
in
d
in
g 
p
ro
te
in
 n
=1
3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
R
G
T0
_E
N
TF
C
A
B
C
 t
ra
n
sp
o
rt
e
r 
(C
h
) C
D
S 
7
7
7
YP
_0
0
6
3
7
5
9
7
4
3
9
.7
co
n
ti
g0
0
1
5
8
|2
2
0
1
U
n
iR
e
f1
0
0
_D
4
SK
B
1
 S
h
ik
im
a
te
 d
e
h
yd
ro
ge
n
a
se
 n
=1
1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
SK
B
1
_E
N
TF
C
a
ro
E 
(C
h
)
YP
_0
0
6
3
7
5
9
7
5
4
0
.4
co
n
ti
g0
0
1
5
8
|2
1
0
0
U
n
iR
e
f1
0
0
_H
8
LE
5
1
 T
ra
n
sc
ri
p
ti
o
n
a
l r
e
gu
la
to
r,
 P
SR
 p
ro
te
in
 n
=1
3
2
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LE
5
1
_E
N
TF
U
m
sr
R
 (C
h
) 
YP
_0
0
6
3
7
5
9
7
6
4
0
.7
co
n
ti
g0
0
1
5
8
|1
9
0
1
U
n
iR
e
f1
0
0
_D
0
A
F9
8
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=6
2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
0
A
F9
8
_E
N
TF
C
G
ly
xa
la
se
 (C
h
) C
D
S 
7
7
9
 (s
m
a
ll
e
r)
YP
_0
0
6
3
7
5
9
7
8
4
1
.1
co
n
ti
g0
0
1
5
8
|1
8
0
1
U
n
iR
e
f1
0
0
_L
2
IB
C
7
 D
N
A
 t
o
p
o
is
o
m
e
ra
se
 n
=1
2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=L
2
IB
C
7
_E
N
TF
C
to
p
A
2
 (C
h
)
YP
_0
0
6
3
7
5
9
7
9
3
8
.2
co
n
ti
g0
0
1
5
8
|1
7
0
1
U
n
iR
e
f1
0
0
_D
0
A
FA
1
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=8
6
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
0
A
FA
1
_E
N
TF
C
H
P
 (C
h
) C
D
S 
7
8
0
YP
_0
0
6
3
7
5
9
8
0
3
5
.3
co
n
ti
g0
0
1
5
8
|1
6
0
1
U
n
iR
e
f1
0
0
_L
2
I7
G
9
 A
d
d
ic
ti
o
n
 m
o
d
u
le
 a
n
ti
d
o
te
 n
=1
8
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=L
2
I7
G
9
_E
N
TF
C
A
b
rB
 t
ra
n
sc
ri
p
to
r 
re
gu
la
to
r 
(C
h
) C
D
S 
7
8
1
YP
_0
0
6
3
7
5
9
8
1
3
2
.9
co
n
ti
g0
0
1
5
8
|1
5
0
1
U
n
iR
e
f1
0
0
_D
4
R
FQ
1
 D
e
a
th
-o
n
-c
u
ri
n
g 
fa
m
il
y 
p
ro
te
in
 n
=1
1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
R
FQ
1
_E
N
TF
C
D
e
a
th
-o
n
-c
u
ri
n
g 
fa
m
il
y 
p
ro
te
in
 (C
h
) C
D
S 
7
8
2
YP
_0
0
6
3
7
5
9
8
2
3
5
.3
co
n
ti
g0
0
1
5
8
|1
3
1
0
U
n
iR
e
f1
0
0
_H
8
LE
4
5
 L
-l
a
ct
a
te
 d
e
h
yd
ro
ge
n
a
se
 n
=2
0
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
4
5
_E
N
TF
U
d
e
h
yd
ro
ge
n
a
se
 (C
h
) C
D
S 
7
8
3
YP
_0
0
6
3
7
5
9
8
3
3
8
.3
C
o
m
G
 p
ro
te
in
  5
YP
_0
0
6
3
7
5
9
8
4
2
8
.7
co
n
ti
g0
0
1
5
8
|1
2
1
0
U
n
iR
e
f1
0
0
_C
9
B
5
N
1
 H
e
li
x-
tu
rn
-h
e
li
x 
d
o
m
a
in
-c
o
n
ta
in
in
g 
p
ro
te
in
 n
=6
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=C
9
B
5
N
1
_E
N
TF
C
a
ra
C
 t
ra
n
sc
ri
p
ri
o
n
a
l r
e
gu
la
to
r 
(C
h
) C
D
S 
7
8
5
YP
_0
0
6
3
7
5
9
8
5
3
3
.7
co
n
ti
g0
0
1
5
8
|1
1
1
0
U
n
iR
e
f1
0
0
_E
4
I5
F7
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=4
3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=E
4
I5
F7
_E
N
TF
C
H
P
 (C
h
) C
D
S 
7
8
6
YP
_0
0
6
3
7
5
9
8
6
3
5
.4
co
n
ti
g0
0
1
5
8
|1
0
1
0
U
n
iR
e
f1
0
0
_I
3
U
1
W
7
 M
FS
 fa
m
il
y 
m
a
jo
r 
fa
ci
li
ta
to
r 
tr
a
n
sp
o
rt
e
r 
n
=1
3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=I
3
U
1
W
7
_E
N
TF
C
M
FS
 t
ra
n
sp
o
rt
e
r 
(C
h
) C
D
S 
7
8
7
YP
_0
0
6
3
7
5
9
8
7
3
8
.8
co
n
ti
g0
0
1
5
8
|9
1
0
U
n
iR
e
f1
0
0
_D
4
Q
W
X
6
 A
lp
h
a
-L
-r
h
a
m
n
o
si
d
a
se
 n
=2
1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
Q
W
X
6
_E
N
TF
C
A
lp
h
a
-L
-r
h
a
m
n
o
si
d
a
se
 (C
h
) C
D
S 
7
8
8
YP
_0
0
6
3
7
5
9
8
8
3
7
.1
co
n
ti
g0
0
1
5
8
|8
1
0
U
n
iR
e
f1
0
0
_H
8
LE
3
9
 P
TS
 s
ys
te
m
, a
sc
o
rb
a
te
-s
p
e
ci
fi
c 
II
C
 c
o
m
p
o
n
e
n
t 
n
=1
2
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
3
9
_E
N
TF
U
P
TS
 s
ys
te
m
 (C
h
) C
D
S 
7
8
9
YP
_0
0
6
3
7
5
9
8
9
4
0
.4
co
n
ti
g0
0
1
5
8
|7
1
0
U
n
iR
e
f1
0
0
_H
8
LE
3
8
 P
TS
 s
ys
te
m
, a
sc
o
rb
a
te
-s
p
e
ci
fi
c 
II
B
 c
o
m
p
o
n
e
n
t 
n
=1
8
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
3
8
_E
N
TF
U
P
TS
 s
ys
te
m
 (C
h
) C
D
S 
7
9
0
YP
_0
0
6
3
7
5
9
9
0
3
6
.1
co
n
ti
g0
0
1
5
8
|6
1
0
U
n
iR
e
f1
0
0
_E
4
IQ
W
8
 P
h
o
sp
h
o
e
n
o
lp
yr
u
va
te
-d
e
p
e
n
d
e
n
t 
su
ga
r 
p
h
o
sp
h
o
tr
a
n
sf
e
ra
se
 s
ys
te
m
, E
II
A
 2
 n
=3
6
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=E
4
IQ
W
8
_E
N
TF
C
B
gl
G
 a
n
ti
te
rm
in
a
to
r 
(C
h
) C
D
S 
7
9
1
YP
_0
0
6
3
7
5
9
9
1
3
8
.3
co
n
ti
g0
0
1
5
8
|5
1
0
U
n
iR
e
f1
0
0
_H
8
LE
3
6
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=2
0
1
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
3
6
_E
N
TF
U
H
P
 (C
h
) C
D
S 
7
9
3
YP
_0
0
6
3
7
5
9
9
3
3
5
.3
co
n
ti
g0
0
1
5
8
|4
1
0
U
n
iR
e
f1
0
0
_H
8
LE
3
5
 O
xi
d
o
re
d
u
ct
a
se
 fa
m
il
y,
 N
A
D
-b
in
d
in
g 
R
o
ss
m
a
n
n
 fo
ld
 p
ro
te
in
 n
=1
3
2
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
3
5
_E
N
TF
U
d
e
h
yd
ro
ge
n
a
se
 (C
h
) C
D
S 
7
9
4
YP
_0
0
6
3
7
5
9
9
4
3
5
.4
co
n
ti
g0
0
1
5
8
|3
1
0
U
n
iR
e
f1
0
0
_E
4
I5
E9
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=4
6
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=E
4
I5
E9
_E
N
TF
C
H
P
 (C
h
) C
D
S 
7
9
5
YP
_0
0
6
3
7
5
9
9
5
2
9
.8
co
n
ti
g0
0
1
5
8
|2
1
0
U
n
iR
e
f1
0
0
_J
7
B
8
7
1
 T
ra
n
sc
ri
p
ti
o
n
a
l r
e
gu
la
to
r,
 R
p
iR
 fa
m
il
y 
n
=3
1
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=J
7
B
8
7
1
_E
N
TF
C
rp
iR
 (C
h
)
YP
_0
0
6
3
7
5
9
9
6
3
7
co
n
ti
g0
0
1
5
8
|1
1
0
U
n
iR
e
f1
0
0
_H
8
LE
3
3
 P
e
p
ti
d
a
se
 C
6
0
 n
=1
3
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
3
3
_E
N
TF
U
sr
tC
1
 (C
h
)
YP
_0
0
6
3
7
5
9
9
7
3
9
.5
co
n
ti
g0
0
1
1
8
|1
0
0
U
n
iR
e
f1
0
0
_L
2
H
B
V
4
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=4
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=L
2
H
B
V
4
_E
N
TF
C
Δp
ilu
s ;C
hͿ C
D“
 ϳϵ
ϳ
YP
_0
0
6
3
7
6
0
0
0
3
8
.4
co
n
ti
g0
0
1
1
8
|2
1
0
U
n
iR
e
f1
0
0
_J
6
YP
J5
 H
TH
 d
o
m
a
in
 p
ro
te
in
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 5
0
3
 R
e
p
ID
=J
6
YP
J5
_E
N
TF
C
e
b
p
R
 (C
h
)
YP
_0
0
6
3
7
6
0
0
1
3
4
.1
co
n
ti
g0
0
1
1
8
|3
1
0
U
n
iR
e
f1
0
0
_H
8
LE
2
8
 T
e
tR
/A
cr
R
 fa
m
il
y 
tr
a
n
sc
ri
p
ti
o
n
a
l r
e
gu
la
to
r 
n
=1
4
2
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
2
8
_E
N
TF
U
re
gu
la
to
r 
(C
h
) C
D
S 
7
9
8
YP
_0
0
6
3
7
6
0
0
2
3
6
.7
co
n
ti
g0
0
1
1
8
|4
1
0
U
n
iR
e
f1
0
0
_H
8
LE
2
7
 A
B
C
 t
ra
n
sp
o
rt
e
r,
 A
TP
-b
in
d
in
g 
p
ro
te
in
 n
=1
9
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
2
7
_E
N
TF
U
A
B
C
 t
ra
n
sp
o
rt
e
r 
(C
h
) C
D
S 
7
9
9
YP
_0
0
6
3
7
6
0
0
3
3
6
.4
co
n
ti
g0
0
1
1
8
|5
1
0
U
n
iR
e
f1
0
0
_H
8
LE
2
6
 E
ff
lu
x 
A
B
C
 t
ra
n
sp
o
rt
e
r,
 p
e
rm
e
a
se
 p
ro
te
in
 n
=1
2
8
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
2
6
_E
N
TF
U
A
B
C
 t
ra
n
sp
o
rt
e
r 
(C
h
) C
D
S 
8
0
0
YP
_0
0
6
3
7
6
0
0
4
3
8
.6
co
n
ti
g0
0
1
1
8
|6
1
0
U
n
iR
e
f1
0
0
_C
9
C
1
0
1
 T
ra
n
sc
ri
p
ti
o
n
a
l r
e
gu
la
to
r 
n
=2
3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=C
9
C
1
0
1
_E
N
TF
C
ci
a
R
 (C
h
)
YP
_0
0
6
3
7
6
0
0
5
3
4
.7
co
n
ti
g0
0
1
1
8
|7
1
0
U
n
iR
e
f1
0
0
_C
9
B
5
L3
 H
is
ti
d
in
e
 k
in
a
se
 n
=1
1
0
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=C
9
B
5
L3
_E
N
TF
C
ci
a
H
 (C
h
)
YP
_0
0
6
3
7
6
0
0
6
3
6
.4
co
n
ti
g0
0
1
1
8
|8
1
0
U
n
iR
e
f1
0
0
_D
4
Q
W
Z2
 C
o
n
se
rv
e
d
 p
ro
te
in
 n
=5
1
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=D
4
Q
W
Z2
_E
N
TF
C
H
P
 (C
h
) C
D
S 
8
0
1
YP
_0
0
6
3
7
6
0
0
7
3
9
.2
co
n
ti
g0
0
1
1
8
|9
1
0
U
n
iR
e
f1
0
0
_H
8
LE
2
1
 S
it
e
-s
p
e
ci
fi
c 
ty
ro
si
n
e
 r
e
co
m
b
in
a
se
 X
e
rC
-f
a
m
il
y 
n
=1
3
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
2
1
_E
N
TF
U
in
te
gr
a
se
 (C
h
) C
D
S 
8
0
2
YP
_0
0
6
3
7
6
0
0
8
3
5
.1
co
n
ti
g0
0
1
1
8
|1
0
1
0
U
n
iR
e
f1
0
0
_C
9
C
0
Z7
 A
M
P
-d
e
p
e
n
d
e
n
t 
sy
n
th
e
ta
se
 a
n
d
 li
ga
se
 n
=2
6
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=C
9
C
0
Z7
_E
N
TF
C
li
ga
se
 (C
h
) C
D
S 
8
0
3
YP
_0
0
6
3
7
6
0
0
9
3
8
.9
co
n
ti
g0
0
1
1
8
|1
1
1
0
U
n
iR
e
f1
0
0
_E
4
I9
4
7
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=5
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=E
4
I9
4
7
_E
N
TF
C
H
P
 (C
h
) C
D
S 
8
0
4
YP
_0
0
6
3
7
6
0
1
0
2
4
.8
co
n
ti
g0
0
1
1
8
|1
2
1
0
U
n
iR
e
f1
0
0
_H
8
LE
1
9
 P
h
o
sp
h
o
m
e
th
yl
p
yr
im
id
in
e
 k
in
a
se
 n
=1
9
6
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
1
9
_E
N
TF
U
th
iD
2
 (C
h
)
YP
_0
0
6
3
7
6
0
1
1
3
7
.9
co
n
ti
g0
0
1
1
8
|1
3
1
0
U
n
iR
e
f1
0
0
_H
8
LE
1
8
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
9
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
1
8
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
0
5
YP
_0
0
6
3
7
6
0
1
2
4
2
.4
co
n
ti
g0
0
1
1
8
|1
4
1
0
U
n
iR
e
f1
0
0
_H
8
LE
1
7
 U
P
F0
3
4
0
 p
ro
te
in
 E
FA
U
0
0
4
_0
0
9
1
7
 n
=1
4
5
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LE
1
7
_E
N
TF
U
yw
lG
 (C
h
)
YP
_0
0
6
3
7
6
0
1
3
4
2
.5
co
n
ti
g0
0
1
1
8
|1
5
1
0
U
n
iR
e
f1
0
0
_H
8
LE
1
6
 A
lp
h
a
 a
m
yl
a
se
, c
a
ta
ly
ti
c 
d
o
m
a
in
 p
ro
te
in
 n
=8
8
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LE
1
6
_E
N
TF
U
m
a
lA
 (C
h
)
YP
_0
0
6
3
7
6
0
1
4
3
8
co
n
ti
g0
0
1
1
8
|1
6
1
0
U
n
iR
e
f1
0
0
_H
8
LE
1
5
 A
TP
-d
e
p
e
n
d
e
n
t 
p
ro
te
a
se
 A
TP
-b
in
d
in
g 
su
b
u
n
it
 C
lp
X
 n
=6
4
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=H
8
LE
1
5
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
0
6
YP
_0
0
6
3
7
6
0
1
5
4
0
co
n
ti
g0
0
1
1
8
|1
7
1
0
U
n
iR
e
f1
0
0
_H
8
LE
1
4
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=6
5
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=H
8
LE
1
4
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
0
7
YP
_0
0
6
3
7
6
0
1
6
3
7
.1
co
n
ti
g0
0
0
5
8
|1
1
0
U
n
iR
e
f1
0
0
_H
8
LE
1
2
 E
D
D
 d
o
m
a
in
 p
ro
te
in
, D
e
gV
 fa
m
il
y 
n
=1
3
3
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
1
2
_E
N
TF
U
D
e
gV
 fa
m
il
y 
(c
h
) C
D
S 
8
0
8
YP
_0
0
6
3
7
6
0
1
7
3
7
.8
co
n
ti
g0
0
0
5
8
|2
1
0
U
n
iR
e
f1
0
0
_H
8
LE
1
1
 P
o
ly
sa
cc
h
a
ri
d
e
 b
io
sy
n
th
e
si
s 
fa
m
il
y 
p
ro
te
in
 n
=1
4
3
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
1
1
_E
N
TF
U
M
A
TE
 s
u
p
e
rf
a
m
il
y 
(C
h
) C
D
S 
8
0
9
YP
_0
0
6
3
7
6
0
1
8
3
8
.8
co
n
ti
g0
0
0
5
8
|3
1
0
U
n
iR
e
f1
0
0
_H
8
LE
1
0
 B
ra
n
ch
e
d
-c
h
a
in
 a
m
in
o
 a
ci
d
 t
ra
n
sp
o
rt
 p
ro
te
in
 n
=2
0
1
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
1
0
_E
N
TF
U
a
zl
D
 (C
h
)
YP
_0
0
6
3
7
6
0
1
9
4
0
.3
co
n
ti
g0
0
0
5
8
|4
1
0
U
n
iR
e
f1
0
0
_C
9
B
J0
8
 B
ra
n
ch
e
d
-c
h
a
in
 a
m
in
o
 a
ci
d
 t
ra
n
sp
o
rt
e
r 
n
=1
6
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=C
9
B
J0
8
_E
N
TF
C
a
zl
C
 (C
h
)
YP
_0
0
6
3
7
6
0
2
0
4
0
.4
co
n
ti
g0
0
0
5
8
|5
1
0
U
n
iR
e
f1
0
0
_H
8
LE
0
8
 C
a
ti
o
n
 d
if
fu
si
o
n
 fa
ci
li
ta
to
r 
fa
m
il
y 
tr
a
n
sp
o
rt
e
r 
n
=2
0
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
0
8
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
1
0
YP
_0
0
6
3
7
6
0
2
1
3
9
.9
co
n
ti
g0
0
0
5
8
|6
1
0
U
n
iR
e
f1
0
0
_H
8
LE
0
7
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=9
9
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LE
0
7
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
1
1
YP
_0
0
6
3
7
6
0
2
2
3
5
.6
B
e
st
 B
L
A
S
T
 H
it
 A
n
n
o
ta
ti
o
n
 
E
. 
fa
e
c
iu
m
 D
O
 A
n
n
o
ta
ti
o
n
Ana P. Tedim  Chapter 6 
 
240 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 E
. 
F
a
e
c
iu
m
 E
. 
fa
e
c
iu
m
 
 E
. 
fa
e
c
iu
m
 
E
. 
fa
e
c
iu
m
 D
O
 
G
C
 
G
E
H
P
H
2
.1
H
P
H
2
G
E
1
G
e
n
B
a
n
k
 a
c
c
e
ss
io
n
 n
o
.
c
o
n
te
n
t 
(%
)
co
n
ti
g0
0
0
5
8
|7
1
0
U
n
iR
e
f1
0
0
_H
8
LE
0
6
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
9
8
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
0
6
_E
N
TF
U
M
P
 (C
h
) C
D
S 
8
1
2
YP
_0
0
6
3
7
6
0
2
3
3
7
.2
co
n
ti
g0
0
0
5
8
|8
1
0
U
n
iR
e
f1
0
0
_H
8
LE
0
5
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
8
1
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
0
5
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
1
3
YP
_0
0
6
3
7
6
0
2
4
3
7
co
n
ti
g0
0
0
5
8
|9
1
0
U
n
iR
e
f1
0
0
_H
8
LE
0
4
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
3
6
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
0
4
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
1
5
YP
_0
0
6
3
7
6
0
2
6
3
8
.6
co
n
ti
g0
0
0
5
8
|1
0
1
0
U
n
iR
e
f1
0
0
_H
8
LE
0
3
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=2
0
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
0
3
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
1
6
YP
_0
0
6
3
7
6
0
2
7
3
5
.4
co
n
ti
g0
0
0
5
8
|1
1
1
0
U
n
iR
e
f1
0
0
_H
8
LE
0
2
 A
TP
-d
e
p
e
n
d
e
n
t 
Zn
 p
ro
te
a
se
 n
=1
5
3
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LE
0
2
_E
N
TF
U
Zn
 p
ro
te
a
se
 (C
h
) C
D
S 
8
1
7
YP
_0
0
6
3
7
6
0
2
8
3
8
.8
co
n
ti
g0
0
0
5
8
|1
2
1
0
U
n
iR
e
f1
0
0
_H
8
LE
0
1
 N
a
 d
e
p
e
n
d
e
n
t 
n
u
cl
e
o
si
d
e
 t
ra
n
sp
o
rt
e
r,
 N
u
p
C
 fa
m
il
y 
n
=1
5
2
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
0
1
_E
N
TF
U
n
u
p
C
 (C
h
)
YP
_0
0
6
3
7
6
0
2
9
3
7
.4
co
n
ti
g0
0
0
5
8
|1
3
0
0
U
n
iR
e
f1
0
0
_H
8
LE
0
0
 G
u
a
n
yl
a
te
 k
in
a
se
 n
=1
5
1
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LE
0
0
_E
N
TF
U
kd
p
A
 (C
h
)
YP
_0
0
6
3
7
6
0
3
0
3
7
.5
co
n
ti
g0
0
0
5
8
|1
4
1
0
U
n
iR
e
f1
0
0
_C
9
B
T1
1
 A
ce
ty
lt
ra
n
sf
e
ra
se
 n
=9
6
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=C
9
B
T1
1
_E
N
TF
C
a
ce
ty
lt
ra
b
sf
e
ra
se
 (C
h
) C
D
S 
8
1
8
YP
_0
0
6
3
7
6
0
3
1
3
8
.2
co
n
ti
g0
0
0
5
8
|1
5
1
0
U
n
iR
e
f1
0
0
_J
6
YH
G
4
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=5
1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=J
6
YH
G
4
_E
N
TF
C
H
P
 (C
h
) C
D
S 
8
1
9
YP
_0
0
6
3
7
6
0
3
2
3
9
.1
co
n
ti
g0
0
0
5
8
|1
6
1
0
U
n
iR
e
f1
0
0
_H
8
LD
Z7
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=7
9
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LD
Z7
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
2
0
YP
_0
0
6
3
7
6
0
3
3
3
9
.1
co
n
ti
g0
0
0
5
8
|1
7
1
0
U
n
iR
e
f1
0
0
_H
8
LD
Z6
 A
m
in
o
 a
ci
d
 A
B
C
 t
ra
n
sp
o
rt
e
r,
 a
m
in
o
 a
ci
d
-b
in
d
in
g/
p
e
rm
e
a
se
 n
=1
5
3
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LD
Z6
_E
N
TF
U
A
B
C
 t
ra
n
sp
o
rt
e
r 
(C
h
) C
D
S 
8
2
1
YP
_0
0
6
3
7
6
0
3
4
3
9
.7
co
n
ti
g0
0
0
5
8
|1
8
1
0
U
n
iR
e
f1
0
0
_J
6
L6
Z4
 A
B
C
 t
ra
n
sp
o
rt
e
r,
 s
u
b
st
ra
te
-b
in
d
in
g 
p
ro
te
in
, f
a
m
il
y 
3
 n
=6
4
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=J
6
L6
Z4
_E
N
TF
C
A
B
C
 t
ra
n
sp
o
rt
e
r 
(C
h
) C
D
S 
8
2
2
YP
_0
0
6
3
7
6
0
3
5
3
5
.4
co
n
ti
g0
0
0
5
8
|1
9
1
0
U
n
iR
e
f1
0
0
_S
4
EW
4
4
 A
m
id
a
se
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 S
D
1
C
-2
 R
e
p
ID
=S
4
EW
4
4
_E
N
TF
C
a
m
id
a
se
 (C
h
) C
D
S 
8
2
3
YP
_0
0
6
3
7
6
0
3
6
4
2
.4
co
n
ti
g0
0
0
5
8
|2
0
1
0
U
n
iR
e
f1
0
0
_E
4
I7
Z7
 D
ih
yd
ro
o
ro
ta
te
 o
xi
d
a
se
 n
=4
5
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=E
4
I7
Z7
_E
N
TF
C
p
yr
D
2
 (C
h
)
YP
_0
0
6
3
7
6
0
3
7
3
9
.1
co
n
ti
g0
0
0
5
8
|2
1
1
0
U
n
iR
e
f1
0
0
_S
4
EM
F4
 L
ys
is
 p
ro
te
in
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 S
D
1
C
-2
 R
e
p
ID
=S
4
EM
F4
_E
N
TF
C
li
p
o
p
ro
te
in
 (C
h
) C
D
S 
8
2
4
YP
_0
0
6
3
7
6
0
3
8
3
7
.4
co
n
ti
g0
0
0
5
8
|2
2
1
0
U
n
iR
e
f1
0
0
_H
8
LD
Z1
 C
yc
lo
p
ro
p
a
n
e
-f
a
tt
y-
a
cy
l-
p
h
o
sp
h
o
li
p
id
 s
yn
th
a
se
 n
=9
7
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LD
Z1
_E
N
TF
U
cf
a
 (C
h
)
YP
_0
0
6
3
7
6
0
3
9
3
6
.6
co
n
ti
g0
0
0
5
8
|2
3
1
0
U
n
iR
e
f1
0
0
_H
8
LD
Z0
 In
te
gr
a
l m
e
m
b
ra
n
e
 p
ro
te
in
 n
=1
3
8
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LD
Z0
_E
N
TF
U
p
a
rt
ia
l M
P
 (C
h
) C
D
S 
8
2
5
YP
_0
0
6
3
7
6
0
4
1
3
7
.6
co
n
ti
g0
0
0
5
8
|2
4
1
0
U
n
iR
e
f1
0
0
_H
8
LD
Y9
 A
B
C
 t
ra
n
sp
o
rt
e
r,
 p
e
rm
e
a
se
 p
ro
te
in
 n
=1
7
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LD
Y9
_E
N
TF
U
m
a
lD
 (C
h
)
YP
_0
0
6
3
7
6
0
4
2
3
8
.6
co
n
ti
g0
0
0
5
8
|2
5
1
0
U
n
iR
e
f1
0
0
_H
8
LD
Y8
 A
B
C
 t
ra
n
sp
o
rt
e
r,
 p
e
rm
e
a
se
 p
ro
te
in
 n
=1
3
8
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LD
Y8
_E
N
TF
U
m
a
lC
 (C
h
)
YP
_0
0
6
3
7
6
0
4
3
3
8
.2
co
n
ti
g0
0
0
5
8
|2
6
1
0
U
n
iR
e
f1
0
0
_J
7
D
0
P
8
 M
a
lt
o
d
e
xt
ri
n
-b
in
d
in
g 
p
ro
te
in
 M
d
xE
 n
=4
1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=J
7
D
0
P
8
_E
N
TF
C
m
a
lX
 (C
h
)
YP
_0
0
6
3
7
6
0
4
4
3
9
.4
co
n
ti
g0
0
0
5
8
|2
7
1
0
U
n
iR
e
f1
0
0
_H
8
LD
Y6
 A
lp
h
a
 a
m
yl
a
se
, c
a
ta
ly
ti
c 
d
o
m
a
in
 p
ro
te
in
 n
=8
7
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LD
Y6
_E
N
TF
U
n
p
lT
 (C
h
)
YP
_0
0
6
3
7
6
0
4
5
3
7
.5
co
n
ti
g0
0
0
5
8
|2
8
1
0
U
n
iR
e
f1
0
0
_C
9
C
9
M
8
 In
te
gr
a
l m
e
m
b
ra
n
e
 p
ro
te
in
 n
=4
2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=C
9
C
9
M
8
_E
N
TF
C
H
P
 (C
h
) C
D
S 
8
2
6
YP
_0
0
6
3
7
6
0
4
6
3
6
.5
co
n
ti
g0
0
0
5
8
|2
9
1
0
U
n
iR
e
f1
0
0
_H
8
LD
Y4
 M
e
rR
 fa
m
il
y 
tr
a
n
sc
ri
p
ti
o
n
a
l r
e
gu
la
to
r 
n
=9
5
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LD
Y4
_E
N
TF
U
m
e
rR
 (C
h
) C
D
S 
8
2
8
YP
_0
0
6
3
7
6
0
4
8
3
5
.6
co
n
ti
g0
0
0
5
8
|3
0
1
0
U
n
iR
e
f1
0
0
_H
8
LD
Y3
 P
e
ro
xi
re
d
o
xi
n
, O
h
r 
fa
m
il
y 
p
ro
te
in
 n
=1
7
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LD
Y3
_E
N
TF
U
o
sm
C
 (C
h
)
YP
_0
0
6
3
7
6
0
4
9
3
9
.7
co
n
ti
g0
0
0
5
8
|3
1
1
0
U
n
iR
e
f1
0
0
_H
8
LD
Y2
 D
N
A
-b
in
d
in
g 
tr
a
n
sc
ri
p
ti
o
n
a
l r
e
p
re
ss
o
r 
M
a
rR
 n
=8
5
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LD
Y2
_E
N
TF
U
m
a
rR
2
 (C
h
)
YP
_0
0
6
3
7
6
0
5
0
3
8
.1
co
n
ti
g0
0
0
5
8
|3
2
1
0
U
n
iR
e
f1
0
0
_U
2
N
B
7
2
 M
e
m
b
ra
n
e
 p
ro
te
in
 n
=3
1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=U
2
N
B
7
2
_E
N
TF
C
M
P
 (C
h
) C
D
S 
8
2
9
YP
_0
0
6
3
7
6
0
5
1
3
4
.8
co
n
ti
g0
0
0
8
1
|7
2
0
0
U
n
iR
e
f1
0
0
_C
9
B
T3
0
 C
e
ll
 w
a
ll
 s
u
rf
a
ce
 a
d
h
e
si
o
n
 p
ro
te
in
 n
=1
0
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=C
9
B
T3
0
_E
N
TF
C
Δfŵ
sϮϮ
 ;Ch
Ϳ
YP
_0
0
6
3
7
6
0
5
2
4
0
.8
co
n
ti
g0
0
0
8
1
|7
1
1
0
U
n
iR
e
f1
0
0
_H
8
LD
X
9
 M
 p
ro
te
in
 t
ra
n
s-
a
ct
in
g 
p
o
si
ti
ve
 r
e
gu
la
to
r 
n
=1
0
4
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LD
X
9
_E
N
TF
U
re
gu
la
to
r 
( C
h
) C
D
S 
8
3
0
YP
_0
0
6
3
7
6
0
5
3
3
1
.9
co
n
ti
g0
0
0
8
1
|7
0
1
0
U
n
iR
e
f1
0
0
_H
8
LD
X
8
 M
a
n
n
o
n
a
te
 d
e
h
yd
ra
ta
se
 n
=9
8
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LD
X
8
_E
N
TF
U
u
xu
A
 (C
h
)
YP
_0
0
6
3
7
6
0
5
4
3
9
.6
co
n
ti
g0
0
0
8
1
|6
9
1
0
U
n
iR
e
f1
0
0
_H
8
LD
X
7
 M
a
n
n
it
o
l d
e
h
yd
ro
ge
n
a
se
 p
ro
te
in
 n
=8
0
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=H
8
LD
X
7
_E
N
TF
U
u
xu
B
 (C
h
)
YP
_0
0
6
3
7
6
0
5
5
3
8
.3
co
n
ti
g0
0
0
8
1
|6
8
1
0
U
n
iR
e
f1
0
0
_H
8
LD
X
6
 T
ra
n
sc
ri
p
ti
o
n
a
l r
e
gu
la
to
r,
 G
n
tR
 fa
m
il
y 
n
=1
8
7
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LD
X
6
_E
N
TF
U
kd
gR
 (C
h
)
YP
_0
0
6
3
7
6
0
5
6
3
9
.5
co
n
ti
g0
0
0
8
1
|6
7
1
0
U
n
iR
e
f1
0
0
_H
8
LD
X
5
 A
lk
yl
 h
yd
ro
p
e
ro
xi
d
e
 r
e
d
u
ct
a
se
, C
 s
u
b
u
n
it
 n
=1
8
8
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LD
X
5
_E
N
TF
U
a
h
p
C
 (C
h
)
YP
_0
0
6
3
7
6
0
5
7
3
8
.5
co
n
ti
g0
0
0
8
1
|6
6
1
0
U
n
iR
e
f1
0
0
_I
3
U
2
3
8
 P
e
ro
xi
re
d
o
xi
n
 s
u
b
u
n
it
 F
 n
=8
6
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=I
3
U
2
3
8
_E
N
TF
C
a
h
p
F 
(C
h
)
YP
_0
0
6
3
7
6
0
5
8
3
9
co
n
ti
g0
0
0
8
1
|6
5
1
0
U
n
iR
e
f1
0
0
_H
8
LD
X
3
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
9
3
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LD
X
3
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
3
1
YP
_0
0
6
3
7
6
0
5
9
3
7
.6
co
n
ti
g0
0
0
8
1
|6
4
1
0
U
n
iR
e
f1
0
0
_H
8
LD
X
2
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
3
3
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LD
X
2
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
3
2
YP
_0
0
6
3
7
6
0
6
0
3
5
.8
co
n
ti
g0
0
0
8
1
|6
3
1
0
U
n
iR
e
f1
0
0
_J
6
YH
E4
 N
a
+/
H
+ 
a
n
ti
p
o
rt
e
r 
n
=6
8
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=J
6
YH
E4
_E
N
TF
C
N
a
+/
H
+ 
tr
a
n
sp
o
rt
e
r 
(C
h
) C
D
S 
8
3
3
YP
_0
0
6
3
7
6
0
6
1
3
6
.3
co
n
ti
g0
0
0
8
1
|6
2
1
0
U
n
iR
e
f1
0
0
_M
1
R
TD
4
 P
e
n
ic
il
li
n
-b
in
d
in
g 
p
ro
te
in
 5
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=M
1
R
TD
4
_E
N
TF
C
p
b
p
5
 (C
h
)
YP
_0
0
6
3
7
6
0
6
2
3
9
.8
co
n
ti
g0
0
0
8
1
|6
1
1
0
U
n
iR
e
f1
0
0
_C
9
B
T4
1
 C
e
ll
 e
n
ve
lo
p
e
 t
ra
n
sc
ri
p
ti
o
n
a
l a
tt
e
n
u
a
to
r 
n
=3
4
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=C
9
B
T4
1
_E
N
TF
C
p
sr
 (C
h
)
YP
_0
0
6
3
7
6
0
6
4
3
8
.1
co
n
ti
g0
0
0
8
1
|6
0
1
0
U
n
iR
e
f1
0
0
_H
8
LD
W
5
 C
e
ll
 c
yc
le
 p
ro
te
in
, F
ts
W
/R
o
d
A
/S
p
o
V
E 
fa
m
il
y 
n
=7
6
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=H
8
LD
W
5
_E
N
TF
U
ft
sW
3
 (C
h
)
YP
_0
0
6
3
7
6
0
6
5
3
8
.3
co
n
ti
g0
0
0
8
1
|5
9
1
0
U
n
iR
e
f1
0
0
_H
8
LD
W
4
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
9
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LD
W
4
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
3
7
YP
_0
0
6
3
7
6
0
6
8
3
1
.9
co
n
ti
g0
0
0
8
1
|5
8
1
0
U
n
iR
e
f1
0
0
_H
8
LD
W
3
 F
la
vi
n
 r
e
d
u
ct
a
se
-l
ik
e
 d
o
m
a
in
 p
ro
te
in
 n
=1
3
1
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LD
W
3
_E
N
TF
U
re
d
u
ct
a
se
 (C
h
) C
D
S 
8
3
8
YP
_0
0
6
3
7
6
0
6
9
3
7
.6
co
n
ti
g0
0
0
8
1
|5
7
1
0
U
n
iR
e
f1
0
0
_D
4
R
G
K
8
 P
u
ta
ti
ve
 N
-a
ce
ty
lm
a
n
n
o
sa
m
in
e
-6
-p
h
o
sp
h
a
te
 2
-e
p
im
e
ra
se
 n
=2
3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
R
G
K
8
_E
N
TF
C
n
a
n
E 
(C
h
)
YP
_0
0
6
3
7
6
0
7
0
4
0
.5
co
n
ti
g0
0
0
8
1
|5
6
1
0
U
n
iR
e
f1
0
0
_H
8
LD
W
1
 A
SC
H
 d
o
m
a
in
 p
ro
te
in
 n
=1
4
1
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LD
W
1
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
3
9
YP
_0
0
6
3
7
6
0
7
1
3
5
.3
co
n
ti
g0
0
0
8
1
|5
5
1
0
U
n
iR
e
f1
0
0
_D
4
R
G
K
6
 1
-d
e
o
xy
-d
-x
yl
u
lo
se
-5
-p
h
o
sp
h
a
te
 s
yn
th
a
se
 n
=1
2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
R
G
K
6
_E
N
TF
C
d
xs
 (C
h
)
YP
_0
0
6
3
7
6
0
7
2
3
8
.8
co
n
ti
g0
0
0
8
1
|5
4
1
0
U
n
iR
e
f1
0
0
_J
6
P
SU
4
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
8
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=J
6
P
SU
4
_E
N
TF
C
H
P
 (C
h
) C
D
S 
8
4
0
YP
_0
0
6
3
7
6
0
7
3
3
2
.4
co
n
ti
g0
0
0
8
1
|5
3
1
0
U
n
iR
e
f1
0
0
_H
8
LD
V
8
 G
lu
ta
m
in
a
se
 n
=1
4
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LD
V
8
_E
N
TF
U
gl
sA
 (C
h
)
YP
_0
0
6
3
7
6
0
7
6
4
0
.2
co
n
ti
g0
0
0
8
1
|5
2
1
0
U
n
iR
e
f1
0
0
_H
8
LD
V
7
 A
m
in
o
 a
ci
d
 p
e
rm
e
a
se
 fa
m
il
y 
p
ro
te
in
 n
=1
1
0
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
LD
V
7
_E
N
TF
U
ga
d
C
2
 (C
h
)
YP
_0
0
6
3
7
6
0
7
7
3
9
.6
co
n
ti
g0
0
0
8
1
|5
1
1
0
U
n
iR
e
f1
0
0
_H
8
LD
V
6
 A
m
m
o
n
iu
m
 t
ra
n
sp
o
rt
e
r 
fa
m
il
y 
p
ro
te
in
 n
=1
4
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
LD
V
6
_E
N
TF
U
a
m
t 
(C
h
)
YP
_0
0
6
3
7
6
0
7
8
4
2
.1
co
n
ti
g0
0
0
8
1
|5
0
1
0
U
n
iR
e
f1
0
0
_C
2
H
B
9
6
 T
ra
n
sg
ly
co
sy
la
se
 a
ss
o
ci
a
te
d
 p
ro
te
in
 n
=2
2
6
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=C
2
H
B
9
6
_E
N
TF
C
gl
sB
1
 (C
h
)
YP
_0
0
6
3
7
6
0
8
0
3
9
.9
co
n
ti
g0
0
0
8
1
|4
9
1
0
U
n
iR
e
f1
0
0
_H
8
L7
N
1
 A
lk
a
li
n
e
 s
h
o
ck
 p
ro
te
in
 2
3
 fa
m
il
y 
p
ro
te
in
 n
=2
0
2
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L7
N
1
_E
N
TF
U
gl
s2
0
 (C
h
)
YP
_0
0
6
3
7
6
0
8
1
3
4
.8
co
n
ti
g0
0
0
8
1
|4
8
1
0
U
n
iR
e
f1
0
0
_H
8
L7
N
2
 S
m
a
ll
 in
te
gr
a
l m
e
m
b
ra
n
e
 p
ro
te
in
 n
=1
3
2
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L7
N
2
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
4
4
YP
_0
0
6
3
7
6
0
8
2
3
4
.9
co
n
ti
g0
0
0
8
1
|4
7
1
0
U
n
iR
e
f1
0
0
_H
8
L7
N
3
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
3
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L7
N
3
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
4
5
YP
_0
0
6
3
7
6
0
8
3
3
8
.4
co
n
ti
g0
0
0
8
1
|4
6
1
0
U
n
iR
e
f1
0
0
_H
8
L7
N
5
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
4
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L7
N
5
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
4
7
YP
_0
0
6
3
7
6
0
8
5
3
4
co
n
ti
g0
0
0
8
1
|4
5
1
0
U
n
iR
e
f1
0
0
_H
8
L7
N
6
 H
e
li
x-
tu
rn
-h
e
li
x 
d
o
m
a
in
-c
o
n
ta
in
in
g 
p
ro
te
in
 n
=1
9
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L7
N
6
_E
N
TF
U
re
gu
la
to
r 
(C
h
) C
D
S 
8
4
8
YP
_0
0
6
3
7
6
0
8
6
3
4
.6
co
n
ti
g0
0
0
8
1
|4
4
1
0
U
n
iR
e
f1
0
0
_H
8
L7
N
8
 T
ra
n
sg
ly
co
sy
la
se
 a
ss
o
ci
a
te
d
 p
ro
te
in
 n
=2
1
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L7
N
8
_E
N
TF
U
gl
sB
 (C
h
)
YP
_0
0
6
3
7
6
0
8
8
4
1
.2
B
e
st
 B
L
A
S
T
 H
it
 A
n
n
o
ta
ti
o
n
 
E
. 
fa
e
c
iu
m
 D
O
 A
n
n
o
ta
ti
o
n
T
a
b
le
 S
4
 -
 A
n
n
o
ta
ti
o
n
 o
f 
tr
a
n
sf
e
ra
b
le
 r
e
g
io
n
 o
f 
E
. 
fa
e
ci
u
m
 G
E
H
P
H
2
.1
 u
si
n
g
 B
e
st
 B
LA
S
T
 H
it
 a
n
d
 E
. 
fa
e
ci
u
m
 D
O
 a
s 
a
 r
e
fe
re
n
ce
 s
tr
a
in
 (
co
n
t.
) 
Ana P. Tedim  Chapter 6 
 
241 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
a
b
le
 S
4
 -
 A
n
n
o
ta
ti
o
n
 o
f 
tr
a
n
sf
e
ra
b
le
 r
e
g
io
n
 o
f 
E
. 
fa
e
ci
u
m
 G
E
H
P
H
2
.1
 u
si
n
g
 B
e
st
 B
LA
S
T
 H
it
 a
n
d
 E
. 
fa
e
ci
u
m
 D
O
 a
s 
a
 r
e
fe
re
n
ce
 s
tr
a
in
 (
co
n
t.
) 
 E
. 
F
a
e
c
iu
m
 E
. 
fa
e
c
iu
m
 
 E
. 
fa
e
c
iu
m
 
E
. 
fa
e
c
iu
m
 D
O
 
G
C
 
G
E
H
P
H
2
.1
H
P
H
2
G
E
1
G
e
n
B
a
n
k
 a
c
c
e
ss
io
n
 n
o
.
c
o
n
te
n
t 
(%
)
co
n
ti
g0
0
0
8
1
|4
3
1
0
U
n
iR
e
f1
0
0
_L
2
K
6
B
2
 G
e
n
e
ra
l s
tr
e
ss
 p
ro
te
in
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 E
n
G
e
n
0
0
1
6
 R
e
p
ID
=L
2
K
6
B
2
_E
N
TF
C
gl
s3
3
 (C
h
)
YP
_0
0
6
3
7
6
0
8
9
3
8
.2
co
n
ti
g0
0
0
8
1
|4
2
1
0
U
n
iR
e
f1
0
0
_H
8
L7
P
0
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=2
1
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L7
P
0
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
5
0
YP
_0
0
6
3
7
6
0
9
0
3
8
.1
co
n
ti
g0
0
0
8
1
|4
1
1
0
U
n
iR
e
f1
0
0
_H
8
L7
P
1
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
9
3
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L7
P
1
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
5
1
YP
_0
0
6
3
7
6
0
9
1
3
7
.4
co
n
ti
g0
0
0
8
1
|4
0
1
0
U
n
iR
e
f1
0
0
_H
8
L7
P
2
 O
xi
d
o
re
d
u
ct
a
se
, s
h
o
rt
 c
h
a
in
 d
e
h
yd
ro
ge
n
a
se
/r
e
d
u
ct
a
se
 fa
m
il
y 
p
ro
te
in
 n
=1
0
2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=H
8
L7
P
2
_E
N
TF
U
SD
R
 d
e
h
yd
ro
ge
n
a
se
 (C
h
) C
D
S 
8
5
2
YP
_0
0
6
3
7
6
0
9
2
4
1
.9
co
n
ti
g0
0
0
8
1
|3
9
1
0
U
n
iR
e
f1
0
0
_H
8
L7
P
3
 M
g2
+ 
ca
ti
o
n
 t
ra
n
sp
o
rt
e
r 
n
=7
8
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
L7
P
3
_E
N
TF
U
co
rA
3
 (C
h
)
YP
_0
0
6
3
7
6
0
9
3
3
6
.3
co
n
ti
g0
0
0
8
1
|3
8
1
0
U
n
iR
e
f1
0
0
_H
8
L7
P
4
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
3
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L7
P
4
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
5
3
YP
_0
0
6
3
7
6
0
9
4
3
4
.2
co
n
ti
g0
0
0
8
1
|3
7
1
0
U
n
iR
e
f1
0
0
_H
8
L7
P
5
 G
ly
co
sy
l t
ra
n
sf
e
ra
se
 fa
m
il
y 
8
 n
=1
2
7
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L7
P
5
_E
N
TF
U
gl
yc
o
sy
l t
ra
n
sf
e
ra
se
 (C
h
) C
D
S 
8
5
4
YP
_0
0
6
3
7
6
0
9
5
3
6
.5
co
n
ti
g0
0
0
8
1
|3
6
1
0
U
n
iR
e
f1
0
0
_J
6
EI
Z9
 P
u
ta
ti
ve
 g
e
n
e
ra
l s
tr
e
ss
 p
ro
te
in
 A
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 E
R
V
1
 R
e
p
ID
=J
6
EI
Z9
_E
N
TF
C
gl
yc
o
sy
l t
ra
n
sf
e
ra
se
 (C
h
) C
D
S 
8
5
5
YP
_0
0
6
3
7
6
0
9
6
3
5
.3
co
n
ti
g0
0
0
8
1
|3
5
1
0
U
n
iR
e
f1
0
0
_H
8
L7
P
7
 H
A
D
 s
u
p
e
rf
a
m
il
y 
h
yd
ro
la
se
 n
=1
0
5
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
L7
P
7
_E
N
TF
U
H
yd
ro
la
se
 (C
h
) C
D
S 
8
5
6
YP
_0
0
6
3
7
6
0
9
7
3
7
.8
co
n
ti
g0
0
0
8
1
|3
4
1
0
U
n
iR
e
f1
0
0
_J
7
D
0
M
2
 Is
o
ch
o
ri
sm
a
ta
se
 fa
m
il
y 
p
ro
te
in
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 5
0
4
 R
e
p
ID
=J
7
D
0
M
2
_E
N
TF
C
is
o
ch
o
ri
sm
a
ta
se
 (C
h
) C
D
S 
8
5
7
YP
_0
0
6
3
7
6
0
9
8
3
6
co
n
ti
g0
0
0
8
1
|3
3
1
0
U
n
iR
e
f1
0
0
_Q
3
Y3
4
7
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=5
3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=Q
3
Y3
4
7
_E
N
TF
C
H
P
 (C
h
) C
D
S 
8
5
8
YP
_0
0
6
3
7
6
0
9
9
3
2
.1
co
n
ti
g0
0
0
8
1
|3
2
1
0
U
n
iR
e
f1
0
0
_H
8
L7
Q
0
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
4
3
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L7
Q
0
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
5
9
YP
_0
0
6
3
7
6
1
0
0
3
3
.3
co
n
ti
g0
0
0
8
1
|3
1
1
0
U
n
iR
e
f1
0
0
_H
8
L7
Q
1
 T
o
xi
n
-a
n
ti
to
xi
n
 s
ys
te
m
, a
n
ti
to
xi
n
 c
o
m
p
o
n
e
n
t,
 X
re
 d
o
m
a
in
 p
ro
te
in
 n
=1
3
9
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
L7
Q
1
_E
N
TF
U
re
gu
la
to
r 
(C
h
) C
D
S 
8
6
0
YP
_0
0
6
3
7
6
1
0
1
3
6
.2
co
n
ti
g0
0
0
8
1
|3
0
1
0
U
n
iR
e
f1
0
0
_H
8
L7
Q
2
 P
yr
im
id
in
e
 d
im
e
r 
D
N
A
 g
ly
co
sy
la
se
 n
=1
5
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L7
Q
2
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
6
1
YP
_0
0
6
3
7
6
1
0
2
3
8
.8
co
n
ti
g0
0
0
8
1
|2
9
1
0
U
n
iR
e
f1
0
0
_E
4
IC
Y1
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=4
8
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=E
4
IC
Y1
_E
N
TF
C
A
n
ti
-t
o
xi
n
 (C
h
) C
D
S 
8
6
2
YP
_0
0
6
3
7
6
1
0
3
3
5
.5
co
n
ti
g0
0
0
8
1
|2
8
1
0
U
n
iR
e
f1
0
0
_C
9
B
T7
5
 P
re
d
ic
te
d
 p
ro
te
in
 n
=4
9
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=C
9
B
T7
5
_E
N
TF
C
H
P
 (c
h
) C
D
S 
8
6
3
YP
_0
0
6
3
7
6
1
0
4
2
4
.4
co
n
ti
g0
0
0
8
1
|2
7
1
0
U
n
iR
e
f1
0
0
_H
8
L7
Q
5
 M
a
jo
r 
co
ld
 s
h
o
ck
 p
ro
te
in
 C
sp
A
 n
=2
1
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L7
Q
5
_E
N
TF
U
cs
p
A
2
 (C
h
)
YP
_0
0
6
3
7
6
1
0
5
3
9
.8
co
n
ti
g0
0
0
8
1
|2
6
1
0
U
n
iR
e
f1
0
0
_C
2
H
B
D
0
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
9
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=C
2
H
B
D
0
_E
N
TF
C
H
P
 (C
h
) C
D
S 
8
6
4
YP
_0
0
6
3
7
6
1
0
6
3
2
.7
co
n
ti
g0
0
0
8
1
|2
5
1
0
U
n
iR
e
f1
0
0
_H
8
L8
P
0
 H
A
D
 s
u
p
e
rf
a
m
il
y 
h
yd
ro
la
se
 n
=1
3
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
P
0
_E
N
TF
U
H
yd
ro
la
se
 (C
h
) C
D
S 
8
6
6
YP
_0
0
6
3
7
6
1
0
8
3
4
.6
co
n
ti
g0
0
0
8
1
|2
4
1
0
U
n
iR
e
f1
0
0
_S
4
EG
0
1
 M
a
n
n
o
n
a
te
 d
e
h
yd
ra
ta
se
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 S
D
1
C
-2
 R
e
p
ID
=S
4
EG
0
1
_E
N
TF
C
u
xu
A
2
 (C
h
)
YP
_0
0
6
3
7
6
1
0
9
4
0
.7
co
n
ti
g0
0
0
8
1
|2
3
1
0
U
n
iR
e
f1
0
0
_H
8
L8
P
2
 P
TS
 s
ys
te
m
, m
a
n
n
o
se
/f
ru
ct
o
se
/s
o
rb
o
se
-s
p
e
ci
fi
c 
II
A
 c
o
m
p
o
n
e
n
t 
n
=1
3
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
P
2
_E
N
TF
U
P
TS
 s
ys
te
m
 (C
h
) C
D
S 
8
6
7
YP
_0
0
6
3
7
6
1
1
0
4
1
.2
co
n
ti
g0
0
0
8
1
|2
2
1
0
U
n
iR
e
f1
0
0
_H
8
L8
P
3
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=5
5
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=H
8
L8
P
3
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
6
8
YP
_0
0
6
3
7
6
1
1
1
3
7
.4
co
n
ti
g0
0
0
8
1
|2
1
1
0
U
n
iR
e
f1
0
0
_H
8
L8
P
4
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
0
7
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
P
4
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
6
9
YP
_0
0
6
3
7
6
1
1
2
3
5
.1
co
n
ti
g0
0
0
8
1
|2
0
1
0
U
n
iR
e
f1
0
0
_H
8
L8
P
5
 P
TS
 s
ys
te
m
, m
a
n
n
o
se
/f
ru
ct
o
se
/s
o
rb
o
se
-s
p
e
ci
fi
c 
II
B
 c
o
m
p
o
n
e
n
t 
n
=1
3
6
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
P
5
_E
N
TF
U
P
TS
 s
ys
te
m
 (C
h
) C
D
S 
8
7
0
YP
_0
0
6
3
7
6
1
1
3
3
3
.1
co
n
ti
g0
0
0
8
1
|1
9
1
0
U
n
iR
e
f1
0
0
_H
8
L8
P
6
 P
TS
 s
ys
te
m
, m
a
n
n
o
se
/f
ru
ct
o
se
/s
o
rb
o
se
-s
p
e
ci
fi
c 
II
D
 c
o
m
p
o
n
e
n
t 
n
=1
0
0
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
L8
P
6
_E
N
TF
U
m
a
n
Z 
(C
h
)
YP
_0
0
6
3
7
6
1
1
4
4
0
.3
co
n
ti
g0
0
0
8
1
|1
8
1
0
U
n
iR
e
f1
0
0
_H
8
L8
P
7
 P
TS
 s
ys
te
m
, m
a
n
n
o
se
/f
ru
ct
o
se
/s
o
rb
o
se
-s
p
e
ci
fi
c 
II
C
 c
o
m
p
o
n
e
n
t 
n
=1
2
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
P
7
_E
N
TF
U
m
a
n
Y 
(C
h
)
YP
_0
0
6
3
7
6
1
1
5
4
1
.2
co
n
ti
g0
0
0
8
1
|1
7
1
0
U
n
iR
e
f1
0
0
_C
9
B
T8
6
 Ir
o
n
-c
o
n
ta
in
in
g 
a
lc
o
h
o
l d
e
h
yd
ro
ge
n
a
se
 n
=3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=C
9
B
T8
6
_E
N
TF
C
a
lc
o
h
o
l d
e
h
yd
ro
ge
n
a
se
 (C
h
) C
D
S 
8
7
1
YP
_0
0
6
3
7
6
1
1
6
3
8
.3
co
n
ti
g0
0
0
8
1
|1
6
1
0
U
n
iR
e
f1
0
0
_H
8
L8
P
9
 Ir
o
n
-c
o
n
ta
in
in
g 
a
lc
o
h
o
l d
e
h
yd
ro
ge
n
a
se
 n
=9
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
P
9
_E
N
TF
U
a
lc
o
h
o
l d
e
h
yd
ro
ge
n
a
se
 (C
h
) C
D
S 
8
7
2
YP
_0
0
6
3
7
6
1
1
7
3
5
.8
co
n
ti
g0
0
0
8
1
|1
5
1
0
U
n
iR
e
f1
0
0
_E
4
IC
W
6
 4
-p
h
o
sp
h
o
e
ry
th
ro
n
a
te
 d
e
h
yd
ro
ge
n
a
se
 n
=4
6
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=E
4
IC
W
6
_E
N
TF
C
se
rA
2
 (C
h
)
YP
_0
0
6
3
7
6
1
1
8
3
8
.8
co
n
ti
g0
0
0
8
1
|1
4
1
0
U
n
iR
e
f1
0
0
_J
6
S6
N
0
 P
h
o
sp
h
o
gl
u
co
n
a
te
 d
e
h
yd
ro
ge
n
a
se
 n
=2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=J
6
S6
N
0
_E
N
TF
C
gn
d
2
 (C
h
)
YP
_0
0
6
3
7
6
1
1
9
3
7
co
n
ti
g0
0
0
8
1
|1
3
1
0
U
n
iR
e
f1
0
0
_H
8
L8
Q
2
 P
h
o
sp
h
o
su
ga
r 
is
o
m
e
ra
se
 t
ra
n
sc
ri
p
ti
o
n
a
l r
e
gu
la
to
r 
n
=1
3
7
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
Q
2
_E
N
TF
U
gn
tR
 (C
h
)
YP
_0
0
6
3
7
6
1
2
0
3
5
.2
co
n
ti
g0
0
0
8
1
|1
2
1
0
U
n
iR
e
f1
0
0
_H
8
L8
Q
4
 E
st
e
ra
se
 n
=1
0
0
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
Q
4
_E
N
TF
U
li
p
A
 (C
h
)
YP
_0
0
6
3
7
6
1
2
2
3
5
.1
co
n
ti
g0
0
0
8
1
|1
1
1
0
U
n
iR
e
f1
0
0
_C
9
C
0
P
4
 A
lp
h
a
/b
e
ta
 h
yd
ro
la
se
 n
=4
3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=C
9
C
0
P
4
_E
N
TF
C
fm
s7
 (C
h
)
YP
_0
0
6
3
7
6
1
2
3
3
8
.1
co
n
ti
g0
0
0
8
1
|1
0
1
0
U
n
iR
e
f1
0
0
_H
8
L8
Q
6
 Is
o
ch
o
ri
sm
a
ta
se
 fa
m
il
y 
h
yd
ro
la
se
 n
=1
0
6
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
Q
6
_E
N
TF
U
H
yd
ro
la
se
 (C
h
) C
D
S 
8
7
4
YP
_0
0
6
3
7
6
1
2
4
3
6
.3
co
n
ti
g0
0
0
8
1
|9
1
0
U
n
iR
e
f1
0
0
_H
8
L8
Q
7
 T
ra
n
sc
ri
p
ti
o
n
a
l r
e
gu
la
to
r 
Sp
x 
n
=9
7
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
Q
7
_E
N
TF
U
a
rs
C
3
 (C
h
)
YP
_0
0
6
3
7
6
1
2
5
3
4
.7
co
n
ti
g0
0
0
8
1
|8
1
0
U
n
iR
e
f1
0
0
_H
8
L8
Q
8
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=9
7
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
Q
8
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
7
5
YP
_0
0
6
3
7
6
1
2
6
3
3
.4
co
n
ti
g0
0
0
8
1
|7
1
0
U
n
iR
e
f1
0
0
_H
8
L8
Q
9
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
0
3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=H
8
L8
Q
9
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
7
6
YP
_0
0
6
3
7
6
1
2
7
2
9
.7
co
n
ti
g0
0
0
8
1
|6
1
0
U
n
iR
e
f1
0
0
_E
4
IC
V
6
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=4
6
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=E
4
IC
V
6
_E
N
TF
C
H
P
 (C
h
) C
D
S 
8
7
7
YP
_0
0
6
3
7
6
1
2
8
3
5
co
n
ti
g0
0
0
8
1
|5
0
0
U
n
iR
e
f1
0
0
_H
8
L8
R
0
 L
P
X
TG
-m
o
ti
f p
ro
te
in
 c
e
ll
 w
a
ll
 a
n
ch
o
r 
d
o
m
a
in
 p
ro
te
in
 n
=3
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
R
0
_E
N
TF
U
fm
s2
 (C
h
)
YP
_0
0
6
3
7
6
1
2
9
3
9
.8
co
n
ti
g0
0
0
8
1
|4
1
0
U
n
iR
e
f1
0
0
_H
8
L8
R
1
 C
A
A
X
 a
m
in
o
 t
e
rm
in
a
l p
ro
te
a
se
 fa
m
il
y 
p
ro
te
in
 n
=1
3
7
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
R
1
_E
N
TF
U
a
b
i (
C
h
)
YP
_0
0
6
3
7
6
1
3
0
3
8
.1
co
n
ti
g0
0
0
8
1
|3
1
0
U
n
iR
e
f1
0
0
_C
9
B
T9
9
 F
o
ld
a
se
 p
ro
te
in
 P
rs
A
 n
=1
0
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=C
9
B
T9
9
_E
N
TF
C
p
rs
A
2
 (C
h
)
YP
_0
0
6
3
7
6
1
3
1
3
0
.9
co
n
ti
g0
0
0
8
1
|2
1
0
U
n
iR
e
f1
0
0
_H
8
L8
R
3
 F
ru
ct
o
se
-6
-p
h
o
sp
h
a
te
 a
ld
o
la
se
 n
=1
0
7
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
R
3
_E
N
TF
U
ta
l (
C
h
)
YP
_0
0
6
3
7
6
1
3
2
3
7
.1
co
n
ti
g0
0
0
8
1
|1
0
0
U
n
iR
e
f1
0
0
_H
8
L8
R
4
 P
TS
 s
ys
te
m
, g
lu
ci
to
l/
so
rb
it
o
l-
sp
e
ci
fi
c 
II
A
 c
o
m
p
o
n
e
n
t 
n
=1
0
8
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
R
4
_E
N
TF
U
gu
tA
 (C
h
)
YP
_0
0
6
3
7
6
1
3
3
3
3
.8
co
n
ti
g0
0
0
0
8
|9
1
0
U
n
iR
e
f1
0
0
_C
9
B
P
G
5
 P
TS
 s
ys
te
m
, s
o
rb
it
o
l-
sp
e
ci
fi
c 
II
B
C
 c
o
m
p
o
n
e
n
t 
n
=4
8
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=C
9
B
P
G
5
_E
N
TF
C
gu
tN
 - 
P
TS
 s
ys
te
m
 - 
EI
IB
C
-G
U
T_
N
 y
 C
 s
u
p
e
rf
a
m
il
y 
(C
h
) C
D
S 
8
7
8
YP
_0
0
6
3
7
6
1
3
5
3
9
.5
co
n
ti
g0
0
0
0
8
|8
1
0
U
n
iR
e
f1
0
0
_H
8
L8
R
7
 P
TS
 s
ys
te
m
, g
lu
ci
to
l/
so
rb
it
o
l-
sp
e
ci
fi
c 
II
C
 c
o
m
p
o
n
e
n
t 
n
=1
0
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
R
7
_E
N
TF
U
P
TS
 s
ys
te
m
 - 
EI
T-
G
U
T 
su
p
e
rf
a
m
il
y 
(C
h
)  
C
D
S 
8
7
9
YP
_0
0
6
3
7
6
1
3
6
4
0
.4
co
n
ti
g0
0
0
0
8
|7
1
0
U
n
iR
e
f1
0
0
_H
8
L8
R
8
 G
lu
ci
to
l o
p
e
ro
n
 a
ct
iv
a
to
r 
p
ro
te
in
 n
=9
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
R
8
_E
N
TF
U
sr
lR
 (C
h
) -
 D
e
o
R
 fa
m
il
y 
tr
a
n
sc
ri
p
ti
o
n
a
l r
e
gu
la
to
r 
(G
u
tM
) 
YP
_0
0
6
3
7
6
1
3
7
3
8
co
n
ti
g0
0
0
0
8
|6
1
0
U
n
iR
e
f1
0
0
_H
8
L8
R
9
 P
R
D
 d
o
m
a
in
 p
ro
te
in
 n
=7
4
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=H
8
L8
R
9
_E
N
TF
U
so
rb
it
o
l t
ra
n
sc
ri
p
ti
o
n
a
l r
e
gu
la
to
r 
C
D
S 
8
8
0
YP
_0
0
6
3
7
6
1
3
8
3
3
.3
co
n
ti
g0
0
0
0
8
|5
1
0
U
n
iR
e
f1
0
0
_H
8
L8
S0
 O
xi
d
o
re
d
u
ct
a
se
, s
h
o
rt
 c
h
a
in
 d
e
h
yd
ro
ge
n
a
se
/r
e
d
u
ct
a
se
 fa
m
il
y 
p
ro
te
in
 n
=1
0
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
S0
_E
N
TF
U
so
rD
 (C
h
)
YP
_0
0
6
3
7
6
1
3
9
3
8
.8
co
n
ti
g0
0
0
0
8
|4
1
0
U
n
iR
e
f1
0
0
_H
8
L8
S1
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
7
0
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
L8
S1
_E
N
TF
U
H
P
 D
U
F3
7
8
 s
u
p
e
rf
a
m
il
y 
(C
h
) C
D
S 
8
8
1
YP
_0
0
6
3
7
6
1
4
0
3
5
.2
co
n
ti
g0
0
0
0
8
|3
1
0
U
n
iR
e
f1
0
0
_H
8
L8
S2
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
0
0
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=H
8
L8
S2
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
8
2
YP
_0
0
6
3
7
6
1
4
1
3
7
.4
co
n
ti
g0
0
0
0
8
|2
1
0
U
n
iR
e
f1
0
0
_H
8
L8
S3
 A
lp
h
a
 c
ry
st
a
ll
in
 fa
m
il
y 
h
e
a
t 
sh
o
ck
 p
ro
te
in
 n
=9
7
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=H
8
L8
S3
_E
N
TF
U
h
e
a
t 
sh
o
ck
 p
ro
te
in
 H
sp
2
0
 (C
h
) C
D
S 
8
8
3
YP
_0
0
6
3
7
6
1
4
2
3
5
.5
co
n
ti
g0
0
0
0
8
|1
1
0
U
n
iR
e
f1
0
0
_Q
3
X
X
5
8
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=5
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=Q
3
X
X
5
8
_E
N
TF
C
H
P
 (C
h
) C
D
S 
8
8
5
YP
_0
0
6
3
7
6
1
4
4
3
2
.3
co
n
ti
g0
0
0
1
0
|1
1
0
U
n
iR
e
f1
0
0
_H
8
L8
S8
 S
it
e
-s
p
e
ci
fi
c 
ty
ro
si
n
e
 r
e
co
m
b
in
a
se
 X
e
rC
-f
a
m
il
y 
n
=9
0
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
S8
_E
N
TF
U
in
te
gr
a
se
 (C
h
) C
D
S 
8
8
9
YP
_0
0
6
3
7
6
1
4
8
3
6
.7
co
n
ti
g0
0
0
1
0
|2
1
0
U
n
iR
e
f1
0
0
_S
4
EA
C
6
 E
lo
n
ga
ti
o
n
 fa
ct
o
r 
4
 n
=4
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=S
4
EA
C
6
_E
N
TF
C
le
p
A
 G
TP
-b
in
d
in
g 
(C
h
)
YP
_0
0
6
3
7
6
1
4
9
4
2
.3
co
n
ti
g0
0
0
1
0
|3
1
0
U
n
iR
e
f1
0
0
_H
8
L8
T0
 A
ce
ty
lt
ra
n
sf
e
ra
se
, G
N
A
T 
fa
m
il
y 
n
=1
0
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
T0
_E
N
TF
U
a
ce
ty
lt
ra
n
fe
ra
se
 (C
h
) C
D
S 
8
9
0
YP
_0
0
6
3
7
6
1
5
0
3
8
.7
co
n
ti
g0
0
0
1
0
|4
1
0
U
n
iR
e
f1
0
0
_H
8
L8
T1
 N
u
cl
e
o
si
d
e
 2
-d
e
o
xy
ri
b
o
sy
lt
ra
n
sf
e
ra
se
 n
=1
1
1
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
T1
_E
N
TF
U
n
u
cl
e
o
si
d
e
 d
e
o
xy
ri
b
o
sy
lt
ra
n
sf
e
ra
se
 (C
h
) C
D
S 
8
9
1
YP
_0
0
6
3
7
6
1
5
1
3
8
.8
B
e
st
 B
L
A
S
T
 H
it
 A
n
n
o
ta
ti
o
n
 
E
. 
fa
e
c
iu
m
 D
O
 A
n
n
o
ta
ti
o
n
Ana P. Tedim  Chapter 6 
 
242 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
a
b
le
 S
4
 -
 A
n
n
o
ta
ti
o
n
 o
f 
tr
a
n
sf
e
ra
b
le
 r
e
g
io
n
 o
f 
E
. 
fa
e
ci
u
m
 G
E
H
P
H
2
.1
 u
si
n
g
 B
e
st
 B
LA
S
T
 H
it
 a
n
d
 E
. 
fa
e
ci
u
m
 D
O
 a
s 
a
 r
e
fe
re
n
ce
 s
tr
a
in
 (
co
n
t.
) 
 E
. 
F
a
e
c
iu
m
 E
. 
fa
e
c
iu
m
 
 E
. 
fa
e
c
iu
m
 
E
. 
fa
e
c
iu
m
 D
O
 
G
C
 
G
E
H
P
H
2
.1
H
P
H
2
G
E
1
G
e
n
B
a
n
k
 a
c
c
e
ss
io
n
 n
o
.
c
o
n
te
n
t 
(%
)
co
n
ti
g0
0
0
1
0
|5
1
0
U
n
iR
e
f1
0
0
_E
4
IB
5
7
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=4
2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=E
4
IB
5
7
_E
N
TF
C
H
P
 (C
h
) C
D
S 
8
9
2
YP
_0
0
6
3
7
6
1
5
3
3
8
.1
co
n
ti
g0
0
0
1
0
|6
1
0
U
n
iR
e
f1
0
0
_D
0
A
FE
3
 C
h
a
p
e
ro
n
e
 C
lp
B
 n
=7
0
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=D
0
A
FE
3
_E
N
TF
C
C
lp
B
 (C
h
) 
YP
_0
0
6
3
7
6
1
5
4
4
0
co
n
ti
g0
0
0
1
0
|7
1
0
U
n
iR
e
f1
0
0
_R
2
N
H
8
5
 In
te
gr
a
l m
e
m
b
ra
n
e
 p
ro
te
in
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 E
n
G
e
n
0
1
9
1
 R
e
p
ID
=R
2
N
H
8
5
_E
N
TF
C
M
P
 (C
h
) C
D
S 
8
9
4
YP
_0
0
6
3
7
6
1
5
5
3
8
.1
co
n
ti
g0
0
0
1
0
|8
1
0
U
n
iR
e
f1
0
0
_H
8
L8
T5
 M
e
m
b
ra
n
e
 p
ro
te
in
 n
=1
1
2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=H
8
L8
T5
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
9
5
YP
_0
0
6
3
7
6
1
5
6
3
6
.3
co
n
ti
g0
0
0
1
0
|9
1
0
U
n
iR
e
f1
0
0
_H
8
L8
T6
 D
ia
cy
lg
ly
ce
ro
l k
in
a
se
 c
a
ta
ly
ti
c 
su
b
u
n
it
 n
=1
0
2
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
T6
_E
N
TF
U
d
ia
cy
lg
ly
ce
ro
l k
in
a
se
 (C
h
) C
D
S 
8
9
6
YP
_0
0
6
3
7
6
1
5
7
3
9
.3
co
n
ti
g0
0
0
1
0
|1
0
1
0
U
n
iR
e
f1
0
0
_H
8
L8
T7
 P
e
p
ti
d
a
se
 T
 n
=1
6
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
T7
_E
N
TF
U
p
e
p
T 
(Z
in
c-
p
e
p
ti
d
a
se
)
YP
_0
0
6
3
7
6
1
5
8
3
8
.9
co
n
ti
g0
0
0
1
0
|1
1
1
0
U
n
iR
e
f1
0
0
_H
8
L8
T8
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
7
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
T8
_E
N
TF
U
H
P
 (C
h
) C
D
S 
8
9
7
YP
_0
0
6
3
7
6
1
5
9
4
0
.8
co
n
ti
g0
0
0
1
0
|1
2
1
0
U
n
iR
e
f1
0
0
_H
8
L8
T9
 S
A
M
-d
e
p
e
n
d
e
n
t 
m
e
th
yl
tr
a
n
sf
e
ra
se
 fa
m
il
y 
p
ro
te
in
 n
=1
0
2
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
T9
_E
N
TF
U
m
e
th
yl
tr
a
n
sf
e
ra
se
 (C
h
) C
D
S 
8
9
8
YP
_0
0
6
3
7
6
1
6
0
4
0
.9
co
n
ti
g0
0
0
1
0
|1
3
1
0
U
n
iR
e
f1
0
0
_H
8
L7
Q
4
 IS
L3
 fa
m
il
y 
tr
a
n
sp
o
sa
se
 n
=6
9
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=H
8
L7
Q
4
_E
N
TF
U
IS
Ef
a
1
1
 (I
SL
3
 fa
m
il
y)
3
8
.4
co
n
ti
g0
0
0
1
0
|1
4
1
0
U
n
iR
e
f1
0
0
_H
8
L8
U
0
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
0
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
U
0
_E
N
TF
U
Li
p
o
p
ro
te
in
 9
 (C
h
) C
D
S 
8
9
9
YP
_0
0
6
3
7
6
1
6
1
3
9
.9
co
n
ti
g0
0
0
1
0
|1
5
1
0
U
n
iR
e
f1
0
0
_H
8
L8
U
1
 P
ri
m
o
so
m
a
l p
ro
te
in
 D
n
a
I n
=2
0
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
U
1
_E
N
TF
U
d
n
a
I (
C
h
)
YP
_0
0
6
3
7
6
1
6
2
4
0
.7
co
n
ti
g0
0
0
1
0
|1
6
1
0
U
n
iR
e
f1
0
0
_H
8
L8
U
2
 R
e
p
li
ca
ti
o
n
 in
it
ia
ti
o
n
 a
n
d
 m
e
m
b
ra
n
e
 a
tt
a
ch
m
e
n
t 
p
ro
te
in
 n
=1
0
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
U
2
_E
N
TF
U
d
n
a
B
2
 (C
h
)
YP
_0
0
6
3
7
6
1
6
3
3
9
.2
co
n
ti
g0
0
0
1
0
|1
7
1
0
U
n
iR
e
f1
0
0
_H
8
L8
U
3
 T
ra
n
sc
ri
p
ti
o
n
a
l r
e
p
re
ss
o
r 
N
rd
R
 n
=2
1
5
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
U
3
_E
N
TF
U
n
rd
R
 (C
h
)
YP
_0
0
6
3
7
6
1
6
4
3
8
.6
co
n
ti
g0
0
0
1
0
|1
8
1
0
U
n
iR
e
f1
0
0
_H
8
L8
U
4
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=9
9
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
L8
U
4
_E
N
TF
U
e
rp
Q
 (C
h
)
YP
_0
0
6
3
7
6
1
6
5
3
9
.9
co
n
ti
g0
0
0
1
0
|1
9
1
0
U
n
iR
e
f1
0
0
_D
0
A
FF
5
 D
e
p
h
o
sp
h
o
-C
o
A
 k
in
a
se
 n
=7
3
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=D
0
A
FF
5
_E
N
TF
C
co
a
E 
(C
h
)
YP
_0
0
6
3
7
6
1
6
6
4
1
.1
co
n
ti
g0
0
0
1
0
|2
0
1
0
U
n
iR
e
f1
0
0
_H
8
L8
U
6
 F
o
rm
a
m
id
o
p
yr
im
id
in
e
-D
N
A
 g
ly
co
sy
la
se
 n
=1
0
3
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
U
6
_E
N
TF
U
m
u
tM
 (C
h
)
YP
_0
0
6
3
7
6
1
6
7
4
2
.5
co
n
ti
g0
0
0
1
0
|2
1
1
0
U
n
iR
e
f1
0
0
_C
9
B
P
J4
 D
N
A
 p
o
ly
m
e
ra
se
 n
=4
6
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=C
9
B
P
J4
_E
N
TF
C
p
o
lA
 (C
h
)
YP
_0
0
6
3
7
6
1
6
8
3
9
.8
co
n
ti
g0
0
0
1
0
|2
2
1
0
U
n
iR
e
f1
0
0
_H
8
L8
U
8
 In
h
ib
it
o
r 
o
f a
p
o
p
to
si
s-
p
ro
m
o
ti
n
g 
B
a
x1
 n
=1
2
7
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
U
8
_E
N
TF
U
M
P
 (C
h
) C
D
S 
9
0
0
YP
_0
0
6
3
7
6
1
6
9
3
9
.9
co
n
ti
g0
0
0
1
0
|2
3
1
0
U
n
iR
e
f1
0
0
_H
8
L8
U
9
 M
a
o
C
 li
ke
 d
o
m
a
in
 p
ro
te
in
 n
=1
5
8
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
U
9
_E
N
TF
U
d
e
h
yd
ra
ta
se
 (C
h
) C
D
S 
9
0
1
YP
_0
0
6
3
7
6
1
7
0
3
8
.5
co
n
ti
g0
0
0
1
0
|2
4
1
0
U
n
iR
e
f1
0
0
_H
8
L8
V
0
 U
D
P
-N
-a
ce
ty
lm
u
ra
m
a
te
--
L-
a
la
n
in
e
 li
ga
se
 n
=1
2
9
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
L8
V
0
_E
N
TF
U
m
u
rC
 (C
h
)
YP
_0
0
6
3
7
6
1
7
1
3
8
.3
co
n
ti
g0
0
0
1
0
|2
5
1
0
U
n
iR
e
f1
0
0
_H
8
L8
V
1
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
2
6
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
V
1
_E
N
TF
U
H
P
 - 
Yd
cF
-l
ik
e
 s
u
p
e
rf
a
m
il
y 
(C
h
) C
D
S 
9
0
2
YP
_0
0
6
3
7
6
1
7
2
3
9
co
n
ti
g0
0
0
1
0
|2
6
1
0
U
n
iR
e
f1
0
0
_H
8
L8
V
2
 P
ro
te
in
 S
p
rT
-l
ik
e
 n
=1
5
0
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
V
2
_E
N
TF
U
Zi
n
c-
m
e
ta
ll
o
p
ro
te
a
se
 (C
h
) C
D
S 
9
0
3
YP
_0
0
6
3
7
6
1
7
3
3
9
.3
co
n
ti
g0
0
0
1
0
|2
7
1
0
U
n
iR
e
f1
0
0
_H
8
L8
V
3
 R
N
A
 b
in
d
in
g 
p
ro
te
in
 S
1
 n
=1
1
9
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
V
3
_E
N
TF
U
te
x 
(C
h
)
YP
_0
0
6
3
7
6
1
7
4
4
1
.3
co
n
ti
g0
0
0
1
0
|2
8
1
0
U
n
iR
e
f1
0
0
_J
6
EW
M
7
 S
e
r/
Th
r 
p
h
o
sp
h
a
ta
se
 fa
m
il
y 
p
ro
te
in
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 E
R
V
1
 R
e
p
ID
=J
6
EW
M
7
_E
N
TF
C
p
p
h
A
 (C
h
)
YP
_0
0
6
3
7
6
1
7
5
4
0
.1
co
n
ti
g0
0
0
1
0
|2
9
1
0
U
n
iR
e
f1
0
0
_H
8
L8
V
5
 U
P
F0
1
7
6
 p
ro
te
in
 E
FA
U
0
0
4
_0
1
5
5
8
 n
=1
2
6
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
V
5
_E
N
TF
U
rh
o
D
 (C
h
) C
D
S 
9
0
4
YP
_0
0
6
3
7
6
1
7
6
4
1
.6
co
n
ti
g0
0
0
1
0
|3
0
0
0
U
n
iR
e
f1
0
0
_H
8
L8
V
7
 G
ly
o
xa
la
se
 fa
m
il
y 
p
ro
te
in
 n
=1
4
3
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
V
7
_E
N
TF
U
gl
o
A
 (C
h
)
YP
_0
0
6
3
7
6
1
7
7
3
8
.3
co
n
ti
g0
0
0
6
4
|3
2
1
0
U
n
iR
e
f1
0
0
_S
4
EX
V
9
 P
u
ta
ti
ve
 A
TP
 s
yn
th
a
se
 F
0
, A
 s
u
b
u
n
it
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 S
D
1
C
-2
 R
e
p
ID
=S
4
EX
V
9
_E
N
TF
C
N
a
+ 
sy
m
p
o
rt
e
r 
(C
h
) C
D
S 
9
0
5
YP
_0
0
6
3
7
6
1
7
8
4
0
.7
co
n
ti
g0
0
0
6
4
|3
1
1
0
U
n
iR
e
f1
0
0
_H
8
L8
V
9
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=2
2
7
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
V
9
_E
N
TF
U
H
P
 (C
h
) C
D
S 
9
0
6
YP
_0
0
6
3
7
6
1
7
9
3
8
.2
co
n
ti
g0
0
0
6
4
|3
0
1
0
U
n
iR
e
f1
0
0
_H
8
L8
W
0
 P
h
o
sp
h
o
gl
yc
o
la
te
 p
h
o
sp
h
a
ta
se
 n
=1
1
6
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
W
0
_E
N
TF
U
H
A
D
 h
yd
ro
la
se
 (C
h
) C
D
S 
9
0
7
YP
_0
0
6
3
7
6
1
8
0
3
8
.5
co
n
ti
g0
0
0
6
4
|2
9
1
0
U
n
iR
e
f1
0
0
_S
4
E0
B
6
 2
,3
-b
is
p
h
o
sp
h
o
gl
yc
e
ra
te
-d
e
p
e
n
d
e
n
t 
p
h
o
sp
h
o
gl
yc
e
ra
te
 m
u
ta
se
 n
=2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=S
4
E0
B
6
_E
N
TF
C
gp
m
A
3
 (C
h
)
YP
_0
0
6
3
7
6
1
8
1
3
9
.3
co
n
ti
g0
0
0
6
4
|2
8
1
0
U
n
iR
e
f1
0
0
_H
8
L8
W
2
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
2
6
 T
a
x=
En
te
ro
co
cc
u
s 
R
e
p
ID
=H
8
L8
W
2
_E
N
TF
U
H
P
 (C
h
) C
D
S 
9
0
8
YP
_0
0
6
3
7
6
1
8
2
3
5
.6
co
n
ti
g0
0
0
6
4
|2
7
1
0
U
n
iR
e
f1
0
0
_L
2
R
P
N
8
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=L
2
R
P
N
8
_E
N
TF
C
re
gu
la
to
r 
(C
h
) C
D
S 
9
0
9
YP
_0
0
6
3
7
6
1
8
3
3
6
co
n
ti
g0
0
0
6
4
|2
5
1
0
U
n
iR
e
f1
0
0
_H
8
L8
W
4
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
3
1
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
W
4
_E
N
TF
U
H
P
 (C
h
) C
D
S 
9
1
0
YP
_0
0
6
3
7
6
1
8
4
3
7
.3
co
n
ti
g0
0
0
6
4
|2
4
1
0
U
n
iR
e
f1
0
0
_H
8
L8
W
5
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=9
4
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
W
5
_E
N
TF
U
H
P
 (C
h
) C
D
S 
9
1
1
YP
_0
0
6
3
7
6
1
8
5
4
0
.4
co
n
ti
g0
0
0
6
4
|2
3
1
0
U
n
iR
e
f1
0
0
_H
8
L8
W
6
 U
n
ch
a
ra
ct
e
ri
ze
d
 p
ro
te
in
 n
=1
3
3
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
W
6
_E
N
TF
U
H
P
 (C
h
) C
D
S 
9
1
2
YP
_0
0
6
3
7
6
1
8
6
4
2
.7
co
n
ti
g0
0
0
6
4
|2
2
1
0
U
n
iR
e
f1
0
0
_H
8
L8
W
7
 A
B
C
 t
ra
n
sp
o
rt
e
r,
 p
e
rm
e
a
se
 p
ro
te
in
 n
=1
2
3
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
W
7
_E
N
TF
U
la
cG
2
 (C
h
)
YP
_0
0
6
3
7
6
1
8
7
3
8
co
n
ti
g0
0
0
6
4
|2
1
1
0
U
n
iR
e
f1
0
0
_H
8
L8
W
8
 A
B
C
 t
ra
n
sp
o
rt
e
r,
 p
e
rm
e
a
se
 p
ro
te
in
 n
=1
2
8
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
W
8
_E
N
TF
U
la
cF
2
 (C
h
)
YP
_0
0
6
3
7
6
1
8
8
3
6
.7
co
n
ti
g0
0
0
6
4
|2
0
1
0
U
n
iR
e
f1
0
0
_U
2
N
FT
9
 A
B
C
 t
ra
n
sp
o
rt
e
r 
su
b
st
ra
te
-b
in
d
in
g 
p
ro
te
in
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 C
R
L1
8
7
9
 R
e
p
ID
=U
2
N
FT
9
_E
N
TF
C
A
B
C
 t
ra
n
sp
o
rt
e
r 
(C
h
) C
D
S 
9
1
3
YP
_0
0
6
3
7
6
1
8
9
4
1
.7
co
n
ti
g0
0
0
6
4
|1
9
1
0
U
n
iR
e
f1
0
0
_H
8
L8
X
0
 R
e
sp
o
n
se
 r
e
gu
la
to
r 
re
ce
iv
e
r 
d
o
m
a
in
 p
ro
te
in
 n
=9
0
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
X
0
_E
N
TF
U
re
gu
la
to
r 
(C
h
) C
D
S 
9
1
4
YP
_0
0
6
3
7
6
1
9
0
3
8
.2
co
n
ti
g0
0
0
6
4
|1
8
1
0
U
n
iR
e
f1
0
0
_C
9
B
Y7
9
 R
e
sp
o
n
se
 r
e
gu
la
to
r 
re
ce
iv
e
r 
n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 1
,2
3
1
,4
0
8
 R
e
p
ID
=C
9
B
Y7
9
_E
N
TF
C
a
ra
C
-l
ik
e
 (C
h
) C
D
S 
9
1
5
YP
_0
0
6
3
7
6
1
9
1
3
5
.8
co
n
ti
g0
0
0
6
4
|1
7
1
0
U
n
iR
e
f1
0
0
_H
8
L8
X
2
 S
e
n
so
r 
h
is
ti
d
in
e
 k
in
a
se
 n
=1
2
0
 T
a
x=
Fi
rm
ic
u
te
s 
R
e
p
ID
=H
8
L8
X
2
_E
N
TF
U
K
in
a
se
 (C
h
) C
D
S 
9
1
6
YP
_0
0
6
3
7
6
1
9
2
3
7
.8
co
n
ti
g0
0
0
6
4
|1
6
0
0
U
n
iR
e
f1
0
0
_R
2
N
H
B
3
 P
re
p
h
e
n
a
te
 d
e
h
yd
ra
ta
se
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 E
n
G
e
n
0
1
9
1
 R
e
p
ID
=R
2
N
H
B
3
_E
N
TF
C
p
h
e
A
YP
_0
0
6
3
7
6
1
9
3
4
3
.2
co
n
ti
g0
0
0
6
4
|1
5
0
1
U
n
iR
e
f1
0
0
_D
4
R
A
C
9
 S
h
ik
im
a
te
 k
in
a
se
 n
=1
5
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
R
A
C
9
_E
N
TF
C
a
ro
K
YP
_0
0
6
3
7
6
1
9
4
3
8
.6
co
n
ti
g0
0
0
6
4
|1
4
0
1
U
n
iR
e
f1
0
0
_D
4
SM
4
7
 3
-p
h
o
sp
h
o
sh
ik
im
a
te
 1
-c
a
rb
o
xy
vi
n
yl
tr
a
n
sf
e
ra
se
 n
=4
3
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
SM
4
7
_E
N
TF
C
a
ro
A
YP
_0
0
6
3
7
6
1
9
5
4
5
.5
co
n
ti
g0
0
0
6
4
|1
3
0
1
U
n
iR
e
f1
0
0
_L
2
ID
W
0
 P
re
p
h
e
n
a
te
 d
e
h
yd
ro
ge
n
a
se
 n
=3
4
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=L
2
ID
W
0
_E
N
TF
C
ty
rA
YP
_0
0
6
3
7
6
1
9
6
4
0
.7
co
n
ti
g0
0
0
6
4
|1
2
0
1
U
n
iR
e
f1
0
0
_D
4
SM
4
5
 C
h
o
ri
sm
a
te
 s
yn
th
a
se
 n
=3
8
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
SM
4
5
_E
N
TF
C
a
ro
C
YP
_0
0
6
3
7
6
1
9
7
4
5
co
n
ti
g0
0
0
6
4
|1
1
0
1
U
n
iR
e
f1
0
0
_D
4
SM
4
4
 3
-d
e
h
yd
ro
q
u
in
a
te
 s
yn
th
a
se
 n
=1
9
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
SM
4
4
_E
N
TF
C
a
ro
B
YP
_0
0
6
3
7
6
1
9
8
4
2
.3
co
n
ti
g0
0
0
6
4
|1
0
0
1
U
n
iR
e
f1
0
0
_C
2
H
B
L1
 3
-d
e
o
xy
-7
-p
h
o
sp
h
o
h
e
p
tu
lo
n
a
te
 s
yn
th
a
se
 n
=3
1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=C
2
H
B
L1
_E
N
TF
C
a
ro
F
YP
_0
0
6
3
7
6
1
9
9
4
2
.7
co
n
ti
g0
0
0
6
4
|9
0
1
U
n
iR
e
f1
0
0
_D
4
R
A
D
5
 B
e
ta
 g
a
la
ct
o
si
d
a
se
 s
m
a
ll
 c
h
a
in
 n
=2
5
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
R
A
D
5
_E
N
TF
C
la
cZ
YP
_0
0
6
3
7
6
2
0
1
4
1
.1
co
n
ti
g0
0
0
6
4
|8
0
1
U
n
iR
e
f1
0
0
_J
6
YI
B
9
 G
ly
co
sy
l h
yd
ro
la
se
 fa
m
il
y 
2
, T
IM
 b
a
rr
e
l d
o
m
a
in
 p
ro
te
in
 n
=1
5
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=J
6
YI
B
9
_E
N
TF
C
la
cL
YP
_0
0
6
3
7
6
2
0
2
3
9
.1
co
n
ti
g0
0
0
6
4
|7
0
0
U
n
iR
e
f1
0
0
_S
4
EL
1
1
 A
lp
h
a
-g
a
la
ct
o
si
d
a
se
 n
=1
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 O
C
2
A
-1
 R
e
p
ID
=S
4
EL
1
1
_E
N
TF
C
ga
lA
2
YP
_0
0
6
3
7
6
2
0
3
4
0
.2
co
n
ti
g0
0
0
6
4
|6
0
1
U
n
iR
e
f1
0
0
_D
4
R
A
D
8
 G
a
lR
 n
=1
5
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
R
A
D
8
_E
N
TF
C
ga
lR
/p
u
rR
YP
_0
0
6
3
7
6
2
0
4
/0
5
4
1
.8
co
n
ti
g0
0
0
6
4
|4
0
1
U
n
iR
e
f1
0
0
_D
4
R
A
D
9
 A
lp
h
a
/b
e
ta
 h
yd
ro
la
se
 d
o
m
a
in
 p
ro
te
in
 n
=2
6
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
R
A
D
9
_E
N
TF
C
p
e
p
ti
d
a
se
 (C
h
) C
D
S 
9
1
8
YP
_0
0
6
3
7
6
2
0
6
3
9
.3
co
n
ti
g0
0
0
6
4
|3
0
1
U
n
iR
e
f1
0
0
_D
4
SM
3
7
 M
e
th
io
n
in
e
 s
yn
th
a
se
, v
it
a
m
in
-B
1
2
 in
d
e
p
e
n
d
e
n
t 
n
=1
2
 T
a
x=
En
te
ro
co
cc
u
s 
fa
e
ci
u
m
 R
e
p
ID
=D
4
SM
3
7
_E
N
TF
C
a
b
se
n
t 
in
 D
O
4
1
.9
B
e
st
 B
L
A
S
T
 H
it
 A
n
n
o
ta
ti
o
n
 
E
. 
fa
e
c
iu
m
 D
O
 A
n
n
o
ta
ti
o
n
Ana P. Tedim  Chapter 6 
 
243 
 
Table S4 - Annotation of transferable region of E. faecium GEHPH2.1 using Best BLAST Hit and E. 
faecium DO as a reference strain (cont.) 
E. faecium HPH2- wild type strain; E. faecium GE1- recipient strain; E. faecium TCHPH2.2-transconjugant. Blue box with "1"- 
Sequence of the transferred pbp5 genetic plataform present in both the transconjugant (TCHPH2.2) and in wild type strain (HPH2) 
but not in the recipient strain (GE1). White box with "0"- Sequence of the transconjugant (TCHPH2.2) absent either in wild type 
(HPH2) and/or recepient strains (GE1). White box with "1"- Sequence of the transconjugant (TCHPH2.2) also present in the 
recipient strain (GE1) but absent in the wild type (HPH2), thus not being not part of the transfered region. 
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Table S5. Epidemiological data of all E. faecium strains used in this study bioinformatic analysis. 
 
Strain type PBP5 Ampicillin pbp 5
analyzed alleles Susceptibility platform
E980 WT A0 C30 S 94 1.2 Community surveillance Netherlands 1998 IX ABQA01000020.1
 E1972 WT A0 C30 NA 94 1.2 Clinical isolate Germany 2000 IX AHXR01000007.1
E1861 WT A0 C31 S 289 1.2 Hospital surveillance Spain 2001 IX AHXP01000002.1
E1007 WT B C47 S 61 1.2 Community surveillance Netherlands 1998 I AHWP01000007.1
E2039 WT B C47 NA 296 1.2 Clinical isolate Germany 2000 I AHXS01000006.1
D356 WT B C47 NA 361 1.2 NA NA NA I ATIT01000093.1
Com15 WT B C48 S (P) 583 1.2 Community surveillance USA 2006 I ACBD01000014.1
E1604 WT B C66 S 75 1.2 Cheese Norway 1956 I-likel AHXD01000013.1
E1613 WT B C33 S 77 1.3 Fish burger Norway 1964 I AHXE01000011.1
TX1337RF WT B C34 NA 172 1.3 Human GI tract NA NA I AMAA01000092.1
Com12 WT B C21 S (P) 107 1.5 Community surveillance USA 2006 I ACBC01000012.1
TX1330 WT B C21 S 107 1.5 Human GI tract NA NA I ACHL01000102.1, ACHL01000101.1
PC4.1 WT B C21 NA 720 1.5 Community surveillance Australia NA I ADMM0100002.1
E1590 WT B C36 S 163 1.5 Community surveillance Ireland 2001 I AHXC01000004.1
E3083 WT B C47 S 327 1.5 Clinical isolate Netherlands 2000 I AHXZ01000002.1
E3548 WT B C49 S 328 1.5 Clinical isolate Netherlands 2004 I AHYB01000002.1
E1133 WT A1R C11 R 117 2.1a Hospital surveillance USA 2001 VIII-likek AHWR01000016.1
E4453 WT A1R C11 R 192 2.1a Dog Netherlands 2008 I AEDZ01000364.1
U0317 WT A1R C15 R 78 2.1a Clinical isolate Netherlands 2005 I ABSW01000111.1
E2560 WT A1R C15 R 78 2.1a Clinical isolate Netherlands 2006 I  AHYI01000006.1
E6045 WT A1R C15 NA 78 2.1a Clinical isolate Portugal 2010 IV AHYL01000021.1
VRE108 WT A1R C15 NA 192 2.1a Human Denmark 2010 I AIVC01000031.1
1,231,502 WT A1R C15 R 203 2.1a Clinical isolate USA NA I GG688486.1, ACAX01000001.1
S447 WT A1R C15 R 203 2.1a Clinical isolate USA 2004 I JH806868.1, AMAD01000018.1
R446 WT A1R C15 R 203 2.1a Clinical isolate USA 2004 I JH808025.1, AMAJ01000023.1
ERV165 WT A1R C15 NA 203 2.1a Non-clinical isolate NA NA I AMAV01000037.1
E422 WT A1R C15 R 203 2.1a Clinical isolate Ecuador 2006-2008 I-liked ZP_1842609.1, AMAZ01000004.1
Aus0085 WT A1R C15 R 203 2.1a Clinical isolate Australia 2009 I NC_021994.1
V689 WT A1R C15 R 412 2.1a Clinical isolate Venezuela NA I AMAC01000037.1
R499 WT A1R C15 R 412 2.1a Human NA NA I AMAF01000040.1
R496 WT A1R C15 R 412 2.1a Human NA NA I AMAH01000068.1
ERV168 WT A1R C15 NA 412 2.1a Non-clinical isolate NA NA I AMAU01000153.1
ERV161 WT A1R C15 NA 412 2.1a Clinical isolate NA NA I AMAW01000027.1
P1140 WT A1R C15 R 412 2.1a Clinical isolate Peru 2006-2008 I JH808980.1, AMAM01000021.1
VRE13 WT A1R C15 NA 412 2.1a Human Denmark 2010 I AIVE01000014.1
515 WT A1R C15 R 549 2.1a Human NA NA I AMBE01000026.1
E2297 WT A1R C16 NA 117 2.1a Clinical isolate USA 2001 XX AHXV01000007.1
ERV1 WT A1R C24 NA 412 2.1a Human airways NA NA I JH813696.1, AMAY01000126.1
E1321 WT A1R C27 R 78 2.1a Clinical isolate Italy 1999 II-liked AHYF01000006.1
C621 WT A1R C38 NA 412 2.1a Clinical isolate Colombia 2006-2008 I AMBB01000025.1
E0333 WT A1R C4 R 80 2.1a Clinical isolate Israel 1997 XIV-likeg AHWL01000001.1
HM1071 WT A1R C4 R (P) 117 2.1a NA NA 1994 XV AITX01000027.1
E6012 WT A1R C41 NA 78 2.1a Hospital surveillance Latvia 2010 I-likea AHYK01000012.1
E2369 WT A1R C45 R 78 2.1a Clinical isolate Hungary 2005 XIX AHYH01000012.1
GESN71_1 TC A1R C68 R 393 2.1a Piggery Portugal 2006 I This study, JN208885.1
E4389 WT A1R C7 R 78 2.1a Dog Denmark 2007 XIV AHYJ01000006.1, AHYJ01000005.1
E1644 WT A1R C9 R 78 2.1a Clinical isolate Germany 2002 I AHYG01000012.1
UAA724 WT A1R C11 NA 50 2.1b NA France 1993 I AIUO01000031.1
C373 WT A1R C11 R 148 2.1b Community surveillance Portugal 2001 I This study
E4452 WT A1R C11 R 266 2.1b Dog Netherlands 2008 I AEOU01000130.1
E0680 WT A1M C22 S 151 2.1b Pig Germany NA VII AHWN01000006.1
E0045 WT A1M C23 S 9 2.1b Poultry UK 1992 V-likei AHWH01000023.1
E1185 WT A1M C23 S 26 2.1b Clinical isolate France NA V-likei AHWS01000017.1
HM1072 WT A1M C23 R (P) 26 2.1b NA NA 1994 V AITY01000037.1
9731349-1 WT A1M C23 NA 82 2.1b Pig Denmark 1997 V AITA01000032.1
7330381-1 WT A1M C23 NA 133 2.1b Pig Denmark 2001 V AISO01000021.1
9930238-2 WT A1M C23 NA 133 2.1b Pig Denmark 1999 V AITJ01000019.1
841V03 WT A1M C23 S 147 2.1b Pig Denmark 2003 V AISU01000016.1
E1575 WT A1M C23 S 158 2.1b Poultry Belgium 1995 V-likei AHWZ01000016.1
9830565-4 WT A1M C23 NA 185 2.1b Pig Denmark 1998 V AITG01000020.1
7330614-1 WT A1M C23 NA 185 2.1b Pig Denmark 2001 V AISR01000013.1
HM1073 WT A1M C23 R (P) 771 2.1b NA NA 1994 V AITZ01000019.1
E0688 WT A1M C23 S 5 2.1b Pig Spain NA V  AHWO01000001.1
E1552 WT A1M C23 S 5 2.1b Hospital surveillance Netherlands 2002 V AHWW01000007.1
HF50104 WT A1M C23 S 5 2.1b Pig USA NA V AITR01000020.1
HF50215 WT A1M C23 S 5 2.1b Pig USA NA V AITW01000030.1
E0269 WT A1S C28 S 9 2.1b Poultry Netherlands 1996 X AHWK01000016.1, AHWK0100001.1
E0164 WT A1S C28 S 26 2.1b Poultry Netherlands 1996 I AHWJ01000010.1
E1630 WT A1S C32 S 69 2.1b Community surveillance Netherlands 1981 I AHXK01000019.1
E3346 WT A1S C32 S 69 2.1b Clinical isolate Netherlands 2002 I AHYA01000007.1
504 WT A1M C35 R 649 2.1b Human NA NA I AMBM01000063.1
E1627 WT A1M C39 S 66 2.1b Hospital surveillance Netherlands 1979 I AHXJ01000003.1
UAA910 WT A1M C55 NA 66 2.1b NA Switzerland 1996 V-likei AIUS01000017.1
E4215 WT A1M C44 NA 310 2.1b Poultry Sweden 2004 VI AHYE01000033.1
109_A1 WT A1M C55 NA 123 2.1b Human Denmark 1995-1998 V-likej AISL01000023.1
UAA718 WT A1M C55 NA 636 2.1b NA France 1994 V AIUI01000020.1
UAA719 WT A1M C55 NA 636 2.1b NA France 1994 V-likei AIUJ01000018.1
UAA431 WT A1M C56 NA 636 2.1b NA France 1989 V-likei AJDJ01000012.1
UAA715 WT A1M C56 NA 636 2.1b NA France 1994 V-likei AIUG01000030.1
UAA714 WT A1M C56 NA 636 2.1b NA France 1994 V AIUF01000015.1
E1634 WT A1M C57 S 66 2.1b Non-clinical isolate NA 1982 V-likei AHXL01000003.1
F9730129-1 WT A1M C58 NA 245 2.1b Poultry Denmark 1997 XIII AITN01000033.1
UAA722 WT A1M C60 NA 9 2.1b NA France 1994 XII AIUM01000025.1
UAA723 WT A1R C72 NA 50 2.1b NA France 1993 II AIUN01000017.1
GE28798_1 WT A1R C8 R 310 2.1b Clinical isolate Portugal 1999 III This study
E2134 WT A1R C9 R 12 2.1b Poultry Netherlands 2004 I AHXU01000020.1
E1293 WT A1R C9 R 50 2.1b Clinical isolate Italy NA I AHWU01000013.1
UAA1023 WT A1R C9 NA 50 2.1b NA France 1996 I AIZZ01000046.1
UAA1024 WT A1R C9 NA 50 2.1b NA France 1996 I AJAA01000028.1
P1123 WT A1R C15 R 79 2.3a Clinical isolate Peru 2006-2008 I JH810542.1, AMAP01000100.1
P1986 WT A1R C15 R 494 2.3a Clinical isolate Peru 2006-2008 I JH808239.1, AMAK01000017.1
E1573 WT A1R C17 S 21 2.3a Bison Belgium 1994 I AHWX01000001.1
 GMD5E WT A1R C17 NA 92 2.3a Human GI tract NA NA I-likea AJRF02000007.1
D355 WT A1R C17 NA 92 2.3a NA NA NA I ATIU01000010.1
UAA430 WT A1R C17 NA 640 2.3a NA France 1989 I AJDI01000015.1
164306 WT A1M C2 R 190 2.3a Clinical isolate Portugal 1998 V This study, JN208882.1
D353 WT A1M C22 NA 832 2.3a NA NA NA I ATIW01000019.1
Date GeneBank accession numberStrain Clade ST BAPS Source Country
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Table S5. Epidemiological data of all E. faecium strains used in this study bioinformatic analysis 
(cont.). 
 
Strain type PBP5 Ampicillin pbp 5
analyzed alleles Susceptibility platform
UAA210 WT A1M C23 NA 25 2.3a NA France 1986 V AJBN01000025.1
 UAA407 WT A1M C23 NA 25 2.3a NA France 1986 V AJDG01000015.1
E1620 WT A1M C23 S 67 2.3a Clinical isolate Netherlands 1957 I AHXF01000060.1
EnGen0308 WT A1M C23 NA 88 2.3a NA NA NA V AJDM01000021.1
UAA1022 WT A1M C23 NA 88 2.3a NA Switzerland 1996 V-likej AIZY01000017.1
E1626 WT A1R C24 R 92 2.3a Clinical isolate Netherlands 1965 I AHXI01000005.1
E1679 WT A1R C27 R 114 2.3a Clinical isolate Brazil 1998 I-liked ABSC01000284.1
E1904 WT A1R C27 R 210 2.3a Clinical isolate Netherlands 2001 I AHXQ01000004.1
10/96A WT A1R C27 NA 281 2.3a Clinical isolate Brazil 1996 I AXOL01000027.1
E1050 WT A1R C43 S 92 2.3a Community surveillance Netherlands 1998 I AHWQ01000005.1
VAN327 WT A0 C54 S 417 2.3a NA NA NA I-likea ASEC01000004.1
VAN335 WT A0 C54 S 417 2.3a Poultry Denmark 2010 I-likea AIUZ01000021.1
HM1074 WT A1M C59 R (P) 79 2.3a NA NA 1994 V AIUA01000011.1
D344 WT A1R C71 R 25 2.3a Clinical isolate USA NA NA AF362954.1
GMD1E WT A1R C74 NA 92 2.3a Human GI tract NA NA I-likee AJQX01000102.1
E1039 WT A1M C14 S 42 2.3b Community surveillance Netherlands 1998 I-likec  ACOS01000009.1
E0679 WT A1M C23 S 150 2.3b Pig Belgium NA V AHWM01000004.1
H196 WT A1M C1 R 390 3.1 Clinical isolate Portugal 2002 V This study, KC479673.1
1,231,408 WT A1R C11 R 582 3.1 Clinical isolate USA 2006 I-liked GG688547.1, ACBB01000047.1
GEH323_3 TC A1R C12 R 280 3.1 Clinical isolate Portugal 2002 I This study, KC479674.1
E1071 WT A1R C13 S 32 3.1 Hospital surveillance Netherlands 2000 I ABQI01000087.1
P1139 WT A1R C15 NA 280 3.1 Clinical isolate Peru 2006-2008 I JH809204.1, AMAN01000049.1
513 WT A1R C15 R 736 3.1 Human NA NA I AMBG01000061.1
NY1-1 WT A1R C15 NA 736 3.1 Human GI tract NA NA I AJDR01000051.1
NY1-2 WT A1R C15 NA 736 3.1 Clinical isolate NA NA I AJDS01000052.1
NY1-3 WT A1R C15 NA 736 3.1 Human GI tract NA NA I AJDT01000045.1
NY1-4 WT A1R C15 NA 736 3.1 Clinical isolate NA NA I AJDU01000056.1
NY1-5 WT A1R C15 NA 736 3.1 Human GI tract NA NA I AJDV01000041.1
NY1-6 WT A1R C15 NA 736 3.1 Clinical isolate NA NA I AJDW01000039.1
NY3-1 (X2) WT A1R C15 NA 736 3.1 Human GI tract NA NA I AJDX01000030.1
NY2-1 (X2) WT A1R C15 NA 736 3.1 Human GI tract NA NA I ASWQ01000008.1
NY2-2 (X2) WT A1R C15 NA 736 3.1 NA NA NA I ASWR01000005.1
NY2-3 (X2) WT A1R C15 NA 736 3.1 Clinical isolate NA NA I ASWS01000005.1
R497 WT A1R C15 R 752 3.1 Human NA NA I AMAG01000075.1
E1623 WT A1R C17 S 22 3.1 Clinical isolate Netherlands 1960 I AHXH01000005.1
VAN342 WT A1R C17 S 22 3.1 Poultry Denmark 2010 I AIVA01000020.1
H17243 WT A1R C17 NA 22 3.1 Human Denmark 1995 I AITO01000025.1
D352 WT A1R C17 NA 32 3.1 NA NA NA I ATIX01000015.1
E1576 WT A1R C17 S 159 3.1 Oyester South Africa 2001 I AHXA01000008.1
GEHPH2_1 TC A1R C20 R 125 3.1 Clinical isolate Portugal 2007 I This study
E1636 WT A1M C23 R 106 3.1 Clinical isolate Netherlands 1961 I-likeb ABRY01000062.1
503 WT A1R C25 R 280 3.1 Human NA NA I JH809465.1, AMBN01000040.1
H352 WT A1R C4 R 280 3.1 Clinical isolate Portugal 2000 II This study
E1622 WT A1R C42 S 104 3.1 Mouse Netherlands 1959 I AHXG01000003.1
VAN219 WT A1M C62 S 784 3.1 Poultry Denmark 2010 I AIUW01000023.1
VAN222 WT A1M C62 S 784 3.1 Poultry Denmark 2010 I AIUX01000013.1
VAN476 WT A1M C62 S 785 3.1 NA NA NA I ASEB01000017.1
P1190 WT A1R C7 R 125 3.1 Clinical isolate Peru 2006-2008 XVII JH808818.1, AMAL01000087.1
NRRL B-2354 (ATCC WT A1R C73 S 860 3.1 Milk and dairy utensils USA 1927 I CP004063.1
E1578 WT A1R C17 S 160 3.2 Pig Germany 2001 I AHXB01000009.1
7330446-2 WT A1M C23 NA 6 3.2 Pig Denmark 2001 V AISP01000010.1
9730357-1 WT A1M C23 NA 6 3.2 Pig Denmark 1997 V AISZ01000017.1
9730219-1 WT A1M C23 NA 6 3.2 Pig Denmark 1997 V AISY01000007.1
9731352-4 WT A1M C23 NA 6 3.2 Pig Denmark 1997 V AITB01000017.1
9830512-2 WT A1M C23 NA 6 3.2 Pig Denmark 1998 V AITE01000025.1
HF50204 WT A1M C23 NA 6 3.2 Pig USA NA V AITV01000023.1
7330519-3 WT A1M C23 NA 6 3.2 Pig Denmark 2001 V AISQ01000013.1
7330884-2 WT A1M C23 NA 6 3.2 Pig Denmark 2001 V-likej AISS01000009.1
7430166-3 WT A1M C23 NA 6 3.2 Pig Denmark 2002 V AIST01000016.1
9830091-5 WT A1M C23 NA 6 3.2 Pig Denmark 1998 V AITC01000013.1
9931110-4 WT A1M C23 NA 6 3.2 Pig Denmark 1999 V AITK01000010.1
A17 WT A1M C23 NA 6 3.2 Pig Denmark 1995 V-likej AITL01000019.1
E8SV3 WT A1M C23 NA 6 3.2 Pig Denmark 1995 V AITM01000017.1
H17575 WT A1M C23 NA 6 3.2 Human Denmark 1995 V AITQ01000016.1
S658-3 WT A1M C23 NA 6 3.2 Pig Denmark 2002 V AIUD01000018.1
HF50105 WT A1M C23 S 6 3.2 Pig USA NA V AITS01000013.1
HF50106 WT A1M C23 S 6 3.2 Pig USA NA V AITT01000026.1
HF50203 WT A1M C23 S 6 3.2 Pig USA NA V AITU01000017.1
509 WT A1R C11 R 17 3.3a Human NA NA VIII-likek AMBJ01000257.1
511 WT A1R C15 R 17 3.3a Human NA NA I AMBH01000038.1
514 WT A1R C15 R 17 3.3a Human NA NA I AMBF01000038.1
VRE110 WT A1R C15 NA 18 3.3a Human Denmark 2010 I AIVD01000049.1
R494 WT A1R C15 R 664 3.3a Human NA NA I AMAI01000028.1
1,231,410 WT A1R C16 R 17 3.3a Clinical isolate USA NA I-liked  GG962468.1, ACBA01000014.1
R501 WT A1R C16 R 17 3.3a Human NA NA I AMAE01000246.1
ERV69 WT A1R C16 NA 17 3.3a Human NA NA I AMAR01000209.1
ERV38 WT A1R C16 NA 17 3.3a Human NA NA I AMAS01000051.1
DOm WT A1R C17 R 18 3.3a Clinical isolate USA 1992 XI NC_017960.1
C68 WT A1R C18 R 16 3.3a Hospital surveillance USA 1996 VIII 66703717.1, ACJQ01000082.1
GEE4_1 TC A1R C19 R 132 3.3a Hospital sewage Portugal 2011 II This study, JN208889.1
UAA950 WT A1R C24 NA 16 3.3a NA USA 1996 I AJDP01000022.1
UAA949 WT A1R C24 NA 16 3.3a NA USA 1996 XVI AJDO01000031.1
UAA951 WT A1R C24 NA 16 3.3a NA USA 1996 XVI AIZT01000035.1
E417 WT A1R C24 R 17 3.3a Clinical isolate Ecuador 2006-2008 I JH813696.1, AMBA01000202.1
ERV26 WT A1R C26 NA 17 3.3a Human airways NA NA I JH809881.1, AMAT01000050.1
E1392 WT A1R C27 R 64 3.3a Hospital surveillance UK 2000 I AHWV01000002.1
ERV102 WT A1R C38 NA 17 3.3a Human oral cavity NA NA I JH811939.1, AMAX01000171.1
E1162 WT A1R C4 R 17 3.3a Clinical isolate France NA NA ABQJ01000017.1
TX0133a04 WT A1R C4 R 17 3.3a Clinical isolate USA NA II-likeg AEBC01000061.1
TX0133C WT A1R C4 R 17 3.3a Clinical isolate USA NA II-likeg AEBG01000194.1
TX0082 WT A1R C4 R 17 3.3a Clinical isolate USA NA XIV-likeg AEBU01000140.1
TX0133B WT A1R C4 R 17 3.3a Clinical isolate USA NA II-likeg AECI01000046.1
TX0133a01 WT A1R C4 R 17 3.3a Clinical isolate USA 2006 II-likeg AECJ01000122.1
UAA825 WT A1R C4 NA 17 3.3a NA France 1996 II-likec AIUQ01000018.1
UAA725 WT A1R C4 NA 17 3.3a NA France 1994 II AIUP01000033.1
BAPS Source Country Date GeneBank accession numberStrain Clade ST
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Table S5. Epidemiological data of all E. faecium strains used in this study bioinformatic analysis 
(cont.). 
 
Abbreviations: ND- not determined; NA-not available; USA-United States of America; UK-United Kingdom; WT-wild type; R-
resistant; S-susceptible; R(P)-Resistance to penicillin, ampicillin resistance phenotype unkown; S(P)- susceptible to penicillin. aextra 
stop codon in FtsW; bsequenced by NGS not possible to identify sequence before pbp5 gene; cextra stop codon in psr gene; 
dsequenced by NGS not possible to identify sequence before ftsW gene; eextra stop codon in ftsW gene;sequenced by NGS not 
possible to identify sequence after ion efflux gene; fsequenced by NGS not possible to identify sequence before HisPh; gsequenced 
by NGS not possible to identify sequence before ISEfm1; hsequenced by NGS not possible to identify sequence after ISEfm1 and 
before HisPh gene; isequenced by NGS not possible to identify sequence before ISEf1; jdifferent genetic background before ISEf1; 
ksequenced by NGS not possible to identify sequence after ISEnfa3;  lextra stop codon in pbp5 gene; mE. faecium DO strain is 
classified as ampicillin resistance (MIC=16 mg/L) by Galloway-Peña et al [Antimicrob Agents Chemother. 2011,  55(7): 3272–3277]. 
The other E. faecium with amino acid combination of C17 were classified as susceptible by Willems et al. [mBio. 2012, 3(4): 
e00151-12]; nE1636 was classified as ampicillin resistant (CMI=25mg/L) though the pbp5 sequence did not present mutations 
associated with ampicillin resistance the authors suggest that this low level resistance migh be related with other mechanism of 
resistance (van Schaik et al BMC genomics. 2010, 11:239). 
 
Strain type PBP5 Ampicillin pbp 5
analyzed alleles Susceptibility platform
UAA911 WT A1R C4 NA 17 3.3a NA Switzerland 1996 II-likef AIUT01000036.1
UAA909 WT A1R C4 NA 17 3.3a NA Switzerland 1996 II-likeh AIUR01000020.1, AIUR01000021.1
UAA1007 WT A1R C4 NA 17 3.3a NA NA 1996 II AIZV01000020.1, AIZV01000021.1
UAA1484 WT A1R C4 NA 17 3.3a NA NA 1992 II AJAF01000050.1
UAA720 WT A1R C4 NA 17 3.3a NA France 1993 II AIUK01000047.1
UAA952 WT A1R C4 NA 17 3.3a NA USA 1996 II AIZU01000018.1
GE70411_2 TC A1R C4 R 670 3.3a Clinical isolate Portugal 1997 II This study, JN208888.1
HPH6 WT A1R C5 R 18 3.3a Clinical isolate Portugal 2007 II This study, KC479675.1
529940 WT A1R C6 R 16 3.3a Clinical isolate Portugal 2000 II This study, JN208883.1
TX0133A WT A1R C64 R 17 3.3a Clinical isolate USA 2006 II-likeg AECH01000021.1
VRE84 WT A1R C69 NA 17 3.3a Human Denmark 2010 I AIVF01000028.1
AUS0004 WT A1R C7 R 17 3.3a Clinical isolate Australia 1998 II NC_017022.1
UAA1025 WT A1R C7 NA 17 3.3a NA France 1996 II-likeg AJAB01000030.1
UAA1019 WT A1R C7 NA 17 3.3a NA NA 1996 II AIZX01000035.1
1,230,933 WT A1R C7 R 18 3.3a Clinical isolate USA 2005 NA ACAS01000028.1
P1137 WT A1R C7 R 18 3.3a Clinical isolate Peru 2006-2008 XVIII AMAO01000169.1
510 WT A1R C7 R 18 3.3a Human NA NA XIV-likeg AMBI01000132.1
ERV99 WT A1R C7 NA 18 3.3a Clinical isolate NA NA XIV-likeg AMAQ01000006.1
C1904 WT A1R C7 NA 18 3.3a Clinical isolate Colombia 2006-2008 XIV-likeg AMBD01000237.1
C497 WT A1R C7 R 18 3.3a Clinical isolate Colombia 2006-2008 XIV-likeg AMBC01000119.1
506 WT A1R C7 R 18 3.3a Human NA NA II-likeg JH813945.1, AMBK01000250.1
E1731 WT A1R C7 R 18 3.3a Clinical isolate Tanzania NA II AHXO01000011.1
E2883 WT A1R C7 R 18 3.3a Clinical isolate Netherlands 2002 XIV-likeg AHXX01000007.1
UAA1433 WT A1R C7 NA 18 3.3a NA France 2000 II AJAE01000027.1
VD79C1_5 TC A1R C7 R 18 3.3a Community surveillance Portugal 2001 II This study
GEE49_1 TC A1R C8 R 132 3.3a Hospital sewage Portugal 2001 III This study, JN208884.1
SN449 WT A1R C8 R 132 3.3a Piggery Portugal 2007 III This study, JN208887.1
E197 WT A1R C8 R 368 3.3a Hospital sewage Portugal 2001 III This study
UAA947 WT A1R C9 NA 18 3.3a NA USA 1996 I AIZR01000020.1
UAA716 WT A1M C22 NA 87 3.3b NA France 1994 VII AIUH01000039.1
E0120 WT A0 C37 S 27 3.3b Clinical isolate Netherlands 1995 I AHWI01000003.1
E1574 WT A0 C37 S 27 3.3b Dog Belgium 1995 I AHWY01000003.1
E2071 WT A0 C37 S 27 3.3b Poultry Denmark 2001 I AHXT01000013.1
E2966 WT A1R C17 NA 326 4 Clinical isolate Netherlands 2005 I AHXY01000021.1
E2620 WT B C29 S 331 4 Clinical isolate Netherlands 2006 I  AHXW01000008.1
E1258 WT A1S C40 S 127 7.1 Clinical isolate Spain NA I  AHWT01000005.1
D357 WT A1S C40 NA 127 7.1 NA NA NA I ATIS01000033.1
1,231,501 WT B C47 S 52 7.1 Clinical isolate USA 2005 I ACAY01000033.1
1,141,733 WT B C51 S 52 7.1 Clinical isolate USA 2005 I ACAZ01000019.1
UAA944 WT A1R C70 NA 20 7.1 NA USA 1996 XXI AIUU01000031.1
UAA945 WT A1R C70 NA 20 7.1 NA USA 1996 XXI AIUV01000032.1
VAN345 WT A1R C75 S 38 7.1 Poultry Denmark 2010 I AIVB01000020.1
VAN332 WT A1R C75 S 38 7.1 Poultry Denmark 2010 I AIUY01000015.1
SE97F1 WT A1R C10 R NA NA Poultry Portugal 2001 I This study, KC479676.1
GMD4E WT A1R C17 NA New NA Human GI tract NA NA I-likea AJRD01000046.1
GMD2E WT A1R C17 NA New NA Human GI tract NA NA I-likea AJQZ01000046.1
GMD3E WT A1R C17 NA New NA Human GI tract NA NA I-likea AJRB03000042.1
H17494 WT A1R C17 NA NA NA Human Denmark 1995 I AITP01000026.1
7230532-1 WT A1M C23 NA New NA Pig Denmark 2000 V AISN01000018.1
KH36SYN WT A1M C23 NA NA NA Human Netherlands NA V AIUC01000009.1
EnGen0305 WT A1M C23 NA New NA NA NA NA V-likei AJDL01000022.1
UAA721 WT A1M C23 NA New NA NA France 1994 V-likej AIUL01000016.1
SN194 WT A1R C3 R NA NA Piggery Portugal 2006 V This study, JN208886.1
BM4107 WT B C46 S NA NA Clinical isolate NA NA I AF364092.1
D63r WT B C50 S (P) NA NA Clinical isolate France NA NA X84860.1
505 WT A0 C52 R New NA Human NA NA I AMBL01000029.1, AMBL01000072.1
UAA1280 WT A0 C53 NA New NA NA France 1998 I AJAD01000011.1
D366 WT A1M C61 S NA NA NA NA NA NA X84859.1
9439 WT A1R C63 R NA NA NA NA NA NA X92687.1
EFM-1 WT A1M C65 R (P) NA NA NA NA NA NA X84861.1
H80721 WT A1R C67 R NA NA NA NA NA NA X84862.1
BM4538 WT A1R C7 NA NA NA Clinical isolate France 2001 II AXOJ01000014.1
NEF1 WT A1R C7 R NA NA NA France 2009 II-likeh AXOK01000016.1, AXOK01000017.1
Strain Clade ST BAPS Source Country Date GeneBank accession number
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ABSTRACT 
Background: Vancomycin resistance Enterococcus faecium has increasingly been reported worldwide. 
The predominant genotype, Tn1546-vanA, is mostly located on RepA_N and Inc18 family plasmids. The 
aim of this study was to determine the fitness cost imposed by the acquisition of Tn1546-
plasmids in different hosts.  
Methods: Globally spread Tn1546-plasmids containing RepA_N (3 pRUM, 2 pLG1) and/or Inc18 (n=4) 
and/or pHTβ (n=1) replication modules and prototype plasmids RepA_N (pRUM) and Inc18 (pRE25, 
pIP501) were analyzed. Plasmid transferability and fitness cost were assessed using E. faecium (GE1RF, 
64/3) and Enterococcus faecalis (JH2-2, FA202, UV202) strains. Growth curves were performed using 
Bioscreen C and Relative Growth Rates were calculated in presence/absence of vancomycin. Plasmid 
stability was analysed after 300 generations. Whole genome sequencing (Illumina MiSeq) of both non-
evolved and evolved strains (GE1RF and 64/3, n=49) was performed. SNP calling was preformed using 
breseq software using non-evolved strains for comparison. 
Results: All E. faecium plasmids were transferred into different E. faecium backgrounds but only 
plasmids carrying Inc18 family modules were transferred into E. faecalis. Most Tn1546-plasmids and 
prototype-plasmids reduced the host͛s fitŶess ;-2%-18%). Fitness cost of Tn1546 expression varies 
according with the transposon variant and background (9%-49%). Stability of Tn1546-plasmids was 
verified in all cases, sometimes with loss of phenotypic resistance and plasmid modules. Mutation 
analysis revealed point mutations and/or indels mostly in the chromosome of evolved strains associated 
with essential bacterial functions (e.g. DNA replication and repair, carbohydrate and amino acid 
metabolism). 
Conclusions: The host-specificity of E. faecium Tn1546-plasmids might play an important role in the 
confinement of vancomycin resistance almost exclusively to this species. Even though Tn1546-plasmids 
seem to impose a significant burden to the host strain, their stability in the absence of selective pressure 
and high conjugation rates might explain their maintenance E. faecium populations, perpetuating the 
presence of VRE strains worldwide.  
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INTRODUCTION 
Vancomycin Resistant Enterococci (VRE) have increasingly been reported worldwide since their first 
description in the late 1980s, and have become endemic in many geographical areas 
1
. Resistance to 
vancomycin has been mostly associated with Enterococcus faecium while vancomycin resistant 
Enterococcus faecalis remains infrequent 
2,3
.  
In E. faecium several genotypes have been associated with vancomycin resistance, being vanA among 
the most prevalent 
1,2
. The vanA gene cluster is part of Tn1546, a member of the Tn3 family, usually 
associated with conjugative plasmids 
1,4–6
. A number of Tn1546 variants have been described but only 
those containing IS1216V and ISEf1 are widely distributed among human, animal, and environmental 
strains 
7–9
. Tn1546 is frequently associated with enterococcal plasmids belonging to Inc18 (pIP501 and 
pRE25 derivatives) and RepA_N (derivatives of narrow-host plasmids pRUM and pLG1) families 
1,5,10–12
. 
The localization of Tn1546 in broad host range plasmids, as those of the Inc18 family, is a potential 
threat for dissemination to other bacterial species, as Staphylococcus aureus 
2,5,12
. 
Because of the frequent location of Tn1546 in broad-host plasmids with high conjugative efficiency, the 
tight association of only few types of Tn1546 with particular hospital associated BAPS groups (BAPS 2.1a, 
3.3a1 and 3.3a2), and the infrequent transfer to other species was unexpected, and remains to be 
explained. A possible hypothesis is that various Tn1546 variants could spread in their plasmid vehicles 
across bacterial populations, but only a limited number of hosts ensure their stable maintenance 
1,12–14
. 
These hosts are probably those with a higher intrinsic fitness, and/or resistant to other antibiotics, 
and/or where the uptake of plasmids harboring particular Tn1546 variants might impose a lower fitness 
cost, in the absence or during antibiotic exposure.  
Only a few studies have evaluated the fitness cost of vancomycin resistance and/or Tn1546 carrying 
plasmids, being frequently limited to a single recipient strain and/or involving insufficiently 
characterized plasmids 
15–20
. However, when the fitness cost of vancomycin resistance (vanA) was 
evaluated in S. aureus, in the presence and absence of induction, it was shown that in the absence of 
the inducer (vancomycin) the fitness cost of Tn1546 was negligible and probably due to basal induction 
of the vancomycin resistance operon. However, an important reduction of bacterial host fitness was 
observed when the vancomycin resistance operon was induced by vancomycin, probably due to the 
complex metabolic changes associated with the expression of the vanA operon 
17
. A few studies 
performed in E. faecium regarding the fitness cost of Tn1546 carrying plasmids showed that these 
plasmids reduce the fitness of the host. However, they appear to be stable, and the initial fitness cost 
seems to be rapidly reduced by compensatory changes in sequential evolution experiments 
15,16
. 
The aim of this study was to determine the fitness cost imposed by the acquisition of worldwide 
disseminated enterococcal plasmids carrying different Tn1546 variants in different hosts. The intrinsic 
fitness of different E. faecium host specific populations was also studied. 
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MATERIAL AND METHODS 
Tn1546-vanA plasmids. E. faecium strains harbouring highly transferable narrow or broad host 
plasmids involved in the spread of Tn1546-vanA worldwide were analysed (Figure 1). These strains were 
classified as E. faecium BAPS 3.3a1 (ST18, ST132), BAPS 3.3a2 (ST17, ST16), BAPS 2.1a (ST78) BAPS 2.1b 
(ST5) and BAPS 2.3a (ST25) 
13,14
. The Tn1546-vanA plasmids selected for this study have been known for 
their apparent epidemicity and persistence in the hospital setting 
21
. These plasmids contained 
sequences associated with Inc18 (rep1 and rep2), RepA_N (rep17 and rep20) and pHTβ (rep22) plasmid 
families. Prototype plasmids for Inc18 [pIP501 and pRE25 (GenBank NC_008445)] and RepA_N plasmid 
families [pRUM (GenBank NC_005000)] were also studied for comparative purposes 
22–24
. 
Plasmid analysis and transferability. Plasmid content was detected by Pulsed Field Gel 
Electrophoresis (PFGE) of S1 nuclease digested genomic DNA and characterization of replication initiator 
proteins (REP), relaxases (REL) and maintenance systems (partition and toxin-antitoxin systems) by PCR, 
hybridization and further sequencing 
21,25–28
.  
Transferability of plasmids among enterococcal species was determined by filter mating experiments at 
1:1 donor-recipient ratio and overnight incubation. Transconjugants were selected on Brain Heart 
Infusion (BHI) agar plates containing fusidic acid (20μg/mL), rifampicin (30μg/mL) and vancomycin 
(6μg/mL) or erythromycin (20μg/mL) after incubation at 37ºC (24h) 29,30. Conjugation frequencies were 
calculated as the proportion of transconjugants per recipient CFUs. Transconjugants were confirmed by 
PCR detection of vanA and ermB genes 
31,32
; and by PFGE of SmaI-digested genomic DNA (Takara Bio 
Inc., Shiga, Japan) 
33
. Rifampicin and fusidic acid-resistant E. faecium GE1RF (ST515, BAPS 2.3b) and 
64/3(ST21, BAPS 2.3a), and E. faecalis JH2-2, FA202 and UV202 (all belonging to ST8, BAPS 1), were used 
as recipient strains.  
Growth kinetics. The growth kinetics of field E. faecium isolates (see supplementary table S1), 
laboratory receptor E. faecium strains GE1RF and 64/3 and E. faecalis strains JH2-2, and transconjugants 
harbouring Tn1546-vanA carrying plasmids were performed in the incubator/spectrophotometer 
Bioscreen C (ThermoLab Systems, Vantaa, Finland) adapting the method described by Foucault et al 
(Foucault et al., 2009). Briefly, strains were grown overnight (18h) at 37ºC in BHI broth with vancomycin 
(1/50 of the MIC) and without vancomycin. Overnight cultures were diluted 1:1000 into fresh BHI broth, 
approximately 10
5
 bacteria/mL, and 300µl of this bacterial suspension was transferred into a 100-well 
microplate. Optical density (OD) was measured at 600nm every 15 min for 20h. In order to guarantee 
culture optical homogeneity the plates were agitated for 10s before each OD measurement. For each 
strain, 5 biological replicates were essayed in duplicate in each experiment (10 readings per strain per 
experiment). Two independent experiments were performed for all strains analysed 
17
. Conditions of 
induction or non-induction with vancomycin were maintained throughout the entire experiment. 
Variants of this procedure were used to analyze possible changes in the E. faecium growth dynamics at 
42ºC.  
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Growth rates (µ) were determined in the interval estimated to be exponential phase using the 
GrowthRates 2.1 program 
34
. The fitness cost of the plasmids and expression of Tn1546-vanA was 
determined by calculating the RGRPL and RGRTn using the following formulas: 
����݈ = �ሺݐݎ�݊ݏܿ݋݆݊ݑ݃�݊ݐ �݅ݐℎ݋ݑݐ ݅݊݀ݑܿݐ݅݋݊ሻ�ሺ݅ݏ݋݃݁݊݅ܿ ݌݈�ݏ݉݅݀ ݂ݎ݁݁ ݏݐݎ�݅݊ሻ  
����݊ = �ሺݐݎ�݊ݏܿ݋݆݊ݑ݃�݊ݐ �݅ݐℎ ݅݊݀ݑܿݐ݅݋݊ሻ�ሺݐݎ�݊ݏܿ݋݆݊ݑ݃�݊ݐ �݅ݐℎ݋ݑݐ ݅݊݀ݑܿݐ݅݋݊ሻ 
Plasmid stability. Three independent colonies from each strain (receptors and transconjugants, see 
supplementary Figure S1) were inoculated into 5mL of BHI broth and incubated at 37ºC overnight (22-
24h). Subsequently, cultures were diluted 1:1000 into fresh BHI broth and incubated at 37ºC overnight 
(22-24h). This procedure was repeated up to 300 generations. Bacterial cultures were plated at 0, 100, 
200 and 300 generations on BHI agar plates and subsequently 100 colonies of each plate were randomly 
picked and re-streaked into BHI agar plates and BHI agar plates supplemented with the appropriate 
antibiotic (6μg/mL of vancomycin for strains containing pH182, pH311 and pBM4165, or 20μg/mL of 
erythromycin for the strains containing pIP501, pRE25 and pRUM) 
22–24
. Plasmid loss frequency was 
initially calculated by determining the ratio of susceptible colonies to the total number of colonies. 
Antibiotic susceptibility (stability/loss) was further confirmed phenotypically by disc diffusion method, 
and genotypically by PCR detection of vanA and ermB genes 
31,32
. The presence/absence of plasmid was 
confirmed by PFGE-S1 nuclease digested genomic DNA as well as by confirming the presence of all 
plasmid modules previously observed in each of the plasmids studied as described above (Table 1).  
Analysis of evolved strains. Whole genome sequencing (WGS, Illumina MiSeq) of 49 transconjugants, 
24 E. faecium GE1 (7 non-evolved and 17 evolved strains) and 25 E. faecium 64/3 (7 non-evolved and 18 
evolved strains), obtained in the plasmid stability experiment was performed. Sequencing was carried 
out with an Ilumina MiSeq platform to obtain 100-200 bp paired-end reads (supplementary Figure S1). 
DNA extraction (Promega Wizard Genomic DNA Purification kit) was done according manufacturer 
instructions. For non-evolved strains, reads were revised and sequencing errors were corrected with 
Lighter software 
35
, the best k-mer length was estimated with KmerGenie 
36
, and the final assembly was 
performed with Spades 
37
. SNPs analysis of evolved strains was performed against non-evolved strains 
using Breseq v0.26.1 pipeline (http://barricklab.org/twiki/bin/view/Lab/ToolsBacterial 
GenomeResequencing)
38
. Protein functions were assigned according Uniprot and KEGG databases. 
Plasmid analysis of non-evolved strains was performed by PLACNET in order to determine both plasmid 
content in these strains and to identify the location of mutations in evolved strains 
39
.  
Clonal relatedness and genome size. E. faecium field strains used in this study and their 
epidemiological characteristics are listed in Table S1. Clonal relatedness between E. faecium stains was 
established by PFGE using SmaI-digested genomic DNA (Takara Bio Inc., Shiga, Japan), multilocus 
sequence typing (MLST) and Bayesian analysis of population structure (BAPS) as previously described 
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13,14,33,40
. Genome size was established by PFGE using AscI-digested genomic DNA (New England Biolabs, 
Ipswich, MA, USA). The following electrophoresis conditions were used: 10 to 40s pulses for 26h at 14ºC 
and 6V/cm
2
. OG1 was used a DNA weight marker 
41,42
. 
Statistical analysis. Statistics were calculated using R analytical Studio 
43
, ANOVA and Tukey's honest 
significance test (for multiple all in all comparison). Chi-Square test was used when comparing two 
populations. Values of p<0.01 were considered statistically significant. 
RESULTS 
Fitness cost of Tn1546-vanA carrying plasmids in laboratory E. faecium and E. faecalis 
strains.  
Both Tn1546-vanA carrying plasmids and prototype plasmids of the Inc18 and RepA_N plasmid families 
analysed in this study conferred different fitness cost on distinct clonal backgrounds (Figure 1 and 2). 
With the exception of pE1644 (rep20+rel6, fitness gain of 2.0%, not statistically significant), all tested E. 
faecium Tn1546-vanA carrying plasmids conferred a fitness cost to E. faecium GE1RF (n=7, ranging from 
4.4% to 9.2%) and also in E. faecium 64/3 (n=5), although to a lesser extent (0.3% and 7.7%). The two E. 
faecium plasmids that transferred to E. faecalis JH2-2 (pBM4165 and pH305) showed a high fitness cost 
in this strain (17.5% and 39.4%, respectively). 
Among plasmids of the Inc18 family, pIP816 (rep1+rep2+rel6+TAAxe-Txe) exhibited the highest fitness cost 
values in both GE1RF (9.2%) and 64/3 (7.7%). Conversely, pIP501 and pRE25 did not impose a significant 
cost to the E. faecium strains studied, only pRE25 showed a significant fitness cost in E. faecalis JH2-2 
(13.9%). Other mosaic plasmids containing plasmid modules of the Inc18 family (pE1651, rep1; pBM4165, 
rep1+rep2; pH311, rep1+rep2+rel6+TAεζ and pH305, rel6+TAεζ), reduced the fitness of E. faecium GE1RF 
[6.8%, 6.9%, 4.4% (not statistically significant) and 4.6%, respectively]. Aside from pIP816, the only 
plasmid that showed a significant fitness cost in E. faecium 64/3 was also an Inc18+RepA_N plasmid 
(pBM4165, 5.0%) (Figure 1 and 2).  
The RepA_N-pRUM family plasmid studied (pH182, rep17+rel6) also conferred a significant fitness cost to 
E. faecium GE1RF (5.9%) as did the pRUM prototype in both E. faecium backgrounds (GE1RF - 18.4%, 
and 64/3 – 4.2%).  
Fitness cost of Tn1546-vanA expression in isogenic E. faecium and E. faecalis backgrounds.  
The fitness cost of Tn1546-vanA expression varies according with the transposon variant being 
expressed and with the clonal and plasmid backgrounds in which they are located (Figures 1 and 2).  
The expression of Tn1546 variant A when located in pBM4165 (Inc18+RepA_N) conferred a fitness cost 
of 9.4%, in E. faecium GE1RF, 13.6% in E. faecalis JH2-2 and no cost in E. faecium 64/3. 
Ana P. Tedim  Chapter 7 
 
255 
 
 
Figure 1. Tn1546-vanA and prototype plasmids used in this study.  
Rep1 – rep1/pIP501; Rep2 – rep2/pRE25; Rep17 – rep17/pRUM; Rep22 – repϮϮ/pHTβ; Rel3 – rel3/pRUM; Rel6 – rel6/pEF1; Rel7 – rel7/pIP501; Rel8 – 
relϴ/pHTβ; ωεζ – Toxin-Antitoxin system of plasmid pSM19035; Axe-Txe – Toxin-Antitoxin system of plasmid pRUM. *statistically 
significant. Plasmid in bold - plasmid carrying Tn1546-vanA. Abbreviations: ND – Not Determined; NO TC – No transconjugant was 
obtained; No Van – No vancomycin induction; Van – Vancomycin induction; RGR – Relative Growth Rate; PL – Plasmid; Tn – 
Transposon Tn1546-vanA. 
The Tn1546 variants PP-4 (containing an ISEf1 insertion in the vanX-vanY intergenic region), when 
expressed in pH182 (RepA_N), and variant D, in plasmid pH305 (Inc18+RepA_N), conferred a similar 
fitness cost in E. faecium GE1RF and E. faecium 64/3 (14.1% vs 11.3% and 13.8% vs 17.2%, respectively). 
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Interestingly, in the case of E. faecalis JH2-2 the expression of Tn1546 variant D improves the fitness of 
the background by 18.0% (Figures 1 and 2). 
Other transposon variants exhibiting indels and duplications as Tn1546 variant PP-23, in pH311 
(Inc18+RepA_N) or Tn1546 variant X, in pE1651 ;IŶĐϭϴ+pHTβ) imposed a high fitness cost in GE1RF 
(48.3% vs 49.3%) and 64/3 strains (29.1%, only analysed for pH311) (Figures 1 and 2). 
 
Figure 2. Box and whiskers plot representing growth rates of E. faecium Tn1546-vanA carrying 
plasmids with and without vancomycin induction and prototype plasmids (pRE25, pIP501 and pRUM).  
Plasmid and Tn1546-vanA expression was tested in different backgrounds (E. faecium GE1RF and 64/3 and E. faecalis JH2-2) when 
plasmids conjugate into those backgrounds. Plasmids are classified according with RIP plasmid family and Tn1546 type. 
*statistically significant. 
Plasmid Host-Range.  
Plasmid transferability rates (conjugation frequencies) varied among plasmids and, for the same 
plasmid, between the recipients strains used. Most of E. faecium plasmids transferred at high 
frequencies (10
-2
 to 10
-4
) into all E. faecium receptors used. Two plasmids (pH305 and pBM4165) 
transferred to both E. faecalis and E. faecium at different frequencies (10
-7
 and 10
-5
,
 
respectively) (Figure 
1). 
While the Inc18 family prototype plasmids pRE25 and pIP501 were transferred from E. faecalis to most 
of the E. faecalis and E. faecium recipients used (10
-2
 to 10
-5
); the original pRUM plasmid from E. faecium 
was only able to be transferred into E. faecium reĐipieŶts ;≈ϭϬ-5) (Figure 1). 
In host stability experiments.  
E. faecium Tn1546-carrying plasmids were highly stable up to 300 generations in both E. faecium GE1RF 
and E. faecium 64/3, even though the presence of these plasmids was not always associated with a 
resistance phenotype. In general all plasmids were more stable in E. faecium 64/3 than in E. faecium 
GE1RF (Figure 3 and S1). 
For the plasmid pH311, the few E. faecium GE1RF and E. faecium 64/3 isolates for which vancomycin 
resistant phenotype reversion occurred (1.0-3.0%) contained a plasmid carrying the same backbone, and 
the vanA gene (3/5). Characterization of Tn1546 showed changes in its structure that might be related 
with the absence of vancomycin resistance. For strains harbouring pH182, the phenotype reversion also 
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occurred sporadically (1.0-4.0%) but in this case, it was accompanied by the loss of Tn1546 and changes 
in plasmid size in most cases, although without the loss of the plasmid and plasmid modules. 
Conversely, the reversion to a vancomycin susceptible phenotype was frequent (up to 100%) in strains 
containing plasmid pBM4165 and occurred more rapidly in E. faecium GE1RF (100% at 200 generations) 
than in E. faecium 64/3 (up to 92.0% at 300 generations). The reversion of phenotype was accompanied 
by the loss of Tn1546 without the loss of the plasmid or plasmid modules (Figure 3 and S1). 
 
Figure 3. Antibiotic resistant phenotype loss of Tn1546-vanA carrying plasmids in E. faecium GE1RF 
and E. faecium 64/3. 
Antibiotic resistance does not always correspond with plasmid loss. A) Antibiotic resistance phenotype loss for pH311 (A5 - 
GE1RF::pH311300::vanA; A6 - GE1RF::pH311300::ΔvanA; A30 - 64/3::pH311300::vanA; A31 - 64/3::pH311300::ΔvanA); B) Antibiotic 
resistance phenotype loss for pH182 (A8 - GE1RF::pH182300::vanA; A9 - GE1RF::pH182300::ΔvanA; A33 - 64/3::pH182300::vanA; A34 - 
64/3::pH182300::ΔvanA); C) Antibiotic resistance phenotype loss for pBM4165 (A11 - GE1RF::pBM4165100::vanA; A12 - 
GE1RF::pBM4165100::ΔvanA; A13 - GE1RF::pBM4165300::ΔvanA; A36 - 64/3::pBM4165100::vanA; A37 - 64/3::pBM4165300::vanA; A38 
- 64/3::pBM4165300::ΔvanA); D) Antibiotic resistance phenotype loss for pIP501 (A15 - GE1RF::pIP501100::ermB; A16 - 
GE1RF::pIP501100::ΔermB; A17 - GE1RF::pIP501300::ermB; A18 - GE1RF::pIP501300::ΔermB; A40 - 64/3::pIP501100::ermB; A41 - 
64/3::pIP501100::ΔermB; A42 - 64/3::pIP501300::ermB; A43 - 64/3::pIP501300::ΔermB); E) Antibiotic resistance phenotype loss for 
pRE25 (A20 - GE1RF::pRE25100::ermB; A21 - GE1RF::pRE25100::ΔermB; A22 -. GE1RF::pRE25300::ermB; A23 - GE1RF::pRE25300::ΔermB; 
A45 - 64/3::pRE25100::ermB; A46 - 64/3::pRE25100::ΔermB; A47 - 64/3::pRE25300::ermB; A48 - 64/3::pRE25300::ΔermB); F) Antibiotic 
resistance phenotype loss for pRUM (A25 - GE1RF::pRUM300::ermB; A50 - 64/3::pRUM300::ermB). 
The behaviour of prototype plasmids pRUM and pRE25 was similar to that of Tn1546-carrying plasmids 
pH311 and pH182, respectively. Strains harbouring pRUM rarely lost the erythromycin resistant 
phenotype (up to 1.0%) in both E. faecium GE1RF and E. faecium 64/3, and also plasmid size and 
backbone integrity were maintained in most cases. Prototype plasmid pRE25 was found to be less stable 
in E. faecium than pRUM (plasmid loss of 7.0-27.0% in E. faecium GE1RF and 0-17.0% in E. faecium 64/3) 
and, in some instances, the loss of erythromycin resistance was accompanied by plasmid loss but in 
other cases the plasmid was present with different size due to then loss of one or more plasmid 
modules that constitute the plasmid backbone. Contrarily, the prototype plasmid pIP501 had low 
stability in E. faecium backgrounds, being easily lost, particularly in E. faecium GE1RF (68.0-96.0% vs 8.0-
23.0% in E. faecium 64/3). The reversion to an erythromycin susceptible phenotype frequently coincided 
with plasmid loss (Figure 3 and S1).  
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Figure 4. PLACNET analysis of non-evolved strains in E. faecium GE1RF.  
A) PLACNET of GE1RF; B) PLACNET analysis of GE1RF::pH311; C) PLACNET analysis of GE1RF::pH182; D) PLACNET analysis of 
GE1RF::pBM4165; E) PLACNET analysis of GE1RF::pIP501; F) PLACNET analysis of GE1RF::pRE25; G) PLACNET analysis of 
GE1RF::pRUM. 
Whole genome analysis of evolved strains.  
PLACNET analysis of non-evolved strains helped to identify the possible plasmids present in these strains 
(Figures 4 and 5). All evolved strains sequenced showed point mutations, deletions, duplications and 
possibly recombination regions when they were compared with their corresponding parental strains. 
These alterations in the genomes were found both in the chromosome and plasmids. In general more 
mutations were detected in E. faecium 64/3 than in E. faecium GE1RF (Figures 6 and 7).  
The most frequent functions affected in the chromosome of E. faecium GE1RF and E. faecium 64/3 
were: DNA replication and repair (6 E. faecium GE1RF and 17 E. faecium 64/3), transposition and 
genome plasticity (7 E. faecium GE1RF and 7 E. faecium 64/3), environmental information processing (3 
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E. faecium GE1RF and 10 E. faecium 64/3), tissue adherence (5 E. faecium GE1RF and 5 E. faecium 64/3), 
transcription regulators (11 E. faecium 64/3), inorganic ion transport and metabolism (1 E. faecium 
GE1RF and 8 E. faecium 64/3), cellular and cell wall enzymes (2 E. faecium GE1RF and 3 E. faecium 64/3), 
and genetic information processing (1 E. faecium GE1RF and 3 E. faecium 64/3).  
 
Figure 5. PLACNET analysis of non-evolved strains in E. faecium 64/3.  
A) PLACNET of 64/3; B) PLACNET analysis of 64/3::pH311; C) PLACNET analysis of 64/3::pBM4165; D) PLACNET analysis of 
64/3::pIP501; E) PLACNET analysis of 64/3::pRUM. 
Plasmid changes included point mutations in REP of the Inc18 family (for plasmids pH311, pBM4165 and 
pIP501 in E. faecium GE1RF not in E. faecium 64/3); deletions of plasmid modules (REP, REL and TA 
systems) and antibiotic resistance determinants. The last ones were found in both E. faecium GE1RF and 
E. faecium 64/3 justifying loss of plasmid modules and phenotypical resistance to vancomycin and/or 
erythromycin. 
In E. faecium GE1RF, an A160T mutation within an ISL3-like element, a 292bp deletion in the intergenic 
region encoding for 16S rRNA and tRNA, and a 211bp deletion within IS6770 were observed for most 
strains sequenced. Aside from the deletion in IS6770, a point mutation (K100E) was also found in some 
strain pairs (Figure 6).  
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Among E. faecium 64/3, a frameshift mutation in N-acetylmuramoyl-L-alanine amidase (involved in 
peptidoglycan metabolism) and a point mutation in ArpU family transcriptional regulator were detected 
in some strains pairs (Figure 7). For some strain pairs, specific genome changes were found in evolved 
strains of E. faecium GE1RF and E. faecium 64/3 strains. 
For pairs carrying pH182 plasmid in E. faecium GE1RF (A8-A9), we detected a mutation in the beta 
subunit of RNA polymerase (D85V) and in E. faecium 64/3 (A33-A34), a 34bp duplication in a 
transcription regulator of the DeoR family; two point mutations (S44A and E399D) in the DNA 
polymerase IV (dinB2); and five point mutations in several hypothetical proteins.  
For the pair carrying plasmid pBM4165 in E. faecium 64/3 (A36-A38), the following changes were 
observed: a mutation (*95L) in the stop codon of a fructose PTS system that could have restored protein 
function, a mutation in the intergenic region of tRNA‑Asp/tRNA‑Met, a 374bp deletion in a protein with 
LPXTG-motif possibly associated with tissue adherence as well as several deletions of plasmid modules 
were found in this pair of evolved strains. 
For strains carrying pIP501 in E. faecium GE1RF (A15-A18), a T32A mutation in an IS30 family 
transposase was found. In the 300 generations evolved strains (A17-A18) two point mutations in DNA 
replication and repair associated proteins, RNA polymerase β-subunit (Y486C) and rpoN1 (R428L) were 
also found. Several mutations on the repR gene of pIP501 were found in the evolved erythromycin 
susceptible strains (A16 and A18). In case of strains carrying pIP501 in E. faecium 64/3 (A40-A43), a 2bp 
frameshift mutation in a collagen binding protein (cell wall adherence) and an intergenic mutation 
between TerC family integral membrane protein and signal peptidase I (spsB) were found. A point 
mutation (D181Y) in a CorA-like Mg
2+
 transporter protein (inorganic ion transport and metabolism) was 
found strains susceptible to erythromycin (A41 and A43).  
In E. faecium GE1RF strains carrying pRE25 (A20-A23), an intergenic mutation between a hypothetical 
protein and a LIVCS family branched chain amino acid cation symporter (brnQ2) was found. Several 
deletions were also found in the erythromycin susceptible strains (A21 and A23). For strains carrying 
pRE25 in E. faecium 64/3 (A45-A48) several point mutations were found: in an oligopeptide ABC 
superfamily ATP binding cassette transporter (dppE; G8S); in a putative ABC transporter ATP‑binding 
protein YheS (yheS4; A358T); and in an IS1216V belonging to the IS6 family (S92A). Also a 1bp deletion 
was found in a CorA-like Mg
2+
 transporter protein in erythromycin susceptible strains (A46 and A48).  
E. faecium PFGE-estimation of genome sizes.  
Genome sizes were highly variable, ranging from 2.05Mb [1
st
 vancomycin resistant E. faecium (VREfm), 
ST25 (BAPS 2.3a)] and 3.08Mb, [1
st
 linezolid resistant E. faecium isolated ST203 (BAPS 2.1a)] with an 
average genome size of 2.51±0.28Mb (Supplementary Table S1). Animal associated Clade A2 hade the 
smaller average genome (2.32±0.23Mb) and hospital associated Clade A1 had the largest genomes 
(2.66±0.23Mb) (Figure 8). No significant differences in genome size were observed between VSEfm and 
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VREfm strains (2.50±0.25Mb and 2.52±0.33Mb, respectively) (Figure 9). However, significant (p<0.0001) 
differences in average genome size were found when analysing VREfm and VSEfm for ampicillin 
resistance with ASEfm having a smaller genome size compared to AREfm (Figure 9).  
 
Figure 8. Growth Rate analysis of E. faecium clades at 37ºC and 42ºC. A) Box and whiskers plot of the 
different E. faecium clades (A1, A2 and B) at 37ºC and 42ºC. B) Summary table of Growth Rates and 
Genome size by clade and BAPS group.  
 
Figure 9. Growth Rates of E. faecium wild type strains according with vancomycin and ampicillin 
resistance. A) Box and whiskers plot representing growth rates  of E. faecium wild type strains 
according with vancomycin and ampicillin resistance; B) Summary table of growth rates and Genome 
size by vancomycin and ampicillin resistance. 
Fitness of E. faecium representative wild-type clones at 37ºC and 42ºC.  
E. faecium presented a significantly higher (p<0.01) average growth rate at 42ºC (0.01236±0.00284) than 
at 37ºC (0.01127±0.00178). A significant difference (p<0.0001) in growth rates was observed between 
isolates of the three E. faecium genomic clades, with Clade B having the best average growth rate at 
37ºC and 42 ºC (Figure 8). BAPS 1 (equivalent to Clade B) had the significantly higher (p<0.0001) average 
growth rate compared to all other BAPS groups. At 37ºC average growth rate within Clade A2 varied 
greatly, even though, statistically significant differences were only observed between some BAPS groups 
(BAPS 3.1: BAPS 2.1b and BAPS2.3a; BAPS 7: BAPS 2.1b and BAPS 2.3a; BAPS3.3b – BAPS2.3a). Within 
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Clade A1 the differences in average GR between the three BAPS groups were statistically significant 
(p<0.0001) (Figure 8). VSEfm strains were found to have a significantly higher (p<0.0001) GR than VREfm 
strains. Moreover, the analysis of ampicillin resistance within VSEfm and VREfm showed that AREfm 
have a significant (p<0.0001) lower GR than those ASEfm (Figure 9). 
DISCUSSION 
The plasmid modules present in E. faecium Tn1546-vanA carrying plasmids seem to influence plasmid 
host range, as has also been demonstrated in previous works where E. faecium plasmids transfer into E. 
faecalis only when modules of broad host range Inc18 (rep1) family plasmids are present 
30
.  
All the plasmids analysed in this work conferred variable fitness cost depending on the bacterial 
recipient E. faecium and E. faecalis hosts. The results seem to demonstrate that some E. faecium clades 
or lineages might be more adapted to the presence of mobile genetic elements than others and, 
probably, that some plasmids are also better adapted to some clades or species than others 
44
.  
Induction of the expression of Tn1546-vanA showed a high fitness cost, variable in depending on the 
Tn1546 variant, and the bacterial host in which it was being expressed, in line with what was 
demonstrated for vancomycin resistant S. aureus strains. In S. aureus the fitness cost was attributed to 
the metabolic changes that the complex vancomycin resistance mechanism induces in the cell, leading 
to the elimination of chromosomal encoded peptidoglycan precursors (D-Ala-D-Ala) which are replaced 
by Tn1546 encoded precursors (D-Ala-D-Lac) 
6,17
. The differences in fitness observed between different 
Tn1546 variants might be due to the efficiency of expression of enzymes encoded in Tn1546, as variant 
A (the first described) presented a lower fitness cost compared with the others variants studied, 
suggesting that the presence of ISs and other genetic material within Tn1546 might hamper its͛ fuŶĐtioŶ.  
Interestingly, and in spite of their fitness cost, most Tn1546-vanA carrying plasmids were stably 
maintained after 300 generations in the absence of selective pressure. Some of these plasmids carry 
known, highly effective, TA systems, which might account for their stability even when the vancomycin 
resistance genotype/phenotype was lost. Reversion of vancomycin resistant phenotype was seldom 
observed similarly to what has been described previously 
45
. However, in the case of plasmid pBM4165 
phenotype reversion was frequent and mostly due to the deletion of the part of Tn1546. It would be 
interesting to further study these strains in order to understand this phenomenon as it might carry some 
possible ideas for new therapeutic innovations in the treatment of VRE. 
Even though, Inc18 plasmid family prototype, pIP501, had a low fitness cost for the host, it was easily 
lost in the 300 generations sequential evolution experiment. We may hypothesise that either TA system 
present in our copy of this plasmid was non-functional or that at the beginning of the experiment there 
was a mixed population, relatively frequent in Enterococci, of host cells (Host::pIP501 and 
Host::ΔpIPϱϬϭͿ aŶd that the diffeƌeŶĐe iŶ fitŶess ďetǁeeŶ the populatioŶs ǁas eŶough foƌ the host Đells 
without pIP501 to outgrow those with pIP501 
46
. 
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The majority of the changes observed in evolved strains were in the chromosome. This observation is in 
consonance with other studies that show compensatory mutations associated with host-plasmid 
adaptatioŶ aƌe loĐated iŶ the host͛s Đhƌoŵosoŵe 46,47. The changes observed in the plasmids were 
mostly related with deletion of plasmid modules although some mutations were found, as in the case of 
pIP501, that might be related with plasmid replication within the cell. The higher number of mutations 
in Tn1546-vanA carrying plasmids host compared to the plasmid-free evolved host suggests that the 
majority of them might be related with the presence of the plasmid.  
The majority of mutations found in evolved strains were related with DNA replication and repair 
mechanisms indicating that increased mutation rates might be relevant for a rapid host-plasmid 
adaptation 
48,49
. Alterations in the global transcription regulation (leading to higher transcription rates in 
non-evolved strains and back to normal levels in evolved strains) have also been described for 
streptomycin resistant mutants of Salmonella Typhimurium and in a Pseudomonas aeruginosa carrying a 
mercury resistance plasmid as a consequence of resistance adaptation 
45,49,50
. Changes found in 
carbohydrate and amino acid metabolism, several PST systems and inorganic ion transport systems 
might be related with the metabolic burden imposed by the plasmid leading to o higher nutrient uptake 
and processing 
49
. Curiously, even though the same functions were affected in E. faecium GE1RF and E. 
faecium 64/3 the mutations for the strains of the different background carrying the same plasmids here 
different indicating that even when confronted with the same plasmid, the hosts might have alternative 
evolutionary pathways 
45
. Further research is needed in order to understand the role these mutations 
might play in host-plasmid adaptation. 
The differences in genome size observed between clades A1, A2 and B were consistent with previous 
works describing that the clade A1 had a larger genome followed by clade B and clade A2 
51,52
. There are 
not clear relations between small genome size and higher replication rate 
53
. Our observations were 
consistent with the reduction in fitness due to the presence of a higher number of acquired antibiotic 
resistance and virulence genes in clade A1. These differences might also account, up to some extent, for 
the differences found in fitness between clades, with more susceptible clade B having a better fitness 
than multi-drug resistant clade A1 
16–18,54–56
. The differences in fitness among clades were maintained at 
42ºC, temperature at which E. faecium seems to had a significantly better fitness, probably related of 
the ubiquitous lifestyle of this species 
51,57
. Interestingly, no significant differences in fitness were found 
between VSE and VRE E. faecium in this study, possibly due to the tight regulation of Tn1546 by the two 
component system vanS-vanR, and also by the fact that Tn1546 carrying plasmids seem to be highly 
adapted to certain E. faecium clonal backgrounds 
17,18
. 
In summary, the stringent E. faecium host-specificity of Tn1546-vanA carrying plasmids might explain, 
up to some extent, the confinement of vancomycin resistance almost exclusively to this species. Even 
though the majority of Tn1546-vanA carrying plasmids studied seem to impose a significant burden to 
the host strain, their stability in the absence of selective pressure as well as their high conjugation rates 
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between E. faecium strains might explain their maintenance and conjugative spread among E. faecium 
populations, perpetuating the presence of VRE strains worldwide.  
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Figure S1. List of sequenced evolved and non-evolved strains with antibiotic resistance (genotypical 
and phenotypical) and plasmid characteristics.  
Abbreviations: CH - Chromosome. 
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Figure S2. Box and whiskers plot of growth rates at 37ºC and 42ºC of all E. faecium wild type strains 
used in this study. 
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1. Population structure of E. faecium isolates from non-hospitalized and 
hospitalized humans, both colonized and infected  
Enterococci have been known as members of the human gut microbiota and opportunist pathogens for 
more than a century. Studies regarding the population structure of enterococci are restricted to E. 
faecalis and E. faecium, most E. faecium strains being VRE strains isolated during hospital outbreaks. 
There are only a few studies that have addressed the diversity and population structure of vancomycin 
susceptible enterococci present in the human GI tract or causing nosocomial infections (1–4). Even 
though, E. faecium is the focus of this PhD dissertation there is impossible to fully understand their 
diversity without first discussing the total diversity of enterococci in the human gut.  
The high recovery rate of enterococci in human faeces (71%-80%, of the persons analysed) in both 
hospitalized patients and community-based humans was similar to that obtained in previous works (2–
4), although the influence of the age observed in other studies was not confirmed in our series. E. 
faecalis was consistently predominant in the faecal microbiota in young and elderly individuals with the 
exception of hospitalized elderly patients where E. faecium was predominant. The presence of other 
enterococcal species showed an inversely proportional trend to that of E. faecium indicating common 
functional requirements of E. faecium and others species and also changes in ecological conditions (diet, 
health and antibiotic treatment) that might shape the selection for particular clones as has been 
demonstrated for chicken or calves (2, 5–11). 
As previously mentioned, the analysis of the population structure of E. faecium by ClonalFrame or BAPS 
analysis of MLST data allowed establishing the independent origin of major ST17, ST18 and ST78 
lineages, previously located within the CC17 using goeBURST (12–15). In this PhD dissertation, we 
significantly extended previous studies of populations structure using BAPS at qualitative (by including a 
significant number of isolates from individuals of different ages and from both hospital and community 
settings) and quantitative levels (duplicating the number of STs included, 837 STs and 1116 STs, vs 492 
STs). The two new BAPS analysis performed yield similar number of BAPS groups (8 and 9, respectively), 
four of them being predominant, namely BAPS 1, BAPS 2, BAPS 3 and BAPS 7 (15.2%, 39.5%, 30.9%, and 
6.8%, respectively) and were validated through correlation analysis with the BAPS analysis described by 
Willems et al (13). Moreover, the correlation coefficient between the BAPS analysis described in 
Chapters 1 and 2 revealed little discrepancies either at BAPS group or at subgroup level indicating that, 
for E. faecium, BAPS analysis is both reproducible and robust and may accurately describe the E. faecium 
population structure. The inclusion of more STs in the second BAPS analysis performed permitted the 
accurate separation of two clonal lineages, ST17 and ST18, associated with antibiotic resistance and the 
hospital setting. The different origin for these clonal lineages had been previously suggested (13) but not 
confirmed. This also showed that the higher the number of STs included in the BAPS analysis, the more 
accurate the prediction of the E. faecium population structure.  
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Furthermore, BAPS analysis performed in chapter 1 confirmed the presence of evolutionary and 
functionally heterogeneous clades for the E. faecium species proposed by other studies (13, 16–18). E. 
faecium isolates of BAPS 1 and BAPS 3.3b, all ampicillin susceptible and mostly associated with non-
hospitalized individuals, corresponding to the ͞ĐoŵŵuŶitǇ populatioŶ͟ that seem to be enriched in 
pathways of complex carbohydrate utilization linked to host diet (16). These populations were highly 
represented in different age groups of colonized non-hospitalized individuals although its incidence was 
slightly reduced in the elderly (13, 16). Conversely, E. faecium BAPS 2.1a (lineage ST78), BAPS 3.3a1 
(lineage ST18) and BAPS 3.3a2 (lineage ST17) subgroups, corresponding to Clade A1 oƌ ͞hospital 
populatioŶ͟ mostly comprises ampicillin and/or vancomycin resistant strains (13, 16). As it was 
demonstrated in Chapter 1, isolates of these BAPS groups were predominantly detected in isolates 
causing infections among elderly hospitalized patients. It is of note that the rates of these populations 
might be underestimated in both inpatients and healthy humans if you do not pre-enrich the sample, 
probably due to low colonization densities.  
The analysis of the population structure and diversity of E. faecium causing BSI was performed in 
Chapter 2 and comprised isolates collected during a 20 year period. The observed increase in both the 
number of E. faecium BSI cases in cancer patients (gastroenterology, haematology and oncology wards) 
and the number of ampicillin resistant E. faecium high-risk clones (ST17, ST203, ST117 and ST80) in the 
2006-2015 period in Hospital Universitario Ramón y Cajal, can also be indirectly inferred from the data 
of multicentre studies (19, 20), studies confined to a single institution (21), or studies focused on VREfm, 
MDR E. faecium, or particular groups of patients (e.g. cancer patients) (22, 23). 
Previous antibiotic treatment has largely considered one of the main risk factors for acquisition of 
enterococci BSI (24). TheƌapǇ ǁith ďƌoad speĐtƌuŵ β-lactams, including carbapenems, to treat MDR 
Enterobacteriaceae in onco-haematological patients with febrile neutropenia (22) or the use of 
levofloxacin to prevent such infections in these patients has dramatically increased since the mid-2000s 
in many hospitals including ours (23), and has been recognized as one of the main risk factors for 
colonization and subsequence BSI by MDR Gram positive organisms (22, 25, 26). Differences in 
chemotherapy or clinical practice guidelines also seem to influence acquisition and intestinal persistence 
of ampicillin resistant E. faecium (23).  
The recovery from blood cultures of E. faecium of all 7 BAPS groups including those that are normal 
components of the human gut microbiota (BAPS 1 and BAPS 3.3b, being the most representative as 
mentioned above), suggested that bacterial translocation, colonization by contiguity (UTIs) and invasive 
processes, of stochastic nature, can be facilitated by either an enhanced population size (due to 
colonization and/or overgrowth of the antibiotic resistant clones) or by the number of patients 
ĐoloŶized ďǇ a ĐeƌtaiŶ stƌaiŶ, ĐlassiĐallǇ kŶoǁŶ as ͞ĐoloŶizatioŶ pƌessuƌe͟ (that enhance the chances of 
transmission) (7, 8, 27, 28). The predominance of STs of major human lineages ST17, ST18 and ST78, 
previously designed as HiRCCs showed a temporal trend in most clinical surveys including our BSI series 
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(29, 30). The apparent ĐloŶal ͞ǁaǀes͟ of different HiRCCs with a recent expansion of the E. faecium ST78 
at global level (13, 31) implies the successive selection, expansion, and evolution of certain clones, 
following hospital microepidemics (18, 32). Besides clonal expansion of specific strains, an increasingly 
high intra-clonal diversification of E. faecium strains belonging to ST17, ST18 and ST78 lineages, was 
found in this and also in other works (33), ƌefleĐtiŶg the ͞ex unibus plurum͟ eǀolutioŶaƌǇ dǇŶaŵiĐs (34). 
The phenomena, initially observed for S. aureus (35), could be applied as a general scenario for different 
species.  
The contemporary increase of isolates within BAPS 2.1a (ST117, ST192, ST203) and BAPS 3.3a2 (ST17) in 
the hospital environment is intriguing. Recent studies have highlighted the relevance of microbial 
inheritance in basic processes of infectious diseases (28) and the impact of antibiotic treatments in the 
composition and structure of microbial communities (36). Although cross transmission among 
individuals remains a key factor in the epidemiology of E. faecium, the importance of the various 
resident E. faecium populations, eventually changing in frequency with antibiotic exposure and age, 
comes to light in Chapters 1 and 2 of this dissertation. The apparent specialization of certain 
subpopulations of E. faecium either in colonization or infections might therefore be associated with 
several other host associated factors, and also differences in harboured selectable characters, as 
antibiotic resistance genes. Interestingly, some groups evolve independently from the acquisition of 
ampicillin resistance, suggesting a certain genetic isolation as seems to be the case of different lineages 
within BAPS 3.3b and BAPS 1. These results further confirm a population structure comprised of 
ecotypes representing specialization in different hosts (37, 38). It has been recently demonstrated that 
heterogeneity of S. aureus populatioŶs that ĐoloŶize huŵaŶs, desigŶated as ͞Đlouds͟, leads to a possiďle 
global adaptive benefit for certain clones and finally for the overall species, that is enhanced by 
horizontal gene transfer (HGT) (39, 40). This might also explain what was observed in E. faecium. One of 
the most remarkable features of major human lineages of this species is the content of mobile genetic 
elements (2). 
2. MGE diversity in E. faecium, particularly those responsible for antimicrobial 
resistance 
Horizontal gene transfer (HGT) plays a fundamental role in the evolution of bacterial species but it was 
only recently that the occurrence of HGT events between ecologically distant groups of bacteria (with 
similar G+C content), was demonstrated (41–44). The network analysis of resistance determinants 
(antibiotics, heavy metals and biocides) in Firmicutes showed in Chapter 3 of this dissertation reveals the 
presence, either located in the chromosome and/or plasmids, of the same resistance determinants in 
different species from this phylum, which illustrates a high diversity of interactions within different 
bacterial communities. It still remains unknown the extent to which the HGT and specific MGE and 
species have contributed to the evolution of the phylum Firmicutes and particularly of the genera 
Enterococcus. It has been demonstrated that the association of resistance determinants with site-
specific recombination systems and insertion sequences located in plasmids and/or chromosomes 
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favours homologous recombination through the interplay among different elements (45–49). The 
heterogeneous distribution of resistance determinants observed in Firmicutes associated with the 
presence of systems that protect bacteria against de acquisition of exogenous DNA (R-M systems and 
CRISPR) (50–52) indicates that HGT may indeed play an important role in bacterial ecology and 
evolution.  
It had been suggested, and was further observed in work presented in chapter 3, that the number of 
MGEs greatly varies among different bacterial species. Nevertheless, consistent patterns, particularly 
regarding plasmids, have been found among the different member strains from the same species (53–
55). This suggest an evolutionary co-adaptation between plasmids and bacteria, issue that has been well 
studied in Enterococcus, particularly in E. faecium and E. faecalis, due to their clinical relevance and 
frequent acquisition of resistance determinants.  
Enterococci frequently carry species-specific RCR plasmids (e. g. pRI1 in E. faecium) and RepA_N 
plasmids (pLG1-like megaplasmids in E. faecium) (53, 54). RepA_N plasmids seem to contribute to the 
evolvability of enterococci species as they enhance their ability to colonize and invade (54, 56, 57). Aside 
from these narrow host rage plasmids, enterococci also carry Inc18 broad host range plasmids, originally 
identified in streptococci. The heterogeneous Inc18 plasmid family has greatly contributed to the spread 
of resistance to different antibiotics including vancomycin. Nevertheless, genes encoding antibiotic 
resistance in enterococci are also been located on plasmids containing RIPs of other plasmid families, 
plasmid chimeras with more than one RIP being frequently detected. The presence of more than one RIP 
might be associated with recombination between narrow and broad host plasmids, like Inc18 plasmids 
in order to stabilize the incoming useful trait (53). Some of these chimeric plasmids have largely 
contributed to the worldwide dissemination of aminoglycoside (ermB) and vancomycin (vanA) 
resistance among E. faecium of human and animal origin. Aside from these chimeras, narrow host rage 
plasmids have contributed for the local dissemination of gentamicin (Tn4001) aŶd β-lactams (blaZ) 
resistance among E. faecium. 
The emergence of E. faecium (ST17, ST18, ST78) hospital adapted lineages carrying several antibiotic 
resistance plasmids highlights the role that these elements might play in the adaptation of these species 
to a particular ecological conditions (13, 58, 59). Chapter 4 and Chapter 5 described the influence of 
both clonal and plasmid backgrounds in the spread and persistence of vancomycin resistance among E. 
faecium. Predominant local AREfm of major human lineages ST17, ST18 and ST78 appear to have 
contributed to the high rates of vancomycin resistance observed nowadays after acquisition of vanA or 
vanB transposons. This is reflected by the eŵďleŵatiĐ ĐloŶal V‘Efŵ ͞ďlooŵiŶgs͟ that haǀe oĐĐuƌƌed iŶ 
the US, Australia (ST203), Sweden (ST192), Portugal (ST18/ST132), Brazil and Canada (ST412) or The 
Netherlands (ST117) (54, 60–70). However, events of HGT among distinct clonal backgrounds also 
occurred when the prevalence of VREfm rapidly increase or when VRE became endemic (31, 71). 
Chapter 5 analyses VREfm from Portugal and shows how isolates of the major human lineages ST18 
Ana P. Tedim  Discussion 
 
281 
 
(BAPS 3.3a1), ST78 (BAPS 2.1a) and to a lesser extent ST17 (BAPS 3.3a2) influence the transmission of 
Tn1546 in a region (72, 73). The results indicate the importance of local clonal evolution due to 
variation, drift and short-distance migration. This evolution diving forces can lead to changes in 
colonization ability, pathogenicity or even host range, the fittest clonal variants being able to facilitate 
the local and eventually international transmission that was revised in Chapter 4, (74–78).  
The diversity of plasmids able to acquire van operons and their ability to recombine in chimeric plasmids 
is noteworthy and played a critical role in the spread of Tn1546-vanA both at local (Chapter 5) and at 
international levels (Chapter 4). The predominant recovery of pRUM::Tn1546 highly related to the 
original pRUM plasmid recovered in an early outbreak VREfm isolate (79) from the USA and the frequent 
isolation of Inc18::Tn1546 similar to the first vanA plasmid pIP816 (80, 81) among VREfm from humans 
and animals in Europe since late 1980s to date (82–85), revealed the contribution of pRUM and pIP186 
to the evolvability of Tn1546 in different continents.  
Even though these pRUM and Inc18 plasmid types appear to have greatly contribute to the 
dissemination of vancomycin resistance in E. faecium, any enterococcal plasmid can act as a vehicle for 
Tn1546 or even CTn5382, eventually causing self-limited outbreaks. They include pLG1-like 
megaplasmids (57, 60, 86–89), or pHTß-like plasmids (responsible for early outbreaks in Japan and the 
USA) (90, 91). Finally, chimeras of plasmids from E. faecium, E. faecalis (pheromone responsive 
plasmids) or S. aureus (pRUM) (79) reflect the relevance of  HGT events between different species and 
genera of Firmicutes (Freitas et al., 2009a). 
In vitro transfer of E. faecium Tn1546-vanA plasmids to E. faecalis was infrequent (Chapter 6) and highly 
dependent on the modules present in the plasmid backbone. More specifically, it only occurred  when 
RIPs of the Inc18 broad host range family (rep1/pIP501) were present in the E. faecium plasmids in 
agreement with previous studies (93). This might explain, up to some extent, the higher prevalence of 
vancomycin resistance in E. faecium compared with that of other pathogens (31, 59). 
3. To determine the influence of MGE encoding antibiotic resistance on the 
fitness of bacterial populations. 
In Chapter 6 of this PhD dissertation, transferability of a large chromosomal region containing pbp5, 
associated with ampicillin resistance in E. faecium, was confirmed and the chromosomal platform 
described as well as several new mutations in PBP5.  
The role PBP5 plays in E. faecium resistance to cephalosporins and penicillins resistance might have 
facilitated the selection of subpopulations able to cause infections in humans (94). A steady increase of 
the number of E. faecium isolates with reduced susĐeptiďilitǇ to β-lactams has been detected in clinical 
settings since the 1940s, and such increase parallels the number of infections caused by this species 
(95). In agreement with previous studies, seven changes (A68T, E85D, S204G, 466´S/D, M485A/T, E629V 
and P667S) were consistently observed in most AREfm. Also, several mutations were identified in 
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different E. faecium groups with different ampicillin susceptibility that indicate that a variety of 
eǀolutioŶaƌǇ ƌoutes, aŶd iŶteƌŵediate steps ǁeƌe possiďle siŵilaƌlǇ to ǁhat oďseƌǀed foƌ diffeƌeŶt β-
lactamase enzymes of Gram negative organisms (96).  
Only two E. faecium strains lacking pbp5 have been documented, GE1 and D344S. The D344S strain is 
susceptible to cephalosporin and ampicillin due to the spontaneous deletion of a 160 kb genome region 
that includes pbp5 and other genes including some encoding other PBPs. This deletion occurred due to 
the interaction of CTn5386 (a 60kb element that comprises both pbp5 and vanB2 genes) with Tn916 
(97). The causes for the loss of the region in which is pbp5 is located in the GE1 laboratory strain are 
unknown but it might be due to the fitness cost of this region in a non-specialized environment 
(laboratory conditions) (98).  
The mechanism responsible to the transfer of the ≈ϯϬϬkď ƌegioŶ ĐaƌƌǇiŶg pbp5 was not evident from the 
genetic analysis obtained due to the lack of sequences related to conjugative transposon(s) or even ISs 
that could be part of a composite transposon. A possible transference of chromosomal regions by an 
Hfr-like (High frequency recombination) mechanisms involving specific plasmids (as for most 
transconjugants plasmids were also present) cannot be discarded (56). We cannot exclude acquisition of 
this DNA fragments through transformation neither.  
The transfer of a chromosomal region containing not only the pbp5 but also traits that enhance survival 
in the gastrointestinal tract of mammals as the resistance to stress by acids and bile or the ability to use 
substrates produced by the host as maltodextrines and sialic acids in all available E. faecium isolates but 
GE1RF, suggests a possible ancient acquisition of the platform to adapt to these hosts. This was further 
confirmed by the experimental conjugative transfer of pbp5 between isolates of different E. faecium 
clades (clade A1, A2 and B) and by comparative genomic analysis. 
In chapter 7, Tn1546-vanA carrying plasmids conferred medium to high fitness cost in different E. 
faecium backgrounds as had been previously suggested for newly transferred plasmids or for plasmids 
that are not adapted to the host cell (99, 100). Such fitness differences seem to demonstrate that some 
E. faecium clades or lineages might be better adapted to the acquisition of mobile genetic elements 
than others (16) and/or that some plasmids are better adapted to some species than others, as happen 
with the megaplasmids belonging to the RepA_N family (rep22/pLG1), that are almost exclusively found in 
E. faecium (89).  
Induction of the expression of Tn1546-vanA showed a high fitness cost in both filed isolates and 
laboratory isogenic background. Previous studies performed in vancomycin resistant S. aureus also 
showed that the induction of vancomycin resistance had a high fitness cost for the host strain. This high 
fitness cost was attributed to the metabolic changes that the vancomycin resistance mechanism induces 
in the cell and that leads to the elimination of chromosomal encoded peptidoglycan precursors (D-Ala-
D-Ala) to Tn1546 encoded precursors (D-Ala-D-Lac) (99, 101). Fitness cost of Tn1546 was also dependent 
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on the Tn1546 variant in which the van gene is located. These differences might be due to the efficiency 
of expression of enzymes encoded by Tn1546 due to the presence of ISs in the transposon, as the 
original Tn1546  onfer a low cost compared with other truncated Tn1546 variants studied.  
In spite of the lack of fitness that Tn1546-vanA carrying plasmids confer to the host, most of the 
plasmids were stably maintained during 300 generations without selective pressure. Some of these 
plasmids carry known, highly effective, toxin-antitoxin systems (79, 102, 103) which might account for 
their persistence even when vancomycin resistance phenotype and/or genotype were eventually lost. 
Nonetheless, reversion of vancomycin resistance was seldom observed for most of the Tn1546-vanA 
plasmids studied similarly to what was previously described in other studies (104).  
The majority of mutations found in evolved strains compared to non-evolved were related with DNA 
replication and repair indicating that high mutation rates might be important for a rapid host-plasmid 
adaptation (105, 106). Alterations in the global transcription regulation, a remarkable change in E. 
faecium 64/3 evolved strains, have also been often documented in evolved strains of Gram-negative 
species. In these studies, the presence of the resistance plasmid led to an increase in the transcription 
rates and afterwards to values similar to the non-evolved strains due to compensatory mutations in the 
two component regulatory system galA/galS (104, 106, 107). Thus, compensatory mutations in 
transcription regulation would contribute to a reduced expression of plasmid genes might play a 
fundamental role in host-plasmid adaptation (106). Changes found in carbohydrate and amino acid 
metabolism, several PST systems and inorganic ion transport systems might also contribute to the 
metabolic burden imposed by the plasmid due to o high uptake and process of nutrients (106). Finally, 
even though mutations in similar genes were found in E. faecium GE1 and E. faecium 64/3 carrying the 
same plasmids, most of them were disparate indicating that they followed different evolutionary 
pathways after acquisition of foreign DNA (104).  
Also in Chapter 7, differences in the genome size of isolates in clades A1, A2 and B are described, clade 
A1 having the largest genome followed by clade B and then, clade A2 (16, 108). These observations are 
consistent with the high number of adaptive acquired genes (antibiotic resistance, virulence) in clade A1 
strains compared with clade A2 and clade B. The differences in genome size and the content in acquired 
genetic material might have also contributed to the differences in fitness of strains of Clade B (ASEfm) 
and clade A1 (AREfm), the former ones having a best fitness values as is described in chapter 7. It has 
always been stated that de acquisition of an antibiotic resistance trait (point mutation or by horizontal 
gene transfer) is associated with the loss of fitness by the bacterial host (99, 100, 109–112).. We could 
hypothesize that the loss of fitness was due to ampicillin resistance as we did not find any significant 
differences in fitness between VSE and VRE in this study. The absence of significant differences between 
VSE and VRE wild type strains might be related with the tight regulation of Tn1546 by the two 
component system vanS-vanR impeding the expression of vancomycin resistance when no inductor is 
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present and also by the fact that the plasmids carrying Tn1546 seem to be highly adapted to certain E. 
faecium clonal backgrounds (99, 100) 
Finally, another indicative of E. faecium ubiquitousness and adaptability is its better fitness when growth 
at 42ºC when compared at 37ºC. Even though E. faecium has been mostly recovered from the human 
gut, this species is also a member of the gut flora of animals with higher body temperatures than 
humans as such as pigs (38.8ºC) and chickens (41.8ºC) (113, 114).  
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No thief, however skillful, can rob one of knowledge, and that is why knowledge is the 
best and safest treasure to acquire. 
L. Frank Baum 
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1. Different enterococcal populations were predominant in the microbiota of hospitalized and non-
hospitalized individuals of different age groups, E. faecium being the most common one in elderly. 
Intraspecies diversity was also demonstrated; ampicillin susceptible E. faecium of BAPS 1 and 
BAPS 3.3b were associated with non-hospitalized individuals while ampicillin resistant E. faecium 
of BAPS groups 2.1a and BAPS 3.3a were common among hospitalized patients (Chapter 1). 
2. The high clonal diversity of E. faecium able to cause BSI pointed out the human gut as the origin of 
such infections. Changes in the GI tract microbiota of hospitalized patients due to host conditions 
(e.g. age) or external factors (e.g. antibiotic treatment and/or other selective pressures in the 
hospital setting), appears to have facilitated the selection and the consequent increase in the 
population size of antibiotic resistant E. faecium clones, leading to a shift in the composition of E. 
faecium populations that increased the chances to be infected by MDR strains and to transmit 
MDR strains in the hospital setting (Chapter 2).  
3. The variable occurrence of certain E. faecium clones in individuals of different age and origin in a 
kind of source-sink dynamics, with frequent cases of coexistence, and preservation of rare clonal 
populations, suggested a frequency-dependent evolution of enterococcal populations, which 
could prevent the extinction of genotypes with specific ecological roles in the bacterial community 
that exploited particular environments (Chapters 1 and 2).  
4. The asymmetric number and type of plasmids associated with disparate populations of E. faecium 
suggested an evolutionary co-adaptation between plasmids and their clonal background. The high 
number of plasmids in specialized E. faecium lineages that are most frequently recovered from 
hospitalized patients highlights its influence in the rapid adaptation, selection and persistence of 
specialized populations under changing conditions as antibiotic treatments (Chapter 3).  
5. Both convergent evolution and horizontal gene transfer of pbp5 seem to be responsible for the 
blooming of ampicillin resistant E. faecium. Fluctuations in the population size of ampicillin 
resistant E. faecium liŶeages due to seleĐtiǀe pƌessuƌe eǆeƌted ďǇ the iŶĐƌeased use of β-lactams 
in hospitals, and further fixation of different ampicillin resistant E. faecium clonal lineages within 
dynamic landscapes, may explain their quantitative success (Chapter 6).  
6. The spread of vancomycin resistance in E. faecium is mainly due to narrow (pRUM) and broad host 
(Inc18) plasmids in the US and Europe, respectively. Moreover, the diversity of Tn1546-vanA 
carrying plasmids, mostly chimeras of narrow and broad host range plasmids, reflects the 
frequent HGT events between populations of enterococci and other Firmicutes. The ability of 
Tn1546-vanA carrying plasmids to transfer but also to recombine provides a key-variability 
component in the basic scenario of coevolvability between plasmids and hosts. In this interactive 
landscape HGT played a relevant role in shaping the transmission dynamics of vancomycin-
resistance determinants among highly related ͞ĐeŶtƌal͟ clonal backgrounds that have already 
Ana P. Tedim  Conclusions 
 
294 
 
been circulating for decades. Such transmission dynamics would also explain the unexpected 
diversity of plasmids and plasmid chimeras even in isolates belonging to the same clone, reflecting 
secondary micro-evolutionary events (Chapters 4 and 5). 
7. The narrow host range of the predominant Tn1546-harbouring plasmids in combination with the 
fact that the majority of them confer a significant burden to the host strain and a remarkable 
stability in the absence of selective pressure, might explain, up to some extent, their long-term 
maintenance and continuous transfer among E. faecium populations, perpetuating the presence 
of VRE worldwide (Chapter 7).  
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Write what you know. That should leave you with a lot of free time. 
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Population Biology of Intestinal Enterococcus Isolates from
Hospitalized and Nonhospitalized Individuals in Different Age Groups
Ana P. Tedim,a,b,c Patricia Ruiz-Garbajosa,a,b,d Jukka Corander,e Concepción M. Rodríguez,a,b,c Rafael Cantón,a,b,d Rob J. Willems,f
Fernando Baquero,a,b,c Teresa M. Coquea,b,c
Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spaina; Unidad de Resistencia a
Antibióticos y Virulencia Bacteriana Asociada al Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spainb; Centros de Investigación Biomédica en Red de
Epidemiología y Salud Pública (CIBER-ESP), Madrid, Spainc; Spanish Network for Research in Infectious Diseases (REIPI), Madrid, Spaind; Department of Mathematics and
Statistics, University of Helsinki, Helsinki, Finlande; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlandsf
The diversity of enterococcal populations from fecal samples from hospitalized (n  133) and nonhospitalized individuals (n 
173) of different age groups (group I, ages 0 to 19 years; group II, ages 20 to 59 years; group III, ages >60 years) was analyzed.
Enterococci were recovered at similar rates from hospitalized and nonhospitalized persons (77.44% to 79.77%) of all age groups
(75.0% to 82.61%). Enterococcus faecalis and Enterococcus faecium were predominant, although seven other Enterococcus spe-
cies were identified. E. faecalis and E. faecium (including ampicillin-resistant E. faecium) colonization rates in nonhospitalized
persons were age independent. For inpatients, E. faecalis colonization rates were age independent, but E. faecium colonization
rates (particularly the rates of ampicillin-resistant E. faecium colonization) significantly increased with age. The population
structure of E. faecium and E. faecalis was determined by superimposing goeBURST and Bayesian analysis of the population
structure (BAPS). Most E. faecium sequence types (STs; 150 isolates belonging to 75 STs) were linked to BAPS groups 1 (22.0%),
2 (31.3%), and 3 (36.7%). A positive association between hospital isolates and BAPS subgroups 2.1a and 3.3a (which included
major ampicillin-resistant E. faecium human lineages) and between community-based ampicillin-resistant E. faecium isolates
and BAPS subgroups 1.2 and 3.3b was found. Most E. faecalis isolates (130 isolates belonging to 58 STs) were grouped into 3
BAPS groups, BAPS groups 1 (36.9%), 2 (40.0%), and 3 (23.1%), with each one comprising widespread lineages. No positive asso-
ciations with age or hospitalization were established. The diversity and dynamics of enterococcal populations in the fecal micro-
biota of healthy humans are largely unexplored, with the available knowledge being fragmented and contradictory. The study
offers a novel and comprehensive analysis of enterococcal population landscapes and suggests that E. faecium populations from
hospitalized patients and from community-based individuals differ, with a predominance of certain clonal lineages, often in as-
sociation with elderly individuals, occurring in the hospital setting.
Enterococci are relatively minor constituents of the human gas-trointestinal microbiota (less than 1%) but are able to cause a
wide diversity of infections, mostly in patients with underlying
diseases (1, 2). High-density colonization by antibiotic-resistant
enterococci increases the risk of bacteremia and transmission;
however, the population structure and ecological and evolution-
ary forces influencing the population dynamics of gut colonizers
largely remain unknown (3–5). Next-generation sequencing has
provided a wealth of data about the influence of characteristics of
the host (age, diet, health status, and antibiotic treatment) on the
diversity and population frequency of different bacterial groups,
including enterococci (6–10). However, the information provided
by current metagenomic analysis, based on 16S rRNA (11, 12), or
by the traditional culture-based studies (1, 13, 14) precludes any
possible analysis of enterococci at the subspecies level. Further-
more, the available information about the frequency and diversity
of enterococcal species in the fecal microbiota by host age is frag-
mented and contradictory (1, 15).
Different methods based on multilocus sequence typing
(MLST), comparative genomic hybridization, and whole-genome
sequencing revealed intraspecies diversity for Enterococcus faecalis
and Enterococcus faecium, which are the predominant enterococ-
cal species colonizing the human gastrointestinal tract (16–25). E.
faecium has a population structure that has split into two major
phylogenomic clusters, designated clade B, which includes com-
munity-based human isolates, and clade A, which comprises iso-
lates from humans and animals, with a clade A1 being enriched
with isolates from hospitalized patients. Specifically, strains be-
longing to the sequence type (ST) 17 (ST17), ST18, and ST78
lineages, which are found within clade A1, are often resistant to
antibiotics and are the most frequently associated with the hospi-
tal environment (22, 26, 27). E. faecalis, on the other hand, seems
to lack such a clear clade structure, probably because this species
occupies a larger variety of ecological microniches, thus having
access to a more heterogeneous spectrum of alleles than E. faecium
(28). As a result, no clear genotypic differences are observed be-
tween hospital and community isolates (25, 28, 29), even though
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some clonal complexes (CCs) are more prevalent either among
hospitalized patients, e.g., CC6-ST6, CC9-ST9, CC28-ST87, and
CC40-ST40, or among community healthy volunteers, e.g., ST16
and CC58 (30–33). Recombination, which was previously de-
tected in enterococci (17, 34, 35), may have a considerable impact
on patterns of evolutionary descent, as displayed by sequence-
based gene trees or even by popular allele-based population snap-
shots provided by eBURST analysis. This may obscure the genetic
relatedness of strains and clones and, as such, interfere with
epidemiological and clinical investigations, in particular, when
strains are assigned to specific CCs. In addition, knowledge about
the population structure of enterococcal species is biased by an
overrepresentation of contemporary multidrug-resistant (MDR)
clinical isolates belonging to a few high-risk clonal complexes of-
ten associated with nosocomial outbreaks and frequently associ-
ated with elderly individuals (36–38). Studies analyzing early iso-
lates have documented a more diverse enterococcal population
able to cause disease acquired either nosocomially or in the com-
munity and often associated with nonelderly adults and children.
Isolates causing infections or colonizing these populations have
less frequently been analyzed at the molecular level (33, 39–41).
The objective of this study was to assess for the first time the
population structure of enterococci in the feces of both hospital-
ized and nonhospitalized individuals within different age groups.
In addition, Bayesian analysis of the population structure (BAPS),
a nonphylogenetic method able to find the best partition of a set of
isolates into subpopulations, was applied, broadening former re-
sults obtained for E. faecium and providing the first analysis to
probabilistically assign E. faecalis strains to evolutionary groups.
MATERIALS AND METHODS
Bacterial samples. Three hundred six fecal samples were collected be-
tween April 2009 and April 2011 at the Ramón y Cajal University Hospital
(HRyC) and its community care area of influence. HRyC is a tertiary care
public hospital with 1,155 beds that provides specialized attention to a
population of about 600,000 habitants in the northern area of Madrid,
Spain, who primarily attend 20 primary health centers (PHCs) of the
Madrid Health Service (SERMAS). This study was conducted according
to applicable government regulations and approved studies by institu-
tional research policies (e.g., reference CEIC-106/09 [A. M. Sánchez-Díaz,
C. Cuartero, J. D. Rodríguez, S. Lozano, J. M. Alonso, M. J. Rodríguez-
Domínguez, A. P. Tedim, R. del Campo, J. López, R. Cantón, and P.
Ruiz-Garbajosa, unpublished data]).
The samples analyzed were recovered from 173 patients with nonse-
vere diseases that attended a PHC or had a consultation at HRyC (and for
whom no hospitalization was registered in the 6 months prior to sample
collection) and from 133 hospitalized patients admitted to HRyC. The
fecal samples were submitted to HRyC for stool culture with or without a
specific request for Clostridium difficile or parasite detection and were
anonymously processed so that the patients’ demographic information
was kept confidential. Hospitalized patients were mostly located in med-
ical wards (78.2%), surgical wards (8.3%), and intensive care units (ICUs;
9.8%). All but 20 samples from hospitalized patients were collected after
more than 48 h of hospital admission. However, these 20 patients had a
history of several recent previous hospitalizations (see Tables S1 and S2 in
the supplemental material).
Samples were also classified into three age groups according to the
host’s age. These three groups are designated with roman numerals as
group I (young people 0 to 19 years old, n  92 [30%], 57 nonhospitalized
persons and 35 hospitalized patients), group II (adults 20 to 59 years old,
n  108 [35%], 62 nonhospitalized persons and 46 hospitalized patients),
and group III (elderly individuals 60 years old, n  106 [35%], 54
nonhospitalized persons and 52 hospitalized patients). Only one sample
per patient was analyzed (see Tables S1 and S2 in the supplemental mate-
rial).
Sample processing. About 0.5 g of each fecal sample was suspended in
1 ml of saline solution, plated on plain m-Enterococcus agar (Difco, De-
troit, MI, USA) or m-Enterococcus agar supplemented with either ampi-
cillin (10 g/ml) or vancomycin (6 g/ml), and incubated for 48 h at
37°C. For each sample, one colony per morphology type and plate was
selected (28) for further studies. In order to enhance the recovery of mi-
nority populations of ampicillin-resistant enterococci and vancomycin-
resistant enterococci (VRE), 0.1 ml of the original suspension of each
sample was preenriched in brain heart infusion (BHI) broth (Difco, De-
troit, MI, USA) supplemented with 2 g/ml of ampicillin or 2 g/ml of
vancomycin, incubated for 24 h at 37°C, and subsequently plated on m-
Enterococcus agar (Difco, Detroit, MI, USA) containing ampicillin (10
g/ml) or vancomycin (6 g/ml), respectively.
Identification, antibiotic susceptibility, and virulence traits. Bacte-
rial identification was performed by the amplification of species-specific
genes, D-alanine–D-alanine ligase (ddl) for E. faecalis and aac(6=)-Ii for E.
faecium, as previously described (42, 43), and by matrix-assisted laser
desorption ionization–time of flight mass spectrometry (Bruker, Dalton-
ics, Bremen, Germany). Susceptibility to ampicillin, vancomycin, teico-
planin, streptomycin, gentamicin, ciprofloxacin, levofloxacin, erythro-
mycin, tetracycline, and chloramphenicol (Oxoid, Basingstoke, United
Kingdom) was determined by the disc diffusion method according to
CLSI guidelines (44).
The presence of putative virulence genes encoding the E. faecium en-
terococcal surface protein (esp), glycosyl hydrolase (hylE. faecium), and col-
lagen-binding adhesin (acm) and the E. faecalis enterococcal surface
protein (esp), hyaluronidase (hylE. faecalis), cytolysin/hemolysin (cylA), gel-
atinase (gelE), and aggregation substance (asa1) was investigated by PCR
and sequencing, as described before (45, 46).
Clonal relatedness. The clonal relationship among isolates of each
enterococcal species was established by pulsed-field gel electrophoresis
(PFGE) and MLST as previously described (16, 47), and the relationships
are detailed in Tables S1 and S2 in the supplemental material. Clusters of
related STs for E. faecalis (differing in no more than two of the seven
MLST loci) were considered to belong to the same CC using the goe-
BURST algorithm (48, 49). CCs were defined on the basis of goeBURST
analysis of the 524 STs present in the E. faecalis MLST database (http:
//efaecalis.mlst.net/).
Analysis of population structure. A BAPS software was used to
probabilistically assign E. faecalis and E. faecium STs to nonoverlapping
evolutionary groups (27, 50). BAPS clustering was performed with the
second-order Markov model and the standard MLST data input option in
a hierarchical manner. For E. faecium, the major clusters identified at the
first stage were reanalyzed after excluding the remaining data. The ratio-
nale for this approach is to increase the statistical power to detect the more
fine-scale genetic structure of a population when analyzing particular lin-
eages separately from the remaining population. In all BAPS analyses, 10
runs of the estimation algorithm were performed using a priori upper
bounds (10 to 30 for the major group analysis and 2 to 10 for the subgroup
analysis) for the number of clusters over the interval, and in each case the
runs converged to a nearly identical partition of the data in question,
indicating a high level of peakedness of the posterior distribution (esti-
mated P  1.000).
The accuracy of BAPS for establishing the E. faecium population struc-
ture was determined using different sample sizes and discarding the in-
clusion of E. faecalis as the outgroup (see Fig. S1 to S3 in the supplemental
material) (27). Correlation analysis was performed for each of the com-
parisons mentioned above using Microsoft Excel 2010 software. This
study constitutes the first application of BAPS to investigate E. faecalis
population and evolutionary genetics by the same approach that was pre-
viously used for E. faecium (27).
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Statistical analysis. The statistical significance of the results was cal-
culated by the chi-square test; P values of 0.05 were considered statically
significant.
The STATA generalized estimating equations (GEE) model (which
takes into account clone-related data) (51) was used for calculating odd
ratios (ORs) and 95% confidence intervals (CIs) related to the coloniza-
tion isolates. The analyses were done by comparison with major BAPS
subgroup 3.3a (BAPS 3.3a) for E. faecium and BAPS group 1 (BAPS 1) for
E. faecalis.
For the analysis of all isolates available in MLST databases, ORs be-
tween BAPS groups and different sources (hospitalized patients, nonhos-
pitalized persons, and animals) were calculated. Environmental, food,
and other sources were also considered, but due to the low number of
isolates in these categories, OR analysis was not performed.
RESULTS
Prevalence and diversity of enterococcal species in human fecal
samples. Enterococci were recovered by culture from 78.8% of the
individuals analyzed (n  241/306) and at similar rates between
hospitalized and nonhospitalized individuals (77.4% versus
79.8%) and among all age groups (75.0 to 82.6%). The enterococci
recovered corresponded to three of the five groups of enterococci
previously described by Facklam et al. (52) on the basis of pheno-
typic and genotypic characteristics, which used to be designated
by roman numerals (1). The rate at which individuals were colo-
nized by different species varied in each age group, with E. faecalis
and E. faecium being the predominant species identified (Fig. 1
and 2). Among nonhospitalized persons, E. faecalis and E. faecium
colonization rates were age independent (E. faecalis/E. faecium
ratios, 1.14, 0.71, 1.12 for age groups I, II, and III, respectively).
The E. faecalis colonization rate among hospitalized patients was
also age independent, but the E. faecium colonization rate and
particularly the ampicillin-resistant E. faecium colonization rate
significantly (P  0.01) increased with age (E. faecalis/E. faecium
ratios, 1.90, 0.71, and 0.65 for age groups I, II, and III, respectively)
(Fig. 1 and 3). Besides E. faecium and E. faecalis, both classified
FIG 1 Proportion of nonhospitalized and hospitalized individuals colonized with enterococci by age group. The E. faecalis/E. faecium colonization ratios in
nonhospitalized persons by age group were as follows: group I (0 to 19 years old), 1.08; group II (20 to 59 years old), 0.68; and group III (60 years old), 1.08.
The E. faecalis/E. faecium colonization ratios in hospitalized patients were as follows: group I (0 to 19 years old), 2.25; group II (20 to 59 years old), 0.75; and group
III (60 years old), 0.68.
FIG 2 Proportion of nonhospitalized and hospitalized individuals colonized by different Enterococcus spp. by age group.
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within enterococcal group II described by Facklam et al. (52),
other species within enterococcal groups I (20 E. avium, 7 E. raffi-
nosus, 2 E. malodoratus isolates), II (4 E. casseliflavus isolates, 3 E.
gallinarum isolates, 1 E. thailandicus isolate), and group III (8 E.
hirae isolates) were identified (Fig. 2).
Colonization by more than one enterococcal species was a fre-
quent event. The simultaneous recovery of both E. faecalis and E.
faecium (13.7%, n  42/306) was increasingly observed as age
increased (P  0.01) (for age groups I, II, and III, 6.5% [n  6/92],
13.9% [n  15/108], and 19.8% [n  21/106], respectively), sug-
gesting that the increased rate of E. faecium colonization in hospi-
talized patients in age groups II and III did not interfere with the E.
faecalis colonization rate, although it might have influenced the
E. faecalis clonal composition. Low rates of cocolonization by E.
faecalis and Enterococcus spp. (5.23%, 16/306), E. faecium and En-
terococcus spp. (4.25%, 13/306), or E. faecalis, E. faecium, and
other enterococcal species (0.65%, 2/306) were also detected.
Ampicillin resistance (22.2%, n  68/306) was detected among
E. faecium (94.1%, n  64/68) and E. raffinosus (5.9%, n  4/68)
isolates. Ampicillin-resistant E. faecium isolates were more signif-
icantly associated with hospitalized patients (44.7%, n  46/103)
than with nonhospitalized individuals (13.0%, n  18/138). A low
number of individuals colonized with VRE, all of which were
identified to be vancomycin-resistant E. faecalis isolates, was also
detected (1.6%, n  5/306, consisting of 2 nonhospitalized and 3
hospitalized individuals of different ages) (see Table S2 in the sup-
plemental material).
The population structure of the E. faecium and E. faecalis iso-
lates is detailed below. For other enterococci, isolates of the same
species exhibited different PFGE types, with the exception of some
E. avium isolates (data not shown). All these species were resistant
to quinupristin-dalfopristin, were often resistant to erythromycin
(E. avium, E. hirae, E. raffinosus, E. gallinarum, E. casseliflavus) and
tetracycline (E. raffinosus), and eventually became resistant to
levofloxacin (E. raffinosus, E. gallinarum) and high concentrations
of streptomycin (E. avium, E. raffinosus, E. gallinarum) and gen-
tamicin (E. avium, E. raffinosus).
BAPS analysis of E. faecium population structure. A BAPS
analysis was used to infer the population structure of the E. fae-
cium isolates according to previous findings that demonstrated
that eBURST analysis is not sufficient to reliably delineate the
patterns of recent evolutionary descent of E. faecium (27, 53). The
analysis was repeated by taking into account the significant en-
largement of the MLST database (http://efaecium.mlst.net/), in
which the number of STs increased from 492 to 837 in the 2 years
since the time of publication of the original 2012 study (27).
A hierarchical BAPS clustering analysis of the currently avail-
able 837 E. faecium STs representing 2,402 isolates of different
origins yielded 8 BAPS groups. The majority of STs grouped in
BAPS 1, BAPS 2, BAPS 3, and BAPS 7 (15.1%, 39.7%, 31.5%, and
8.5%, respectively), while BAPS 4, BAPS 5, BAPS 6, and BAPS 8
were much more infrequently detected (1.3%, 1.9%, 0.8% and
1.2%, respectively). BAPS nested analysis subdivided BAPS 1 into
six subgroups (BAPSs 1.1 to 1.6) and BAPS 2 (BAPSs 2.1a, 2.1b,
2.3a, 2.3b), BAPS 3 (BAPSs 3.1, 3.2, 3.3a, 3.3b), and BAPS 7
(BAPSs 7.1 to 7.4) into four subgroups each (Table 1). The origi-
FIG 3 Proportion of nonhospitalized and hospitalized individuals colonized by ampicillin-resistant E. faecium by age group. The proportions of hospitalized/
nonhospitalized individuals colonized by ampicillin-resistant E. faecium were as follows for the different age groups: group I (0 to 19 years old), 0.75; group II (20
to 59 years old), 2.14; and group III (60 years old), 4.
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nal BAPS subgroups 2.1, 2.3, and 3.3 described by Willems et al.
(27) have now been split into two subgroups each, and here these
are arbitrarily designated BAPSs 2.1a and 2.1b, BAPSs 2.3a and
2.3b, and BAPSs 3.3a and 3.3b, for backwards compatibility (see
Fig. S3 in the supplemental material).
Next, we analyzed the congruence between the BAPS grouping
of the 492 STs using the BAPS assignment previously described by
Willems et al. (27) and the BAPS grouping from this study. A
correlation coefficient of 0.5958 indicates some discrepancies
between the partitioning of the 492 STs. These discrepancies,
probably related to the presence of an E. faecalis outgroup in the
BAPS analysis of Willems et al. (27), are mostly due to STs that
moved from BAPS 2 (15 STs), BAPS 3 (25 STs), and BAPS 5 (1 ST)
in the 2012 study (27) to BAPS 7 in our study (see Fig. S1 in the
supplemental material). Subsequently, the 492 E. faecium STs in-
cluded in the work of Willems et al. (27) were compared to the
BAPS grouping of the same 492 STs obtained using the extended
E. faecium MLST database of 837 STs in order to infer the influ-
ence of the sample size on BAPS assignment. The correlation co-
efficient analysis revealed almost perfect correlations for the clas-
sification of BAPS groups (0.9996) and BAPS subgroups (0.9988)
on the basis of 492 and 837 STs (see Fig. S2 and S3 in the supple-
mental material) and that only a small number of changes in BAPS
assignment (44/837 STs, 5.2%) occurred at either the group or the
subgroup level when the number of STs analyzed was significantly
increased. This further indicates that, for E. faecium, BAPS analy-
sis is both reproducible and robust and may accurately describe
the E. faecium population structure.
Since the extended data set of 837 STs slightly changed the
BAPS grouping of STs, we decided to recalculate the ORs to assess
the significance of the association between the BAPS groups and
the origins of the isolates (see Table S3 in the supplemental mate-
rial). This revealed that isolates from hospitalized individuals were
positively associated with BAPSs 2.1a and 3.3a and negatively
associated with all other BAPS groups. Conversely, isolates of all
BAPS groups from nonhospitalized individuals were negatively
associated with BAPSs 2.1a and 3.3a but positively associated with
BAPS 1.2 and BAPS 3.3b (Fig. 4).
Isolates of animal origin were negatively associated with BAPS
3.3a and BAPS 1.2 but showed a positive association with BAPSs
TABLE 1 E. faecium BAPS analysis data
BAPS group BAPS subgroup No. of STs % STs No. of isolates
BAPS 1 1.1 9 1.08 11
1.2 61 7.29 100
1.3 12 1.43 16
1.4 2 0.24 2
1.5 36 4.30 41
1.6 6 0.72 6
Subtotal 126 15.05 176
BAPS 2 2.1a 88 10.51 577
2.1b 133 15.89 321
2.3a 78 9.32 135
2.3b 33 3.94 49
Subtotal 332 39.67 1,082
BAPS 3 3.1 72 8.60 122
3.2 28 3.35 59
3.3a 107 12.78 679
3.3b 57 6.81 92
Subtotal 264 31.54 952
BAPS 4 11 1.31 11
BAPS 5 16 1.91 19
BAPS 6 7 0.84 9
BAPS 7 7.1 54 6.45 120
7.2 6 0.72 6
7.3 10 1.19 14
7.4 1 0.12 2
Subtotal 71 8.48 142
BAPS 8 10 1.19 11
Total 837 2,402
FIG 4 E. faecium BAPS group distribution by isolate origin. This distribution by isolate origin was calculated by inclusion of all isolates present in the E. faecium
MLST database (http://efaecium.mlst.net/) in August 2013.
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1.5, 2.1a, 2.1b, 2.3a, 2.3b, 3.1, 3.2, and 7.1 (Fig. 4; see also Table S3
in the supplemental material).
Genotypic relatedness of E. faecium isolates colonizing dif-
ferent age groups. The 150 E. faecium isolates obtained from 142
samples in this study corresponded to 75 distinct STs. Forty-seven
STs, representing 62.7% of the studied isolates, were STs first re-
ported here (see Table S1 in the supplemental material). The re-
maining ones corresponded to globally spread STs, like ST78 (n 
34, 7 STs), ST17 (n  14, 1 ST), and ST18 (n  6, 1 ST), and also
ST102 (n  20, 7 STs), ST22 (n  13, 9 STs), ST94 (n  12, 7 STs),
ST9 (2, 2 STs), and ST5 (1 ST), which were previously detected
among community-based isolates (see Table S1 in the supplemen-
tal material). The 75 STs were partitioned into BAPS 1 (24 STs,
22.0% of isolates), BAPS 2 (19 STs, 31.3% of isolates), BAPS 3 (20
STs, 36.7% of isolates), BAPS 7 (8 STs, 7.3% of isolates), and BAPS
8 (3 STs, 2.7% of isolates) (Fig. 5).
STs classified as BAPS 1 mainly corresponded to subgroup 1.2
(n  27 [81.2%], 19 STs). The proportion of isolates with STs that
grouped in BAPS 1 steadily decreased with age (Fig. 5 and 6), but
isolates of this group were still prevalent among the adults of
FIG 5 Population structure of E. faecium colonization by origin (A), by age group (B), and by susceptibility to ampicillin (C). AREfm, ampicillin-resistant E.
faecium; ASEfm, ampicillin-susceptible E. faecium.
FIG 6 E. faecium BAPS group distribution in human colonization by age group.
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group II (15/27). All strains within BAPS 1 were ampicillin sus-
ceptible and were mainly recovered from nonhospitalized persons
(23/27, P  0.01).
Within BAPS 2, subgroup 2.1a was predominant (70.2%, 33/
47) and increasingly detected with age, constituting the predom-
inant group in elderly patients (Fig. 5 and 6). Most isolates were
recovered in hospitals, exhibited ampicillin resistance, and har-
bored genes encoding adhesive surface protein (Esp) and colla-
gen-adhesin (Acm) (27/33 and 31/33, respectively), which are as-
sociated with colonization and pathogenicity (see Table S1 in the
supplemental material). STs contained within BAPS 2.1a were
ST117 (n  25), ST203 (n  4), ST80 (n  1), ST323 (n  1),
ST324 (n  1), and ST612 (n  1). E. faecium ST117 (strain show-
ing PFGE type CEfm1), apart from predominantly being a colo-
nizing clone, was also frequently associated with severe infections
in patients in HRyC (54). The other BAPS 2 subgroups, namely,
BAPS 2.3b (n  6 [12.8%], 5 STs), BAPS 2.3a (n  4 [8.5%], 4
STs), and BAPS 2.1b (n  4 [8.5%], 4 STs) were detected in both
hospitalized and nonhospitalized individuals (Fig. 5 and 6).
BAPS 3 was represented by subgroups 3.1, 3.2, 3.3a, and 3.3b.
Most isolates in BAPS 3.1 (6 STs, 18.2% of isolates) were ampicil-
lin-susceptible E. faecium isolates (9/10) from nonhospitalized in-
dividuals (7/10) (P  0.01) in age groups I and II (Fig. 5 and 6; see
also Table S1 in the supplemental material). Isolates in BAPS 3.3a
and BAPS 3.3b, previously described to be BAPS 3.3, differed in
their susceptibility to ampicillin. BAPS 3.3a (n  20 [36.4%], 14
ST17 and 6 ST18 isolates) comprised ampicillin-resistant E. fae-
cium isolates (19/20, P  0.01) that contained hyl from E. faecium
(16/20) and that were predominantly recovered from hospitalized
patients (16/20, P  0.01). Conversely, BAPS 3.3b (11 STs, 43.6%
of isolates) was significantly associated with ampicillin-suscepti-
ble E. faecium isolates (21/24, P  0.01), mostly from nonhospi-
talized persons (18/24, P  0.01).
BAPS 7.1 was the most predominant subgroup within BAPS 7
and comprised 5 STs representing 8 isolates. Finally, 3 STs com-
prising BAPS 8 and representing 4 isolates (2 ST698 isolates, 1
ST689 isolate, and 1 ST690 isolate), all of which were ampicillin-
susceptible E. faecium isolates (of which 3 were esp), were recov-
ered from nonhospitalized persons (see Table S1 in the supple-
mental material).
Differences in the rates of recovery of ampicillin-resistant en-
terococci (56.3%, 36/64) but not in the rates of recovery of van-
comycin-resistant enterococci (100%, 5/5) were noticed when
samples were cultured without or with selective enrichment. Am-
picillin-resistant E. faecium isolates that were cultured only after
enrichment mostly belonged to BAPS 2.1a (n  14; 9 ST117 iso-
lates, 3 ST203 isolates, 1 ST80 isolate, and 1 ST323 isolate) and
BAPS 3.3a (n  8; 6 ST17 and 2 ST18 isolates), and the majority of
these isolates were recovered from hospitalized patients. Isolates
of other BAPS groups were also found and are described in Table
S1 in the supplemental material.
BAPS analysis of E. faecalis population structure. Previous
studies based on MLST have suggested that recombination may
play an important role in the diversification of E. faecalis (17, 20,
21). As methods to infer evolutionary descent are highly influ-
enced by recombination, we analyzed the E. faecalis population
structure using Bayesian-based population genetic modeling im-
plemented in BAPS software, in addition to goeBURST analysis.
The sample included 1,310 isolates corresponding to 523 STs
available in a public database (http://efaecalis.mlst.net/).
A maximum likelihood-based phylogenetic reconstruction of
STs using concatenated MLST gene sequences placed ST80 far
apart from all other STs. When ST80 (amounting to only 1 isolate
from the MLST database) was excluded from the analysis to better
observe differences among tree features, practically all clades
showed low bootstrap support, which supports previous analyses
indicating that recombination may obscure the phylogenetic sig-
nal in nucleotide-based phylogenetic reconstructions in E. faeca-
lis. A hierarchical BAPS clustering analysis subdivided the E. faeca-
lis population into 5 BAPS groups (Fig. 7). Most of the STs and
isolates were distributed among BAPSs 1, 2, and 3 (44.7%, 27.5%,
and 20.6%, respectively), while BAPSs 4 (1.0%) and 5 (6.1%) rep-
resented only a small fraction of the STs analyzed (see Table S4 in
the supplemental material).
FIG 7 E. faecalis BAPS group distribution by origin. This analysis of the distribution by origin included all isolates present in the E. faecalis MLST database
(http://efaecalis.mlst.net/) in August 2013.
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OR calculations revealed that isolates from hospitalized pa-
tients were not significantly associated with any of the BAPS
groups, while BAPS 2 was positively associated with isolates from
nonhospitalized persons (OR  1.8507, P  0.01) and negatively
associated with animal isolates (OR  0.4659, P  0.01) (Fig. 7;
see also Table S5 in the supplemental material). Although signals
of microevolutionary hospital specialization within the different
BAPS groups were not found, some STs were enriched in isolates
from hospitalized patients: ST6 (107/123), ST64 (12/18), ST9 (22/
25), ST28 (16/17), ST87 (15/16), ST49 (4/4), ST88 (4/4), and
ST159 (4/4). Furthermore, isolates from animals were frequently
found to be ST58 (8/8), ST82 (25/27), and ST174 (11/11).
We also analyzed the E. faecalis population for traces of signif-
icant admixtures, as recombination is the driving force of admix-
ture dynamics and it might influence the evolvability of specific
amplified lineages. Admixtures were significantly present in some
STs from animal and community-based hosts. However, addi-
tional analyses revealed that admixtures were not significantly
found in STs that were unique or shared between hosts, STs from
hospital or nonhospital origin, STs from human and nonhuman
origin, or STs that represented antibiotic-resistant isolates (data
not shown). The combination of these results suggests that the
majority of E. faecalis isolates seem to belong to a single recom-
bining population that exchanges alleles regardless of the genetic
background (BAPS groups), ecological origin (isolation source,
hospital or nonhospital, human or nonhuman), or antibiotic re-
sistance phenotype.
The influence of the sample size (and, therefore, the underlying
diversity) in the accuracy of BAPS for establishing the E. faecalis
population structure was assessed using two data sets (see Fig. S4
in the supplemental material). The first data set consisted of 433
STs available in the MLST database (http://efaecalis.mlst.net/) be-
fore, including the new E. faecalis STs found in this study. The
second data set included 523 STs available in the MLST database at
the end of 2013. In both analyses, ST80 was excluded. The negative
correlation coefficient of 0.6439 obtained when comparing ST
assignments to BAPS groups of the set with 433 STs and those to
BAPS groups of the set with 523 STs was due to the split of BAPS
1 and BAPS 2 and the existence of three more BAPS groups when
using the second, larger data set (see Fig. S4 in the supplemental
material). These results indicate that in E. faecalis, BAPS analysis is
highly influenced by the sample size, as larger samples contain a
higher diversity of strains of different spatial-temporal origins.
Genotypic relatedness of E. faecalis isolates colonizing dif-
ferent age groups. The 130 E. faecalis isolates identified in this
study represented 58 STs (see Table S2 in the supplemental mate-
rial) that were partitioned into E. faecalis BAPS 1 (36.9%), BAPS 2
(40.0%), and BAPS 3 (23.1%). OR calculations revealed that none
of the three BAPS groups were significantly associated with a par-
ticular source or age group, as all the BAPS groups contained
isolates from both hospitalized and nonhospitalized individuals of
all ages in more or less equal numbers (Fig. 8).
Within BAPS 1 (n  48/130 [36.9%], 20 STs), ST6 (n  16) was
predominant and mainly comprised isolates from hospitalized
patients (13/16) and elderly individuals (11/13) (Fig. 8; see also
Table S2 in the supplemental material). All were multidrug resis-
tant (MDR), showing high levels of resistance to gentamicin or
streptomycin and also to erythromycin (100% of isolates), tetra-
cycline (93.8%, 15/16), and levofloxacin (87.5%, 14/16) and ex-
hibiting a highly similar PFGE profile (the ST6-H10 profile) iden-
tical to that of the widespread international mid-Atlantic clone,
which also causes bacteremia in HRyC (55). The 5 vancomycin-
resistant E. faecalis isolates (vanA; data not shown) found in this
study were also ST6-H10. Putative virulence factors asa1 (100%)
and gelE (81.3%) were identified in most ST6 isolates, while cylA
(56.3%) and esp (37.5%) were less frequently identified. Other STs
were represented by a very small number of isolates, which were
usually susceptible to antibiotics and which had a highly variable
presence of virulence factors.
Within BAPS 2 (n  52/130 [40.0%], 26 STs), ST40 isolates
(n  15) were predominant. These isolates were recovered from
both nonhospitalized and hospitalized individuals of different
ages, often harbored gelE (88.2%) and, less frequently, asa1
(41.2%) and esp (47.1%), and were resistant to tetracycline
(70.6%) and erythromycin (47.1%). Similar to the findings for
BAPS 1, other STs were represented by a single isolate or very few
isolates that often contained esp (see Table S2 in the supplemental
material). Among them were STs that were identified over several
decades to be ST55, ST30, or ST19 (31, 33).
Finally, BAPS 3 (n  30/130, 12 STs) was predominantly com-
prised of ST16 and ST179, previously classified to be CC16 by
goeBURST analysis (7 ST16 and 11 ST179 isolates). These STs also
included isolates from both nonhospitalized and hospitalized in-
dividuals of different ages that often harbored asa1 (99.4%), esp
(77.8%), or gelE (61.1%) and that were often resistant to different
antibiotics (see Table S2 in the supplemental material). Other STs
classified before as CC28 by goeBURST analysis (1 isolate each of
ST333, ST518, and ST519) and recovered from adults or elderly
hospitalized patients were also enriched in isolates that harbored
putative virulence factors (all harbored asa1, gelE, esp, and cylA)
and that were also MDR (with all isolates showing high levels of
resistance to gentamicin and streptomycin, tetracycline, erythro-
mycin, and levofloxacin) (see Table S2 in the supplemental mate-
rial).
DISCUSSION
This study describes a consistently high rate of recovery of entero-
cocci from feces from both hospitalized and nonhospitalized in-
dividuals and individuals in different age groups, similar to the
findings reported in other studies, in which the rates of recovery
ranged from 71% to 80% (1, 56, 57). These equilibrated constant
rates of colonization indicate a major resiliency of the genus En-
terococcus under heterogeneous conditions imposed by age,
changing environments, and highly variable host niches. Previous
studies (6, 58–60) have described changes in the rates of recovery
of the genus Enterococcus in fecal microbiota with aging, which
was not confirmed in our work, and a consistent predominance of
the species E. faecalis in the fecal flora of young and elderly indi-
viduals, which is essentially consistent with our findings, with the
important exception of the growing predominance of E. faecium
in elderly individuals, particularly hospitalized elderly patients.
Other studies yielded contradictory information about the fre-
quency and diversity of E. faecium and other enterococcal species
in the fecal microbiota (1, 15). Shifts in the prevalence of Entero-
coccus populations might result from fluctuating changes in the
environmental conditions over time as a result of changes in diet
(10) or changes in health status or antibiotic treatment (1, 5, 61–
64), all of which delineate particular selective landscapes in hos-
pitals (58, 61). Aging interacts with these conditions, and age-
dependent enterococcal colonization dynamics have also been
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demonstrated for chickens and calves (1, 65), probably as an in-
teraction with antibiotic consumption (1, 66, 67).
Considering the currently available diversity of known geno-
types, the superimposing of goeBURST analysis of the clonal
relationship among multiple isolates with BAPS allowed the de-
tection of a low number of presumptive evolutionarily and func-
tionally heterogeneous clades for the E. faecium species (22, 25–
27). BAPS 1 E. faecium isolates, associated with the clade B
phylogenetic lineage (a clade with isolates with pathways of com-
plex carbohydrate utilization linked to host diet and with a major-
ity of ampicillin-susceptible E. faecium strains), were highly rep-
resented in the different age groups, although their incidence was
slightly reduced in the elderly (26, 27). Conversely, BAPS 2.1a and
BAPS 3.3a (containing most of the ampicillin-resistant E. faecium
strains), associated with clade A1 (26, 27) and mostly found in
elderly hospitalized patients, represented E. faecium strains that
are spreading in hospitals and causing clinical infections. The rates
of these populations in the nosocomial and the community set-
tings might be underestimated, as we have demonstrated here that
if you do not preenrich the sample, some of the clones that are
even more widespread might escape screening, probably due to
low colonization densities. The observed population structure of
E. faecium indicates a certain specialization of subpopulations for
the colonization of particular age groups, which is usually associ-
ated with several other host-associated factors and also differences
in the selectable characteristics harbored by the isolates, such as
antibiotic resistance genes. Interestingly, some groups evolve in-
dependently from the acquisition of ampicillin resistance, sug-
gesting a certain genetic isolation, which seems to be the case for
different lineages within BAPS 3.3b, BAPS 1, and BAPS 2. These
results further confirm a population structure comprised of
ecotypes representing specialization in different hosts (16, 68).
E. faecalis populations showed a considerable level of genetic
diversity. Because of that and in contrast to the findings for E.
faecium, no BAPS groups were significantly associated with aging,
hospital exposure, or host species, and with the exception of BAPS
2, none of the BAPS groups showed a positive association with
nonhospitalized individuals. The wide recovery of certain STs
(e.g., ST6, ST16, ST40, or ST55) able to colonize hospitalized and
nonhospitalized humans (this study) and also animals (30, 31, 69)
may be related to the more generalist lifestyle of this enterococcal
species, which weakens the possibility of the recognition of
ecotypes associated with a particular environment, at least by
using the same approach that was so useful with E. faecium. How-
ever, despite possible limitations in the methods available for
analysis of the E. faecalis population structure, it is now clear that
FIG 8 Population structure of E. faecalis colonization by origin (A), by age group (B), and by susceptibility to gentamicin (C). GmS, gentamicin susceptible;
HLRGm, high-level resistance to gentamicin.
Tedim et al.
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certain multihost E. faecalis subpopulations, such as ST6 or ST16,
have developed different strategies of adaptation to harsh and
fluctuating habitats (31, 33). Among these are the lack of loci
for cluster regulatory interspaced short palindromic repeats
(CRISPR; a bacterial defense system against foreign DNA that
facilitates the acquisition of foreign DNA, such as antibiotic resis-
tance and virulence genes) (70) and the frequent acquisition of
phages (71).
Other enterococcal species have largely been recognized to be
part of the human fecal microbiota (1), and this was confirmed in
our study. The inverse parallel trends in the frequencies of popu-
lations of these species and the frequency of E. faecium are of
particular interest. The dynamics of colonization by these species
might reflect differences in the functional requirements of the host
with age and deserve further analysis.
This study provides a novel, integrated, and comprehensive
image of the landscape of Enterococcus populations in a balanced
amount of nonhospitalized and hospitalized individuals of differ-
ent ages and suggests that a number of enterococcal lineages might
be predominant in certain age groups and/or hospital environ-
ments. However, a number of clones are spread in different types
of individuals and their prevalence is reduced in others in a kind of
source-sink dynamics (72–74), with frequent cases of coexistence
and the preservation of rare clonal populations being found. This
suggests a frequency-dependent evolution of enterococcal popu-
lations which prevents the extinction of different genotypes that
do not play equivalent ecological roles (75–78).
The work also illustrates the high degree of plasticity of E.
faecium and E. faecalis genomes, as reflected by admixture analysis
(27; this study), which showed variable intraclonal PFGE patterns
(31, 63) (see Tables S1 and S2 in the supplemental material) and
recombination of large fragments of the chromosome (79–83;
our unpublished results). The consequences of such a high
degree of variability have scarcely been explored from a popu-
lation-based perspective. However, it can be expected that ge-
nome plasticity would contribute to the variation and selection
of genes from a common intraspecies genetic pool needed for
adaptation to environments imposing different stress condi-
tions. Future progress in understanding enterococcal popula-
tion biology will require a global analysis combining many eco-
logical features, population dynamics, and population genetics
(78, 84, 85).
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ABSTRACT The phylum Firmicutes is one of the most abundant
groups of prokaryotes in the microbiota of humans and animals
and includes genera of outstanding relevance in biomedicine,
health care, and industry. Antimicrobial drug resistance is now
considered a global health security challenge of the 21st century,
and this heterogeneous group of microorganisms represents a
signiﬁcant part of this public health issue.
The presence of the same resistant genes in unrelated
bacterial genera indicates a complex history of genetic
interactions. Plasmids have largely contributed to the spread
of resistance genes among Staphylococcus, Enterococcus,
and Streptococcus species, also inﬂuencing the selection and
ecological variation of speciﬁc populations. However,
this information is fragmented and often omits species outside
these genera. To date, the antimicrobial resistance problem has
been analyzedunder a “single centric” perspective (“gene tracking”
or “vehicle centric” in “single host-single pathogen” systems)
that has greatly delayed the understanding of gene and plasmid
dynamics and their role in the evolution of bacterial communities.
This work analyzes the dynamics of antimicrobial resistance
genes using gene exchange networks; the role of plasmids in
the emergence, dissemination, and maintenance of genes
encoding resistance to antimicrobials (antibiotics, heavy metals,
and biocides); and their inﬂuence on the genomic diversity of the
main Gram-positive opportunistic pathogens under the light
of evolutionary ecology. A revision of the approaches to
categorize plasmids in this group of microorganisms is given
using the 1,326 fully sequenced plasmids of Gram-positive
bacteria available in the GenBank database at the time the article
was written.
INTRODUCTION
Firmicutes constitutes one of the dominant bacteria
phyla of human and animal gut microbiota. It comprises
a number of genera of outstanding relevance in health
care and industry such as Staphylococcus, Listeria, and
lactic acid bacteria (LAB), a group of microorganisms
that ferment carbohydrates into lactic acid and that
includes the genera Enterococcus, Lactobacillus, Lacto-
coccus, Leuconostoc, Pediococcus, Streptococcus, and
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Weisella. Furthermore, species of Negativicutes (Sele-
nomonas, Veillonella) and Clostridium have clinical in-
terest for humans and animals (Table 1).
Antibiotic resistance (AbR) in this heterogeneous
group of organisms constitutes a signiﬁcant part of the
public health problem. The most recent report by the
Centers for Disease Control and Prevention in the United
States provides a ranking list of AbR human pathogens
according to their threat level to society and the atten-
tion that such a problem requires. Gram-positive or-
ganisms were grouped in the categories of “urgent”
(Clostridium difﬁcile), “serious” (methicillin-resistant
Staphylococcus aureus [MRSA], antibiotic-resistant
Streptococcus pneumoniae, vancomycin-resistant En-
terococcus [VRE]), and “concerning” (erythromycin-
resistant Streptococcus pyogenes and clindamycin-
TABLE 1 Fully characterized plasmids from low G+C bacteria available in GenBank database (updated September 2014)
Plasmid
Phylum/class Order Family Total AbR MetR AbR+MetR
Actinobacteria 252 16 40 7
Actynomicetales Streptomycetaceae 56 2 4 2
Corynebacteriaceae 38 10 7 3
Nocardiaceaea 30 0 9 0
Mycobacteriaceaeb 29 2 7 2
Micrococcaceaec 27 1 7 0
Pseudonocardiaceaed 9 0 1 0
Propionibacteriaceae 7 0 0 0
Gordonaciaee 6 0 3 0
Microbacteriaceaee 4 0 0 0
Streptosporangiaceaef 2 0 0 0
Nocardiopsaceae 1 0 0 0
Nocardioidaceae 1 0 0 0
Promicromonosporaceaeg 1 0 0 0
Micromonosporaceae 1 0 0 0
Kineosporiineae 2 0 1 0
Brevibacteriaceae 2 0 0 0
Frankiaceae 3 0 0 0
Tsukamurellaceae 1 0 0 0
Biﬁdobacteriales Biﬁdobacteriaceae 29 0 0 0
Firmicutes 1,073 244 178 85
Negativicutes Selenomonadales 17 0 1 0
Clostridia 86 7 4 0
Erysipelotrix 1 0 0 0
Bacilli 969 237 121 85
Lactobacillales
Lactobacillaceae 172 16 19 3
Streptococcaceae 133 15 4 0
Enterococcaceae 74 24 3 2
Leuconostoc 29 0 9 0
Carnobacteriaceae 6 0 1 0
Oenococcus 6 0 0 0
Weisella 4 0 0 0
Bacillales Staphylococcaceae 275 175 118 80
Bacillaceae 223 5 9 0
Listeriaceae 14 1 8 0
Paenobacillaceae 9 0 0 0
Macrococcus 8 1 0 0
Planococcaceae 6 0 1 0
Bacillales group XII 4 0 0 0
Alicyclobacillaceae 3 0 0 0
Bhargaceae 2 0 0 0
aNocardiaceae (4 Nocardia, 25 Rhodococcus)
bMycobacteriaceae (Mycobacterium plus Amycolicicoccus)
cMicrococcaceae (4 Micrococcus, 23 Arthrobacter)
dPseudonocardiaceae (2 Amycolatopsis, 6 Pseudonocardia, 1 Saccharomonospora)
eMicrobacteriaceae (4 Clavibacter)
fStreptosporangiaceae (1 Planobispora, 1 Streptosporangium)
gPromicromonosporaceae (Xylanimonas)
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resistant Streptococcus agalactiae) on the basis of the
limited therapeutic options to treat infections caused
by these bacteria-resistant variants (1). LAB, which are
used as probiotics and in the preparation of various
products (dairy, fermented meat and seafood, fermented
cereals and vegetables, wine), are deﬁned as “generally
regarded as safe” (GRAS) microorganisms by the U.S.
Food and Drug Administration. However, the potential
risk to transfer acquired AbR genes recently found in
LAB species to animal and human pathogens is a cause
for concern. AbR LAB may also contaminate industrial
processes, leading to economic losses (2). In addition,
the possibility that opportunistic or commensal bacteria
and nonpathogen organisms could serve as reservoirs
of AbR genes is increasingly recognized (3). Conse-
quently, several European and American regulatory
agencies have recently recommended the mandatory
screening of some species such as Enterococcus faecalis
and Enterococcus faecium as indicators of the presence
of AbR in foods and food animals and as a mirror of
the patterns of antibiotic use in veterinary medicine and
agriculture (4, 5). Finally, it is worth mentioning that
AbR in a context of the wide use of antibiotics favors
the selection of clonal lineages of multihost species with
zoonotic potential (e.g., S. aureus, E. faecium, Clos-
tridium perfringens) as well as emblematic zoonotic spe-
cies such as Listeria monocytogenes (see below).
The presence of the same AbR genes in ecologically
connected (but also in unconnected) bacterial genera,
mentioned above, indicates a complex history of genetic
interactions in which AbR genes have parasitized the
natural circuits of adaptive gene ﬂow. Plasmids have
largely contributed to the spread of AbR and other
adaptive genes among members of Staphylococcus, En-
terococcus, and to a lesser extent, species of the Strep-
tococcus pyogenic group (6–8), thus inﬂuencing the
selection of particular subspecies populations due to the
acquisition of AbR (8–10). However, the global adap-
tive role of plasmids of other genera remains largely
unexplored outside single pathogens colonizing or in-
fecting single “relevant” hosts. The “single centric” pers-
pective, focusing on “gene tracking” or “vehicle centric”
(plasmid, transposon, or other mobile genetic elements
[MGEs]) in “single host-single pathogen” systems ham-
pers a comprehensive view of gene and plasmid dy-
namics and their role in the evolvability of bacterial
communities. An integrative view of plasmid ecology is
needed to understand community evolvability.
In this work, we analyze the development of AbR in
Firmicutes within an ecological framework using gene
exchange networks. We also discuss the role of plasmids
in the emergence, spread, and maintenance of genes
encoding resistance to antimicrobials (antibiotics, heavy
metals, and biocides) and their inﬂuence on the genomic
diversity of the main Gram-positive opportunistic path-
ogens in the light of evolutionary ecology. Finally, a
critical revision of plasmid classiﬁcations in this group
of microorganisms is also provided under this eco-evo
perspective by analyzing the 1,326 fully sequenced plas-
mids of Gram-positive bacteria (Firmicutes and Actino-
bacteria) available in the GenBank database at the time
this article was written.
AN ECO-EVO PERSPECTIVE TO
ANALYZE HGT IN FIRMICUTES
Recent phylogenomic analyses using networks revealed
a history of horizontal gene transfer (HGT) events even
among highly structured and ecologically disconnected
groups of bacteria (11–13). These events are more likely
to occur in the case of donors and recipients with a
similar G+C content (differing in <5% for 86% of
connected pairs) (14) and involving plasmids able to me-
diate exchange of information between close or distant
chromosomal backgrounds (12, 15). Although limited
by the current number of available genome sequences,
such studies evidenced sound differences in “betweeness”
among different bacterial groups and plasmids of
Firmicutes. LAB frequently undergo HGT events among
similar species (11), with streptococci acting as a hub
for interactions with more distant ecological groups (12),
and some plasmids of the Inc18 family possibly contrib-
uting to the spread of AbR genes among different bacte-
rial species (15). To analyze this situation in more detail,
we constructed a gene exchange network that comprises
all genes conferring resistance to antibiotics and heavy
metals described in Firmicutes so far (Fig. 1 and 2). This
network clearly shows that many resistance genes in
different bacterial genera can present plasmid and/or
chromosomal locations, illustrating the diversity of in-
teractions, often plasmid mediated, within bacterial com-
munities (Fig. 1 and 2). Available (and often fragmented)
knowledge from different ﬁelds enabled us to state that
the dynamics of bacterial populations are inﬂuenced
by the interplay of selection processes at different levels
of organization (genes, MGEs, clones, species) and their
associated environments (16–20). Because of that, the
complexity resulting from such interplay cannot be un-
derstood using either single centric studies or the above-
mentioned phylogenomic analysis of HGT networks.
The presence of the same genes in different genetic
contexts implies contacts and exchanges between bac-
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FIGURE 1 Protein content network (PCN) of AbR proteins found in plasmids and chro-
mosomes of Firmicutes and Actinobacteria. To determine the AbR protein catalog of
Gram-positive strains (chromosomes and plasmids), a Blastp search was performed of
all their proteomes against the ARG-ANNOT database (http://en.mediterranee-infection
.com/article.php?laref=283&titre=arg-annot) using a cut-oﬀ of 1e-30 and 85% of identity.
The presence of the Gram-positive AbR proteins identiﬁed above in all bacterial species
(only complete sequences, not partial) was determined using a similar Blast search (blastp,
1e-30 E-value and 85% identity) against the NCBI GenBank database. The nodes corre-
spond to bacterial species (circular nodes; each color indicates one genus) and AbR pro-
teins (square nodes). Nodes were connected by an edge when a positive hit between AbR
proteins and one or more strains of a given species were identiﬁed. Edges further indicate
the location of the AbR genes associated with each AbR protein of the Gram-positive
catalog. Solid lines represent chromosomal location, and dotted lines represent plasmid
location. When an AbR gene was located in both chromosomes and plasmids, both lines
were plotted. doi:10.1128/microbiolspec.PLAS-0039-2014.f1
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teria belonging to different genera, probably facilitated
in complex bioﬁlms and environments allowing high
local bacterial densities. HGT via transduction or con-
jugative mechanisms has been extensively documented
in Lactobacillales and is a prominent process for niche-
speciﬁc adaptation in different genera (12, 21–23), with
plasmids and conjugative transposons being the most
relevant providers of communal adaptive gene pools in
microbial ensembles sharing complex niches.
An important question is if resistance genes contrib-
uted to the recombination between different replicons
and, consequently, to their evolvability. The frequent
association of resistance genes with site-speciﬁc recom-
bination systems and insertion sequences located either
in plasmids or in chromosomes favors homologous re-
combination and therefore different events of integra-
tion or excision, as well as the interplay among different
elements (19, 24–28). Restriction-modiﬁcation (RM)
systems and clustered regularly interspaced short palin-
dromic repeats (CRISPR) are the main posttransfer bar-
riers protecting a given host cell from invasion by foreign
DNA either by conjugation transformation or trans-
duction (9, 29, 30). Some RM systems speciﬁcally limit
the acquisition of plasmids to some pathogens which
may inﬂuence their clonal structure (e.g., RM types I, III,
and IV in S. aureus) (31, 32). This may also explain the
lack of plasmids in certain species such as S. pneumoniae
or the narrow host range of plasmids from some Clos-
tridium species (33, 34). Anti-RM systems such as ana-
logues of ArdA (alleviation of restriction of DNA)
proteins that act against type I restriction systems (de-
tected in Tn916 and CTn6000) or other genes predicted
to be involved in methylation (e.g., in CTn6000 and
Tn1721) are involved in the restricted spread of certain
MGEs, as well as in certain clonal expansions. There
is evidence that the presence of complete CRISPR loci
is inversely proportional to the presence of MGEs in
Clostridium and Staphylococcus (34, 35), a situation
that has also been suggested to occur for Streptococcus
and Enterococcus (34, 36, 37). In agreement with this
statement, Fig. 1 and 2 reﬂect a heterogeneous distri-
bution of AbR and heavy metal and biocide resistance
(MetR and BcR) genes in different genera. Particularly
interesting is the conﬁnement of vancomycin resistance
within enterococci and of some AbR, MetR, and BcR
genes within staphylococci and clostridia, a situation
that is in part due to the barriers shaping different pop-
ulations (see next sections).
Fluctuating environments, concentration gradients,
and high population sizes, all frequent in different
“source-sink” ecologies such as bacterial populations
under antimicrobial selective pressure, favor DNA trans-
fer and the selection of some clonal and plasmid variants
(38–42). Such selective processes favor the emergence of
novel variants, resulting from genetic drift, or migration
to heterogeneous environments. Recent studies demon-
strated that plasmid transfer occurs in vivo more fre-
quently than in experimental evolution assays (43), and
that gradients in populations under selection pressure by
diverse antimicrobials favor selection of multidrug re-
sistance (MDR) plasmids (44, 45).
The inﬂuence of plasmids has been extensively dis-
cussed in the literature from different evolutionary pers-
pectives (20, 46–48), but only limited information about
plasmid ecology and the speciﬁc roles that plasmids
actively play within microbial systems in situ is avail-
able. Mosaic MGEs have often been documented in
Firmicutes, reﬂecting a different epidemiological history
of contacts with strains of the same or different species.
Some mosaic MGEs have been ﬁxed, making the inter-
pretation of results by using traditional classiﬁcation
schemes extremely difﬁcult (49).
PLASMID DIVERSITY AND
CLASSIFICATION SYSTEMS
Efforts in plasmid characterization and classiﬁcation
are justiﬁed for the understanding of plasmid biology.
Nowadays, plasmid categorization is relevant from the
public and environmental health perspective to follow
the movement of genes coding for resistance to anti-
microbials (antibiotics, heavy metals, biocides), coloni-
zation and virulence factors for humans and animals,
and/or other adaptive traits that drive ecological success
(bacteriocins, metabolic traits) and consequently in-
crease the population size of bacteria harboring MGEs.
In fact, only a “representative diversity” of bacterial
plasmids has been systematically analyzed in a few
genera of multihost opportunistic pathogens of interest
in biomedicine, with a particular emphasis on species
of the Enterobacteriaceae, Pseudomonadaceae, Staphy-
lococcaceae, and Enterococcaceae families (7, 50–53).
The diversity of plasmids from Lactococcus (54), Lac-
tobacillus (55), C. perfringens (56), Micrococcus (57),
and Biﬁdobacterium (58) has also been analyzed from
different perspectives.
Plasmid diversity within a particular bacterial species
in the Firmicutes phylum started to be comprehensively
analyzed in the 1960s just after the discovery of staphy-
lococcal plasmids. These elements were initially cate-
gorized into three main classes designated by roman
numerals on the basis of size, replication machinery,
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ability to be transferred, phenotypic and functional
characteristics, and host range (7, 51, 53, 59, 60). Class I
comprised high copy number plasmids (10 to 60 copies
per cell) of less than 5 kb with a rolling circle replica-
tion (RCR) mechanism that often harbored one or two
AbR genes (usually conferring resistance to tetracycline,
chloramphenicol, macrolides, and trimethoprim). Class
II comprised low copy number plasmids (4 to 6 copies
per cell) of 15 to 40 kb, with a theta replication mecha-
nism, which typically carried resistance to antibiotics
(β-lactams, aminoglycosides, and macrolides), heavy
metals (arsenic, cadmium, and mercury), and/or anti-
septics (quaternary ammonium compounds). Class III
comprised plasmids similar to those found in class II
which were transferred by conjugation (61). Afterward,
Richard Novick and others classiﬁed staphylococcal
plasmids in 15 incompatibility (Inc) groups based on the
ﬁnding that two plasmids with the same replication (rep)
proteins cannot be stably maintained in the same cell
(50, 62, 63). Plasmids of most Inc groups correspond
to class I (10 Inc groups of apparently closely related
plasmids) and class II (diverse plasmids that belong to
the same Inc group) (53). Following the same Inc nu-
meral designation criteria, Brantl et al. categorized a few
streptococcal plasmids that replicated via a theta mecha-
nism and that were regulated by an antisense RNA that
mediated transcriptional attenuation, such as the Inc18
family (64) (see below). Pheromone-responsive plasmids
of enterococci were also subgrouped into different in-
compatibility groups on the basis of distinct responses to
small peptides or pheromones which are secreted by
plasmid-free donors (65).
A multiplex-PCR typing system based on the diversity
of replication initiator proteins (RIPs) developed by
Jensen et al. (59) has recently been applied for the char-
acterization of Firmicutes plasmids, mainly staphylo-
cocci (66) and enterococci (67–71) of human, animal,
and environmental origin. According to this typing sys-
tem, RIP variants are designated as “rep” followed by a
subindex number and are arbitrarily called Rep fami-
lies. Although this system is very useful to enlarge the
knowledge of scarcely explored plasmid diversity in con-
temporary isolates of enterococci and staphylococci, its
application is limited to known plasmids, mainly AbR
plasmids of these genera, as illustrated in various surveys
and this study (59, 66, 68, 71).
The diversity of mobilization (MOB) systems has also
recently been used to classify plasmids and other con-
jugative elements in different bacterial groups includ-
ing Firmicutes (72, 73). The approach relies on the
variability of relaxases (RELs), which form part of the
plasmid MOB region, are involved in the initiation of
DNA transfer, and that, aside from the origin of transfer
(oriT), are present in both conjugative and mobilizable
plasmids as well as in other conjugative elements (74).
To date, only ﬁve (MOBP, MOBQ, MOBV, MOBC, and
MOBT) out of seven known REL families have been
identiﬁed in Firmicutes (7, 72, 74). MOBQ, MOBC, and
MOBT are present in conjugative elements, and MOBV
is present in mobilizable plasmids. MOBP has been iden-
tiﬁed in both conjugative and mobilizable elements (7,
72, 73). The application of this PCR-based classiﬁca-
tion scheme is obviously limited to the typing of known
RELs. Frequent plasmidmosaicism, redundancy, and co-
existence of different “core” genes, and the interplay of
plasmids with other conjugative elements that contain
homologs of RIPs and RELs, complicates the establish-
ment of a robust plasmid core ontology and precludes
the use of typing approaches similar to those used in
Gram-negative organisms such as plasmid multilocus
sequence type (http://pubmlst.org/plasmid/).
Whole-genome (plasmid/chromosome) sequencing
provides accurate and nonbiased information on plas-
mid backbones. Although the number of fully sequenced
FIGURE 2 PCN of metal-biocide (MetR/BcR) proteins found in plasmids and chromo-
somes of Firmicutes and Actinobacteria. To determine the MetR/BcR protein catalog of
Gram-positive strains (chromosomes and plasmids), a Blastp search was performed of all
their proteomes against the BacMet database (http://bacmet.biomedicine.gu.se/) using a
cut-oﬀ of 1e-30 and 85% of identity. The presence of the Gram-positive MetR/BcR pro-
teins identiﬁed above in all bacterial species (only complete sequences, not partial) was
determined using a similar Blastp search (blastp, 1e-30 evalue and 85% identity) against the
NCBI GenBank database. The nodes correspond to bacterial species (circular nodes) and
MetR/BcR proteins (triangular nodes). Nodes were connected by an edge when a positive
hit between MetR/BcR proteins on one or more strains of a given species was identiﬁed.
Edges further indicate the location of the MetR/BcR genes associated with each MetR/BcR
protein of the Gram-positive catalog. Solid lines represent chromosomal location,
and dotted lines represent plasmid location. When a MetR/BcR gene was located in both
chromosomes and plasmids, both lines were plotted. doi:10.1128/microbiolspec.PLAS
-0039-2014.f2
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plasmids in databases is still limited, we used a plasmid
homology network analysis of the 1,326 fully sequenced
plasmids of Firmicutes and Actinobacteria to study the
diversity of plasmids carrying genes coding for AbR
and MetR/BcR and the impact of plasmids in the evolv-
ability of contemporary AbR bacterial populations of
Firmicutes.
Figures 3 and 4 illustrate the existence of group-
speciﬁc plasmid populations, with a number of plasmids
being shared between Lactobacillales (mainly Entero-
coccus and Streptococcus) and Bacillales (Staphylococ-
cus), which are greatly implicated in the spread of AbR
and MetR/BcR. These shared plasmids include RCR and
theta-replicating plasmids of different families, which
have been recently analyzed at the molecular level (7,
75, 76). Next in this section, we will analyze the diversity
of these groups and highlight the usefulness of current
typing systems for each group. However, it is of note
that the main genera of Firmicutes carry a variable
number of plasmids containing several replication and
transfer systems, some of them being able to be trans-
ferred. The interplay between genes, plasmids, and
populations will be analyzed under an ecological per-
spective in the section “Gene and Plasmid Flow Shapes
the Evolutionary Ecology of Firmicutes.”
Rolling Circle Replication Plasmids
RCR plasmids are classiﬁed in a few families according
to the RIP and the double origin of replication (dso) (see
comprehensive reviews in references 75, 77–79). Most of
the RCR plasmids known to date have been found in
species of Firmicutes, Proteobacteria, Cyanobacteria,
and Spirochaetes, and some of them have been identiﬁed
in genetically distant hosts. The production of single-
stranded DNA and the mechanism of replication of these
plasmids enhance their ability to recombine, by either
homologous recombination or illegitimate recombina-
tion with other RCRs and theta replicating plasmids
FIGURE 3 Plasmid homology network. The genomic homology network was performed
using “All-versus-All” genomic Megablast (238) of 1,326 fully sequenced plasmids from
low G+C bacterial species (Firmicutes and Actinobacteria phyla) available at public gene
databases. The nodes correspond to bacterial plasmids (circular nodes; diﬀerent colors
representing diﬀerent genera). Two nodes are connected by an edge if they share ho-
mologous DNA. doi:10.1128/microbiolspec.PLAS-0039-2014.f3
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(Fig. 5 to 10 and text below). RCR plasmids are also
frequently integrated into chromosomes (e.g., pUB110
within SCCmec cassettes in methicillin-resistant S. aureus
or pC194/pUB110 [catA] in S. pneumoniae genomes) (80).
In Firmicutes, four groups of RCR plasmids have been
deﬁned according to RIP similarity, namely Rep_trans
(PF025486), Rep_1 (PF14046), Rep_2 (PF01719), and
Rep_L, which are historically represented by plasmids
pT181, pUB110, pMV158, and pSN2, respectively
(53, 75, 77, 81). Within these families, some members
have been ﬁxed by selection and might be maintained
by the vertical expansion of certain clones, aside from
HGT, with the emergence of variants from time to time.
Figures 11 to 14 and Supplementary Table S1 show the
similarity of genes encoding RIPs of all available fully se-
quenced plasmids and the correspondence to the Rep
families described by Jensen et al. (59). These plasmidsmay
contain different adaptive genes (AbR, heat shockproteins,
or bacteriocins), although most of them are classiﬁed as
“cryptic,” without any clear adaptive function.
The Rep_1 family
The Rep_1 family comprises plasmids with RIPs of the
families rep13 (associated with catA7, which encodes re-
sistance to chloramphenicol), rep21 (cryptic or eventually
carrying lnuA, coding for resistance to lincosamides),
rep22 (carrying a variety of AbR genes), and other under-
represented members categorized as repUnique7. How-
FIGURE 4 PCN of AbR and MetR/BcR proteins located on plasmids of Firmicutes and
Actinobacteria. PCN of AbR and MetR proteins found in Gram-positive plasmids. We
formed the PCN by representing plasmids as circular nodes, AbR as square nodes,
and MetR/BcR as triangular nodes, connecting two nodes (plasmid and AbR or MetR/BcR)
if one plasmid has this AbR or MetR/BcR. The presence of the MetR/BcR gene was de-
termined by blasp of all plasmid proteins against the BacMet database. The presence
of the AbR gene was determined by blasp of all plasmid proteins against the ARG-
ANNOT database. The colors for the genus are the same as those in Fig. 3. doi:10.1128
/microbiolspec.PLAS-0039-2014.f4
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ever, the available typing systems are unable to classify
relevant Rep_1 plasmid members including plasmids
containing heat shock proteins in Streptococcus thermo-
philus, plasmid-borne bacteriocins in S. pyogenes (82),
or S. pneumoniae plasmids (80, 83), among others
(Fig. 11). Remarkably, RIPs of this Rep_1 group are
often detected in mosaic plasmids of staphylococci and
enterococci (Fig. 5 and 7), some plasmid chimeras being
ﬁxed and persistently recovered for years. For example,
emblematic mosaics theta/RCR plasmids of staphylo-
cocci (e.g., cointegrates of RepA_N/pSK41 and Rep_1/
pUB110, which encode resistance to gentamicin) and
E. faecalis (e.g., pAMα1) have both been selected in
those lineages since the early 1970s (7, 71, 84).
The Rep_trans group
Plasmids of the Rep_trans group are clustered in two
large branches (Fig. 12). One branch comprises plasmids
of Staphylococcus that harbor tetK (rep7) and catA8/
catA7 (rep7b) with different MOB genes. Such plasmids
have been reported in S. aureus since their ﬁrst detection
in the early 1950s (84) and were eventually described
in contemporary E. faecalis isolates (68, 85). A second
branch contains pRI1-like plasmids (rep14), which cor-
respond to plasmids of different enterococcal species
(E. faecium, Enterococcus hirae, Enterococcus mundtii)
isolated from foodborne animals and hospital patients
(7, 59, 71, 86). These plasmids can be mobilized by other
AbR conjugative theta replicating plasmids present in
the same cell (71, 87), and it seems they are widely
spread among enterococcal populations.
The Rep_2 group
The Rep_2 group (Fig. 13) comprises numerous pro-
miscuous elements able to replicate in distant hosts
which have been extensively analyzed at the molecu-
lar level by Espinosa et al. using pMV158 as a model
(75). Plasmids carrying ermT (an inducible methylase
conferring resistance to ﬁrst-line macrolide-lincosamide
antibiotics such as erythromycin and clindamycin), from
group A Streptococci (GAS) and group B Streptococci
(GBS), are the sole representatives of AbR in this group.
They appear to be responsible for the rise of macrolide
resistance among GAS and GBS in hospitals since the
mid-1990s (8).
The Rep_L group
In contrast to the above-mentionedRCRplasmid groups,
proteins within the Rep_L family (Fig. 14) are repre-
sented in public gene databases by a very few RIPs of
Staphylococcus, Selenomonas (class Negativicutes), and
Butyrivibrio (Clostridia) species, all these genera being
frequent components of the oral ﬂora of humans and
the rumen of some animal species. These plasmids are
responsible for the widespread ermC in staphylococci
(rep10). Interestingly, the emergence of both ermT-Rep_2
and ermC-Rep_L plasmids seems to be associated with
the abusive use of tylosin in cattle, ampliﬁed by the lo-
cation of these AbR genes in RCR plasmids, and further
transferred to other populations of Firmicutes (8, 88, 89).
RCR plasmids were associated with REL of the group
MOBV1 (72, 73, 75), although representatives of all
the RCR groups mentioned above that lack REL were
detected in databases. Interestingly, RELs ofMOBP1 and
MOBT families were also found, and their presence is
probably due to the co-integration of RCR with theta-
replicating plasmids (see below).
Theta-Replicating Plasmids
Four families of plasmids that replicate by a theta
mechanism, three that comprise conjugative plasmids
(RepA_N, Inc18, and pMG1) and one in groups small
nonconjugative elements (Rep_3), are involved in the
capture, spread, and maintenance of AbR among dif-
ferent genera of Firmicutes. Members of the RepA_N
and Inc18 families are often enriched in insertion se-
quences, mainly IS257, IS256, IS1216, ISL3, and IS431,
that facilitate co-integration, rearrangements, and de-
letions among elements of Staphylococcus, Enteroco-
ccus, LAB, and Clostridium of different origins (6, 7,
28, 90–95). Such recombination events seem to have
facilitated the origin of the great mosaicism of MDR
plasmids that often carry more than one RIP, lack trans-
fer andmaintenance modules, and eventually carry more
than one REL (Fig. 5 and 7). The transfer mechanisms
of RepA_N pSK41-like plasmids and the Inc18-like
plasmids are similar and are categorized as type IV se-
cretion systems (96).
The Rep_3 family
Plasmids containing RIPs with the Rep_3 domain
(Fig. 15) are common among disparate bacterial genera
including Staphylococcus, Enterococcus, Streptococcus,
Lactobacillus, and Enterobacteriaceae (7). Figure 15
shows the diversity of RIPs among fully sequenced plas-
mids of Firmicutes, and Fig. 5 to 10 reﬂect the features
of known members of this family within each genus
of biomedical interest. In enterococci, Rep_3 plasmids
(<15 kb) have been found in isolates recovered from
hospitalized patients, animals (pigs, cows), cheese, milk,
and dry-fermented sausage, frequently associated with
the production of bacteriocins that are active against a
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variety of Gram-positive genera (7). In Lactobacillus
and Lactococcus, they harbor bacteriocins and, even-
tually, AbR genes. Rep_3 plasmids play a relevant role
as vehicles of AbR among staphylococci. Plasmids from
S. aureus are overrepresented by closely related variants
containing Rep5, which are associated with genes coding
for penicilinase and resistance to heavy metals (cadmium
and arsenic) (51, 53, 66, 84). Staphylococcal plasmids
within this group include AbR plasmids from coagulase-
negative strains of animal origin, some of themwith RIPs
that would not be detected by current typing systems
(97, 98).
The Inc18 family
First described in the 1990s, the Inc18 family comprises
a highly heterogeneous group of broad host range, low
copy number plasmids (<10 per cell) that replicate by a
theta mechanism, regulated by an antisense RNA that
mediates transcriptional attenuation and that are able
to conjugate on solid media at high frequencies (64,
99). The transfer system of pIP501 has been extensively
studied and constitutes a paradigm of conjugation sys-
tems, showing signiﬁcant similarity with the tra regions
of RepA_N plasmids pGO1 and pSK41 from S. aureus
and pMRC01 from Lactococcus lactis (96, 100).
The Inc18 group is traditionally represented by three
emblematic plasmids: pSM19035 (101) and pIP501
from S. agalactiae and pAMβ1 from E. faecalis (64,
101–104). It gets its name from the apparent incom-
patibility of these plasmids with each other described in
seminal studies in the ﬁeld and following the nomen-
clature of Inc groups started by Richard Novick for
staphylococcal plasmids (50, 60, 64, 105). Inc18 plas-
mids frequently carry the postsegregational killing sys-
tems, ες, and type I partition cassette prgPprgO, which
are associated with a variety of RIPs and seem to con-
tribute to their persistence in different populations in the
absence of antibiotic selection pressure (7, 106, 107).
Detailed molecular characterization of such plasmids
is described elsewhere (64, 99, 108) and shows a re-
markably high modular interplay among different Inc18
plasmids, leading to the high modularity observed in
plasmid sequences (see Fig. 5 to 10 and text below).
Inc18 plasmids have contributed remarkably to the
spread of AbR (macrolides, chloramphenicol, amino-
glycosides, and glycopeptides) and MetR (copper and
mercury) among streptococci and other phylogeneti-
cally distant genera of Gram-positive (S. aureus, Listeria,
Bacillus subtilis, Lactobacillus, Leuconostoc, various
Clostridium species) and Gram-negative bacteria (108–
111). Plasmid relatives of pAMβ1 (harboring ermAM,
later on recognized as ermB, and conferring resistance
to macrolides, lincosamides, and streptogramines) and
pIP501 (carrying ermB and catA7pC221, which confers
resistance to chloramphenicol) were rapidly spread dur-
ing the 1970s and have frequently been detected among
streptococci of groups A, B, and D (enterococci) since
then (110, 112–114) (see also Supplementary Table S1
for contemporary representatives of this plasmid group).
Initially, the successful spread of intact AbR plasmids
among clones of various streptococcal genera, including
S. pneumoniae, and S. aureus was reported, despite the
lack of stability in these last two clonal backgrounds
(110, 113). Inc18 plasmids conferring resistance to
aminoglycosides (kanamycin, streptomycin, and neo-
mycin) and to macrolides were also detected in 1972,
in the emblematic Streptococcus (Enterococcus) fae-
calis strain JH1 that carried pJH1 (an MDR plasmid,
presumably Inc18) and pJH2 (a RepA_N pheromone-
responsive plasmid carrying hemolysin and bacteriocins).
pJH1 represented the ﬁrst description of conjugative
transfer of AbR plasmids in enterococci (114). Amino-
glycoside resistance in pJH1 relatives was due to the pres-
ence of Tn5405, a transposon comprising three genes
in tandem (an aminoglycoside 6-adenyltransferase [aad],
a streptothricin acetyltransferase [sat], and an amino-
glycoside-phosphotransferase [aph3]). These genes were
identiﬁed later on in S. pyogenes, S. agalactiae, S. aureus,
Campylobacter coli, C. perfringens, and C. difﬁcile (now
Peptoclostridium difﬁcile).
More recently, diverse Inc18 plasmids carrying
Tn1546 in enterococci and staphylococci have emerged
FIGURE 6 Hierarchical clustering dendrogram of plasmids from enterococci. The matrix
distance used for building the UPGMA dendrogram is based on the Raup-Crick distance of
the orthologous protein proﬁle of each plasmid. For each plasmid, a presence/absence
protein proﬁle was made using cut-oﬀ values of 80% identity and 80% coverage. Protein
clustering was made by using CD-HIT (239). Diﬀerent background colors are used
to emphasize branches of related plasmids and are the same as those deﬁned in Fig. 5.
Names to the left of the dendrogram indicate the RIP family. Background colors were
used to point out plasmid groups frequently involved in mobility of AbR genes and
E. faecalis pheromone-responsive plasmids. Circles indicate RIPs identiﬁed in each plas-
mid according to data shown in Fig. 7. doi:10.1128/microbiolspec.PLAS-0039-2014.f6
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in different locations. In Europe, Inc18::Tn1546 plas-
mids (such as pVEF1, pEVF2, pVEF3, and pVEF4) seem
to have evolved from pIP816 (the ﬁrst Inc18::Tn1546
was isolated in France in 1987). They lack a transfer
system and appear to be conﬁned to E. faecium (70, 115,
116). Inc18::Tn1546 plasmids from the United States
are linked to E. faecalis isolates (pWZ909, pWZ1668,
pWZ7140) and contain a complete transfer system (117,
118). A plethora of multiresistant mosaic Inc18 plasmids
containing up to three RIPs, including RepR of pIP501
(CAA35647.1) and RepS of pRE25 (YP_783890.1),
have been described in different Firmicutes (70, 71,
116, 119). These plasmids have an arsenal of inser-
tion sequences, mainly IS1216 and ISL3, which facili-
tate genetic exchange with different genetic elements
of different origins and the acquisition of different AbR
(tetS) and MetR (tcrB, mer operon). These ISs also fa-
cilitate the co-integration with other RCR (e.g., pC221,
which is cointegrated in pRE25) or theta replication
plasmids as pheromone responsive (116, 119–121) or
some pSK41-like elements. Figure 16 shows the diversity
of Inc18 RIPs that can be identiﬁed by typing systems.
All these RIPs have a primase domain PriCT_1 that
allowed their identiﬁcation as belonging to the Inc18
family. Fig. 6, 7, and 9 illustrate the mosaicism of Inc18
plasmids in enterococci and Listeria.
The pMG1/pHT plasmids
The pMG1/pHT plasmids are related to those of the
Inc18 family (RIP homolog approximately 30% identi-
cal to Inc18 initiators, including the PriCT_1 domain
[Fig. 16]) (122), although they also show high homology
with the pXO2 virulence plasmid from Bacillus anth-
racis. Because many open reading frames of pHT and
pMG1 plasmids do not show signiﬁcant homology with
any reported proteins, they used to be categorized as a
new type of highly efﬁcient conjugative plasmids with a
MOBP family REL. This plasmid group is represented by
relatives of pHT (pHTα, pHTβ, and pHTγ) and pMG1,
which have greatly facilitated the dissemination of re-
sistance to glycopeptides (Tn1546_vanA) and high-level
resistance to aminoglycosides (Tn4001-like elements)
among human E. faecium and E. avium isolates from the
United States and Japan (123, 124) and, to a lesser ex-
tent, European countries (7, 70, 71, 122).
The RepA_N family
This is a large family of plasmids (also including a few
phages) that are widespread among the low G+C Gram-
positive bacteria and which possess RIP homologs to
the RepA protein of pAD1 (76). The ﬁve groups of RepA
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homologs identiﬁed are phylogenetically congruent with
their host background (Fig. 17), suggesting that the rep-
licons have evolved along with their current hosts and
that intergenus movement of RepA_N plasmids does
not often occur. Such RepA_N clusters correspond to
plasmids from Staphylococcus (MetR/bla pSK1 and
pSK41 MDR plasmids), plasmids from Enterococcus
(E. faecalis pheromone-responsive plasmids and E. fae-
cium non-pheromone-responsive plasmids related to
pRUM, pLG1, or untypeable megaplasmids), plasmids
from Lactobacillus and Lactococcus, phage homologs
from Streptococcus (S. pneumoniae, S. thermophilus),
and plasmids from B. subtilis (e.g., pLS32). Staphylo-
coccal and enterococcal RepA_N plasmids have greatly
contributed to the spread of AbR genes among humans
and, eventually, animals and will be further described
below. They also facilitate the movement of other non-
conjugative plasmids and large genomic regions (36,
125, 126).
RepA_N staphylococcal plasmids (Fig. 5)
Large staphylococcal MDR plasmids use evolutionarily
related theta-mode replication, although they can be fur-
ther divided into three types: the MetR/beta-lactamase-
producing plasmids, the pSK1 family, and pSK41-like
conjugative elements. All these are compatible and can
be identiﬁed as the rep19, rep20, and rep15 families, re-
spectively, according to Jensen’s plasmid typing system
(59, 127, 128). The pSK41 family (rep15) is the largest
group of conjugative plasmids in staphylococci, tradi-
tionally represented by pSK41, pG01, and pJE1, which
emerged in the early 1980s associated with resistance to
gentamicin due to the presence of Tn4001 (84, 129).
They often confer resistance to other antibiotics such as
neomycin, tobramycin and kanamycin (due to the inte-
gration of pUB110 plasmids that harbor the aadD gene),
antiseptics (due to the presence of qac genes) (130),
and eventually trimethoprim (mediated by Tn4001),
penicillins (due to the presence of Tn552::blaZ), and
others. Plasmids of this group may also confer resistance
to mupirocin (131–133) and vancomycin (134, 135),
represented by pUSA03 (which harbors ileS and tetK)
and pWL1043 (which contains Tn1546, Tn4001,
Tn4002, Tn552, and qacC). The pSK41-like plasmids
are able to mobilize other plasmids present in the same
bacterial cell (133, 136, 137). The pSK1 and MetR/beta-
lactamase plasmids belong to the same incompatibility
groups and are also compatible with pSK41 plasmids.
Despite their inability to self-transfer, these groups of
plasmids have been detected in many staphylococcal
species.
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RepA_N enterococcal plasmids
This cluster groups pheromone-responsive plasmids of
E. faecalis and pRUM- and pLG1-like plasmids of
E. faecium (7) (Fig. 6 and 7).
Pheromone-responsive plasmids. Pheromone-responsive
plasmids represent a paradigm of elements in the biology
ofMGEs and are, together with Inc18 plasmids, the best-
known plasmids described to date. For details about the
mechanism of replication, conjugation, and evolvability
of this plasmid group see references 7, 49, 65, 92, and
138. Plasmids that respond to pheromones are present in
most contemporary E. faecalis isolates from humans and
birds but are only occasionally found among E. faecium.
Synthesis of pheromones is conﬁned to E. faecalis, al-
though Enterococcus hirae, S. aureus, and Streptococcus
gordonii may secrete cAM373-like peptides that facili-
tate the conjugation of pAM373 from E. faecalis (139).
The description of cAM373-responsive plasmids coding
for resistance to glycopeptides (Tn1546-vanA) highlights
the potential risk of the spread of glycopeptide resist-
ance in staphylococci in institutions where VRE are en-
demic (134, 140). Although pheromone plasmids are
unable to replicate in S. aureus, their transference and
establishment in this host might occur by co-integration
with other plasmids able to replicate in this species.
In addition, some pAD1 relatives enhance the rate of
mobilization of plasmids, conjugative transposons, and
PAIs (125).
Plasmids of this family can be classiﬁed on the basis
of responses to pheromones in different incompatibil-
ity groups (139) or according to RIP diversity (59, 68)
within rep8 (pAM373) and rep9 (further split into sub-
groups rep9a(pAD1) and rep9b(pTEF2)) families (59, 68).
Transfer systems of MOBC orMOBP families have been
detected in plasmids of this family.
Pheromone-responsive plasmids may encode puta-
tive virulence traits (aggregation substance, hemolysin/
bacteriocin) and a diversity of AbR elements located
on transposable elements such as Tn916-like (tetM),
Tn4001 (aac-aph), Tn1546 (vanA), Tn1549 (vanB), and
a composite transposon containing a β-lactamase gene
ﬂanked by two IS4 copies (7). The par locus encodes a
unique antisense-regulated toxin-antitoxin system pres-
ent in the plasmid pAD1, but par homologs have been
detected on other plasmids and chromosomes of E. fae-
calis and Staphylococcus, Clostridium, Listeria, and
Lactobacillus species (141). Toxin-antitoxin systems as-
sociated with other plasmid families such as ες and relBE
have been detected on members of this plasmid group,
reﬂecting rearrangements with representatives of other
plasmid families (7). Even though to date, only a fewmem-
bers of pheromone-responsive plasmids have been fully
sequenced, typing surveys reveal a wide diversity of plas-
mids among populations, often containing RIPs, RELs, or
regions from plasmids of different origins (68, 71).
pRUM-like plasmids. pRUM-like plasmids (represented
by pRUM, p5373c, pS177, and pDO2) are mosaic plas-
mids of variable size (>30 kb) that comprise diverse ge-
netic elements of different origins (transposons, insertion
sequences, small theta-replicating plasmids, bacteriocin
clusters). They can be identiﬁed as the rep17 family ac-
cording to PCR-based typing systems (59) but differ in
the RIP sequence, the MOB system, and the presence
of the toxin-antitoxin Axe-Txe locus (71, 142, 143).
Both Inc18 and pRUM plasmids are driving the spread
of glycopeptide resistance among contemporary isolates
of E. faecium by carrying Tn1546 (vanA) or Tn1549
(vanB). Two types of pRUM plasmids are currently
widespread among VRE and vancomycin-susceptible
E. faecium isolates from different hosts. One contains
RepA and Axe-Txe from pRUM and, eventually, the
mobilization system of pC223 from S. aureus (70, 71,
142–144). The other type is characterized by a RepA
protein that is 95% identical to RepA-pRUM, lacking
postsegregational killing Axe-Txe and the presence of a
MOBP7 relaxase originally detected in pEF1, a plasmid
with an environmental origin. Tn1546 is frequently lo-
cated on both types of pRUM plasmids, frequently con-
taining replicons of other plasmid families (author’s
unpublished results).
FIGURE 11 Similarity of rep-like sequences encoding RIPs of the Rep_1 family. A neighbor-
joining tree of gene sequences coding for RIPs of the Rep_1 family was built using MEGA
6.06. A cut-oﬀ equal to or higher than 80% and a bootstrap analysis based on 1,000
permutations were applied to the analysis. Alignment of nucleotide sequences was per-
formed using ClustalW2 (http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/),
and sequences showing an identity equal to or higher than 80% were clustered in groups
that were highlighted by diﬀerent backgrounds colors. Black dots indicate the RIP of the
plasmid used for further comparison in Figs. 5 to 10. doi:10.1128/microbiolspec.PLAS
-0039-2014.f11
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FIGURE 12 Similarity of rep-like sequences encoding RIPs of the Rep_trans family. A
neighbor-joining tree of gene sequences coding for RIPs of the Rep_trans family was built
using MEGA 6.06. A cut-oﬀ equal to or higher than 80% and a bootstrap analysis based on
1,000 permutations were applied to the analysis. Alignment of nucleotide sequences was
performed using ClustalW2 (http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/),
and sequences showing an identity equal to or higher than 80% were clustered in groups
that were highlighted by diﬀerent backgrounds colors. Black dots indicate the RIP of the
plasmid used for further comparison in Figs. 5 to 10. *Truncated gene. **Similar to E. faecalis
ant6-Ia and aadE. Abbreviations: ND, not determined. doi:10.1128/microbiolspec.PLAS
-0039-2014.f12
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Large plasmids. Plasmids larger than 150 kb are widely
distributed amongE. faecium,Enterococcus durans, and
E. hirae from different origins, but they have not been
detected among E. faecalis (71, 144–150). To date, only
a handful of E. faecium megaplasmids have been fully
sequenced (AUS0085_p1 [NC_021987], pNB2354_1
[NC_020208], DO_3 [NC_017963], and pLG1, al-
though this last one has not been closed [148]). All
of them contain a RIP similar to RepApAD1, making them
part of theRepA_N family (Fig. 7 and 17, Supplementary
Table S1) (59, 71, 148). A similar RIP has also been
found in a 130-kb plasmid (NC_021987) from a VRE
ST203 E. faecium strain isolated in 2009 in Australia
(151). Although RIP sequences of pLG1 plasmids are
often identiﬁed among enterococcal megaplasmids,
most of them do not hybridize with known RIP genes
included in published schemes (71, 148, 152). Entero-
coccal megaplasmids carry genes involved in sugar
metabolism (mannitol, glycerol, sorbitol, rafﬁnose, com-
plex carbohydrates), AbR (macrolides, glycopeptides,
aminoglycosides), MetR (copper-tcrYAZB), and en-
hanced adhesion (71, 126, 144, 147–149, 152–154).
They are frequently involved in the acquisition or per-
sistence of AbR among E. faecium isolates from food
animals (144, 150).
GENE AND PLASMID FLOW SHAPES THE
EVOLUTIONARY ECOLOGY OF FIRMICUTES
As described in previous sections, the acquisition of
novel traits encoding adaptive resistance to antimicro-
bials in Firmicutes is mainly due to genes located on
plasmids and transposable elements. This acquisition is,
certainly, regulated by interactions at genetic and eco-
logical (social) levels. Interplay between genes, mobile
genetic elements, and microbial populations and their
relation with the host population and local or global
environments shapes the plasmid ﬂow. Such ﬂow can
be modiﬁed by “external” (supra-cellular) changes, in-
cluding variations in the host population structure and
FIGURE 13 Similarity of rep-like se-
quences encoding RIPs of the Rep_2
family. A neighbor-joining tree of gene
sequences coding for RIPs of the Rep_2
family was built using MEGA 6.06. A cut-
oﬀ equal to or higher than 80% and a
bootstrap analysis based on 1,000 per-
mutations were applied to the analysis.
Alignment of nucleotide sequences was
performed using ClustalW2 (http://www
.ebi.ac.uk/Tools/phylogeny/clustalw2
_phylogeny/), and sequences showing an
identity equal to or higher than 80% were
clustered in groups that were highlighted
by diﬀerent background colors. Black
dots indicate the RIP of the plasmid used
for further comparison in Figs. 5 to 10.
doi:10.1128/microbiolspec.PLAS-0039
-2014.f13
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size (e.g., mass rearing, crowding) and their associated
chemical or behavioral landscape (e.g., use of different
antimicrobials, immunization, global food supply, inter-
national travel). These changes ultimately determine the
density and diversity of particular bacterial populations
in particular habitats, leading to ecological specializa-
tion, clonalization, and gradual emergence of gene ﬂow
barriers (23, 155, 156), a process that mimics the general
dynamics of speciation, as bacterial clones and species
constitute ecological units of microbial biodiversity.
The challenge to deﬁne “units of biodiversity” in
microbial community ecology has approached the con-
cept of genes as “deﬁning elements of networks and
metacommunities” (155). In such a context, extra-
chromosomal elements greatly inﬂuence the HGT in-
teractions between microbial organisms and are the
FIGURE 14 Similarity of rep-like sequences encoding RIPs of the Rep_L family. A neighbor-
joining tree of gene sequences coding for RIPs of the Rep_L family was built using MEGA
6.06. A cut-oﬀ equal to or higher than 80% and a bootstrap analysis based on 1,000
permutations were applied to the analysis. Alignment of nucleotide sequences was per-
formed using ClustalW2 (http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/),
and sequences showing an identity equal to or higher than 80% were clustered in groups
that were highlighted by diﬀerent background colors. Black dots indicate the RIP of the
plasmid used for further comparison in Figs. 5 to 10. doi:10.1128/microbiolspec.PLAS
-0039-2014.f14
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building forces for the establishment of “gene exchange
communities” (155, 157). The selective power of anti-
microbials (antibiotics [Ab], heavy metal, biocides) may
then shape this multilevel bacterial population biology
(158, 159), involving genes, plasmids (MGEs), bacterial
clones and species, and gene exchange communities. The
evolutionary tradeoff between early and late stages of
adaptation to such selective pressures may determine
the local evolvability of clonal and plasmid populations
by increasing the number of genotypes resulting from
chromosomal and plasmid recombination processes that
facilitate further ecological differentiation (18). To es-
tablish effective public health interventions to ﬁght the
AbR problem in its eco-biological dimension, we then
need to deﬁne the gene exchange communities relevant
for the acquisition, evolution, and spread of resistance
(160, 161). Below, we will speciﬁcally discuss the role of
AbR genes and plasmids in the ecological differentiation
of bacterial populations of the main Firmicutes genera.
Antimicrobial Resistance Genes and
Bacterial Population Ecology
The environmental origin of AbR genes has been ex-
tensively discussed, but very few AbR genes identiﬁed
in the environment are found in human or animal path-
ogens, which indicates severe bottlenecks for their ac-
quisition and transmission (162, 163). However, the gut
microbiota is increasingly considered a signiﬁcant res-
ervoir of AbR genes (3), which is supported by studies
that associate widely spread AbR genes of relevance in
clinical therapy, such as ermB, ermT, ermC (encoding
resistance to macrolides), vanB (coding for resistance
to glycopeptides), and cfr (coding for resistance to dif-
ferent antimicrobials), with members of the normal
microbiota such as species of the Clostridium group
XIVa now reclassiﬁed as family Lachnospiraceae (Clos-
tridium bolteae, Clostridium innocuum–like, Clostridi-
um lavalense, Clostridium symbiosum) and some lactic
bacteria (3, 88, 164–168).
Recent work demonstrates that a given AbR gene
(or genetic element such as Tn1549_vanB) may be in-
dependently acquired by different clonal populations in
the intestine of a particular host (165). Once an AbR
gene is present in gut commensals (independent of the
origin of the gene), members of the normal intestinal
ﬂora of humans and animals can exchange such genes
among themselves or with bacterial pathogens, which
might be present in low numbers or just be passing
through the intestine after being transferred from other
body sites or with food intake, using different inter-
mediates in the case of distant bacteria (3, 165, 169).
The rapid emergence in Firmicutes of genes coding
for AbR, MetR, and BcR immediately after their intro-
duction and signiﬁcant (often massive) use in different
settings has been demonstrated for chloramphenicol
(catA), tetracyclines (tetL), macrolides (ermB), neomycin
(aad), gentamicin (aac6aph2), trimethoprim (dfr), beta-
lactams (blaZ), and antiseptics (qac) in hospitals during
the 1950s to 1970s, and for tylosin (ermC, ermT), phe-
nicols (fex), pleuromutilins (cfr), and zinc-bacitracin in
animals during the 1990s, thus supporting the hypoth-
esis of the existence of a previous gastrointestinal reser-
voir of genes that were selected for the ﬁrst time as AbR
genes (gene exaptation) (84, 88, 91).
Plasmids and Bacterial Population Ecology
The number and types of Firmicutes plasmids and
integrative-conjugative elements (currently considered
as plasmids under the perspective of evolutionary biol-
ogy [22]) greatly vary with the different bacterial spe-
cies, certainly as a result of both ecological specialization
and selective events resulting from exposure to different
anthropogenic activities. Most (if not all) of the con-
temporary isolates belonging to different species of
staphylococci, enterococci, lactobacilli, and others con-
tain plasmids of different families in a consistent pattern
(for instance, RCR, small theta, or megaplasmids in
E. faecium; pheromone plasmids in E. faecalis) (7, 68,
71). Such frequent plasmid-bacteria host correspon-
dence indicates a basic coadaptive evolutionary relation
between two different types of organisms.
For a long time, plasmids were considered as “orga-
nisms,” units of a continuous lineage with an individual
evolutionary history, and hence producing evolved
populations, in line with the Luria and other seminal
works in the ﬁeld (46, 240). However, plasmids are not
necessarily discrete units or individuals as classically
considered in evolutionary theory (20, 170, 240).
Organisms are units of selection, evolutionary units in
a sense “evolutionary individuals,” deﬁned as any entity
that, independently from the number of elements that
enters into its composition or from its hierarchical level of
complexity, is selected and evolves as a unit (170, 171).
The frequent out-of-equilibrium events that characterize
the interplay between bacterial hosts, plasmids, and gene
populations is explained because selective events might
act independently on these different evolutionary indi-
viduals, as predicted in the “levels of selection” concep-
tual frame (20, 172–174). However, it is of note that we
should recognize “levels of individuality”; for instance, a
substantial number of Firmicutes plasmids have a lower-
level self-identity than their bacterial hosts (18, 155)
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because of the more complex genetic interplay with other
mobile genetic elements which in turn are also “leaky
individuals,” frequently mosaics of individuals with a
partial or contingent self-identity, produced under the
effect of adaptive challenges when confronting variable
environments (155, 175). Even if this problem of “indi-
vidual constancy” (176) makes it difﬁcult to study the
network of plasmids and hosts in Firmicutes, and such a
network were biased by sampling, we should accept the
existence of a certain interactive frame.
Valeria Souza, still following Maynard Smith’s ideas
about the population structure of bacteria, proposed
in 1997 to classify plasmid-bacteria interactions in four
patterns, namely, (i) the plasmid-host clonal pattern,
where the plasmid phylogeny is mirrored by host phy-
logeny; (ii) the limited transfer pattern, in which the plas-
mid ﬂow is limited to closely related (genetically and/or
ecologically) strains; (iii) panmictic plasmid spread, in
the case of plasmids that circulate among a variety of
hosts (the stability of the association being dependent
on the beneﬁts and costs of plasmid carriage); and
(iv) epidemic plasmid dispersal, in which “successful”
plasmids spread in bacterial populations because they
provide a clear advantage in high-potency selective land-
scapes (49, 170). Although illustrative and useful for
epidemiological purposes, this single centric view should
not replace the complex interplay between different
elements that may result in the emergence of different
chimeric conﬁgurations (49, 177). Therefore, these
“patterns” should be currently understood as possible
interactive states, even though some of them could be
more ephemeral than others, depending on the coevo-
lutionary history, the adaptive demands of the plasmids,
and the bacterial populations and communities.
Plasmids and Population Biology of Firmicutes
This section will focus on the genera of Firmicutes that
are relevant to the problem of AbR (1).
Streptococcus
The genus Streptococcus, a main hub in gene networks
in this and other studies (11, 12), is one of the most
heterogeneous groups within the phyla Firmicutes. Re-
markably, the 138 known species of streptococci found
as opportunistic pathogens or commensals (many of
them zoonotic pathogens) in humans, horses, pigs, cows,
and ﬁsh have recently been divided into seven species
groups on the basis of 16S rDNA gene sequencing,
chemotaxonomic approaches, and DNA hybridization,
namely the bovis, pyogenic, mitis, mutans, salivarius,
anginosus, and unknown groups (178–180). HGT seems
to play a relevant role in the adaptation and cohesive-
ness of the groups (179). Available information about
streptococcal plasmids is scarce, with only a few plas-
mids being fully sequenced, representing an unbalanced
sample of species and ecological groups (Supplementary
Table S1). Figure 10 illustrates the 20 AbR plasmids
currently found in streptococci.
The streptococcal groups bovis and mutans rarely
harbor plasmids, although they can be relevant in the
adaptation of particular species. S. thermophilus, a non-
pathogenic species in the bovis group that is used in
the dairy industry (181), contains a set of plasmids
harboring heat shock proteins; Streptococcus mutans, a
member of the human indigenous ﬂora that is trans-
mitted mostly from mother to child, often carries 5- to
6-kb cryptic plasmids that parallel the evolution of line-
ages associated with racial cohorts and geographical
locations (182). Megaplasmids in the group salivarius
coding for different lantibiotics favor their persistence in
the oral cavity (183). Conversely, the pyogenic group,
which is represented by species of clinical interest such as
S. agalactiae and S. pyogenes (also called GAS and GBS,
respectively), frequently carry plasmids that code for
AbR genes aside from bacteriocins. Inc18 plasmids are
widely spread among streptococci and seem to have
determined the selection of certain populations resistant
to chloramphenicol, aminoglycosides, and macrolides
since the late 1970s in different groups of streptococci
and enterococci (105, 110, 184). Rep_2 plasmids car-
rying erm(T) seem to have recently spread among GAS
and GBS clinical isolates of different countries, having
contributed to the increase of macrolide resistance rates
in these species since the mid-1990s, either by clonal
FIGURE 15 Similarity of rep-like sequences encoding RIPs of the Rep_3 family. A neighbor-
joining tree of gene sequences coding for RIPs of the Rep_3 family was built using MEGA
6.06. A cut-oﬀ equal to or higher than 80% and a bootstrap analysis based on 1,000
permutations were applied to the analysis. Alignment of nucleotide sequences was per-
formed using ClustalW2 (http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/),
and sequences showing an identity equal to or higher than 80% were clustered in groups
that were highlighted by diﬀerent background colors. Black dots indicate the RIP of the
plasmid used for further comparison in Figs. 5 to 10. Abbreviations: ND, not determined.
doi:10.1128/microbiolspec.PLAS-0039-2014.f15
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expansion, in the case of GAS, or by plasmid transfer-
ence among unrelated clonal backgrounds, in the case
of GBS (8, 185).
These erm(T)-containing plasmids are also spread
among other non-streptococcal species, such as En-
terococcus, Staphylococcus, and Lactobacillus (89, 186,
187). Often, streptococcal plasmids are mobilized by
coresident integrative-conjugative elements belonging to
the ICESa2603 family (188). Resistance to macrolides
(ermB,mefA), tetracyclines (tetM, tetS, and other mosaic
tet genes), aminoglycosides (aph3, aadA6, Tn4001), or
vancomycin (vanA, vanB) is commonly detected among
isolates of this group, but the location of determinants
seems to be linked to transposable elements often in-
volving insertion sequences (reviewed in reference 181).
Streptococcus suis, a particularly virulent emerging zoo-
notic pathogen that remains an outlier to the mitis,
sanguinis, and anginosus groups is known to carry
plasmids, although they have been scarcely character-
ized (189, 190). Relevant AbR genes coding for chlor-
amphenicol (cfr and fexA) and lincosamides (lnu)
embedded in composite regions similar to those present
in plasmids of E. faecalis have been located in strepto-
coccal plasmids of approximately 100 kb (191). Smaller
plasmids carrying tetB associated with Gram-negative
species have been described (192).
Enterococcus
The genus Enterococcus comprises different species,
members of the intestinal ﬂora of animals and humans
able to cause disease in their hosts (193). Although
seminal works in the ﬁeld of plasmid biology focus on
particular enterococcal plasmids and transposons, such
as pheromone-responsive plasmids or Tn916, which
became paradigms of different mechanisms of conjuga-
tion, the plasmidome of enterococcal species has scarcely
been analyzed (7). Recent studies revealed that most
strains of E. faecium and E. faecalis, the two main spe-
cies detected in humans and animals, carry a number
of plasmids of different families that include species-
speciﬁc plasmids (e.g., narrow host range RCRs and
RepA_N plasmids such as megaplasmids in E. faecium
and pheromone-responsive plasmids in E. faecalis) and
broad host range plasmids (e.g., Inc18), plasmid
chimeras being abundant and still difﬁcult to classify
(Fig. 6 and 7; see previous section and comprehen-
sive reviews in references 7, 141). Megaplasmids of
E. faecium or pheromone-responsive E. faecalis plas-
mids enhance the ability to colonize, invade, and form
bioﬁlms (65, 126, 154). Conjugative plasmids may in-
ﬂuence the mobilization of nonconjugative elements
and chromosomal regions and facilitate the acquisition
of different adaptive traits and genome evolvability
(71, 125, 126). Most enterococcal plasmids are able
to acquire and disseminate AbR genes by different
mechanisms of genetic exchange. However, the role of
plasmids in the population structure and evolvability of
these enterococcal species has been poorly addressed
(194–197) due to the overrepresentation of recent clin-
ical and animal isolates of speciﬁc lineages commonly
associated with AbR included in most studies (7, 141)
and due to the lack of available plasmid sequences.
Similar plasmids have been found in E. faecium and
other enterococcal species that may play equivalent
functional roles in the gastrointestinal tract such as En-
terococcus avium, Enterococcus rafﬁnosus, E. durans,
and E. hirae (195, 198).
AbR genes are located on plasmids that often contain
different replicons associated with different narrow
(RCR, RepA_N) and broad host range (Inc18) plas-
mids. Inc18 streptococcal plasmids greatly inﬂuenced
the worldwide increase of aminoglycoside-macrolide
resistance among E. faecalis isolates from humans and
animals during the 1970s (199). They also contributed
to the spread of vancomycin resistance among E. fae-
cium of animal origin in Europe and E. faecalis from
hospitalized patients in the United States (7, 70, 71).
Diverse narrow host range plasmids have been involved
in local expansions of enterococci conferring resistance
to ﬁrst-line antibiotics such as gentamicin (Tn4001) or
beta-lactams (ΔTn552 blaZ) (152) and beta-lactamase-
producing E. faecalis and E. faecium (152) (200–202),
which highlights the role of endogenous plasmids and
recombination in the adaptation of particular lineages
FIGURE 16 Similarity of rep-like sequences encoding RIPs with the PriCT_1 domain. A
neighbor-joining tree of gene sequences coding for RIPs with PriCT_1 domains was built
using MEGA 6.06. A cut-oﬀ equal to or higher than 80% and a bootstrap analysis based on
1,000 permutations were applied to the analysis. Alignment of nucleotide sequences was
performed using ClustalW2 (http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/),
and sequences showing an identity equal to or higher than 80% were clustered in groups
that were highlighted by diﬀerent background colors. Black dots indicate the RIP of the
plasmid used for further comparison in Figs. 5 to 10. Abbreviations: ND, not determined.
doi:10.1128/microbiolspec.PLAS-0039-2014.f16
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(E. faecium ST17, ST18, ST78 and E. faecalis ST6 and
ST16) (7, 67, 144, 203).
Analysis of the same AbR genes in different species
(cfr, bac, lincosamide resistance genes) reﬂects the im-
pact of recombination events between genes, MGEs,
and different populations of Firmicutes (Staphylococcus,
Clostridium, Lactobacillus, Lactococcus, and Entero-
coccus) and other Gram-negative organisms (200, 204)
in the gastrointestinal tract of animals and humans (120,
144, 205, 206).
Staphylococci
These organisms are opportunistic pathogens and mem-
bers of the commensal ﬂora of skin and mucous mem-
branes of humans and animals (207–209) and, thus, are
part of a microbial community with limited contact with
members of other main genera of Firmicutes that inhabit
distinct body sites (210). Figures 1 and 2 show the lim-
ited plasmid connectivity of staphylococci with other
genera. However, HGT and the acquisition of AbR and
MetR is relevant in the evolvability of this genus, mainly
due to genetic exchange events between closely related
species (Fig. 5) (9, 211–213). Comprehensive reviews
address the essentially clonal population structure of
S. aureus (214–216) and other staphylococcal species
(207) and also the impact of HGT in the evolutionary
history of staphylococcal populations (9, 217–219),
with emphasis on the description of the plasmids asso-
ciated with AbR genetic elements (9, 51, 84, 220) and
their inﬂuence on the variability of lineages (217, 219,
221–224).
Plasmids, transposons, and staphylococcal chromo-
somal cassettes (SCCmec) are infrequently transferred
among isolates of a different origin. A close association
of MGE and particular staphylococcal lineages has been
suggested (31, 225),with country-speciﬁc variations (208,
226). This highlights the relevance of local conditions and
the emergence of gene ﬂow barriers in the ecological dif-
ferentiation of staphylococcal lineages such as in the case
of S. aureus CC30 (219, 227). The origin, rapid spread,
and evolution of staphylococcal populations resistant to
beta-lactams was mainly inﬂuenced by the interplay of
genetic elements including plasmids (84, 177).
Clostridium
Clostridium is a large and extremely heterogeneous ge-
nus that has traditionally groupedmore than 100 species
widely distributed in the gut microbiota of mammals,
amphibians, and insects and in soils. An extensive up-
date of clostridial classiﬁcation is included in the latest
edition of Bergey’s Manual, although many unrelated
species still retain the Clostridium name, causing major
confusion in the clostridial taxonomy (228). To date,
only 60 plasmids have been fully sequenced, mainly
corresponding to C. perfringens, Clostridium botuli-
num, and other group I clostridia species (1 Clostridium
butyricum, 2 Clostridium kluyveri, 3 Clostridium ace-
tobutylicum). Some species in which plasmids were
analyzed have been moved to other genera such as
Clostridium aciduricidi (now Anaerococcus prevotii
type XII) andClostridium thermocellum (now belonging
to the family Ruminococcaceae). Several sequenced
plasmids correspond to the same strain and are mostly
from contemporary isolates, thus limiting the possible
knowledge about the role of plasmids in the evolution
of these species (Supplementary Table S1). Only narrow
host range conjugative plasmids of C. perfringens
(CpCP) or linear megaplasmids from C. butyricum have
been associated with AbR.
CpCP plasmids belong to the pCW3 family and are
widely spread among isolates of C. perfringens, carrying
genes encoding AbR (tetracycline [tetAB(P)], chlor-
amphenicol [catP-Tn4451], lincomycin [lnuP-tISCpe8])
and/or enterotoxins, ε-toxin, or iota-toxin production
that determine different toxinotypes (56, 229–231). All
pCW3-like plasmids have a conjugative transfer locus
of 11 open reading frames (orfs) (tcp [transfer C. per-
fringens]) that includes an integrase and a T4CP protein
but lacks relaxase (73, 231). A transposable origin simi-
lar to that of Tn916 has been suggested for the tcp mod-
ule of pCW3-like plasmids, which would have acquired
a replication machinery speciﬁc to this species. Often,
FIGURE 17 Similarity of rep-like sequences encoding RIPs of the RepA_N family.
A neighbor-joining tree of gene sequences coding for replication initiator proteins of
the RepA_N family was built using MEGA 6.06. A cut-oﬀ equal to or higher than 80% and
a bootstrap analysis based on 1,000 permutations were applied to the analysis. Alignment
of nucleotide sequences was performed using ClustalW2 (http://www.ebi.ac.uk/Tools
/phylogeny/clustalw2_phylogeny/), and sequences showing an identity equal to or higher
than 80% were clustered in groups that were highlighted by diﬀerent background colors.
Black dots indicate the RIP of the plasmid used for further comparison in Figs. 5 to 10.
*Truncated gene. +Similar to E. faecalis ant6-Ia and aadE. Abbreviations: ND, not deter-
mined. doi:10.1128/microbiolspec.PLAS-0039-2014.f17
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C. perfringens isolates harbor more than one pCW3
plasmid, which carry different adaptative traits and par-
tition machineries. The presence of different partition
systems explains the coexistence of different plasmids
with the same type of RIP in the same cell (56, 231–233).
These plasmids can be transferred (and eventually
serve as donors of AbR genes) but cannot replicate in
other species such as P. difﬁcile, Clostridium sordelli, or
Clostridium septicum, which could explain the conﬁne-
ment of some AbR genes in these populations (234). An
evolutionary scenario for CpCP has been reported, with
pCW3 (tetAB-P) and pIP401 (tetAB-P and Tn4451)
being suggested as the precursors of this family, which
would have acquired different toxins by homologous re-
combination involving composite transposons ﬂanked
by insertion sequences (56). Large linear plasmids con-
taining AbR have recently been described in neuro-
toxigenic C. butyricum, one of the six phylogroups
able to produce the botulinum toxin (34, 235). These
plasmids contain four beta-lactamase genes, transcrip-
tional regulators and two-component regulatory systems,
involved in the regulation of expression of the bont/A
gene and a region with a functional CRISPR-cas locus
that provides a defense against invading genetic elements
present in the intestinal environment.
Acquired resistance to tetracyclines (tetM, tetL, tetK,
tetO, tetW), chloramphenicol, macrolides (ermB, lnu),
and bacitracin (a bacitracin efﬂux pump and an over-
produced undercaprenol kinase gene located on a ge-
netic island ﬂanked by copies of IS1216) has been
reported in human and animal clostridium species in-
cludingC. perfringens, often associated with conjugative
transposons and plasmids widespread in other species
(234, 236, 237). A detailed analysis of AbR networks
suggests further ecological connections with mobile ge-
netic elements of other prokaryotic groups (Fig. 1 and 2).
CONCLUSION
This work offers for the ﬁrst time an integrated and com-
prehensive analysis of the dynamics of AbR genes in
Gram-positive bacteria and highlights the need for a
population view to analyze the problem of antibiotic re-
sistance. The article analyzed the relevance of the plas-
midome in the emergence, spread, and maintenance of
genes encoding resistance to antimicrobials (antibiotics,
heavy metals, and biocides) and their inﬂuence on the
structure of bacterial populations in the light of evolu-
tionary ecology. A critical revision of plasmid typing
systems highlights the limitation of available knowledge
about plasmid diversity in this group of bacteria.
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Abstract
Vancomycin-resistance in enterococci (VRE) is associated with isolates within ST18, ST17, ST78 Enterococcus faecium (Efm)
and ST6 Enterococcus faecalis (Efs) human adapted lineages. Despite of its global spread, vancomycin resistance rates in
enterococcal populations greatly vary temporally and geographically. Portugal is one of the European countries where
Tn1546 (vanA) is consistently found in a variety of environments. A comprehensive multi-hierarchical analysis of VRE isolates
(75 Efm and 29 Efs) from Portuguese hospitals and aquatic surroundings (1996–2008) was performed to clarify the local
dynamics of VRE. Clonal relatedness was established by PFGE and MLST while plasmid characterization comprised the
analysis of known relaxases, rep initiator proteins and toxin-antitoxin systems (TA) by PCR-based typing schemes, RFLP
comparison, hybridization and sequencing. Tn1546 variants were characterized by PCR overlapping/sequencing. Intra- and
inter-hospital dissemination of Efm ST18, ST132 and ST280 and Efs ST6 clones, carrying rolling-circle (pEFNP1/pRI1) and
theta-replicating (pCIZ2-like, Inc18, pHTb-like, two pRUM-variants, pLG1-like, and pheromone-responsive) plasmids was
documented. Tn1546 variants, mostly containing ISEf1 or IS1216, were located on plasmids (30–150 kb) with a high degree
of mosaicism and heterogeneous RFLP patterns that seem to have resulted from the interplay between broad host Inc18
plasmids (pIP501, pRE25, pEF1), and narrow host RepA_N plasmids (pRUM, pAD1-like). TAs of Inc18 (v-e-f) and pRUM (Axe-
Txe) plasmids were infrequently detected. Some plasmid chimeras were persistently recovered over years from different
clonal lineages. This work represents the first multi-hierarchical analysis of VRE, revealing a frequent recombinatorial
diversification of a limited number of interacting clonal backgrounds, plasmids and transposons at local scale. These
interactions provide a continuous process of parapatric clonalization driving a full exploration of the local adaptive
landscape, which might assure long-term maintenance of resistant clones and eventually fixation of Tn1546 in particular
geographic areas.
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Introduction
Since its first description in the late 80’s, vancomycin-resistant
enterococci (VRE) have been increasingly reported worldwide, but
presenting remarkable geographical and temporal differences in
local rates (http://www.cddep.org/ResistanceMap/bug-drug/
EFa-VC) [1-3]. Vancomycin-resistant Enterococcus faecium (VREfm)
became endemic in most North American hospitals since the mid
909s [1,2,4–6] while their overall occurrence in Europe remained
low until recently, when VRE nosocomial outbreaks started to be
increasingly reported in some European countries (Annual Report
of the European Antimicrobial Resistance Surveillance Network,
EARS-Net, 2009) [1,3,7,8]. Despite E. faecium (Efm) being less
frequently found than Enterococcus faecalis (Efs) in clinical isolates, it
is far more frequently resistant to vancomycin, one of the last-line
intravenous antibiotic resources for therapy. However, although
the rate of vancomycin-resistant E. faecalis (VREfs) has remained
low, they are steadily increasing in both the US and in EU
countries (http://www.cddep.org/ResistanceMap/bug-drug/
EFe-VC) [3].
Vancomycin resistance among enterococci is mostly due to the
spread of Tn1546 (vanA genotype) and Tn1549 (vanB genotype),
which are generally identified on plasmids and chromosome,
respectively [3]. The few studies in which plasmids carrying
Tn1546 from human or animal isolates were characterized
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revealed they belong to plasmid families RepA_N (pheromone-
responsive plasmids and derivatives of pRUM and pLG1), Inc18
and pHTb [9–18] suggesting an apparent plasmid promiscuity of
this transposon influencing its dissemination among enterococcal
populations.
Recent analysis of enterococcal populations in the clinical
setting depicts a rugged epidemiological profile, with successive
waves of isolates causing infections, which belong to specific
lineages of E. faecium (ST17, ST18 and ST78, previously
considered within the same clonal complex (CC) 17), and E.
faecalis (ST6, ST40) [19–21]. However, regional differences in the
rates of VRE cannot be only explained by clonal replacement
dynamics as suggested for other pathogens [22–24].
The aim of this study was to address the dynamics of
vancomycin resistance among enterococci in Portugal, one of
the developed countries with higher rates of both VREfm (21–
23%) and VREfs (1.8–4.1%) (www.earss.rivm.nl; http://www.
cddep.org/ResistanceMap/bug-drug/EFe-VC), and where VanA
is prevalent over VanB [3,25–27], by analyzing the clonal and
plasmid backgrounds influencing the spread and persistence of
Tn1546. Our study suggests that clonalization, the local selection
of distinct clonal variants giving rise to durable bacterial lineages,
might result and be modified by the local spread and
recombinatorial dynamics of mobile genetic elements, thus
providing new clues about the local multi-hierarchical evolution-
ary biology of vancomycin resistance.
Results
Local dynamic landscape drives the spread and fixation
of vancomycin resistance in Portuguese hospitals
We have determined that the enterococcal population from the
Portuguese hospitals is formed by an ensemble of MLST/PFGE
clones. Efm isolates fit in three out of six phylogenomic groups
recently established by using Bayesian Analysis of Population
Structure (BAPS), namely BAPS groups 2, 3 and 5 [19] (Figure 1).
Most of the isolates cluster into the predominant BAPS group 3
[subgroup 3–3 comprising main human lineages ST18 (ST18 and
ST132) and ST17 (ST16); and subgroup 3–1 comprising ST280],
and the BAPS group 2 (including ST80 and ST656/ST78 lineage,
ST5/CC5, ST190/CC9), which have been previously associated
with isolates from humans and both animals and humans,
respectively [10,19,25,28–30]. A number of clones cluster in the
small Efm BAPS group 5 (ST366, ST367, ST369), which seems to
comprise mosaic genomes [19]. Isolates of Efs belong to ST6/
CC2, ST30, ST55, ST117, and ST159 lineages although, to the
date of this publication, Efs population has not been clustered in
different BAPS groups. Among all them, isolates within ST18 Efm
and ST6 Efs lineages were predominant, in line with the intra- and
interhospital spread of particular highly transmissible Efm and Efs
clones recovered in Portuguese hospitals since the late 90s
[22,25,31,32]. While ST6 Efs was widely disseminated in all
hospitals analyzed in this country [26], specific Efm lineages were
overrepresented in Coimbra (ST18) and Oporto (ST132, a single
locus variant, SLV, of ST18). Strains belonging to ST18 (showing
PFGE types H70 and H78), ST132 (PFGE type H88) and ST280
(with PFGE types 71 and H100) were spread in different hospitals
(Figure 1 and Figure 2).
It is worthwhile to note the possible relatedness between isolates
of different STs (Figure 1 and 2). They include some isolates linked
to BAPS 3–3 subgroup as ST18, ST80, ST125, ST132, ST368,
ST369, all SLVs of each other, with PFGE patterns differing in
less than 8 bands difference. Similarly, strains identified as ST280
and ST391, both linked to BAPS group 3–1, showed related
PFGE patterns despite being trilocus variants (# 8 bands
difference).
vanA-Tn1546 is located on highly transferable mosaic
plasmids involving narrow host pRUM and pAD1
derivatives
The plasmid content of the isolates studied appears in Figure 2.
Efm isolates carried a variable number of plasmids (n = 1–6) which
contained specific sequences of different families including rolling-
circle plasmids (RCR) related to pRI1 and small theta plasmids
related to pCIZ2, RepA_N (pRUM-like, pLG1), pHTb (present in
all ST132 isolates), and Inc18 (pRE25 and pEF1-related). All Efs
contained RCR plasmids and pheromone responsive-plasmids.
vanA-Tn1546 was located on plasmids ranging from 30 to
150 kb, successfully transferred by conjugation in 95% (n= 71/75)
of Efm and 97% (n= 28/29) of Efs, with a variable frequency
(1021–1028). Transferable plasmids were identified as members of
pRUM and Inc18 families or were mosaic plasmids of pRUM,
Inc18 and pheromone plasmids (see sections below). Although
some of these mosaic plasmids were detected in both Efm and Efs
hosts, species-specific plasmid variants were predominant.
We have classified the enterococcal plasmids according to the
content in rep/rel/TA systems, and RFLP profiles (Table 1,
Figure 2). For the better interpretation of the results, we should
keep in mind that members of the most common plasmid families
classified in this and other studies as Inc18-like (pRE25, pIP501,
pVEF1, pVEF2, pVEF3, pIP816, pEF1, pWZ909) or pRUM-like
(pRUM, p5753cB, pS177) exhibit a high degree of modular
dissociability or propensity for independent variation and shuffling,
and may contain multiple replicons or be devoid of conjugation
systems, thus making it very difficult to establish an accurate
classification and to trace the origin of certain elements [9,33–40].
See Clewell et al. for a comprehensive updated revision of
enterococcal plasmids [9]. In the following sections we will
describe vancomycin resistant plasmids of Efm and Efs.
vanA plasmids of E. faecium
They were classified in two broad groups according to the
plasmid replication modules and the background epidemiological
context, i) pRUM-like variants (Rep17.2/pRUM-like+ Rel6/pEF1
6Rep1/pIP5016 Rep2/pRE25/pEF1/TAInc18), ii) mosaics of Inc18-
pRUM-like (Rep2/pRE25/pEF1 6 Rep17.2/pRUM/TAAxe-Txe). High-
ly transmissible pAD1-Inc18 mosaic plasmids from major Efs
clones were also identified among Efm but they will be described
in the next section.
i) pRUM derivatives (rep17.2/pRUM-like+rel6/pEF1) of variable size
(30–120 kb) were detected since the mid 90 s from a diversity
of clonal backgrounds. pRUM plasmids showing different
ClaI-digested DNA RFLP patterns were identified carrying a
whole copy of Tn1546 (RFLP_1, RFLP_2, RFLP_20, 30–
80 kb), IS1216::Tn1546 (RFLP_8–12, 40–120 kb) or
ISEf1::Tn1546 (RFLP_3–7, RFLP_13, 50–95 kb). Despite
the heterogeneity of plasmid profiles, RFLP_3–6 or
RFLP_8–10 shared a variable number of common bands
that suggest a relationship among them (see Table 1 and
Figure 3 for details about relationships among plasmids).
pRUM-like plasmids exhibiting distinct RFLP profiles and
carrying different transposon variants were isolated in early
and recent isolates of different clonal backgrounds (Figure 2).
They include ST190, carrying a 60 kb plasmid RFLP_1
type; ST670 carrying a 85 kb exhibiting a RFLP_4 plasmid
type; ST656 carrying a 30 kb plasmid designated as
RFLP_20, and ST18, ST132, ST280, carrying different
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transposon variants. These results suggest multiple indepen-
dent acquisitions of pRUM-like plasmids and further
rearrangements with other elements, some plasmid variants
being efficiently transferred among a diversity of different
clones. It is of interest to highlight that epidemic ST18 PFGE
types H83 (1996) and H92 (2000) harboured two pRUM-like
plasmids. One was the rep17.2/pRUM-like::rel6/pEF1 vancomy-
cin resistant plasmid showing RFLP_2 and RFLP_12 and the
other was a 25 kb carrying a rep17.1/pRUM gene and a copy of
the Axe-Txe toxin-antitoxin system (rep17.1/pRUM+TAAxe-Txe)
identical to the pRUM derivatives described to date (pRUM,
p5753cB and pS177) (GenBank accession number
GQ900487; Figure 2) [12,38,39] and other vancomycin
resistant plasmids circulating at international level (Freitas et
al., unpublished data). Diversification in the Rep sequences of
these pRUM-like plasmids (homology of 96% at nucleotide
level and 95% at protein level) might have resulted in the
compatibility with similar (but not identical) plasmids in the
same clonal background along extended periods of time.
ii) Inc18 plasmids and mosaic Inc18-pRUM plasmids. Clonally
related ST132 and ST18 Efm isolates from Oporto
contained Inc18 plasmids (Rep1/pIP501 6 Rep2/pRE25/pEF1,
RFLP_14–15) or mosaic plasmids of Inc18 and pRUM
(Rep2/pRE25/pEF1+Rep1/pIP501+TAInc18+Rep17.2/pRUM-like+
RelpEF1, RFLP_16–19), all carrying IS1216-Tn1546 vari-
ants. Plasmids showing RFLP types 16–19 were highly similar
(5 bands/12 bands in common), RFLP_19 being persistently
recovered from clonally related ST132, ST368 and ST369
isolates, collected from hospitalized patients of HSA near by
sewage plant and the river Douro from 2001 to 2003. This
RFLP_19 has been also identified in a VREfm isolate
recovered from swine in 2007 (Tn1546 type ‘‘PP-31’’,
RFLP_19.1), highlighting the remarkable stability of particular
VanA Inc18 plasmids in ensembles of related clones able to
spread in different hosts [10]. A diversity of Tn1546::IS1216
Figure 1. Population of vancomycin resistant Enterococcus faecium. Abbreviations: ST, sequence types; CC, clonal complex; BAPS, Bayesian
Analysis of Population Structure; HUC, Hospital Universita´rio de Coimbra; HSA, Hospital Santo Anto´nio; HSJ, Hospital Sa˜o Joa˜o; HST, Hospital Sa˜o
Teoto´nio; HPH, Hospital Pedro Hispano; CHCB, Centro Hospitalar da Cova da Beira; HVR, Hospital S. Pedro. A colored circle represents each PFGE type
(white numbers/letters; H for hospital, SW for sewage, R for river and S for swine clones) and each PFGE type is associated with the corresponding
sequence type (STs are represented in black letter and in colored elipses grouping different PFGE types) and BAPS group (in colored elipses grouping
different STs). The size of the colored circles corresponds to the number of isolates. CC17 (in light blue), CC5 (in light green), CC9 (in light red) and the
singletons ST366, ST367 and ST391 (light yellow) are represented according to the eBURST algorithm (download on 26th January 2012) with black
lines joining single locus variants (SLV). STs that were not identified in this study are represented as light grey nodes to link the sequence types
identified in this study accordingly to eBURST. ST18 strains (H70, H78, H87, H93, H108, H125) and most ST132 strains (H86, H88, H106, SWC) were
clonally related by PFGE (, 7 bands difference). Remarkable relationships among PFGE banding patterns of strains belonging to different STs were
observed (H125/ST18 and H126/ST125; H124/ST391 and H71/ST280, SWM/ST80 and H86/H88/H106/H119/SWC/ST132, and isolates SWA/ST18 and
SWC/ST132 (, 8 bands difference). This figure drawn up was performed in the ‘‘Open Source vector graphics editor Inkscape’’ (version Inkscape-
0.48.2–1).
doi:10.1371/journal.pone.0060589.g001
Plasmids and VRE Clonalization
PLOS ONE | www.plosone.org 3 March 2013 | Volume 8 | Issue 3 | e60589
Figure 2. Clonal and plasmid diversity among VREfm and VREFs from Portugal. Abbreviations: IS, insertion sequence; Efm, Enterococcus
faecium; Efs, Enterococcus faecalis; kb, kilobases; BAPS, Bayesian Analysis of Population Structure; ST, sequence type; CC, clonal complex; rep
(replicases); rel (relaxases); TA (toxin-antitoxin system); HUC, Hospital Universita´rio de Coimbra; HSA, Hospital Santo Anto´nio; HSJ, Hospital Sa˜o Joa˜o;
HST, Hospital Sa˜o Teoto´nio; HPH, Hospital Pedro Hispano; CHCB, Centro Hospitalar da Cova da Beira; HVR, Hospital S. Pedro; SW, sewage wastewaters;
UW, urban wastewaters; R, river; ND, not determined; NI, not identified; UK, unknown. aThe distribution of the different isolates is shown by BAPS
subgroups as described [19]. bPFGE types shown in bold represented widespread clones in Portuguese hospitals and/or aquatic surroundings over
years. cMost Efm isolates expressed resistance to vancomycin, teicoplanin, erythromycin, ampicillin, ciprofloxacin (92–100%) and to a lesser extent to
high levels of kanamycin (65%), gentamicin (41%), streptomycin and tetracycline (28% each). While acm was identified in different CC17 and non-
CC17 lineages (76%), esp was detected in CC17 isolates (35%, ST132 and its SLVs ST368, ST369) and hyl was sporadically found (9%, ST18, ST125,
ST132, SLVs of each other, and ST280 isolates) [25]. Efs isolates (mostly ST6) showed resistance to vancomycin, teicoplanin, erythromycin,
ciprofloxacin, high levels of gentamicin and kanamycin (82–100%), tetracycline and chloramphenicol (65% each) and high levels of streptomycin
(46%), and mostly contained gelE and agg (.90%), cyl (82%) and esp (46%) [26]. dTn1546 designation is based on the results obtained by a PCR assay
described by Woodford et al. consisting on the amplification of overlapped fragments covering the whole Tn1546 [68]. Fragments of unexpected
length were further analysed by sequencing (this study) [27]. eThe total rep/rel/TA content of isolates is represented according to its location on
plasmids of different size ranges. Rep (normal cells), rel (cells with dots) and TA (cells with diagonal stripes) genes belonging to the same plasmid are
represented with the same color and that belonging to the same plasmid family with the same range of colors. The content of VanA plasmids
including rep, rel, and TA genes is indicated according to the plasmid type in which they were identified, as well as by the numeric nomenclature
used by Jensen et al. [72] for replicases (rep1, rep2, rep9, rep14, rep17, rep18a), given new and consistent designations to replicases non described in
reference 72 (rep18b, rep18c, rep20, rep22). Relaxases were designated per numerical order as designed by M. V. Francia (unpublished data). Rolling-
Circle plasmids are represented in green (rep14/pRI1-like, rel1/pRI1), small-theta replicating plasmids in violet (rep18a/pEF418, rep18b/pB82, rep18c/pCIZ2,
rel2/pCIZ2), Inc18-like plasmids in different red tones (rep1/pIP501, rep2/pRE25/pEF1, rel6/pEF1, TAInc18-v-e-f), RepA_N plasmids in different blue tones, pRUM
in dark blue (rep17/pRUM, rel3/pRUM, TApRUM-Axe-Txe), pLG1 in turquoise (rep20/pLG1), pheromone-responsive plasmids in light blue (rep9/pAD1, rel5/pAD1,
rel9/pCF10, parpAD1), and pHTb/pMG1 plasmids in grey (rep22/pHTb, rel8//pHTb). Rep families are named Rep˝n˝ where˝ n˝ indicates the number assigned to
different rep-families according to Jensen et al. [72]. The name of the most representative plasmid of the family is also represented for a better follow-
up of the results (e.g. rep17/pRUM, rep17 from pRUM and related plasmids p5753cB and pS177; rep1/pIP501 rep1 linked to Inc18 plasmids as pIP501,
pIP816 and pRE25; rep9/pAD1, rep9 linked to pCF10, pAD1, pTEF1, pTEF2, pBEE99, pMG2200; rep14/pRI1-like, rep14 associated with RCR plasmids
pEFNP1, pJS42 and/or pRI1; rep18a/pEF418, rep18 from pEF418; and rep22/pHTb, rep of both pHTb and pMG1 plasmids). We further specified the name of
different plasmids associated with a given group if necessary. For example, it results helpful for Inc18 family given the number of plasmids containing
the same rep gene. These plasmids are increasingly identified among isolates of different origins (e.g. rep2/pRE25/pEF1 for designing rep2, as rep and rel
modules of pEF1, a plasmid originally identified in olives [35], seems to be widely present in all Efm clinical isolates). Sequencing identified the
different variants within these families (see text). Rep18b, rep18c and rep20 were not included in Jensen’s scheme [72] and the numbers were assigned
in this paper following that numeration (rep18b/pB82, rep from pB82; rep18c/pCIZ2, rep from pCIZ2; rep20/pLG1, rep from pLG1). Rel genes were arbitrarily
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variants (PP-13, PP-17, PP-20, PP-23, PP-31 and X) which
differed in the number of IS1216 copies, the presence of
insertions identified as short regions of Inc18-like plasmids or
duplicated Tn1546 sequence fragments in different orienta-
tions, were identified among related plasmids showing the
RFLP_19 pattern (Table 1, Figure 4). These results illustrate
the possibility of efficient intraclonal and intraplasmid
diversification of Tn1546::IS1216 variants. Acquisition of a
vanA-Inc18 (rep2/pRE25/pEF1 + rep1/pIP501+ v-e-f) plasmid
carrying a Tn1546::IS1216 ‘‘variant’’, predominant among
poultry from Europe [41] by Portuguese strains containing
VanA-pRUM (rep17.2/pRUM-like+rel6/pEF1) plasmids cannot be
excluded. Recombination between pRUM::Tn1546 and
Inc18::Tn1546 would explain duplicated Tn1546 regions.
iii) Megaplasmids. Tn1546 type ‘‘D’’ was located on a mega-
plasmid carrying rep20/pLG1 and rel6/pEF1 from isolates of a
CC5 Efm clone spreading among swine and humans of
different continents. This transposon has been previously
associated with isolates from swine which frequently exhibit
the G8234T mutation. The variable size (150–190 kb) of
vanA megaplasmids linked to CC5 lineage has been
previously reported [10].
E. faecalis vanA plasmids
The vanA Efs plasmids were Inc18-pheromone-responsive
mosaics, further classified in four main types on the basis of their
RFLP patterns (RFLP_27–30), rep-rel/TA content, and replicase
sequences. These plasmids have been documented in different
Portuguese hospitals since the mid 90 s [26].
Plasmids showing highly related patterns designated as
RFLP_27 (carrying ISEf1-Tn1546) or RFLP_28 (carrying
IS1216-Tn1546) were recovered from both Efs (ST6, ST55,
ST159) and Efm (ST80, ST132). However, despite the similarity
of their RFLP patterns, they differed in the rep/rel/TA content
and transposon variant content (Table 1). Conversely, the finding
of an ST117 Efs isolate from Oporto with two different vanA
plasmids of 150 kb and 300 kb indicates acquisition and further
recombination of widespread pRUM-vanA plasmids from Efm
with narrow host pheromone responsive plasmids of Efs.
The observed differences in transposon variants and plasmid
modules reflect frequent rearrangements during transfer of
plasmids between Efs and/or Efm clonal backgrounds and also
highlight the connectivity of these enterococcal populations
resulting in the acquisition and generation of plasmids with
enhanced host range.
Fixation of vanA-Tn1546 variants is associated with
plasmid connectivity
Tn1546 backbones were classified in three main groups
corresponding to Tn1546 with no insertion sequences (‘‘type A’’
and ‘‘type D’’) and variants containing ISEf1 (5 types) or IS1216
(11 types) at different locations of the Tn1546 backbone (Figure 4).
Variants with a single copy of ISEf1 within the vanX-vanY region at
nt 9044 were located on early (1996–1997) Efm plasmids identified
as Inc18 and pRUM lacking Axe-Txe, and also on early (1996) Efs
Inc18-pAD1 mosaics. Some of them were isolated from strains for
more than one decade, which can be explained by their successful
long-term recovered clonal and plasmid backgrounds.
Variants containing IS1216 were mostly located on Inc18
plasmids or on mosaic plasmids Inc18-pRUM or Inc18-pAD1.
Most variants contained the IS1216 at 8839nt of the transposon
(PP13, PP17, PP20, PP23, PP30) similarly to other Tn1546
variants previously described in Europe [42]. Some of them also
harboured different insertions corresponding to unknown se-
quences (X, PP23) or RCR plasmid sequences (PP10) [43]
suggesting frequent recombination between acquired genes/
plasmids and housekeeping Efm and Efs plasmids (Figure 4).
Tn1546 type D was specifically linked to megaplasmids from CC5
Efm from swine of different continents (Figure 2, Figure 4).
The presence of early plasmids carrying Tn1546 belonging to
different families suggests independent acquisitions of the trans-
poson by pRUM and Inc18 plasmids, which would have been
acquired by diverse Efm and Efs populations. Local fixation would
be influenced by connectivity of plasmid and population
backgrounds enabling further evolvability of transposon variants.
Discussion
This paper shows the local dynamics of Tn1546-vanA among
Enterococci is shaped by horizontal genetic transfer of pRUM and
Inc18 plasmids and by recombination-driven evolution of them
within and between Efs and Efm clones. The clonal diversity
reported in this study has also been observed in areas where the
spread of VRE has been documented [44]. Recent retrospective
analysis of enterococcal populations suggests that the temporal
evolution of the population biology of Enterococci is driven by a
succession of epidemic waves of enterococcal human specific
lineages, Efm ST78 and Efs ST6 emerging in the last decade at
global scale similarly to that reported for other pathogens
[19,23,24]. In Portugal, the population structure of VRE analysed
in this study comprises isolates of main human Efm lineages, ST18
(ST18, ST132) being much more abundant than ST17 (repre-
sented by a single isolate of early ST16 lineage) [31], or ST78
(represented by sporadic ST80 and ST656, the first one linked to
early VRE outbreaks) [25,29]. It is worthwhile highlighting the
recent detection of isolates of another Efm lineage in hospitals of
the Oporto area (http://www.mlst.net) as ST117 Efm (ST78
lineage), which would reflect the increasing trend of isolates
belonging to the ST78 lineage at international level. However,
regional differences in the rates of VRE cannot be fully explained
by clonal replacement dynamics since similar enterococcal clones
appear widely distributed in areas with high and low rates of VRE
(Tedim AP et al., unpublished data). Instead, local conditions,
including type and density of hosts, antibiotic usage, and
transmission facilities, may influence regional differences in the
proportions of VRE, as suggested by mathematical modelling
studies on local trends of antibiotic resistance [45,46]. Clones can
locally evolve by variation, drift and short-distance migration,
leading to changes in colonization ability, pathogenicity or even
host range, the fittest clonal variants being able to facilitate the
spread of antibiotic resistance [23,47–50]. The observed clonal
heterogeneity of the predominant ST18 lineage which comprises
particular ST18 and ST132 strains widespread in different cities,
highlights the role of certain efficiently transmissible clones in the
designated with numbers corresponding to different plasmid types [9] (Francia et al, unpublished data): Rel1, pJS42, pRI1; Rel2, rel from p200B, pCIZ2
and/or pB82 plasmids; Rel3, pRUM; Rel5, rel from pAD1, pTEF1, pAM373 and the pathogenicity island of V583; Rel6, pEF1; Rel8, pHTb and pMG1; Rel9,
pCF10. Toxin-antitoxin systems included Axe-Txe from pRUM, v-e-f from Inc18 plasmids and par from pAD1. Genes hybridizing in the same band as
vanA plasmids appear in bold rectangles.
doi:10.1371/journal.pone.0060589.g002
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Table 1. Plasmids identified in this study.
RFLP type VanA modular profile Size No. isolates Tn1546 PFGE type City Year
RFLP_1 Rep17.2::Rel6 60 1 A ST190_H98 Coimbra 1998
RFLP_2 Rep17.2::Rel6 80 1 A ST18_H92 Coimbra 2000
RFLP_8 c Rep17.2::Rel6 120 1 PP2b ST18_H70 Coimbra 2001
RFLP_9 c Rep17.2::Rel6 60 1 PP2b ST18_H70 Viseu NI
RFLP_10 c Rep17.2::Rel6 60 3 PP2b ST18_H70, H93 Coimbra, Viseu 2002
RFLP_11 Rep17.2::Rel6 60 1 PP27 ST18_H87 Coimbra 2002
RFLP_3 b Rep17.2::Rel6 95 3 PP4 ST18_H108 Coimbra 1998–2000-NI
RFLP_4 b Rep17.2::Rel6 85 2 PP4 ST670_H90; ST18_H81 Coimbra 1997–2001
RFLP_7 Rep17.2::Rel6 50 1 PP5 NI Viseu 2008
RFLP_6 b Rep17.2::Rel6 80 1 PP5 ST18_H70 Coimbra NI
RFLP_5 b Rep17.2::Rel6 90 12 PP3, PP4,
PP5, PP24
ST18_H78, H72, H94,
H123, H129
Coimbra, Porto,
Matosinhos
2001–2007
RFLP_5.2b Rep17.2::Rel6 90 2 PP5 ST280_ H100 Porto, Viseu 2002–2003
RFLP_5.3b Rep17.2::Rel6 90 1 PP5 ST125_H126 Matosinhos 2007
RFLP_5.3’b Rep17.2::Rep2:: Rel6 85 2 PP5 ST132_H103 Coimbra 2002–2003
RFLP_5.2’b Rep17.2::Rep2:: Rel6 90 1 PP4 ST132_H132 Coimbra 2001
RFLP_5.4’b Rep17.2::Rep2:: Rel6 90 1 PP5 ST280_ H71 Viseu 2003
RFLP_5.5b Rep17.2::Rep2:: Rel6 75 1 PP5 ST18_H125 Matosinhos 2007
RFLP_6.4 Rep17.2::Rep2:: Rel6 85 1 PP5 ST366_H99 Coimbra 2000
RFLP_20 Rep17.2::Rep2:: Rel6 30 1 A ST656_H130 Vila Real 2008
RFLP_12 a Rep17.2::Rep2:: Rel6 40 1 PP10 ST18_H83 Coimbra 1996
RFLP_13 b Rep17.2:: Rel6::TAInc18
a 60 1 PP5 ST280_ H71 Oporto 2002
RFLP_18 Rep17.2:: Rep1:: Rel6:: TAInc18 50 1 PP13 ST132_H86 Oporto 2001
RFLP_16 Rep17.2:: Rep1:: Rep2:: Rel6::TAInc18 50 1 PP13 ST18_H78 Oporto 2001
RFLP_17 Rep17.2:: Rep1:: Rep2:: Rel6::TAInc18 110 1 PP13 ST132_H88 Oporto 2001
RFLP_19 Rep17.2:: Rep1:: Rep2:: Rel6::TAInc18 60 3 PP13, PP20, PP23 ST132_H119 Oporto 2002
RFLP_19 Rep17.2:: Rep1:: Rep2:: Rel6::TAInc18 60 2 PP17, PP20 ST368_SWH Oporto 2001
RFLP_19.1 Rep17.2:: Rep1:: Rep2:: Rel6::TAInc18 60 1 X ST369_RP Oporto 2003
RFLP_21 Rep17.2:: Rep2:: Rel6:: TApRUM 65 1 PP15 ST719_H96 Oporto 2001
RFLP_22 Rep17.2:: Rep2:: Rel6:: TApRUM 30 1 PP16 ST132_SWC Oporto 2002
RFPL_27d Rep9: Rep2: Rep1:: Rel5::TApAD1 75–85 4 PP2a, PP4 ST6_HB, ST55_HG,
ST159_HN
Coimbra 1996–2002
RFPL_27.3d Rep9: Rep2: Rep1:: Rel5::TApAD1 85 2 PP4 ST6_HB, ST159_HN Viseu 2001–2002
RFPL_27.1d Rep9: Rep1:: Rel5:: TApAD1 75 1 PP4 ST6_HB Oporto 2001
RFPL_27d Rep9: Rep2: Rep1:: Rel5 85 1 PP9 ST132_H106 Coimbra 2000
RFPL_28.5 Rep9: Rep2 100 1 PP16 ST80_SWM Oporto 2002
RFPL_28 Rep9: Rep2: Rel5:: TApAD1 100 2 PP15, PP16 ST6_HB Oporto 2001–2002
RFLP_29 Rep9: Rep2: Rel5 100 1 A ST6_HB Swine 2007
RFLP_30 Rep9: Rel9 100 1 A ST30_HK Oporto 2001
RFLP_24 Rep2 110 1 PP4 ST80_H80 Coimbra 1997
RFLP_14 Rep2 40 1 PP16 ST132_SWC Oporto 2002
RFLP_15 Rep1:: Rep2 30 2 PP16 ST18_SWA, ST132_SWC Oporto 2001
RFLP_23 Rel6 85 1 PP9 ST16_H74 Coimbra 2000
RFLP_26 Rep20:: Rel6 150 1 D ST5_SA Oporto 2002
RFLP_25 – 120 1 PP5 ST391_H124 Covilha˜ 2007
Abbreviations: RFLP, restriction fragment length polymorphism; ST, sequence type; NI, not identified.
aPlasmid type RFLP_12 (Rep17.2/pRUM-like + Rep2/pRE25/pEF1 + Rel6/pEF1) contains a partial sequence of the replication gene of the RCR plasmid pEFNP1 (GenBank accession
number AB038522), suggesting the integration of this RCR plasmid on the mobile element carrying Tn1546 involving truncation of the rep14/pRI1/pEFNP1.
bPlasmid types RFLP_3, _4, _5, _6 and _13 (Rep17.2/pRUM-like + Rel6/pEF1 and eventually containing Rep1/pIP501, Rep2/pRE25/pEF1 or TAInc18) shared common bands and were
identified in the same or different clonal backgrounds in different cities for extended periods of time.
cPlasmids types RFLP 8, _9 and _10 also shared a variable number of common bands.
dPlasmids showing patterns related to RFLP_27 (75–85 kb; rep9/pAD1 + rel5/pAD1 + rep1/pIP501 + parpAD1 and/or rep2/pRE25/pEF1) initially recovered from the widespread ST6-CC2 Efs clone
in Coimbra in 1996 and other Efs (ST55 and ST159) and Efm clones contained similar ISEf1-Tn1546 variants (PP-2a, PP-4, PP-9). Other highly relatedmosaic Inc18-pAD1-related plasmids
carrying IS1216-Tn1546 were recovered from ST6 VREfs and ST80 VREfm isolates (type˝ IIEfs˝, rep9/pAD1 +rel5/pAD1 + parpAD1 + rep2/pRE25/pEF1 versus type˝ IIEfm˝, rep9/pAD1 + rep2/pRE25/pEF1).
doi:10.1371/journal.pone.0060589.t001
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dissemination of antibiotic resistance. Succesful clones can
eventually be able to disseminate at international level as strains
of ST6 Efs or ST280 Efm within main Efm human lineages
driving or contributing the spread of different traits as Tn1546 or
Tn1549 [51]. One remarkable fact is the similarity among PFGE
patterns of isolates with different STs. Given the high content of
plasmids and transposons of the isolates studied, and the frequent
rearrangements identified among Efm and/or Efs isolates [21],
chromosomal transfer can not be discarded. Recent phylogenomic
analysis based on the degree of admixture among a diversity of
isolates studied suggests that recombination is restricted to isolates
within specific BAPS groups [19]. Most plasmids coding for
vancomycin resistance are found in similar clonal backgrounds.
This observation suggests that recombination does occur within
isolates of similar BAPS groups as recently described [19].
However, the observed mosaicism and enhanced host range of
particular plasmid variants indicates the existence of an unexpect-
edly high degree of connectivity between phylogenetically distant
enterococcal populations and/or in bacterial genetic exchange
communities integrating enterococci.
Broad host and narrow host plasmids carrying vancomycin
resistance would have a high ‘‘betweenness centrality’’, which is a
pivotal index in network theory useful for measuring the load
placed on the given node in the network as well as the node’s
importance to the network than just connectivity [52]. A recent in
silico network analysis of all plasmid sequences available at the
GenBank databases confirms very high˝ betweenness˝ values for some
Inc18 plasmids as pVEF3 (an Inc18 derivative highly spread
among Efm from animals in Europe) [13,37], and also for a
pheromone-responsive plasmid pTEF1 (a plasmid recovered from
ST6_Efs strain V583, highly related to the ST6 described in this
work) [53] (unpublished data). Other plasmids with a high degree
of modular dissociability, would be pRUM-like elements, which may
enhance their complexity resulting in new configurations with
enhanced betweenness. It is tempting to suggest that plasmid
variability has contributed to intra-clonal diversification both in
Efm and Efs, giving rise to a local wealth of clonal variants able to
fully explore the local adaptive landscape. In fact, this and other
studies demonstrate that selected variants of Inc18, pAD1, and
pRUM plasmids can determine differences in the dynamics of
VRE in different areas, further influencing the plasmid host range
and the selection of specific clones within human adapted lineages.
Examples of widespread plasmid variants of Inc18 or pRUM
plasmids coding for vancomycin resistance have been reported
recently. They included Inc18 widespread among Efm poultry
isolates from Europe [13] or among Efs clinical isolates from the
USA, the last one being able to transfer Tn1546 to S. aureus [15];
and mosaics of pRUM variants containing Axe-Txe and Inc18
from humans in different continents (Freitas AR et al. unpublished
data). The identification of chimeric pRUM-Inc18 plasmids
containing rep/rel/TA of Inc18 sequences and Tn1546 variants
widely observed in poultry, hospitals and hospital sewage in the
Oporto area reflects genetic exchanges between enterococci from
different origins and highlights the need to enforce barriers to
avoid the spread of multidrug resistance human pathogens to the
environment and viceversa.
In this scenario, the genetic context of Tn1546 seems to greatly
influence the evolvability of the transposon and explains the high
diversity of variants found in this and other studies [1,27,42,54].
The frequent presence of insertions in the backbone of Tn1546
and the abundance of IS1216 and ISEf1 in enterococcal genomes
[9,55] makes homoplasic evolution of Tn1546 in different
backgrounds possible. However, other IS (IS1251, IS1542,
IS1476, IS19 and IS1485) linked to different plasmid and clonal
backgrounds [9,40] have been identified at different sites of
Tn1546, thus suggesting that chance and selection are responsible
to differences in variants collected in different areas. The
widespread of Inc18 plasmids with a common origin in Europe
[13,56] indicates local fixation of Tn1546 influenced by a founder
effect and further connectivity of plasmid and population
backgrounds enabling further evolvability of transposon variants
as reported in this study.
Our results suggest that VRE spread is facilitated by selected
clones of different lineages through strong interactive processes of
clonalization and plasmid diversification that might occur at local
scales. Despite the maintenance of significant gene flow, a
sympatric, or more probably, parapatric bacterial clonalization
process (when diverging populations share a common or
neighbouring environment), might contribute to the formation of
temporary genetic mosaics and the preservation of ecologically
important genomic traits [57]. Such micro-evolutionary process
will result in an array of clonal complexes forming a population
structure able to exploit the local spatio-temporal patch hetero-
geneities [58]. Note that exploitation of connected microenviron-
ments should accelerate evolution of antibiotic resistance [59]. The
expected result of such a successful population structure is the local
persistence of antibiotic resistant clones, and eventually the local
fixation [60] of vancomycin-resistance [46].
In summary, this study highlights the relevance of studying the
local microecology of genes, elements, lineages and populations to
decipher the robustness of the trans-hierarchical networks
connecting these evolutionary elements in order to describe and
predict the local evolvability of vancomycin-resistance [61].
Traditional surveillance studies are one-off cross sectional surveys
focused on single traits as epidemic strains, genes or mobile genetic
elements over limited periods of time which only gives one shot view
that precludes addressing the long-term dynamics of antibiotic
resistance. The more comprehensive approach described in this
study is needed for understanding in depth the evolution of
complexity in multihierarchical systems as those involved in the
Figure 3. Restriction fragment length polymorphism patterns
of plasmids showing RFLP_5 profiles after digestion with ClaI
(I) and EcoRI (II) restriction enzymes (New England Biolabs Inc,
UK). Lane 1, RFLP_5 (PFGE H78, ST18 Efm,); lane 2, RFLP_5 (PFGE H72,
ST18 Efm); lane 3, RFLP 5.2 (PFGE H100, ST280 Efm), lane 4, RFLP 5 (PFGE
H78, ST18 Efm); lane 5, RFLP_5 (PFGE H78, ST18 Efm); lane 6, RFLP_5.2’
(PFGE H132, ST132 Efm).
doi:10.1371/journal.pone.0060589.g003
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spread of antibiotic resistance among the populations of bacterial
human pathogens.
Materials and Methods
Bacterial strains and epidemiological background
One hundred four VRE clinical isolates carrying Tn1546 from
different regions of Portugal, 75 VREfm and 29 VREfs, were
analyzed in this study. They included: i) clinical isolates from
hospitals of Coimbra (Hospital Universita´rio de Coimbra, HUC),
Oporto (Hospital Santo Anto´nio, HSA), Viseu (Hospital de Sa˜o
Teoto´nio, HST); Matosinhos (Hospital Pedro Hispano, HPH),
Vila Real (Hospital S. Pedro, HVR) and Covilha˜ (Centro
Hospitalar da Cova da Beira, CHCB) located in Northern and
Central Portugal (62 Efm and 26 Efs; 1996–2008); ii) isolates from
waste waters of hospitals (HSA and Hospital de Sa˜o Joa˜o, HSJ) (10
Efm and 3 Efs), and iii) isolates from the estuary of the River
Douro (3 Efm) recovered in the Oporto area during 2001–2003.
Part of the isolates analyzed in this work corresponds to strains
from previous surveillance studies [25–27,62]; this paper consti-
tutes the first description of isolates obtained during 2007 and
2008. Contemporary Portuguese VRE isolates of animal origin
were used for comparative analysis of lateral transfer events [10].
Susceptibility against 15 antibiotics was determined by the agar
dilution method following CLSI standard guidelines. Clonal
relatedness was established by pulsed-field gel electrophoresis
(PFGE), banding patterns were interpreted according to criteria
previously suggested for long-term studies, and multilocus
sequence typing (MLST) as described elsewhere (http://
efaecium.mlst.net) [25,63–65].
The presence of putative virulence traits [collagen-binding
adhesin (acm), enterococcal surface protein (esp), hyaluronidase
(hylE. faecium), cytolysin/hemolysin (cyl), gelatinase (gelE) and aggre-
gation substance (agg)] was searched by using PCR as described
[66,67].
Genetic context of Tn1546
Characterization of Tn1546 backbone was determined by
amplification of overlapping transposon fragments and further
sequencing of PCR products [27,68]. We have accomplished the
analysis for the isolates not studied in previous surveys and have
interpreted the resulting transposon diversity (this study) [27],
under the light of the plasmid and clonal backgrounds identified in
this geographical area.
Plasmid analysis
Isolates (n = 62 Efm and n= 13 Efs) representing the clonal
diversity observed in both species were selected for plasmid
characterization (Table 1, Figure 2). The content and size of
plasmids from transconjugants obtained by filter mating were
determined by using either the technique described by Barton et al.
(plasmids .10 kb) or the alkaline lysis extraction method of Kado
& Liu (plasmids ,10 kb) [51,69,70]. Classification of E. faecium
plasmids was based on the presence of specific modules for
replication (rep-initiator proteins), mobilization (relaxases) and
stability (toxin-antitoxin systems). Relaxases (rel) were sought by a
multiplex-PCR-based relaxase typing method which differentiates
relaxases of the MOBQ, MOBP, MOBC and MOBV families
related to 27 known plasmids [9,71] (Francia MV, unpublished
data). Replication initiator proteins (rep) were investigated by
amplification of 24 replicons, which allows discriminating among
DNA sequences from more than 100 published Gram-positive
plasmids [9,72]. Designation of rep sequences pointed out the
plasmid type in which they were initially identified, as well as the
numeric nomenclature originally used by Jensen et al. (Figure 2s
footnote) [72]. Toxin-antitoxin systems (TA) previously identified
among streptococci and enterococci (Axe-Txe, v-e-f par, mazEF)
or Gram-negative bacteria (relBE) were detected by PCR [73].
PCR products were sequenced in order to confirm the specificity
of the method and to analyze similarities with other well-
characterized plasmids. Genomic location of the Tn1546 and
the rel/rep/TA sequences was determined by hybridization of
vanA and rel/rep/TA specific probes obtained by PCR from DNA
from reference plasmids with S1 or I-CeuI digested genomic DNA
from representative strains [51,69]. Structural relationship be-
tween plasmids of similar size was established by comparison of
their RFLP patterns obtained after digestion with different
restriction enzymes (EcoRI, HindIII and ClaI; see Figure 3).
Plasmid DNA was obtained by using a modified protocol based on
the alkaline lysis method described by Handwerger et al. [74]
consisting of increasing two-fold the volume of lysozyme, SDS/
NaOH and acetate potassium solutions, extending the incubation
period in potassium acetate solution for at least three hours,
precipitating the supernatant obtained after extraction with
phenol-chloroform using ethanol-acetate potassium solution
(2:0.1 vol/vol) at 25uC for at least 2 hours, and resuspending
final DNA pellets in 30 ml of water for further enzyme digestion
analysis.
Molecular techniques
Southern blot DNA transfer and hybridization were performed
by standard procedures [75]. The vanA and rep/rel/TA/bac
probes used in the hybridization assays were generated by PCR
using well known positive controls as template DNA. Labelling
and detection were carried out using Gene Images Alkphos Direct
Labelling system kit, following the manufacturer’s instructions
(Amersham GB/GE Healthcare Life Sciences UK Limited).
PFGE was performed as described previously [76] using the
Figure 4. Genetic maps of Tn1546 variants. Tn1546 variants are represented as previously described by Novais et al. [27] although grouped
differently and specific types have been further explored (PP10, PP30): Tn1546 prototype A corresponds to the original sequence described by Arthur
et al. [77] and D corresponds to Tn1546 variants from animals. Tn1546 variants with ISEf1 within vanX-vanY intergenic region (PP2a, PP4, PP5, PP9,
PP24) and Tn1546 variants with IS1216 insertions at different positions (PP10, PP2b, PP13, PP15, PP16, PP17, PP20, PP23, PP27, PP30, X) are
represented. The positions of genes and open reading frames and the direction of transcription are depicted with open arrows. IS elements are
represented by triangles; other sequences are designated by rectangles. DNA insertions are represented highlighting the first nucleotide upstream
and downstream from the insertion sites whenever known. Deletions are indicated by dots and discontinuous lines indicate sequences that were not
characterized. (a) DNA sequence with homology to ORF3 (unknown protein product) and ORF1 (replication protein) of pEFNP1 plasmid (GenBank
accession number AB038522). (b) DNA sequence with no match to any sequence available in GenBank. (*) PP23 was identified in an isolate
susceptible to teicoplanin; this variant contained an insertion in the vanY gene that would affect the transcription of vanZ and it might explain the
susceptibility to this glycopeptide as previously reported [27]. (**) PP30 was identified in an ST78 isolate susceptible to both glycopeptides (MIC
against vancomycin and teicoplanin of 4 mg/L) carrying vanA-Tn1546. This variant contained alterations within the vanS-vanH intergenic region (an
IS1216 insertion), which is involved in the expression and regulation of the resistance to vancomycin, and it constitutes the first description of a vanA
isolate phenotypically susceptible to vancomycin in Portugal.
doi:10.1371/journal.pone.0060589.g004
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following conditions: switch time of 5 s to 25 s for 6 h, followed by
30 s to 45 s for 18 h (S1 nuclease); 5 s to 30 s for 22 h, 14uC, and
6 V/cm2 (I-CeuI) and 1 s to 20 s for 26 h, 14uC, and 6 V/cm2
(SmaI).
Plasmid sequences
Analysis of nucleotide and aminoacid sequences revealed two
types of sequences amplified with primers used for identification of
rep17/pRUM.They were 100% (designated as Rep17.1/pRUM) or 97%
(96% identity at amino acid level; designated as Rep17.2/pRUM-like)
homologous to that of RepA_pRUM (GenBank accession number
AF507977). Most Rep1/pIP501 aminoacid sequences were 98%–
100% identical to RepE_pIP816, a member of the Inc18 family
(GenBank accession number AM932524), and to a lesser degree to
pRE25, pTEF1 or pSM19035; and Rep2/pRE25/pEF1 showed 96%–
100% amino acid identity to that of pEF1 (GenBank acc. no.
DQ198088). Sequences identified as Rel6/pEF1 showed 98%–100%
homology to orf34_pEF1. Relaxases of the E. faecalis pheromone-
responsive plasmids identified in this study displayed a high homology
with those of known enterococcal pheromone plasmids pAD1,
pAM373 and pTEF1 (orf57_pAD1, GenBank acc. no. AAL59457;
EFA0025_pTEF1, GenBank AE016833; and EP0019_pAM373,
GenBank acc. no. NC_002630). That of plasmid showing RFLP_27
showed a 67–84% homology with the above mentioned pheromone
enterococcal plasmids but 94% identity with a MobC relaxase
(annotated as a hypothetical protein) from a vancomycin-resistant S.
aureus strain (GenBank acc. no. EIK35827).
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